

Supplementary table 1.
Ahmad, F., et al. (2018). "Evidence of inflammasome activation and formation of monocyte-derived ASC specks in HIV-1 positive patients." <u>AIDS (London, England)</u> 32 (3): 299-307.
Altekruse, S. F., et al. (2018). "Cancer burden attributable to cigarette smoking among HIV-infected people in North America." <u>AIDS (London, England)</u> 32 (4): 513-521.
Boivin, M. J., et al. (2018). "Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial." <u>AIDS (London, England)</u> 32 (2): 189-204.
Botha, J., et al. (2018). "Living donor liver transplant from an HIV-positive mother to her HIV-negative child: opening up new therapeutic options." <u>AIDS (London, England)</u> 32 (16): F13-F19.
Brumme, Z. L., et al. (2018). "Extensive host immune adaptation in a concentrated North American HIV epidemic." <u>AIDS (London, England)</u> 32 (14): 1927-1938.
Carrillo, J., et al. (2018). "Memory B cell dysregulation in HIV-1-infected individuals." <u>AIDS (London, England)</u> 32 (2): 149-160.
Chang, C. C., et al. (2018). "Variation in cell-associated unspliced HIV RNA on antiretroviral therapy is associated with the circadian regulator brain-and-muscle-ARNT-like-1." <u>AIDS (London, England)</u> 32 (15): 2119-2128.
Chaudhury, S., et al. (2018). "In-utero exposure to antiretrovirals and neurodevelopment among HIV-exposed-uninfected children in Botswana." <u>AIDS (London, England)</u> 32 (9): 1173-1183.
Chow, F. C., et al. (2018). "Elevated ischemic stroke risk among women living with HIV infection." <u>AIDS (London, England)</u> 32 (1): 59-67.
Chow, F. C., et al. (2018). "Stroke incidence is highest in women and non-Hispanic blacks living with HIV in the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials cohort." <u>AIDS (London, England)</u> 32 (9): 1125-1135.
Chowdhury, F. Z., et al. (2018). "Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers." <u>AIDS (London, England)</u> 32 (18): 2669-2677.
Chung, A. W., et al. (2018). "Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity." <u>AIDS (London, England)</u> 32 (10): 1207-1217.
Cid-Silva, P., et al. (2018). "Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors." <u>AIDS (London, England)</u> 32 (1): 121-125.
Cillo, A. R., et al. (2018). "Blood biomarkers of expressed and inducible HIV-1." <u>AIDS (London, England)</u> 32 (6): 699-708.

Clifford, G. M., et al. (2018). "Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM." <u>AIDS (London, England)</u> 32 (16): 2363-2371.
Cluver, L., et al. (2018). "Multitype violence exposures and adolescent antiretroviral nonadherence in South Africa." <u>AIDS (London, England)</u> 32 (8): 975-983.
d'Elbee, M., et al. (2018). "Preferences for linkage to HIV care services following a reactive self-test: discrete choice experiments in Malawi and Zambia." <u>AIDS (London, England)</u> 32 (14): 2043-2049.
De Francesco, D., et al. (2019). "Do people living with HIV experience greater age advancement than their HIV-negative counterparts?" <u>AIDS (London, England)</u> 33 (2): 259-268.
Domblides, C., et al. (2018). "Nonsmall cell lung cancer from HIV-infected patients expressed programmed cell death-ligand 1 with marked inflammatory infiltrates." <u>AIDS (London, England)</u> 32 (4): 461-468.
Duffau, P., et al. (2018). "Multimorbidity, age-related comorbidities and mortality: association of activation, senescence and inflammation markers in HIV adults." <u>AIDS (London, England)</u> 32 (12): 1651-1660.
El-Sadr, W. M. and E. Goosby (2018). "Building on the HIV platform: tackling the challenge of noncommunicable diseases among persons living with HIV." <u>AIDS (London, England)</u> 32 Suppl 1 : S1-S3.
Engelhard, E. A. N., et al. (2018). "Health-related quality of life of people with HIV: an assessment of patient related factors and comparison with other chronic diseases." <u>AIDS (London, England)</u> 32 (1): 103-112.
Eron, J. J., et al. (2018). "A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients." <u>AIDS (London, England)</u> 32 (11): 1431-1442.
Evans, V. A., et al. (2018). "Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency." <u>AIDS (London, England)</u> 32 (11): 1491-1497.
Favarato, G., et al. (2018). "Protease inhibitors and preterm delivery: another piece in the puzzle." <u>AIDS (London, England)</u> 32 (2): 243-252.
Ford, N., et al. (2018). "Benefits and risks of rapid initiation of antiretroviral therapy." <u>AIDS (London, England)</u> 32 (1): 17-23.
George, V. K., et al. (2018). "Circulating inflammatory monocytes contribute to impaired influenza vaccine responses in HIV-infected participants." <u>AIDS (London, England)</u> 32 (10): 1219-1228.
Golob, J. L., et al. (2018). "HIV DNA levels and decay in a cohort of 111 long-term virally suppressed patients." <u>AIDS (London, England)</u> 32 (15): 2113-2118.
Gong, S., et al. (2018). "Anti-HIV IgM protects against mucosal SHIV transmission." <u>AIDS (London, England)</u> 32 (11): F5-F13.
Hanna, D. B., et al. (2018). "Carotid artery atherosclerosis is associated with mortality in HIV-positive women and men." <u>AIDS</u>

(London, England) 32 (16): 2393-2403.
Hargreaves, J. R., et al. (2018). "Individual and community-level risk factors for HIV stigma in 21 Zambian and South African communities: analysis of data from the HPTN071 (PopART) study." <u>AIDS (London, England)</u> 32 (6): 783-793.
Harris, T. G., et al. (2018). "Achieving the fourth 90: healthy aging for people living with HIV." <u>AIDS (London, England)</u> 32 (12): 1563-1569.
Hoorneborg, E., et al. (2018). "Change in sexual risk behaviour after 6 months of pre-exposure prophylaxis use: results from the Amsterdam pre-exposure prophylaxis demonstration project." <u>AIDS (London, England)</u> 32 (11): 1527-1532.
Horvath, S., et al. (2018). "Perinatally acquired HIV infection accelerates epigenetic aging in South African adolescents." <u>AIDS (London, England)</u> 32 (11): 1465-1474.
Jani, I. V., et al. (2018). "Effect of point-of-care early infant diagnosis on antiretroviral therapy initiation and retention of patients." <u>AIDS (London, England)</u> 32 (11): 1453-1463.
Johnson, M., et al. (2018). "Global partnerships to support noncommunicable disease care in low and middle-income countries: lessons from HIV/AIDS." <u>AIDS (London, England)</u> 32 Suppl 1 : S75-S82.
Juma, K., et al. (2018). "From HIV prevention to non-communicable disease health promotion efforts in sub-Saharan Africa: A Narrative Review." <u>AIDS (London, England)</u> 32 Suppl 1 : S63-S73.
Justice, A. C., et al. (2018). "Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals." <u>AIDS (London, England)</u> 32 (6): 739-749.
Kemp, C. G., et al. (2018). "Implementation science for integration of HIV and non-communicable disease services in sub-Saharan Africa: a systematic review." <u>AIDS (London, England)</u> 32 Suppl 1 : S93-S105.
Koehn, J., et al. (2018). "Extended cell and plasma drug levels after one dose of a three-in-one nanosuspension containing lopinavir, efavirenz, and tenofovir in nonhuman primates." <u>AIDS (London, England)</u> 32 (17): 2463-2467.
Korhonen, C., et al. (2018). "Depressive symptoms and problematic alcohol and other substance use in 1476 gay, bisexual, and other MSM at three research sites in Kenya." <u>AIDS (London, England)</u> 32 (11): 1507-1515.
LaCourse, S. M., et al. (2018). "Stool Xpert MTB/RIF and urine lipoarabinomannan for the diagnosis of tuberculosis in hospitalized HIV-infected children." <u>AIDS (London, England)</u> 32 (1): 69-78.
Lake, J. E., et al. (2018). "Metabolic health across the BMI spectrum in HIV-infected and HIV-uninfected men." <u>AIDS (London, England)</u> 32 (1): 49-57.
Lancki, N., et al. (2018). "Preexposure prophylaxis guidelines have low sensitivity for identifying seroconverters in a sample of young Black MSM in Chicago." <u>AIDS (London, England)</u> 32 (3): 383-392.

Lavender, K. J., et al. (2018). "An advanced BLT-humanized mouse model for extended HIV-1 cure studies." <u>AIDS (London, England)</u> 32 (1): 1-10.
le Roux, S. M., et al. (2018). "Neurodevelopment of breastfed HIV-exposed uninfected and HIV-unexposed children in South Africa." <u>AIDS (London, England)</u> 32 (13): 1781-1791.
Lepik, K. J., et al. (2018). "Adverse drug reactions to integrase strand transfer inhibitors." <u>AIDS (London, England)</u> 32 (7): 903-912.
Lindgren, A. A., et al. (2018). "Lentiviral infection of proliferating brain macrophages in HIV and simian immunodeficiency virus encephalitis despite sterile alpha motif and histidine-aspartate domain-containing protein 1 expression." <u>AIDS (London, England)</u> 32 (8): 965-974.
Liu, G., et al. (2018). "HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer." <u>AIDS (London, England)</u> 32 (6): 795-808.
Lodi, S., et al. (2018). "Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance." <u>AIDS (London, England)</u> 32 (3): 327-335.
Maggiolo, F., et al. (2018). "Post-treatment controllers after treatment interruption in chronically HIV-infected patients." <u>AIDS (London, England)</u> 32 (5): 623-628.
Makinson, A., et al. (2018). "HIV is associated with airway obstruction: a matched controlled study." <u>AIDS (London, England)</u> 32 (2): 227-232.
Matanje Mwagomba, B. L., et al. (2018). "Opportunities and challenges for evidence-informed HIV-noncommunicable disease integrated care policies and programs: lessons from Malawi, South Africa, Swaziland and Kenya." <u>AIDS (London, England)</u> 32 Suppl 1 : S21-S32.
Mathabire Rucker, S. C., et al. (2018). "High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi." <u>AIDS (London, England)</u> 32 (2): 253-260.
McComsey, G. A., et al. (2018). "Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health." <u>AIDS (London, England)</u> 32 (4): 477-485.
McMahon, C. N., et al. (2018). "High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years." <u>AIDS (London, England)</u> 32 (4): 451-459.
Medrano, L. M., et al. (2018). "Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV/hepatitis C virus-coinfected patients." <u>AIDS (London, England)</u> 32 (9): 1095-1105.
Merchante, N., et al. (2018). "Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients." <u>AIDS (London, England)</u> 32 (11): 1423-1430.

Meyer-Rath, G., et al. (2018). "Targeting the right interventions to the right people and places: the role of geospatial analysis in HIV program planning." <u>AIDS (London, England)</u> 32 (8): 957-963.
Missailidis, C., et al. (2018). "The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages." <u>AIDS (London, England)</u> 32 (12): 1589-1598.
Momplaisir, F. M., et al. (2018). "Improving postpartum retention in care for women living with HIV in the United States." <u>AIDS (London, England)</u> 32 (2): 133-142.
Mulligan, N., et al. (2018). "Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV." <u>AIDS (London, England)</u> 32 (6): 729-737.
Neogi, U., et al. (2018). "Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes." <u>AIDS (London, England)</u> 32 (4): 469-476.
Nguyen, V.-K., et al. (2018). "Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV." <u>AIDS (London, England)</u> 32 (4): 523-530.
Nichols, M. J., et al. (2019). "Atrophic brain signatures of mild forms of neurocognitive impairment in virally suppressed HIV infection." <u>AIDS (London, England)</u> 33 (1): 55-66.
Nicol, M. R., et al. (2018). "The role of menopause in tenofovir diphosphate and emtricitabine triphosphate concentrations in cervical tissue." <u>AIDS (London, England)</u> 32 (1): 11-15.
Njuguna, B., et al. (2018). "Models of integration of HIV and noncommunicable disease care in sub-Saharan Africa: lessons learned and evidence gaps." <u>AIDS (London, England)</u> 32 Suppl 1 : S33-S42.
Nugent, R., et al. (2018). "Costs and cost-effectiveness of HIV/noncommunicable disease integration in Africa: from theory to practice." <u>AIDS (London, England)</u> 32 Suppl 1 : S83-S92.
Nunez, O., et al. (2018). "Estimating the number of people living with HIV and the undiagnosed fraction in Spain in 2013." <u>AIDS (London, England)</u> 32 (17): 2573-2581.
O'Halloran, J. A., et al. (2018). "Switching from abacavir to tenofovir disoproxil fumarate is associated with rises in soluble glycoprotein VI, suggesting changes in platelet-collagen interactions." <u>AIDS (London, England)</u> 32 (7): 861-866.
Oldenburg, C. E., et al. (2018). "Impact of early antiretroviral therapy eligibility on HIV acquisition: household-level evidence from rural South Africa." <u>AIDS (London, England)</u> 32 (5): 635-643.
Olesen, J. S., et al. (2018). "HIV-2 continues to decrease, whereas HIV-1 is stabilizing in Guinea-Bissau." <u>AIDS (London, England)</u> 32 (9): 1193-1198.
Olson, A., et al. (2018). "Temporal trends of transmitted HIV drug resistance in a multinational seroconversion cohort." <u>AIDS (London, England)</u> 32 (2): 161-169.

Papasavvas, E., et al. (2018). "Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV." <u>AIDS (London, England)</u> 32 (13): 1763-1772.
Pastakia, S. D., et al. (2018). "Building reliable supply chains for noncommunicable disease commodities: lessons learned from HIV and evidence needs." <u>AIDS (London, England)</u> 32 Suppl 1 : S55-S61.
Patel, P., et al. (2018). "Noncommunicable diseases among HIV-infected persons in low-income and middle-income countries: a systematic review and meta-analysis." <u>AIDS (London, England)</u> 32 Suppl 1 : S5-S20.
Pelchen-Matthews, A., et al. (2018). "Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort." <u>AIDS (London, England)</u> 32 (16): 2405-2416.
Podany, A. T., et al. (2018). "Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide." <u>AIDS (London, England)</u> 32 (6): 761-765.
Pradat, P., et al. (2018). "Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV." <u>AIDS (London, England)</u> 32 (8): 1077-1082.
Rabkin, M., et al. (2018). "Strengthening the health workforce to support integration of HIV and noncommunicable disease services in sub-Saharan Africa." <u>AIDS (London, England)</u> 32 Suppl 1 : S47-S54.
Rabkin, M., et al. (2018). "Integrating cardiovascular disease risk factor screening into HIV services in Swaziland: lessons from an implementation science study." <u>AIDS (London, England)</u> 32 Suppl 1 : S43-S46.
Rizzo, M. D., et al. (2018). "HIV-infected cannabis users have lower circulating CD16+ monocytes and IFN-gamma-inducible protein 10 levels compared with nonusing HIV patients." <u>AIDS (London, England)</u> 32 (4): 419-429.
Rodriguez-Gallego, E., et al. (2018). "A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients." <u>AIDS (London, England)</u> 32 (5): 565-573.
Rojas, J., et al. (2018). "A maintenance 3-day-per-week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub-clinical toxicity." <u>AIDS (London, England)</u> 32 (12): 1633-1641.
Rubin, L. H., et al. (2018). "Microglial activation is inversely associated with cognition in individuals living with HIV on effective antiretroviral therapy." <u>AIDS (London, England)</u> 32 (12): 1661-1667.
Sabin, C. A., et al. (2018). "Abacavir use and risk of recurrent myocardial infarction." <u>AIDS (London, England)</u> 32 (1): 79-88.
Sadanand, S., et al. (2018). "Temporal variation in HIV-specific IgG subclass antibodies during acute infection differentiates spontaneous controllers from chronic progressors." <u>AIDS (London, England)</u> 32 (4): 443-450.
Siefried, K. J., et al. (2018). "Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy." <u>AIDS (London, England)</u> 32 (1): 35-48.

Smit, M., et al. (2018). "The growing burden of noncommunicable disease among persons living with HIV in Zimbabwe." <u>AIDS (London, England)</u> 32 (6): 773-782.
Soontornniyomkij, V., et al. (2018). "Association of antiretroviral therapy with brain aging changes among HIV-infected adults." <u>AIDS (London, England)</u> 32 (14): 2005-2015.
Srinivasa, S., et al. (2019). "Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV." <u>AIDS (London, England)</u> 33 (2): 229-236.
Tchakoute, C. T., et al. (2018). "Breastfeeding mitigates the effects of maternal HIV on infant infectious morbidity in the Option B+ era." <u>AIDS (London, England)</u> 32 (16): 2383-2391.
Thaden, J. T., et al. (2018). "Seroconversion on preexposure prophylaxis: a case report with segmental hair analysis for timed adherence determination." <u>AIDS (London, England)</u> 32 (9): F1-F4.
Thakur, K. T., et al. (2019). "Global HIV neurology: a comprehensive review." <u>AIDS (London, England)</u> 33 (2): 163-184.
Thomsen, D., et al. (2018). "The influence of human leukocyte antigen-types on disease progression among HIV-2 infected patients in Guinea-Bissau." <u>AIDS (London, England)</u> 32 (6): 721-728.
Tsukamoto, T. (2018). "Transcriptional gene silencing limits CXCR4-associated depletion of bone marrow CD34+ cells in HIV-1 infection." <u>AIDS (London, England)</u> 32 (13): 1737-1747.
Vitoria, M., et al. (2018). "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?" <u>AIDS (London, England)</u> 32 (12): 1551-1561.
Vorkoper, S., et al. (2018). "Building on the HIV chronic care platform to address noncommunicable diseases in sub-Saharan Africa: a research agenda." <u>AIDS (London, England)</u> 32 Suppl 1 : S107-S113.
Winckelmann, A., et al. (2018). "Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals." <u>AIDS (London, England)</u> 32 (13): 1793-1802.
Woolnough, E. L., et al. (2018). "Predictors of chronic kidney disease and utility of risk prediction scores in HIV-positive individuals." <u>AIDS (London, England)</u> 32 (13): 1829-1835.
Assoumou, S. A., et al. (2018). "Cost-Effectiveness of One-Time Hepatitis C Screening Strategies Among Adolescents and Young Adults in Primary Care Settings." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (3): 376-384.
Baggs, J., et al. (2018). "Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (7): 1004-1012.
Barocas, J. A., et al. (2018). "Population-level Outcomes and Cost-Effectiveness of Expanding the Recommendation for Age-based Hepatitis C Testing in the United States." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of</u>

America **67**(4): 549-556.

Barzon, L., et al. (2018). "Virus and Antibody Dynamics in Travelers With Acute Zika Virus Infection." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(8): 1173-1180.

Beganovic, M., et al. (2018). "A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **67**(2): 303-309.

Blohm, G. M., et al. (2018). "Evidence for Mother-to-Child Transmission of Zika Virus Through Breast Milk." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(7): 1120-1121.

Blumenthal, K. G., et al. (2018). "The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(3): 329-336.

Boerekamps, A., et al. (2018). "High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(9): 1352-1359.

Boerekamps, A., et al. (2018). "Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV Therapy." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(9): 1360-1365.

Bonomo, R. A., et al. (2018). "Carbapenemase-Producing Organisms: A Global Scourge." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(8): 1290-1297.

Branda, J. A., et al. (2018). "Advances in Serodiagnostic Testing for Lyme Disease Are at Hand." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(7): 1133-1139.

Briel, M., et al. (2018). "Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(3): 346-354.

Brooks, K. M., et al. (2018). "Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **67**(2): 193-201.

Carmona, S., et al. (2018). "Persistent High Burden of Advanced HIV Disease Among Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide Laboratory Cohort." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(suppl_2): S111-S117.

Chamilos, G., et al. (2018). "Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase

Inhibitors Targeting Immune Signaling Pathways." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 140-148.
Chatham-Stephens, K., et al. (2017). "Clinical Features of Foodborne and Wound Botulism: A Systematic Review of the Literature, 1932-2015." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (suppl_1): S11-S16.
Chong, P. F., et al. (2018). "Clinical Features of Acute Flaccid Myelitis Temporally Associated With an Enterovirus D68 Outbreak: Results of a Nationwide Survey of Acute Flaccid Paralysis in Japan, August-December 2015." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 653-664.
Chotiprasitsakul, D., et al. (2018). "Comparing the Outcomes of Adults With Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohort." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (2): 172-177.
Clancy, C. J., et al. (2018). "Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (11): 1678-1686.
Cobey, S., et al. (2018). "Poor Immunogenicity, Not Vaccine Strain Egg Adaptation, May Explain the Low H3N2 Influenza Vaccine Effectiveness in 2012-2013." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (3): 327-333.
Cohen, C., et al. (2018). "In- and Out-of-hospital Mortality Associated with Seasonal and Pandemic Influenza and Respiratory Syncytial Virus in South Africa, 2009-2013." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 95-103.
Cole, J. H., et al. (2018). "No Evidence for Accelerated Aging-Related Brain Pathology in Treated Human Immunodeficiency Virus: Longitudinal Neuroimaging Results From the Comorbidity in Relation to AIDS (COBRA) Project." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (12): 1899-1909.
Degner, N. R., et al. (2018). "Metformin Use Reverses the Increased Mortality Associated With Diabetes Mellitus During Tuberculosis Treatment." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (2): 198-205.
DeMuri, G. P., et al. (2018). "Dynamics of Bacterial Colonization With Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis During Symptomatic and Asymptomatic Viral Upper Respiratory Tract Infection." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (7): 1045-1053.
Deshpande, D., et al. (2018). "Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis." <u>Clinical infectious diseases : an official publication of the</u>

Infectious Diseases Society of America 67 (suppl_3): S293-S302.
Deshpande, D., et al. (2018). "Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (suppl_3): S274-S283.
Dionne-Odom, J., et al. (2018). "High Prevalence of Multidrug-Resistant Mycoplasma genitalium in Human Immunodeficiency Virus-Infected Men Who Have Sex With Men in Alabama." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 796-798.
Diro, E., et al. (2018). "Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (3): 444-451.
Eby, J. C., et al. (2018). "A Healthcare Improvement Intervention Combining Nucleic Acid Microarray Testing With Direct Physician Response for Management of Staphylococcus aureus Bacteremia." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 64-71.
Edwards, J. E., Jr., et al. (2018). "A Fungal Immunotherapeutic Vaccine (NDV-3A) for Treatment of Recurrent Vulvovaginal Candidiasis-A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (12): 1928-1936.
Elnekave, E., et al. (2018). "Salmonella enterica Serotype 4, 5 ,12:i:- in Swine in the United States Midwest: An Emerging Multidrug-Resistant Clade." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (6): 877-885.
Escandon, P., et al. (2019). "Molecular Epidemiology of Candida auris in Colombia Reveals a Highly Related, Countrywide Colonization With Regional Patterns in Amphotericin B Resistance." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 68 (1): 15-21.
Force, I. S. T. (2018). "Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (10): 1631-1635.
Ford, N., et al. (2018). "CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (suppl_2): S152-S159.
Gerding, D. N., et al. (2018). "Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (5): 649-656.
Grigg, M. J., et al. (2018). "Age-Related Clinical Spectrum of Plasmodium knowlesi Malaria and Predictors of Severity." <u>Clinical</u>

infectious diseases : an official publication of the Infectious Diseases Society of America 67 (3): 350-359.
Gumbo, T. and J.-W. C. Alffenaar (2018). "Pharmacokinetic/Pharmacodynamic Background and Methods and Scientific Evidence Base for Dosing of Second-line Tuberculosis Drugs." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (suppl_3): S267-S273.
Gurieva, T., et al. (2018). "The Transmissibility of Antibiotic-Resistant Enterobacteriaceae in Intensive Care Units." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (4): 489-493.
Hill, J. A., et al. (2018). "Kinetics of Double-Stranded DNA Viremia After Allogeneic Hematopoietic Cell Transplantation." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (3): 368-375.
Hocquart, M., et al. (2018). "Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 645-650.
Hua, S., et al. (2018). "Pegylated Interferon-alpha-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (12): 1910-1917.
Huang, D. B., et al. (2018). "A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): 1222-1229.
Huang, K.-H. G., et al. (2018). "The Impact of Reported Beta-Lactam Allergy in Hospitalized Patients With Hematologic Malignancies Requiring Antibiotics." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (1): 27-33.
IeDea and C. C. Collaborations (2018). "Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (6): 893-903.
Inoue, T., et al. (2018). "Gut Dysbiosis Associated With Hepatitis C Virus Infection." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (6): 869-877.
Johnson, K. T., et al. (2018). "Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (7): 1072-1078.
Keller, S. C., et al. (2018). "Rates of and Risk Factors for Adverse Drug Events in Outpatient Parenteral Antimicrobial Therapy." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 11-19.

Kjaer, S. K., et al. (2018). "A 12-Year Follow-up on the Long-Term Effectiveness of the Quadrivalent Human Papillomavirus Vaccine in 4 Nordic Countries." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (3): 339-345.
Kosikova, M., et al. (2018). "Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (10): 1523-1532.
Koss, C. A., et al. (2018). "Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (2): 213-219.
Lai, L., et al. (2018). "Innate, T-, and B-Cell Responses in Acute Human Zika Patients." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 1-10.
Ma, Y., et al. (2018). "The Human Immunodeficiency Virus Care Continuum in China: 1985-2015." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (6): 833-839.
MacNeil, J. R., et al. (2018). "Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): 1276-1281.
Mahale, P., et al. (2018). "Cancer Risk in Older Persons Living With Human Immunodeficiency Virus Infection in the United States." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (1): 50-57.
Malosh, R. E., et al. (2018). "Efficacy and Safety of Oseltamivir in Children: Systematic Review and Individual Patient Data Meta-analysis of Randomized Controlled Trials." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (10): 1492-1500.
McDonald, L. C., et al. (2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (7): e1-e48.
McDonald, L. C., et al. (2018). "Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (7): 987-994.
Mian, M., et al. (2018). "Evaluation of a Novel Global Immunity Assay to Predict Infection in Organ Transplant Recipients." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (9): 1392-1397.
Natori, Y., et al. (2018). "Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis." <u>Clinical infectious diseases : an official publication of the Infectious</u>

Diseases Society of America **66**(4): 617-631.

Natori, Y., et al. (2018). "A Double-Blind, Randomized Trial of High-Dose vs Standard-Dose Influenza Vaccine in Adult Solid-Organ Transplant Recipients." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(11): 1698-1704.

Nguyen, T. V. A., et al. (2018). "Bedaquiline Resistance: Its Emergence, Mechanism, and Prevention." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(10): 1625-1630.

O'Horo, J. C., et al. (2017). "Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(suppl_1): S43-S56.

O'Riordan, W., et al. (2018). "A Comparison of the Efficacy and Safety of Intravenous Followed by Oral Delafloxacin With Vancomycin Plus Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Multinational, Double-Blind, Randomized Study." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **67**(5): 657-666.

Orkin, C., et al. (2019). "Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **68**(4): 535-544.

Osler, M., et al. (2018). "The Continuing Burden of Advanced HIV Disease Over 10 Years of Increasing Antiretroviral Therapy Coverage in South Africa." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(suppl_2): S118-S125.

Ozenci, V., et al. (2018). "Demise of Polymerase Chain Reaction/Electrospray Ionization-Mass Spectrometry as an Infectious Diseases Diagnostic Tool." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **66**(3): 452-455.

Panel, A.-I. H. G. (2018). "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **67**(10): 1477-1492.

Parente, D. M., et al. (2018). "The Clinical Utility of Methicillin-Resistant Staphylococcus aureus (MRSA) Nasal Screening to Rule Out MRSA Pneumonia: A Diagnostic Meta-analysis With Antimicrobial Stewardship Implications." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America **67**(1): 1-7.

Park, J. H., et al. (2018). "Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells." Clinical infectious diseases : an

official publication of the Infectious Diseases Society of America 67 (4): 533-540.
Patel, E. U., et al. (2018). "Age Differences in Perceptions of and Motivations for Voluntary Medical Male Circumcision Among Adolescents in South Africa, Tanzania, and Zimbabwe." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (suppl_3): S173-S182.
Poehling, K. A., et al. (2018). "2015-2016 Vaccine Effectiveness of Live Attenuated and Inactivated Influenza Vaccines in Children in the United States." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 665-672.
Pogue, J. M., et al. (2019). "Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 68 (3): 519-524.
Prabhu, V. S., et al. (2018). "Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (3): 355-362.
Rockstroh, J. K., et al. (2018). "Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (7): 1010-1017.
Serota, D. P., et al. (2018). "Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (6): 965-970.
Shah, M., et al. (2018). "Mumps Outbreak in a Highly Vaccinated University-Affiliated Setting Before and After a Measles-Mumps-Rubella Vaccination Campaign-Iowa, July 2015-May 2016." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 81-88.
Simner, P. J., et al. (2018). "Understanding the Promises and Hurdles of Metagenomic Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 778-788.
Smolak, A., et al. (2018). "Trends and Predictors of Syphilis Prevalence in the General Population: Global Pooled Analyses of 1103 Prevalence Measures Including 136 Million Syphilis Tests." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): 1184-1191.
Tadesse, F. G., et al. (2018). "The Relative Contribution of Symptomatic and Asymptomatic Plasmodium vivax and Plasmodium falciparum Infections to the Infectious Reservoir in a Low-Endemic Setting in Ethiopia." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (12): 1883-1891.
Taiwo, B. O., et al. (2018). "Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week

48 in a Pilot Randomized Trial." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (11): 1794-1797.
Taiwo, B. O., et al. (2018). "ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (11): 1689-1697.
Thao, L. T. P., et al. (2018). "Prognostic Models for 9-Month Mortality in Tuberculous Meningitis." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (4): 523-532.
Thoendel, M. J., et al. (2018). "Identification of Prosthetic Joint Infection Pathogens Using a Shotgun Metagenomics Approach." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (9): 1333-1338.
Traeger, M. W., et al. (2018). "Effects of Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection on Sexual Risk Behavior in Men Who Have Sex With Men: A Systematic Review and Meta-analysis." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (5): 676-686.
Tripura, R., et al. (2018). "A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (6): 817-826.
Tsay, S., et al. (2018). "Approach to the Investigation and Management of Patients With Candida auris, an Emerging Multidrug-Resistant Yeast." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (2): 306-311.
Tumbarello, M., et al. (2019). "Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 68 (3): 355-364.
van Duin, D., et al. (2018). "Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (2): 163-171.
Varughese, T., et al. (2018). "Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (5): 687-692.
Voysey, M. and A. J. Pollard (2018). "Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV)." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 67 (1): 18-24.
Wake, R. M., et al. (2018). "High Cryptococcal Antigen Titers in Blood Are Predictive of Subclinical Cryptococcal Meningitis Among Human Immunodeficiency Virus-Infected Patients." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 686-692.

Wald-Dickler, N., et al. (2018). "Busting the Myth of "Static vs Cidal": A Systemic Literature Review." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (9): 1470-1474.
White, A. C., Jr., et al. (2018). "Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): 1159-1163.
White, A. C., Jr., et al. (2018). "Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): e49-e75.
Wiens, J. and E. S. Shenoy (2018). "Machine Learning for Healthcare: On the Verge of a Major Shift in Healthcare Epidemiology." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (1): 149-153.
Wong, C., et al. (2018). "Multimorbidity Among Persons Living with Human Immunodeficiency Virus in the United States." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (8): 1230-1238.
Wunderink, R. G., et al. (2018). "Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (10): 1504-1510.
Yang, Y., et al. (2018). "Reply to Aguiar and Stollenwerk." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (4): 642-642.
Yu, P. A., et al. (2017). "Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (suppl_1): S57-S64.
Zhong, L.-L., et al. (2018). "High Rates of Human Fecal Carriage of mcr-1-Positive Multidrug-Resistant Enterobacteriaceae Emerge in China in Association With Successful Plasmid Families." <u>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</u> 66 (5): 676-685.
Agarwal, R., et al. (2018). "Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 361-368.
Alcaide, F., et al. (2018). "How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 599-603.
Amat, T., et al. (2018). "The combined use of tigecycline with high-dose colistin might not be associated with higher survival in

critically ill patients with bacteraemia due to carbapenem-resistant <i>Acinetobacter baumannii</i> ." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 630-634.
Arredondo-Garcia, J. L., et al. (2018). "Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 755-763.
Baddley, J. W., et al. (2018). "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules I : anti-tumor necrosis factor-alpha agents)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 2 : S10-S20.
Bartoletti, M., et al. (2018). "A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (5): 546.e541-546.e548.
Bassetti, M., et al. (2018). "Management of KPC-producing <i>Klebsiella pneumoniae</i> infections." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 133-144.
Besser, J., et al. (2018). "Next-generation sequencing technologies and their application to the study and control of bacterial infections." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 335-341.
Bhimji, A., et al. (2018). "Aspergillus galactomannan detection in exhaled breath condensate compared to bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in immunocompromised patients." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 640-645.
Bilgiler, C., et al. (2018). "Prospective multicentre clinical study on inter- and inpatient genetic variability for antimicrobial resistance of <i>Helicobacter pylori</i> ." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (3): 267-272.
Bishop, B., et al. (2018). "The use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for rapid bacterial identification in patients with smear-positive bacterial meningitis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 171-174.
Cambau, E., et al. (2018). "Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1305-1310.
Carrico, J. A., et al. (2018). "A primer on microbial bioinformatics for nonbioinformaticians." <u>Clinical microbiology and infection : the</u>

official publication of the European Society of Clinical Microbiology and Infectious Diseases 24 (4): 342-349.
Carter, E. R., et al. (2018). "Nitroimidazole-refractory giardiasis: a growing problem requiring rational solutions." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 37-42.
Chen, C., et al. (2018). "Enhanced efficacy of the engineered antimicrobial peptide WLBU2 via direct airway delivery in a murine model of Pseudomonas aeruginosa pneumonia." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (5): 547.e541-547.e548.
Chen, J., et al. (2018). "Rapid identification of imported influenza viruses at Xiamen International Airport via an active surveillance program." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (3): 289-294.
Coenye, T., et al. (2018). "Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice?" <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 570-572.
Coppi, M., et al. (2018). "A simple phenotypic method for screening of MCR-1-mediated colistin resistance." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 201.e201-201.e203.
Dagnelie, M. A., et al. (2018). "Cutibacterium acnes molecular typing: time to standardize the method." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1149-1155.
de Thurah, L., et al. (2018). "Concordant testing results between various human papillomavirus assays in primary cervical cancer screening: systematic review." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 29-36.
Dessau, R. B., et al. (2018). "To test or not to test? Laboratory support for the diagnosis of Lyme borreliosis: a position paper of ESGBOR, the ESCMID study group for Lyme borreliosis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 118-124.
Dobner, J. and S. Kaser (2018). "Body mass index and the risk of infection - from underweight to obesity." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 24-28.
Doi, A., et al. (2018). "Shorter duration of antibiotic treatment for acute bacteraemic cholangitis with successful biliary drainage: a retrospective cohort study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1184-1189.
Dubourg, G., et al. (2018). "Rapid phenotypic methods to improve the diagnosis of bacterial bloodstream infections: meeting the

challenge to reduce the time to result." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (9): 935-943.
Eliassen, K. E., et al. (2018). "Comparison of phenoxymethylpenicillin, amoxicillin, and doxycycline for erythema migrans in general practice. A randomized controlled trial with a 1-year follow-up." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1290-1296.
Fernandez-Hidalgo, N., et al. (2018). "Impact of Staphylococcus aureus phenotype and genotype on the clinical characteristics and outcome of infective endocarditis. Amulticentre, longitudinal, prospective, observational study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (9): 985-991.
Freeman, J., et al. (2018). "The ClosER study: results from a three-year pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes, 2011-2014." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 724-731.
Giancola, S. E., et al. (2018). "Prevalence of the Clostridium difficile BI/NAP1/027 strain across the United States Veterans Health Administration." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (8): 877-881.
Giannella, M., et al. (2018). "Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (10): 1077-1083.
Giske, C. G. and G. Kahlmeter (2018). "Colistin antimicrobial susceptibility testing-can the slow and challenging be replaced by the rapid and convenient?" <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 93-94.
Honkanen, M., et al. (2018). "The impact of preoperative bacteriuria on the risk of periprosthetic joint infection after primary knee or hip replacement: a retrospective study with a 1-year follow up." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 376-380.
Huang, H. S., et al. (2018). "Multiplex PCR system for the rapid diagnosis of respiratory virus infection: systematic review and meta-analysis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (10): 1055-1063.
Huits, R., et al. (2018). "Diagnostic accuracy of a rapid E1-antigen test for chikungunya virus infection in a reference setting." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 78-81.
Idelevich, E. A., et al. (2018). "Rapid detection of antibiotic resistance by MALDI-TOF mass spectrometry using a novel direct-on-

target microdroplet growth assay." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 738-743.
Ieven, M., et al. (2018). "Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1158-1163.
Ingels, C., et al. (2018). "Glucose homeostasis, nutrition and infections during critical illness." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 10-15.
Jayol, A., et al. (2018). "Comparison of methods for detection of plasmid-mediated and chromosomally encoded colistin resistance in Enterobacteriaceae." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 175-179.
Jeong, W., et al. (2019). "The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 25 (1): 26-34.
Kalil, A. C., et al. (2018). "Severe infections in critically ill solid organ transplant recipients." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1257-1263.
Kock, R., et al. (2018). "Carbapenem-resistant Enterobacteriaceae in wildlife, food-producing, and companion animals: a systematic review." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1241-1250.
Koetsveld, J., et al. (2018). "Serodiagnosis of Borrelia miyamotoi disease by measuring antibodies against GlpQ and variable major proteins." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1338.e1331-1338.e1337.
Kulengowski, B., et al. (2019). "Polymyxin B Etest compared with gold-standard broth microdilution in carbapenem-resistant Enterobacteriaceae exhibiting a wide range of polymyxin B MICs." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 25 (1): 92-95.
Laaveri, T., et al. (2018). "A prospective study of travellers' diarrhoea: analysis of pathogen findings by destination in various (sub)tropical regions." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (8): 908.e909-908.e916.
Lamy, B., et al. (2018). "How to: accreditation of blood cultures' proceedings. A clinical microbiology approach for adding value to patient care." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (9): 956-963.

Lecorche, E., et al. (2018). "Comparison of methods available for identification of Mycobacterium chimaera." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 409-413.
Lee, S., et al. (2018). "Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 152-158.
Liang, C. A., et al. (2018). "Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (8): 908.e901-908.e907.
Liu, D. S., et al. (2018). "Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 780.e785-780.e788.
Lopez-Medrano, F., et al. (2018). "Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 192-198.
Loubet, P., et al. (2018). "Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 125-132.
Magnan, S., et al. (2019). "Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 25 (2): 210-216.
Maitra, S., et al. (2018). "Accuracy of quick Sequential Organ Failure Assessment (qSOFA) score and systemic inflammatory response syndrome (SIRS) criteria for predicting mortality in hospitalized patients with suspected infection: a meta-analysis of observational studies." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1123-1129.
Malandain, D., et al. (2018). "Assessment of the automated multiplex-PCR Unyvero i60 ITI cartridge system to diagnose prosthetic joint infection: a multicentre study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 83.e81-83.e86.
Manea, E., et al. (2018). "The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (2): 180-184.

<p>Matuschek, E., et al. (2018). "Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(8): 865-870.</p>
<p>Mikulska, M., et al. (2018). "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens I : CD19, CD20 and CD52)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 2: S71-S82.</p>
<p>Moreira, J., et al. (2018). "Epidemiology of acute febrile illness in Latin America." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(8): 827-835.</p>
<p>Moreira-Soto, A., et al. (2018). "Evidence for multiple sylvatic transmission cycles during the 2016-2017 yellow fever virus outbreak, Brazil." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(9): 1019.e1011-1019.e1014.</p>
<p>Musso, D. and V. M. Cao-Lormeau (2018). "Is the Zika threat over?" <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(6): 566-567.</p>
<p>Noda, A. A., et al. (2018). "Bejel in Cuba: molecular identification of Treponema pallidum subsp. endemicum in patients diagnosed with venereal syphilis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(11): 1210.e1211-1210.e1215.</p>
<p>Nogueira, M. L., et al. (2018). "Adverse birth outcomes associated with Zika virus exposure during pregnancy in Sao Jose do Rio Preto, Brazil." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(6): 646-652.</p>
<p>Nunez-Nunez, M., et al. (2018). "The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(2): 105-109.</p>
<p>Nurjadi, D., et al. (2018). "Toll-like receptor 9 (TLR-9) promotor polymorphisms and gene expression are associated with persistent Staphylococcus aureus nasal carriage." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(11): 1210.e1217-1210.e1212.</p>
<p>Ooijevaar, R. E., et al. (2018). "Update of treatment algorithms for Clostridium difficile infection." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24(5): 452-462.</p>
<p>Origuen, J., et al. (2018). "Comparison of the clinical course of Clostridium difficile infection in glutamate dehydrogenase-positive</p>

toxin-negative patients diagnosed by PCR to those with a positive toxin test." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 414-421.
Paul, L. (2018). "Nipah virus in Kerala: a deadly Zoonosis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (10): 1113-1114.
Peker, N., et al. (2018). "Diagnosis of bloodstream infections from positive blood cultures and directly from blood samples: recent developments in molecular approaches." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (9): 944-955.
Pena-Lopez, Y., et al. (2018). "Assessing prediction accuracy for outcomes of ventilator-associated events and infections in critically ill children: a prospective cohort study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 732-737.
Plantinga, N. L., et al. (2018). "Selective digestive and oropharyngeal decontamination in medical and surgical ICU patients: individual patient data meta-analysis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (5): 505-513.
Pulcini, C., et al. (2019). "Developing core elements and checklist items for global hospital antimicrobial stewardship programmes: a consensus approach." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 25 (1): 20-25.
Redelman-Sidi, G., et al. (2018). "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 2 : S95-S107.
Reinwald, M., et al. (2018). "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 2 : S53-S70.
Rello, J., et al. (2018). "Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1264-1272.
Reusken, C. B., et al. (2018). "Laboratory preparedness and response with a focus on arboviruses in Europe." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (3): 221-228.
Riddle, M. S., et al. (2018). "Update on vaccines for enteric pathogens." <u>Clinical microbiology and infection : the official publication of</u>

the European Society of Clinical Microbiology and Infectious Diseases 24 (10): 1039-1045.
Rivero-Juarez, A., et al. (2018). "Prevalence of hepatitis E virus infection in liver donors in Spain." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1218-1219.
Rossen, J. W. A., et al. (2018). "Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 355-360.
Rottier, W. C., et al. (2018). "Development of diagnostic prediction tools for bacteraemia caused by third-generation cephalosporin-resistant enterobacteria in suspected bacterial infections: a nested case-control study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1315-1321.
Ruppe, E., et al. (2018). "Impact of antibiotics on the intestinal microbiota needs to be re-defined to optimize antibiotic usage." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 3-5.
Rupprecht, T. A., et al. (2018). "Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1234-1240.
Satta, G., et al. (2018). "Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential?" <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 604-609.
Schibler, M., et al. (2019). "Diagnostic tools to tackle infectious causes of encephalitis and meningoencephalitis in immunocompetent adults in Europe." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 25 (4): 408-414.
Schrijver, R., et al. (2018). "Review of antimicrobial resistance surveillance programmes in livestock and meat in EU with focus on humans." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 577-590.
Schurch, A. C., et al. (2018). "Whole genome sequencing options for bacterial strain typing and epidemiologic analysis based on single nucleotide polymorphism versus gene-by-gene-based approaches." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 350-354.
Scriven, J. E., et al. (2018). "Mycobacterium chimaera infection following cardiac surgery in the United Kingdom: clinical features and outcome of the first 30 cases." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (11): 1164-1170.

Shrestha, P., et al. (2018). "Febrile illness in Asia: gaps in epidemiology, diagnosis and management for informing health policy." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (8): 815-826.
Sigfrid, L., et al. (2018). "Preparing clinicians for (re-)emerging arbovirus infectious diseases in Europe." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (3): 229-239.
Soldini, S., et al. (2018). "Microbiologic and clinical characteristics of biofilm-forming <i>Candida parapsilosis</i> isolates associated with fungaemia and their impact on mortality." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (7): 771-777.
Stewardson, A. J., et al. (2018). "Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (9): 972-979.
Torres, E., et al. (2018). "Prevalence and transmission dynamics of <i>Escherichia coli</i> ST131 among contacts of infected community and hospitalized patients." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (6): 618-623.
Treepong, P., et al. (2018). "Global emergence of the widespread <i>Pseudomonas aeruginosa</i> ST235 clone." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (3): 258-266.
Tschudin-Sutter, S., et al. (2018). "Guidance document for prevention of <i>Clostridium difficile</i> infection in acute healthcare settings." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (10): 1051-1054.
Ullmann, A. J., et al. (2018). "Diagnosis and management of <i>Aspergillus</i> diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 1 : e1-e38.
Unemo, M., et al. (2018). "Clinical and analytical evaluation of the new Aptima <i>Mycoplasma genitalium</i> assay, with data on <i>M. genitalium</i> prevalence and antimicrobial resistance in <i>M. genitalium</i> in Denmark, Norway and Sweden in 2016." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (5): 533-539.
van der Does, Y., et al. (2018). "Procalcitonin-guided antibiotic therapy in patients with fever in a general emergency department population: a multicentre non-inferiority randomized clinical trial (HiTEMP study)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (12): 1282-1289.
Weiss, G. and P. L. Carver (2018). "Role of divalent metals in infectious disease susceptibility and outcome." <u>Clinical microbiology</u>

and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 24 (1): 16-23.
Werth, B. J., et al. (2018). "Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (4): 429.e421-429.e425.
Wijma, R. A., et al. (2018). "High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (5): 528-532.
Winthrop, K. L., et al. (2018). "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules II : agents targeting interleukins, immunoglobulins and complement factors)." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 Suppl 2 : S21-S40.
Zhang, C., et al. (2018). "The professional status of infectious disease physicians in China: anationwide cross-sectional survey." <u>Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases</u> 24 (1): 82.e85-82.e10.
Adams, E., et al. (2018). "Candida auris in Healthcare Facilities, New York, USA, 2013-2017." <u>Emerging infectious diseases</u> 24 (10): 1816-1824.
Adlhoch, C., et al. (2018). "Protective Measures for Humans against Avian Influenza A(H5N8) Outbreaks in 22 European Union/European Economic Area Countries and Israel, 2016-17." <u>Emerging infectious diseases</u> 24 (10): 1-8.
Ai, J.-W., et al. (2018). "Human Endophthalmitis Caused By Pseudorabies Virus Infection, China, 2017." <u>Emerging infectious diseases</u> 24 (6): 1087-1090.
Anh, N. T., et al. (2018). "Emerging Coxsackievirus A6 Causing Hand, Foot and Mouth Disease, Vietnam." <u>Emerging infectious diseases</u> 24 (4): 654-662.
Armstrong, P. A., et al. (2018). "Multistate Epidemiology of Histoplasmosis, United States, 2011-2014." <u>Emerging infectious diseases</u> 24 (3): 425-431.
Artois, J., et al. (2018). "Changing Geographic Patterns and Risk Factors for Avian Influenza A(H7N9) Infections in Humans, China." <u>Emerging infectious diseases</u> 24 (1): 87-94.
Aubry, M., et al. (2018). "Seroprevalence of Dengue and Chikungunya Virus Antibodies, French Polynesia, 2014-2015." <u>Emerging infectious diseases</u> 24 (3): 558-561.
Babelhadj, B., et al. (2018). "Prion Disease in Dromedary Camels, Algeria." <u>Emerging infectious diseases</u> 24 (6): 1029-1036.

Barbosa, C. M., et al. (2018). "Yellow Fever Virus RNA in Urine and Semen of Convalescent Patient, Brazil." <u>Emerging infectious diseases</u> 24 (1).
Becker, K., et al. (2018). "Plasmid-Encoded Transferable mecB-Mediated Methicillin Resistance in Staphylococcus aureus." <u>Emerging infectious diseases</u> 24 (2): 242-248.
Beerens, N., et al. (2018). "Novel Highly Pathogenic Avian Influenza A(H5N6) Virus in the Netherlands, December 2017." <u>Emerging infectious diseases</u> 24 (4).
Belkin, A., et al. (2018). "Candida auris Infection Leading to Nosocomial Transmission, Israel, 2017." <u>Emerging infectious diseases</u> 24 (4): 801-804.
Berhane, A., et al. (2018). "Major Threat to Malaria Control Programs by Plasmodium falciparum Lacking Histidine-Rich Protein 2, Eritrea." <u>Emerging infectious diseases</u> 24 (3): 462-470.
Bordi, L., et al. (2018). "Molecular Characterization of Autochthonous Chikungunya Cluster in Latium Region, Italy." <u>Emerging infectious diseases</u> 24 (1).
Bouchez, V., et al. (2018). "Genomic Sequencing of Bordetella pertussis for Epidemiology and Global Surveillance of Whooping Cough." <u>Emerging infectious diseases</u> 24 (6): 988-994.
Bresee, J., et al. (2018). "Progress and Remaining Gaps in Estimating the Global Disease Burden of Influenza." <u>Emerging infectious diseases</u> 24 (7): 1173-1177.
Chenais, E., et al. (2018). "Identification of Wild Boar-Habitat Epidemiologic Cycle in African Swine Fever Epizootic." <u>Emerging infectious diseases</u> 24 (4): 810-812.
Cheng, V. C. C., et al. (2018). "Japanese Encephalitis Virus Transmitted Via Blood Transfusion, Hong Kong, China." <u>Emerging infectious diseases</u> 24 (1).
Chuma, I. S., et al. (2018). "Widespread Treponema pallidum Infection in Nonhuman Primates, Tanzania." <u>Emerging infectious diseases</u> 24 (6): 1002-1009.
Costantini, V., et al. (2018). "Human Norovirus Replication in Human Intestinal Enteroids as Model to Evaluate Virus Inactivation." <u>Emerging infectious diseases</u> 24 (8): 1453-1464.
Dangel, A., et al. (2018). "Geographically Diverse Clusters of Nontoxigenic Corynebacterium diphtheriae Infection, Germany, 2016-2017." <u>Emerging infectious diseases</u> 24 (7): 1239-1245.
Denning, D. W., et al. (2018). "Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings." <u>Emerging infectious diseases</u> 24 (8).
Dias, J. P., et al. (2018). "Seroprevalence of Chikungunya Virus after Its Emergence in Brazil." <u>Emerging infectious diseases</u> 24 (4): 617-624.

Dirlikov, E., et al. (2018). "Postmortem Findings in Patient with Guillain-Barre Syndrome and Zika Virus Infection." <u>Emerging infectious diseases</u> 24 (1): 114-117.
Divers, T. J., et al. (2018). "New Parvovirus Associated with Serum Hepatitis in Horses after Inoculation of Common Biological Product." <u>Emerging infectious diseases</u> 24 (2): 303-310.
Doshi, R. H., et al. (2018). "Strengthening of Surveillance during Monkeypox Outbreak, Republic of the Congo, 2017." <u>Emerging infectious diseases</u> 24 (6): 1158-1160.
Ferguson, L., et al. (2018). "Influenza D Virus Infection in Feral Swine Populations, United States." <u>Emerging infectious diseases</u> 24 (6): 1020-1028.
Fernandes, M. R., et al. (2018). "Zoonanthroponotic Transmission of Drug-Resistant Pseudomonas aeruginosa, Brazil." <u>Emerging infectious diseases</u> 24 (6): 1160-1162.
Fischer, C., et al. (2018). "External Quality Assessment for Zika Virus Molecular Diagnostic Testing, Brazil." <u>Emerging infectious diseases</u> 24 (5).
Flynn, O., et al. (2018). "Influenza D Virus in Cattle, Ireland." <u>Emerging infectious diseases</u> 24 (2): 389-391.
Fox-Lewis, A., et al. (2018). "Antimicrobial Resistance in Invasive Bacterial Infections in Hospitalized Children, Cambodia, 2007-2016." <u>Emerging infectious diseases</u> 24 (5): 841-851.
Freedman, M., et al. (2018). "Coccidioidomycosis Outbreaks, United States and Worldwide, 1940-2015." <u>Emerging infectious diseases</u> 24 (3): 417-423.
Ge, S., et al. (2018). "Molecular Characterization of African Swine Fever Virus, China, 2018." <u>Emerging infectious diseases</u> 24 (11): 2131-2133.
Govender, N. P., et al. (2018). "Candida auris in South Africa, 2012-2016." <u>Emerging infectious diseases</u> 24 (11): 2036-2040.
Groch, K. R., et al. (2018). "Guiana Dolphin Unusual Mortality Event and Link to Cetacean Morbillivirus, Brazil." <u>Emerging infectious diseases</u> 24 (7): 1349-1354.
Gupta, H., et al. (2018). "Drug-Resistant Polymorphisms and Copy Numbers in Plasmodium falciparum, Mozambique, 2015." <u>Emerging infectious diseases</u> 24 (1): 40-48.
Hassan, M. Z., et al. (2018). "Nipah Virus Contamination of Hospital Surfaces during Outbreaks, Bangladesh, 2013-2014." <u>Emerging infectious diseases</u> 24 (1): 15-21.
Heo, J. Y., et al. (2018). "Molecular Epidemiology of Human Adenovirus-Associated Febrile Respiratory Illness in Soldiers, South Korea1." <u>Emerging infectious diseases</u> 24 (7): 1221-1227.
Hoffman, T., et al. (2018). "Alkhurma Hemorrhagic Fever Virus RNA in Hyalomma rufipes Ticks Infesting Migratory Birds, Europe

and Asia Minor." <u>Emerging infectious diseases</u> 24 (5): 879-882.
Horwood, P. F., et al. (2018). "Co-circulation of Influenza A H5, H7, and H9 Viruses and Co-infected Poultry in Live Bird Markets, Cambodia." <u>Emerging infectious diseases</u> 24 (2): 352-355.
Howlett, P. J., et al. (2018). "Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra Leone." <u>Emerging infectious diseases</u> 24 (8): 1412-1421.
Hsu, C. H., et al. (2018). "Sensitivity and Specificity of Suspected Case Definition Used during West Africa Ebola Epidemic." <u>Emerging infectious diseases</u> 24 (1): 9-14.
Huang, J., et al. (2018). "Epidemiology of Recurrent Hand, Foot and Mouth Disease, China, 2008-2015." <u>Emerging infectious diseases</u> 24 (3).
Hussain, M., et al. (2018). "Epidemiology of Cutaneous Leishmaniasis Outbreak, Waziristan, Pakistan." <u>Emerging infectious diseases</u> 24 (1): 159-161.
Ikeda, M., et al. (2018). "Artemisinin-Resistant Plasmodium falciparum with High Survival Rates, Uganda, 2014-2016." <u>Emerging infectious diseases</u> 24 (4): 718-726.
Jackson, K. A., et al. (2018). "Listeriosis Outbreaks Associated with Soft Cheeses, United States, 1998-2014." <u>Emerging infectious diseases</u> 24 (6): 1116-1118.
Jaramillo-Ochoa, R., et al. (2019). "Effects of Political Instability in Venezuela on Malaria Resurgence at Ecuador-Peru Border, 2018." <u>Emerging infectious diseases</u> 25 (4): 834-836.
Jiang, B.-G., et al. (2018). "Borrelia miyamotoi Infections in Humans and Ticks, Northeastern China." <u>Emerging infectious diseases</u> 24 (2): 236-241.
Kajon, A. E., et al. (2018). "Adenovirus Type 4 Respiratory Infections among Civilian Adults, Northeastern United States, 2011-2015." <u>Emerging infectious diseases</u> 24 (2): 201-209.
Kenyon, C. R. and I. S. Schwartz (2018). "Effects of Sexual Network Connectivity and Antimicrobial Drug Use on Antimicrobial Resistance in Neisseria gonorrhoeae." <u>Emerging infectious diseases</u> 24 (7): 1195-1203.
Kim, J.-H. and H.-K. Cheong (2018). "Increasing Number of Scarlet Fever Cases, South Korea, 2011-2016." <u>Emerging infectious diseases</u> 24 (1): 172-173.
Kolbasov, D., et al. (2018). "African Swine Fever Virus, Siberia, Russia, 2017." <u>Emerging infectious diseases</u> 24 (4): 796-798.
Lahra, M. M., et al. (2018). "Cooperative Recognition of Internationally Disseminated Ceftriaxone-Resistant Neisseria gonorrhoeae Strain." <u>Emerging infectious diseases</u> 24 (4).
Laing, E. D., et al. (2018). "Serologic Evidence of Fruit Bat Exposure to Filoviruses, Singapore, 2011-2016." <u>Emerging infectious</u>

diseases 24 (1): 114-117.
Lee, M. J., et al. (2018). "Effects of Culling on <i>Leptospira interrogans</i> Carriage by Rats." <u>Emerging infectious diseases</u> 24 (2): 356-360.
Lefebvre, B., et al. (2018). "Ceftriaxone-Resistant <i>Neisseria gonorrhoeae</i> , Canada, 2017." <u>Emerging infectious diseases</u> 24 (2).
Lodeiro-Colatosti, A., et al. (2018). "Diphtheria Outbreak in Amerindian Communities, Wonken, Venezuela, 2016-2017." <u>Emerging infectious diseases</u> 24 (7): 1340-1344.
Lutgring, J. D., et al. (2018). "Phenotypic and Genotypic Characterization of Enterobacteriaceae Producing Oxacillinase-48-Like Carbapenemases, United States." <u>Emerging infectious diseases</u> 24 (4): 700-709.
Martella, V., et al. (2018). "Novel Parvovirus Related to Primate Buvaviruses in Dogs." <u>Emerging infectious diseases</u> 24 (6): 1061-1068.
McMullan, R., et al. (2018). "Cronobacter sakazakii Infection from Expressed Breast Milk, Australia." <u>Emerging infectious diseases</u> 24 (2): 393-394.
Mendes, A. C., et al. (2018). "mcr-1 in Carbapenemase-Producing <i>Klebsiella pneumoniae</i> with Hospitalized Patients, Portugal, 2016-2017." <u>Emerging infectious diseases</u> 24 (4): 762-766.
Nagasawa, K., et al. (2018). "Phylogeny and Immunoreactivity of Norovirus GII.P16-GII.2, Japan, Winter 2016-17." <u>Emerging infectious diseases</u> 24 (1): 144-148.
Nakano, S., et al. (2018). "Spread of Meropenem-Resistant <i>Streptococcus pneumoniae</i> Serotype 15A-ST63 Clone in Japan, 2012-2014." <u>Emerging infectious diseases</u> 24 (2): 275-283.
Nguyen, D. T., et al. (2018). "Characteristics Associated with Negative Interferon-gamma Release Assay Results in Culture-Confirmed Tuberculosis Patients, Texas, USA, 2013-2015." <u>Emerging infectious diseases</u> 24 (3): 534-540.
Paniz-Mondolfi, A. E., et al. (2019). "Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas." <u>Emerging infectious diseases</u> 25 (4): 625-632.
Peirano, G., et al. (2018). "Genomic Epidemiology of Global Carbapenemase-Producing <i>Enterobacter</i> spp., 2008-2014." <u>Emerging infectious diseases</u> 24 (6): 1010-1019.
Pekard-Amenitsch, S., et al. (2018). "Isolation of <i>Candida auris</i> from Ear of Otherwise Healthy Patient, Austria, 2018." <u>Emerging infectious diseases</u> 24 (8): 1596-1597.
Pirisinu, L., et al. (2018). "Novel Type of Chronic Wasting Disease Detected in Moose (<i>Alces alces</i>), Norway." <u>Emerging infectious diseases</u> 24 (12): 2210-2218.
Puenpa, J., et al. (2018). "Enterovirus A71 Infection, Thailand, 2017." <u>Emerging infectious diseases</u> 24 (7): 1386-1387.

Read, T. R. H., et al. (2018). "Use of Pristinamycin for Macrolide-Resistant Mycoplasma genitalium Infection." <u>Emerging infectious diseases</u> 24 (2): 328-335.
Rokney, A., et al. (2018). "Emergence of Streptococcus pneumoniae Serotype 12F after Sequential Introduction of 7- and 13-Valent Vaccines, Israel." <u>Emerging infectious diseases</u> 24 (3): 453-461.
Rossi, B., et al. (2018). "Hypervirulent Klebsiella pneumoniae in Cryptogenic Liver Abscesses, Paris, France." <u>Emerging infectious diseases</u> 24 (2): 221-229.
Salaheldin, A. H., et al. (2018). "Multiple Introductions of Influenza A(H5N8) Virus into Poultry, Egypt, 2017." <u>Emerging infectious diseases</u> 24 (5).
Sasmono, R. T., et al. (2018). "Zika Virus Seropositivity in 1-4-Year-Old Children, Indonesia, 2014." <u>Emerging infectious diseases</u> 24 (9).
Schwartz, I. S., et al. (2018). "Emergomycetes canadensis, a Dimorphic Fungus Causing Fatal Systemic Human Disease in North America." <u>Emerging infectious diseases</u> 24 (4): 758-761.
Scully, E. J., et al. (2018). "Lethal Respiratory Disease Associated with Human RhinovirusC in Wild Chimpanzees, Uganda, 2013." <u>Emerging infectious diseases</u> 24 (2): 267-274.
Silva-Costa, C., et al. (2018). "Pediatric Complicated Pneumonia Caused by Streptococcus pneumoniae Serotype 3 in 13-Valent Pneumococcal Conjugate Vaccinees, Portugal, 2010-2015." <u>Emerging infectious diseases</u> 24 (7): 1307-1314.
Simonin, Y., et al. (2018). "Human Usutu Virus Infection with Atypical Neurologic Presentation, Montpellier, France, 2016." <u>Emerging infectious diseases</u> 24 (5): 875-878.
Sommerstein, R., et al. (2018). "Global Health Estimate of Invasive Mycobacterium chimaera Infections Associated with Heater-Cooler Devices in Cardiac Surgery." <u>Emerging infectious diseases</u> 24 (3): 576-578.
Song, R., et al. (2018). "Late or Lack of Vaccination Linked to Importation of Yellow Fever from Angola to China." <u>Emerging infectious diseases</u> 24 (7).
Sridhar, S., et al. (2018). "Rat Hepatitis E Virus as Cause of Persistent Hepatitis after Liver Transplant." <u>Emerging infectious diseases</u> 24 (12): 2241-2250.
Subissi, L., et al. (2018). "Zika Virus Infection during Pregnancy and Effects on Early Childhood Development, French Polynesia, 2013-2016." <u>Emerging infectious diseases</u> 24 (10): 1850-1858.
Tai, A. Y. C., et al. (2018). "Increased Severity and Spread of Mycobacterium ulcerans, Southeastern Australia." <u>Emerging infectious diseases</u> 24 (1).
Tarnagda, Z., et al. (2018). "Dengue Fever in Burkina Faso, 2016." <u>Emerging infectious diseases</u> 24 (1): 170-172.

Vogel, H., et al. (2018). "Rickettsia africae and Novel Rickettsial Strain in Amblyomma spp. Ticks, Nicaragua, 2013." <u>Emerging infectious diseases</u> 24 (2): 385-387.
Wade, A., et al. (2018). "Highly Pathogenic Avian Influenza A(H5N8) Virus, Cameroon, 2017." <u>Emerging infectious diseases</u> 24 (7): 1367-1370.
Wang, X., et al. (2018). "Human African Trypanosomiasis in Emigrant Returning to China from Gabon, 2017." <u>Emerging infectious diseases</u> 24 (2): 400-404.
Wardyn, S. E., et al. (2018). "Whole-Genome Analysis of Recurrent Staphylococcus aureus t571/ST398 Infection in Farmer, Iowa, USA." <u>Emerging infectious diseases</u> 24 (1): 153-154.
Whiley, D. M., et al. (2018). "Direct Detection of penA Gene Associated with Ceftriaxone-Resistant Neisseria gonorrhoeae FC428 Strain by Using PCR." <u>Emerging infectious diseases</u> 24 (8): 1573-1575.
White, S. K., et al. (2018). "Spondweni Virus in Field-Caught Culex quinquefasciatus Mosquitoes, Haiti, 2016." <u>Emerging infectious diseases</u> 24 (9): 1765-1767.
Whitmer, S. L. M., et al. (2018). "New Lineage of Lassa Virus, Togo, 2016." <u>Emerging infectious diseases</u> 24 (3): 599-602.
Wongsurawat, T., et al. (2018). "Case of Microcephaly after Congenital Infection with Asian Lineage Zika Virus, Thailand." <u>Emerging infectious diseases</u> 24 (9).
Wu, J., et al. (2019). "Influenza H5/H7 Virus Vaccination in Poultry and Reduction of Zoonotic Infections, Guangdong Province, China, 2017-18." <u>Emerging infectious diseases</u> 25 (1): 116-118.
Yamayoshi, S., et al. (2018). "Enhanced Replication of Highly Pathogenic Influenza A(H7N9) Virus in Humans." <u>Emerging infectious diseases</u> 24 (4): 746-750.
Yang, F., et al. (2018). "Cache Valley Virus in Aedes japonicus japonicus Mosquitoes, Appalachian Region, United States." <u>Emerging infectious diseases</u> 24 (3): 553-557.
Yang, J., et al. (2018). "Variation in Influenza B Virus Epidemiology by Lineage, China." <u>Emerging infectious diseases</u> 24 (8): 1536-1540.
Yang, Q., et al. (2018). "Westward Spread of Highly Pathogenic Avian Influenza A(H7N9) Virus among Humans, China." <u>Emerging infectious diseases</u> 24 (6): 1095-1098.
Yinka-Ogunleye, A., et al. (2018). "Reemergence of Human Monkeypox in Nigeria, 2017." <u>Emerging infectious diseases</u> 24 (6): 1149-1151.
Zhou, L., et al. (2018). "Clusters of Human Infection and Human-to-Human Transmission of Avian Influenza A(H7N9) Virus, 2013-2017." <u>Emerging infectious diseases</u> 24 (2).

Zhuang, L., et al. (2018). "Transmission of Severe Fever with Thrombocytopenia Syndrome Virus by Haemaphysalis longicornis Ticks, China." <u>Emerging infectious diseases</u> 24 (5).
(2019). "Medicolegal: Conditions Warranting Requirement of Vaccination." <u>JAMA</u> 321 (16): 1638-1638.
Adhikari, N. K. J. and G. D. Rubenfeld (2018). "qSOFA Score for Patients With Sepsis in Low- and Middle-Income Countries." <u>JAMA</u> 319 (21): 2175-2177.
Alexander, S., et al. (2018). "Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial." <u>JAMA</u> 320 (10): 995-1004.
Angus, D. C. (2019). "How Best to Resuscitate Patients With Septic Shock?" <u>JAMA</u> 321 (7): 647-648.
Buckley, L. M. (2019). "What About Recovery." <u>JAMA</u> 321 (13): 1253-1254.
Chao, C.-M. and C.-C. Lai (2019). "Decontamination Strategies for Critically Ill Patients." <u>JAMA</u> 321 (14): 1409-1410.
Chen, L. H. and D. H. Hamer (2018). "Vaccination Strategies During Shortages of Yellow Fever Vaccine-Reply." <u>JAMA</u> 319 (12): 1280-1281.
Curry, S. J., et al. (2018). "Screening for Syphilis Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement." <u>JAMA</u> 320 (9): 911-917.
Datta, R. and M. Juthani-Mehta (2018). "Nitrofurantoin vs Fosfomycin: Rendering a Verdict in a Trial of Acute Uncomplicated Cystitis." <u>JAMA</u> 319 (17): 1771-1772.
Dellinger, R. P., et al. (2018). "Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial." <u>JAMA</u> 320 (14): 1455-1463.
Eisinger, R. W., et al. (2019). "HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable." <u>JAMA</u> 321 (5): 451-452.
El Bcheraoui, C., et al. (2018). "Trends and Patterns of Differences in Infectious Disease Mortality Among US Counties, 1980-2014." <u>JAMA</u> 319 (12): 1248-1260.
Evans, I. V. R., et al. (2018). "Association Between the New York Sepsis Care Mandate and In-Hospital Mortality for Pediatric Sepsis." <u>JAMA</u> 320 (4): 358-367.
Fauci, A. S. (2018). "Addressing the Tuberculosis Epidemic: 21st Century Research for an Ancient Disease." <u>JAMA</u> 320 (13): 1315-1316.
Fischer, B. G., et al. (2019). "Evaluation for Fibrosis After Cure of Hepatitis C." <u>JAMA</u> 321 (15): 1534-1534.
Fitzgerald, B., et al. (2018). "Birth Defects Potentially Related to Zika Virus Infection During Pregnancy in the United States." <u>JAMA</u> 319 (12): 1195-1196.

Frankel, R. M., et al. (2019). "Physicians' Trust in One Another." <u>JAMA</u> .
Gandhi, M., et al. (2019). "Addressing the Sexually Transmitted Infection and HIV Syndemic." <u>JAMA</u> 321 (14): 1356-1358.
Glanz, J. M., et al. (2018). "Association Between Estimated Cumulative Vaccine Antigen Exposure Through the First 23 Months of Life and Non-Vaccine-Targeted Infections From 24 Through 47 Months of Age." <u>JAMA</u> 319 (9): 906-913.
Goldenberg, J. Z., et al. (2018). "Probiotics to Prevent Clostridium difficile Infection in Patients Receiving Antibiotics." <u>JAMA</u> 320 (5): 499-500.
Gostin, L. O. (2018). "New Ebola Outbreak in Africa Is a Major Test for the WHO." <u>JAMA</u> 320 (2): 125-126.
Gostin, L. O., et al. (2019). "Ebola and War in the Democratic Republic of Congo: Avoiding Failure and Thinking Ahead." <u>JAMA</u> 321 (3): 243-244.
Graham, B. S., et al. (2018). "Novel Vaccine Technologies: Essential Components of an Adequate Response to Emerging Viral Diseases." <u>JAMA</u> 319 (14): 1431-1432.
Grob, R., et al. (2019). "Why Physicians Should Trust in Patients." <u>JAMA</u> .
Guirguis-Blake, J. M., et al. (2019). "Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." <u>JAMA</u> 321 (4): 404-406.
Gupta, A., et al. (2018). "Diagnosis and Treatment of Clostridium difficile Infection." <u>JAMA</u> 320 (10): 1031-1032.
Hales, C. M., et al. (2018). "Trends in Prescription Medication Use Among Children and Adolescents-United States, 1999-2014." <u>JAMA</u> 319 (19): 2009-2020.
Haley, C., et al. (2018). "A 58-Year-Old Man With a Macerated Rash of the Neck and Axilla." <u>JAMA</u> 319 (14): 1499-1500.
Hallifax, R. J., et al. (2018). "Trends in the Incidence and Recurrence of Inpatient-Treated Spontaneous Pneumothorax, 1968-2016." <u>JAMA</u> 320 (14): 1471-1480.
Hampton, T. (2018). "Platelets' Role in Adaptive Immunity May Contribute to Sepsis and Shock." <u>JAMA</u> 319 (13): 1311-1312.
Hampton, T. (2019). "Vaccine Protects Mice From Emerging Tick-Borne Flaviviruses." <u>JAMA</u> 321 (9): 825-826.
Harris, P. N. A., et al. (2018). "Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial." <u>JAMA</u> 320 (10): 984-994.
Harvin, J. A., et al. (2018). "Using Quality Improvement to Promote Clinical Trials of Emergency Trauma Therapies." <u>JAMA</u> 320 (18): 1855-1856.
Hayden, M. K. and S. Y. Won (2018). "Carbapenem-Sparing Therapy for Extended-Spectrum beta-Lactamase-Producing E coli and Klebsiella pneumoniae Bloodstream Infection: The Search Continues." <u>JAMA</u> 320 (10): 979-981.

Healy, C. M., et al. (2018). "Association Between Third-Trimester Tdap Immunization and Neonatal Pertussis Antibody Concentration." <u>JAMA</u> 320 (14): 1464-1470.
Hernandez, G., et al. (2019). "Effect of a Resuscitation Strategy Targeting Peripheral Perfusion Status vs Serum Lactate Levels on 28-Day Mortality Among Patients With Septic Shock: The ANDROMEDA-SHOCK Randomized Clinical Trial." <u>JAMA</u> 321 (7): 654-664.
Holland, T. L., et al. (2018). "Effect of Algorithm-Based Therapy vs Usual Care on Clinical Success and Serious Adverse Events in Patients with Staphylococcal Bacteremia: A Randomized Clinical Trial." <u>JAMA</u> 320 (12): 1249-1258.
Hurley, J. C. (2019). "The Role of Endotoxin in Septic Shock." <u>JAMA</u> 321 (9): 902-903.
Huttner, A., et al. (2018). "Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial." <u>JAMA</u> 319 (17): 1781-1789.
Irony, T. Z. (2018). "Case-Control Studies: Using "Real-world" Evidence to Assess Association." <u>JAMA</u> 320 (10): 1027-1028.
Jansson, L. M., et al. (2018). "Perinatal Marijuana Use and the Developing Child." <u>JAMA</u> 320 (6): 545-546.
Jones, R. E., et al. (2018). "Management of Chronic Wounds-2018." <u>JAMA</u> 320 (14): 1481-1482.
Kahal, D. (2019). "Evaluation for Fibrosis After Cure of Hepatitis C." <u>JAMA</u> 321 (15): 1534-1535.
Katz, I. T., et al. (2018). "The Global HIV Epidemic: What Will It Take to Get to the Finish Line?" <u>JAMA</u> 319 (11): 1094-1095.
Kaye, K. S., et al. (2018). "Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial." <u>JAMA</u> 319 (8): 788-799.
Kini, V. and P. M. Ho (2018). "Interventions to Improve Medication Adherence: A Review." <u>JAMA</u> 320 (23): 2461-2473.
Kinnard, E. N., et al. (2018). "Government Actions to Curb the Opioid Epidemic." <u>JAMA</u> 319 (15): 1619-1620.
Klompas, M., et al. (2018). "Antibiotics for Sepsis-Finding the Equilibrium." <u>JAMA</u> 320 (14): 1433-1434.
Kozlowski, S., et al. (2018). "Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population." <u>JAMA</u> 320 (9): 929-931.
Kreijkamp-Kaspers, S., et al. (2018). "Oral Medications to Treat Toenail Fungal Infection." <u>JAMA</u> 319 (4): 397-398.
Kressel, A. B. (2018). "Contact Precautions to Prevent Pathogen Transmission." <u>JAMA</u> 320 (4): 407-407.
Labhardt, N. D., et al. (2018). "Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial." <u>JAMA</u> 319 (11): 1103-1112.
Legrand, M. and J. A. Kellum (2018). "Serum Creatinine in the Critically Ill Patient With Sepsis." <u>JAMA</u> 320 (22): 2369-2370.

Lin, J. S., et al. (2018). "Screening for Syphilis Infection in Pregnant Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." <u>JAMA</u> 320 (9): 918-925.
Marshall, J. C., et al. (2019). "The Role of Endotoxin in Septic Shock-Reply." <u>JAMA</u> 321 (9): 903-903.
Massad, L. S. (2018). "Replacing the Pap Test With Screening Based on Human Papillomavirus Assays." <u>JAMA</u> 320 (1): 35-37.
McCoy, T. H., Jr. and R. H. Perlis (2018). "Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017." <u>JAMA</u> 320 (12): 1282-1284.
Meijer, E., et al. (2018). "Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial." <u>JAMA</u> 320 (19): 2010-2019.
Melnikow, J., et al. (2018). "Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force." <u>JAMA</u> 320 (7): 687-705.
Menon, B. K., et al. (2018). "Association of Clinical, Imaging, and Thrombus Characteristics With Recanalization of Visible Intracranial Occlusion in Patients With Acute Ischemic Stroke." <u>JAMA</u> 320 (10): 1017-1026.
Mercer, M. P., et al. (2019). "Reducing Emergency Department Length of Stay." <u>JAMA</u> .
Moller-Bisgaard, S., et al. (2019). "Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial." <u>JAMA</u> 321 (5): 461-472.
Norton, S. A. and D. M. Morens (2018). "Vaccination Strategies During Shortages of Yellow Fever Vaccine." <u>JAMA</u> 319 (12): 1280-1280.
Ogilvie, G. S., et al. (2018). "Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial." <u>JAMA</u> 320 (1): 43-52.
Oster, A. M., et al. (2018). "Molecular Epidemiology and the Transformation of HIV Prevention." <u>JAMA</u> 319 (16): 1657-1658.
Pasternak, B., et al. (2018). "Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death." <u>JAMA</u> 319 (22): 2333-2335.
Pickkers, P., et al. (2018). "Effect of Human Recombinant Alkaline Phosphatase on 7-Day Creatinine Clearance in Patients With Sepsis-Associated Acute Kidney Injury: A Randomized Clinical Trial." <u>JAMA</u> 320 (19): 1998-2009.
Prescott, H. C. and D. C. Angus (2018). "Enhancing Recovery From Sepsis: A Review." <u>JAMA</u> 319 (1): 62-75.
Riddell, J. t., et al. (2018). "HIV Preexposure Prophylaxis: A Review." <u>JAMA</u> 319 (12): 1261-1268.
Rubin, M. A., et al. (2018). "The Importance of Contact Precautions for Endemic Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci." <u>JAMA</u> 319 (9): 863-864.

Rubin, R. (2018). "Addressing Barriers to Inclusion of Pregnant Women in Clinical Trials." <u>JAMA</u> 320 (8): 742-744.
Rubin, R. (2018). "Is It Possible to Get a Flu Shot Too Early?" <u>JAMA</u> 320 (22): 2299-2301.
Rudd, K. E., et al. (2018). "Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries." <u>JAMA</u> 319 (21): 2202-2211.
Saag, M. S., et al. (2018). "Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel." <u>JAMA</u> 320 (4): 379-396.
Salminen, P., et al. (2018). "Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial." <u>JAMA</u> 320 (12): 1259-1265.
Schenker, Y., et al. (2018). "Use of Palliative Care Earlier in the Disease Course in the Context of the Opioid Epidemic: Educational, Research, and Policy Issues." <u>JAMA</u> 320 (9): 871-872.
Schuetz, P., et al. (2018). "Procalcitonin Testing to Guide Antibiotic Therapy in Acute Upper and Lower Respiratory Tract Infections." <u>JAMA</u> 319 (9): 925-926.
Shapiro, E. D. and G. P. Wormser (2018). "Lyme Disease in 2018: What Is New (and What Is Not)." <u>JAMA</u> 320 (7): 635-636.
Sharfstein, J. M. and Y. Olsen (2019). "Making Amends for the Opioid Epidemic." <u>JAMA</u> 321 (15): 1446-1447.
Shenoy, E. S., et al. (2019). "Evaluation and Management of Penicillin Allergy: A Review." <u>JAMA</u> 321 (2): 188-199.
Spronk, P. E. and B. H. Cuthbertson (2019). "Decontamination Strategies for Critically Ill Patients." <u>JAMA</u> 321 (14): 1409-1409.
Stein, B., et al. (2018). "Evaluation of the Direct Antiglobulin Test (DAT) in the Setting of Mycoplasma pneumoniae Infection." <u>JAMA</u> 319 (13): 1377-1378.
Stey, A., et al. (2018). "How Disruptive Innovation by Business and Technology Firms Could Improve Population Health." <u>JAMA</u> 320 (10): 973-974.
Subramaniam, B., et al. (2019). "Effect of Intravenous Acetaminophen vs Placebo Combined With Propofol or Dexmedetomidine on Postoperative Delirium Among Older Patients Following Cardiac Surgery: The DEXACET Randomized Clinical Trial." <u>JAMA</u> 321 (7): 686-696.
Tang, L. S. Y., et al. (2018). "Chronic Hepatitis B Infection: A Review." <u>JAMA</u> 319 (17): 1802-1813.
Taylor, N., et al. (2019). "Decontamination Strategies for Critically Ill Patients." <u>JAMA</u> 321 (14): 1408-1409.
Thirumurthy, H., et al. (2019). "The Uncertain Effect of Financial Incentives to Improve Health Behaviors." <u>JAMA</u> .
Traeger, M. W., et al. (2019). "Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection." <u>JAMA</u> 321 (14): 1380-1390.

Trusheim, M. R., et al. (2018). "Alternative State-Level Financing for Hepatitis C Treatment-The "Netflix Model"." <u>JAMA</u> 320 (19): 1977-1978.
Uyeki, T. M., et al. (2018). "Gaps in the Clinical Management of Influenza: A Century Since the 1918 Pandemic." <u>JAMA</u> 320 (8): 755-756.
Vinci, R. J. and E. Melendez (2018). "Bundled Strategies for the Care of Children With Presumed Sepsis." <u>JAMA</u> 320 (4): 345-346.
Vox, F., et al. (2018). "Medical Crowdfunding for Scientifically Unsupported or Potentially Dangerous Treatments." <u>JAMA</u> 320 (16): 1705-1706.
Wang, A., et al. (2018). "Management Considerations in Infective Endocarditis: A Review." <u>JAMA</u> 320 (1): 72-83.
Wejnert, C., et al. (2018). "Prevalence of Missed Opportunities for HIV Testing Among Persons Unaware of Their Infection." <u>JAMA</u> 319 (24): 2555-2557.
Wilder, J., et al. (2018). "Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis." <u>JAMA</u> 320 (19): 2031-2032.
Wilder, J., et al. (2019). "Evaluation for Fibrosis After Cure of Hepatitis C-Reply." <u>JAMA</u> 321 (15): 1535-1535.
Wittekamp, B. H., et al. (2019). "Decontamination Strategies for Critically Ill Patients-Reply." <u>JAMA</u> 321 (14): 1410-1410.
Wittekamp, B. H., et al. (2018). "Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial." <u>JAMA</u> 320 (20): 2087-2098.
Wortsman, X. (2018). "Diagnosis and Treatment of Hidradenitis Suppurativa." <u>JAMA</u> 319 (15): 1617-1618.
Zhou, Y.-H. (2018). "Treatment of Chronic Hepatitis B Infection." <u>JAMA</u> 320 (11): 1201-1201.
Andrews, J. R., et al. (2018). "High Rates of Enteric Fever Diagnosis and Lower Burden of Culture-Confirmed Disease in Peri-urban and Rural Nepal." <u>The Journal of infectious diseases</u> 218 (suppl_4): S214-S221.
Ao, Y., et al. (2018). "Genetic Analysis of Reemerging GII.P16-GII.2 Noroviruses in 2016-2017 in China." <u>The Journal of infectious diseases</u> 218 (1): 133-143.
Baldry, M., et al. (2018). "Application of an agr-Specific Antivirulence Compound as Therapy for Staphylococcus aureus-Induced Inflammatory Skin Disease." <u>The Journal of infectious diseases</u> 218 (6): 1009-1013.
Baraniak, I., et al. (2018). "Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia." <u>The Journal of infectious diseases</u> 217 (12): 1907-1917.
Barkume, C., et al. (2018). "Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned." <u>The Journal of infectious diseases</u> 218 (suppl_4): S188-S194.
Borgia, S. M., et al. (2018). "Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of

Hepatitis C Virus Into 8 Genotypes." <u>The Journal of infectious diseases</u> 218 (11): 1722-1729.
Brickley, E. B., et al. (2018). "Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine." <u>The Journal of infectious diseases</u> 217 (3): 371-380.
Buchholz, U. J., et al. (2018). "Live Respiratory Syncytial Virus (RSV) Vaccine Candidate Containing Stabilized Temperature-Sensitivity Mutations Is Highly Attenuated in RSV-Seronegative Infants and Children." <u>The Journal of infectious diseases</u> 217 (9): 1338-1346.
Buseyne, F., et al. (2018). "Clinical Signs and Blood Test Results Among Humans Infected With Zoonotic Simian Foamy Virus: A Case-Control Study." <u>The Journal of infectious diseases</u> 218 (1): 144-151.
Carter, R. J., et al. (2018). "Implementing a Multisite Clinical Trial in the Midst of an Ebola Outbreak: Lessons Learned From the Sierra Leone Trial to Introduce a Vaccine Against Ebola." <u>The Journal of infectious diseases</u> 217 (suppl_1): S16-S23.
Catalano, S., et al. (2018). "Rodents as Natural Hosts of Zoonotic Schistosoma Species and Hybrids: An Epidemiological and Evolutionary Perspective From West Africa." <u>The Journal of infectious diseases</u> 218 (3): 429-433.
Chaudhury, C. S., et al. (2017). "No Improvement in Hemoglobin A1c Following Hepatitis C Viral Clearance in Patients With and Without HIV." <u>The Journal of infectious diseases</u> 217 (1): 47-50.
Comas-Garcia, A., et al. (2018). "Respiratory Syncytial Virus-A ON1 Genotype Emergence in Central Mexico in 2009 and Evidence of Multiple Duplication Events." <u>The Journal of infectious diseases</u> 217 (7): 1089-1098.
Combes, J.-D., et al. (2018). "Prevalence and Risk Factors for Anal Human Papillomavirus Infection in Human Immunodeficiency Virus-Positive Men Who Have Sex with Men." <u>The Journal of infectious diseases</u> 217 (10): 1535-1543.
Cunningham, A. L., et al. (2018). "Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older." <u>The Journal of infectious diseases</u> 217 (11): 1750-1760.
de Gunzburg, J., et al. (2018). "Protection of the Human Gut Microbiome From Antibiotics." <u>The Journal of infectious diseases</u> 217 (4): 628-636.
de Vries, R. D., et al. (2017). "Primary Human Influenza B Virus Infection Induces Cross-Lineage Hemagglutinin Stalk-Specific Antibodies Mediating Antibody-Dependent Cellular Cytotoxicity." <u>The Journal of infectious diseases</u> 217 (1): 3-11.
de Wit, E., et al. (2018). "1918 H1N1 Influenza Virus Replicates and Induces Proinflammatory Cytokine Responses in Extrarespiratory Tissues of Ferrets." <u>The Journal of infectious diseases</u> 217 (8): 1237-1246.
Donken, R., et al. (2018). "High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women." <u>The Journal of infectious diseases</u> 217 (10): 1579-1589.

Dyall, J., et al. (2018). "Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures." <u>The Journal of infectious diseases</u> 218 (suppl_5): S672-S678.
Eichner, M., et al. (2017). "In Colon Epithelia, Clostridium perfringens Enterotoxin Causes Focal Leaks by Targeting Claudins Which are Apically Accessible Due to Tight Junction Derangement." <u>The Journal of infectious diseases</u> 217 (1): 147-157.
Erbelding, E. J., et al. (2018). "A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases." <u>The Journal of infectious diseases</u> 218 (3): 347-354.
Flannery, B., et al. (2018). "Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States." <u>The Journal of infectious diseases</u> 218 (2): 189-196.
Freyne, B., et al. (2018). "Neonatal BCG Vaccination Influences Cytokine Responses to Toll-like Receptor Ligands and Heterologous Antigens." <u>The Journal of infectious diseases</u> 217 (11): 1798-1808.
Goncalves, A., et al. (2018). "Innovative and New Approaches to Laboratory Diagnosis of Zika and Dengue: A Meeting Report." <u>The Journal of infectious diseases</u> 217 (7): 1060-1068.
Guo, Q., et al. (2018). "Immunization With a Novel Human Type 5 Adenovirus-Vectored Vaccine Expressing the Premembrane and Envelope Proteins of Zika Virus Provides Consistent and Sterilizing Protection in Multiple Immunocompetent and Immunocompromised Animal Models." <u>The Journal of infectious diseases</u> 218 (3): 365-377.
Houlihan, C. F., et al. (2018). "Use of Whole-Genome Sequencing in the Investigation of a Nosocomial Influenza Virus Outbreak." <u>The Journal of infectious diseases</u> 218 (9): 1485-1489.
Hu, Z., et al. (2018). "The Role of KLRG1 in Human CD4+ T-Cell Immunity Against Tuberculosis." <u>The Journal of infectious diseases</u> 217 (9): 1491-1503.
Imwong, M., et al. (2019). "Asymptomatic Natural Human Infections With the Simian Malaria Parasites Plasmodium cynomolgi and Plasmodium knowlesi." <u>The Journal of infectious diseases</u> 219 (5): 695-702.
Kaljee, L. M., et al. (2018). "Social and Economic Burden Associated With Typhoid Fever in Kathmandu and Surrounding Areas: A Qualitative Study." <u>The Journal of infectious diseases</u> 218 (suppl_4): S243-S249.
Kapil, P., et al. (2018). "Maternal Vaccination With a Monocomponent Pertussis Toxoid Vaccine Is Sufficient to Protect Infants in a Baboon Model of Whooping Cough." <u>The Journal of infectious diseases</u> 217 (8): 1231-1236.
Kiso, M., et al. (2018). "Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus." <u>The Journal of infectious diseases</u> 217 (6): 887-896.
Kurioka, A., et al. (2018). "Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated Invariant T-Cell Response Through Major Histocompatibility Complex class I-Related Molecule-Dependent and Cytokine-Driven Pathways." <u>The Journal of infectious diseases</u> 217 (6): 988-999.

Kuroda, M. J., et al. (2018). "High Turnover of Tissue Macrophages Contributes to Tuberculosis Reactivation in Simian Immunodeficiency Virus-Infected Rhesus Macaques." <u>The Journal of infectious diseases</u> 217 (12): 1865-1874.
Lamoth, F. and D. P. Kontoyiannis (2018). "The Candida auris Alert: Facts and Perspectives." <u>The Journal of infectious diseases</u> 217 (4): 516-520.
Lamoury, F. M. J., et al. (2018). "Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay." <u>The Journal of infectious diseases</u> 217 (12): 1889-1896.
Lau, S. K. P., et al. (2018). "Receptor Usage of a Novel Bat Lineage C Betacoronavirus Reveals Evolution of Middle East Respiratory Syndrome-Related Coronavirus Spike Proteins for Human Dipeptidyl Peptidase 4 Binding." <u>The Journal of infectious diseases</u> 218 (2): 197-207.
Laurie, K. L., et al. (2018). "Evidence for Viral Interference and Cross-reactive Protective Immunity Between Influenza B Virus Lineages." <u>The Journal of infectious diseases</u> 217 (4): 548-559.
Lee, B., et al. (2018). "Histo-Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy." <u>The Journal of infectious diseases</u> 217 (9): 1399-1407.
Leroux-Roels, G., et al. (2018). "Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial." <u>The Journal of infectious diseases</u> 217 (4): 597-607.
Lindesmith, L. C., et al. (2018). "Antigenic Characterization of a Novel Recombinant GII.P16-GII.4 Sydney Norovirus Strain With Minor Sequence Variation Leading to Antibody Escape." <u>The Journal of infectious diseases</u> 217 (7): 1145-1152.
Lo, N. C., et al. (2018). "Comparison of Strategies and Incidence Thresholds for Vi Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study." <u>The Journal of infectious diseases</u> 218 (suppl_4): S232-S242.
Lozier, M. J., et al. (2018). "Differences in Prevalence of Symptomatic Zika Virus Infection, by Age and Sex-Puerto Rico, 2016." <u>The Journal of infectious diseases</u> 217 (11): 1678-1689.
Machalek, D. A., et al. (2018). "Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination." <u>The Journal of infectious diseases</u> 217 (10): 1590-1600.
Maier, H. E., et al. (2018). "Obesity Increases the Duration of Influenza A Virus Shedding in Adults." <u>The Journal of infectious diseases</u> 218 (9): 1378-1382.
Makvandi-Nejad, S., et al. (2018). "Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the rs12252-C Variant That is Associated With Severe Influenza Infection." <u>The Journal of infectious diseases</u> 217 (2): 257-262.
Manning, J. E., et al. (2018). "Mosquito Saliva: The Hope for a Universal Arbovirus Vaccine?" <u>The Journal of infectious diseases</u> 218 (1): 7-15.
Meinel, C., et al. (2018). "Streptococcus pneumoniae From Patients With Hemolytic Uremic Syndrome Binds Human Plasminogen

via the Surface Protein PspC and Uses Plasmin to Damage Human Endothelial Cells." <u>The Journal of infectious diseases</u> 217 (3): 358-370.
Meshar, D., et al. (2018). "The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016." <u>The Journal of infectious diseases</u> 218 (6): 911-921.
Meyer, M., et al. (2018). "Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs From Ebola Virus Disease." <u>The Journal of infectious diseases</u> 217 (3): 451-455.
Midttun, H. L. E., et al. (2018). "Ascaris Suum Infection Downregulates Inflammatory Pathways in the Pig Intestine In Vivo and in Human Dendritic Cells In Vitro." <u>The Journal of infectious diseases</u> 217 (2): 310-319.
Ming, Z., et al. (2017). "Involvement of Cryptosporidium parvum Cdg7_FLC_1000 RNA in the Attenuation of Intestinal Epithelial Cell Migration via Trans-Suppression of Host Cell SMPD3." <u>The Journal of infectious diseases</u> 217 (1): 122-133.
Montoya, M., et al. (2018). "Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas." <u>The Journal of infectious diseases</u> 218 (4): 536-545.
Moodie, Z., et al. (2018). "Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America." <u>The Journal of infectious diseases</u> 217 (5): 742-753.
Murphy, S. C., et al. (2018). "A Randomized Trial Evaluating the Prophylactic Activity of DSM265 Against Preerythrocytic Plasmodium falciparum Infection During Controlled Human Malarial Infection by Mosquito Bites and Direct Venous Inoculation." <u>The Journal of infectious diseases</u> 217 (5): 693-702.
Namazi, G., et al. (2018). "The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies." <u>The Journal of infectious diseases</u> 218 (12): 1954-1963.
Negri, C. E., et al. (2018). "Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus." <u>The Journal of infectious diseases</u> 217 (7): 1118-1127.
Newton, R., et al. (2018). "Kaposi Sarcoma-Associated Herpesvirus in a Rural Ugandan Cohort, 1992-2008." <u>The Journal of infectious diseases</u> 217 (2): 263-269.
Nolan, V. G., et al. (2018). "Etiology and Impact of Coinfections in Children Hospitalized With Community-Acquired Pneumonia." <u>The Journal of infectious diseases</u> 218 (2): 179-188.
Novakovic, D., et al. (2018). "A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program." <u>The Journal of infectious diseases</u> 217 (2): 208-212.
Obando-Pacheco, P., et al. (2018). "Respiratory Syncytial Virus Seasonality: A Global Overview." <u>The Journal of infectious diseases</u> 217 (9): 1356-1364.
Okamoto, M., et al. (2018). "Molecular Characterization of Respiratory Syncytial Virus in Children With Repeated Infections With

Subgroup B in the Philippines." <u>The Journal of infectious diseases</u> 218 (7): 1045-1053.
Pascal, K. E., et al. (2018). "Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates." <u>The Journal of infectious diseases</u> 218 (suppl_5): S612-S626.
Patel, P., et al. (2018). "Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN Study." <u>The Journal of infectious diseases</u> 217 (6): 953-963.
Pham, H. T., et al. (2018). "The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors." <u>The Journal of infectious diseases</u> 218 (5): 698-706.
Plucinski, M. M., et al. (2018). "Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria." <u>The Journal of infectious diseases</u> 217 (5): 685-692.
Pringle, K. D., et al. (2018). "Trends in Rate of Seizure-Associated Hospitalizations Among Children <5 Years Old Before and After Rotavirus Vaccine Introduction in the United States, 2000-2013." <u>The Journal of infectious diseases</u> 217 (4): 581-588.
Qamar, F. N., et al. (2018). "A Retrospective Study of Laboratory-Based Enteric Fever Surveillance, Pakistan, 2012-2014." <u>The Journal of infectious diseases</u> 218 (suppl_4): S201-S205.
Ragonnet-Cronin, M., et al. (2018). "Recent and Rapid Transmission of HIV Among People Who Inject Drugs in Scotland Revealed Through Phylogenetic Analysis." <u>The Journal of infectious diseases</u> 217 (12): 1875-1882.
Rimoin, A. W., et al. (2018). "Ebola Virus Neutralizing Antibodies Detectable in Survivors of the Yambuku, Zaire Outbreak 40 Years after Infection." <u>The Journal of infectious diseases</u> 217 (2): 223-231.
Riveron, J. M., et al. (2018). "High Plasmodium Infection Rate and Reduced Bed Net Efficacy in Multiple Insecticide-Resistant Malaria Vectors in Kinshasa, Democratic Republic of Congo." <u>The Journal of infectious diseases</u> 217 (2): 320-328.
Rodriguez-Fernandez, R., et al. (2017). "Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis." <u>The Journal of infectious diseases</u> 217 (1): 24-34.
Rojas, L. J., et al. (2017). "An Analysis of the Epidemic of Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae: Convergence of Two Evolutionary Mechanisms Creates the "Perfect Storm"." <u>The Journal of infectious diseases</u> 217 (1): 82-92.
Samai, M., et al. (2018). "The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔG-ZEBOV-GP Vaccine Tolerability and Safety During the West Africa Ebola Outbreak." <u>The Journal of infectious diseases</u> 217 (suppl_1): S6-S15.
Schaber, C. L., et al. (2018). "Breathprinting Reveals Malaria-Associated Biomarkers and Mosquito Attractants." <u>The Journal of infectious diseases</u> 217 (10): 1553-1560.
Spencer, J. L., et al. (2018). "Replication of Zika Virus in Human Prostate Cells: A Potential Source of Sexually Transmitted Virus." <u>The Journal of infectious diseases</u> 217 (4): 538-547.

Spengler, J. R., et al. (2017). "Severity of Disease in Humanized Mice Infected With Ebola Virus or Reston Virus Is Associated With Magnitude of Early Viral Replication in Liver." <u>The Journal of infectious diseases</u> 217 (1): 58-63.
Stepanova, M., et al. (2018). "Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens." <u>The Journal of infectious diseases</u> 217 (7): 1033-1043.
Stevens, M., et al. (2018). "Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study." <u>The Journal of infectious diseases</u> 218 (5): 748-756.
Stewart, C. J., et al. (2018). "Respiratory Syncytial Virus and Rhinovirus Bronchiolitis Are Associated With Distinct Metabolic Pathways." <u>The Journal of infectious diseases</u> 217 (7): 1160-1169.
Strassl, R., et al. (2018). "Quantification of Torque Teno Virus Viremia as a Prospective Biomarker for Infectious Disease in Kidney Allograft Recipients." <u>The Journal of infectious diseases</u> 218 (8): 1191-1199.
Su, T.-H., et al. (2018). "Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy." <u>The Journal of infectious diseases</u> 217 (8): 1193-1201.
Svensson, R. J., et al. (2018). "Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations." <u>The Journal of infectious diseases</u> 218 (6): 991-999.
Tabata, T., et al. (2018). "Zika Virus Replicates in Proliferating Cells in Explants From First-Trimester Human Placentas, Potential Sites for Dissemination of Infection." <u>The Journal of infectious diseases</u> 217 (8): 1202-1213.
Thompson, E. G., et al. (2018). "Prospective Discrimination of Controllers From Progressors Early After Low-Dose Mycobacterium tuberculosis Infection of Cynomolgus Macaques using Blood RNA Signatures." <u>The Journal of infectious diseases</u> 217 (8): 1318-1322.
Thomson, K. A., et al. (2018). "Increased Risk of HIV Acquisition Among Women Throughout Pregnancy and During the Postpartum Period: A Prospective Per-Coital-Act Analysis Among Women With HIV-Infected Partners." <u>The Journal of infectious diseases</u> 218 (1): 16-25.
Urbanowski, M. E., et al. (2018). "Repetitive Aerosol Exposure Promotes Cavitory Tuberculosis and Enables Screening for Targeted Inhibitors of Extensive Lung Destruction." <u>The Journal of infectious diseases</u> 218 (1): 53-63.
Van Dycke, J., et al. (2018). "A Single Nucleoside Viral Polymerase Inhibitor Against Norovirus, Rotavirus, and Sapovirus-Induced Diarrhea." <u>The Journal of infectious diseases</u> 218 (11): 1753-1758.
van Zoest, R. A., et al. (2017). "Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers." <u>The Journal of infectious diseases</u> 217 (1): 69-81.
Volz, E. M., et al. (2018). "Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for

Intervention and Control." <u>The Journal of infectious diseases</u> 217 (10): 1522-1529.
Wertheim, J. O., et al. (2018). "Growth of HIV-1 Molecular Transmission Clusters in New York City." <u>The Journal of infectious diseases</u> 218 (12): 1943-1953.
Wijting, I. E. A., et al. (2018). "HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy." <u>The Journal of infectious diseases</u> 218 (5): 688-697.
Wilson, P., et al. (2018). "Call to Action: Prevention of Mother-to-Child Transmission of Hepatitis B in Africa." <u>The Journal of infectious diseases</u> 217 (8): 1180-1183.
Woestenberg, P. J., et al. (2018). "Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors." <u>The Journal of infectious diseases</u> 217 (2): 213-222.
Wong, S.-S., et al. (2018). "Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study." <u>The Journal of infectious diseases</u> 217 (2): 245-256.
Young, B., et al. (2018). "Duration of Influenza Vaccine Effectiveness: A Systematic Review, Meta-analysis, and Meta-regression of Test-Negative Design Case-Control Studies." <u>The Journal of infectious diseases</u> 217 (5): 731-741.
Young-Xu, Y., et al. (2018). "Relative Vaccine Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among Veterans Health Administration Patients." <u>The Journal of infectious diseases</u> 217 (11): 1718-1727.
Zenklusen, I., et al. (2018). "Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies." <u>The Journal of infectious diseases</u> 217 (10): 1569-1578.
Zhu, L., et al. (2018). "High Level of Neutrophil Extracellular Traps Correlates With Poor Prognosis of Severe Influenza A Infection." <u>The Journal of infectious diseases</u> 217 (3): 428-437.
Zimmer, C. L., et al. (2018). "Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss." <u>The Journal of infectious diseases</u> 217 (10): 1656-1666.
Access, G. B. D. H. and C. Quality (2018). "Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016." <u>Lancet (London, England)</u> 391 (10136): 2236-2271.
Ahmad, N., et al. (2018). "Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis." <u>Lancet (London, England)</u> 392 (10150): 821-834.
Aldridge, R. W., et al. (2018). "Global patterns of mortality in international migrants: a systematic review and meta-analysis." <u>Lancet (London, England)</u> 392 (10164): 2553-2566.
Aldridge, R. W., et al. (2018). "Morbidity and mortality in homeless individuals, prisoners, sex workers, and individuals with substance use disorders in high-income countries: a systematic review and meta-analysis." <u>Lancet (London, England)</u> 391 (10117):

241-250.
Ashley, E. A., et al. (2018). "Malaria." <u>Lancet (London, England)</u> 391 (10130): 1608-1621.
Azzopardi, P. S., et al. (2019). "Progress in adolescent health and wellbeing: tracking 12 headline indicators for 195 countries and territories, 1990-2016." <u>Lancet (London, England)</u> 393 (10176): 1101-1118.
Banyai, K., et al. (2018). "Viral gastroenteritis." <u>Lancet (London, England)</u> 392 (10142): 175-186.
Barouch, D. H., et al. (2018). "Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)." <u>Lancet (London, England)</u> 392 (10143): 232-243.
Bekker, L.-G., et al. (2018). "Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission." <u>Lancet (London, England)</u> 392 (10144): 312-358.
Biccard, B. M., et al. (2018). "Perioperative patient outcomes in the African Surgical Outcomes Study: a 7-day prospective observational cohort study." <u>Lancet (London, England)</u> 391 (10130): 1589-1598.
Burki, T. (2018). "Lassa fever in Nigeria: the great unknown." <u>Lancet (London, England)</u> 391 (10122): 728-728.
Burki, T. (2018). "Increase of West Nile virus cases in Europe for 2018." <u>Lancet (London, England)</u> 392 (10152): 1000-1000.
Burza, S., et al. (2018). "Leishmaniasis." <u>Lancet (London, England)</u> 392 (10151): 951-970.
Cahn, P., et al. (2019). "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials." <u>Lancet (London, England)</u> 393 (10167): 143-155.
Cecconi, M., et al. (2018). "Sepsis and septic shock." <u>Lancet (London, England)</u> 392 (10141): 75-87.
Chang, A. B., et al. (2018). "Bronchiectasis in children: diagnosis and treatment." <u>Lancet (London, England)</u> 392 (10150): 866-879.
Chu, D. K., et al. (2018). "Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis." <u>Lancet (London, England)</u> 391 (10131): 1693-1705.
Collaborators, G. S. (2018). "Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017." <u>Lancet (London, England)</u> 392 (10159): 2091-2138.
DALYs, G. B. D. and H. Collaborators (2018). "Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017." <u>Lancet (London, England)</u> 392 (10159): 1859-1922.
Disease, G. B. D., et al. (2018). "Global, regional, and national incidence, prevalence, and years lived with disability for 354

diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017." <u>Lancet (London, England)</u> 392 (10159): 1789-1858.
Ebola Outbreak Epidemiology, T. (2018). "Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study." <u>Lancet (London, England)</u> 392 (10143): 213-221.
Erondy, N. A., et al. (2018). "Building the case for embedding global health security into universal health coverage: a proposal for a unified health system that includes public health." <u>Lancet (London, England)</u> 392 (10156): 1482-1486.
Farmer, P. E. (2018). "Better and safer treatment for multidrug-resistant tuberculosis." <u>Lancet (London, England)</u> 392 (10150): 798-800.
Fellmeth, G., et al. (2018). "Health impacts of parental migration on left-behind children and adolescents: a systematic review and meta-analysis." <u>Lancet (London, England)</u> 392 (10164): 2567-2582.
Flume, P. A., et al. (2018). "Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity." <u>Lancet (London, England)</u> 392 (10150): 880-890.
Foreman, K. J., et al. (2018). "Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories." <u>Lancet (London, England)</u> 392 (10159): 2052-2090.
Francis, N. A., et al. (2018). "Oral steroids for resolution of otitis media with effusion in children (OSTRICH): a double-blinded, placebo-controlled randomised trial." <u>Lancet (London, England)</u> 392 (10147): 557-568.
Fraser, B. (2018). "Measles outbreak in the Americas." <u>Lancet (London, England)</u> 392 (10145): 373-373.
Fraser, B. (2019). "Providing care for trans women with HIV/AIDS in Peru." <u>Lancet (London, England)</u> 393 (10179): 1399-1400.
Frieden, T. R. and M. R. Bloomberg (2018). "Saving an additional 100 million lives." <u>Lancet (London, England)</u> 391 (10121): 709-712.
Gaudinski, M. R., et al. (2019). "Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study." <u>Lancet (London, England)</u> 393 (10174): 889-898.
Gaudinski, M. R., et al. (2018). "Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials." <u>Lancet (London, England)</u> 391 (10120): 552-562.
Ghosn, J., et al. (2018). "HIV." <u>Lancet (London, England)</u> 392 (10148): 685-697.
Gillison, M. L., et al. (2019). "Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial." <u>Lancet (London, England)</u> 393 (10166): 40-50.

Global Burden of Disease Health Financing Collaborator, N. (2018). "Spending on health and HIV/AIDS: domestic health spending and development assistance in 188 countries, 1995-2015." <u>Lancet (London, England)</u> 391 (10132): 1799-1829.
Goisis, A., et al. (2019). "Medically assisted reproduction and birth outcomes: a within-family analysis using Finnish population registers." <u>Lancet (London, England)</u> 393 (10177): 1225-1232.
Goosby, E., et al. (2018). "The Lancet Commission on tuberculosis: building a tuberculosis-free world." <u>Lancet (London, England)</u> 391 (10126): 1132-1133.
Goyal, V., et al. (2018). "Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis (BEST-2): a multicentre, double-blind, non-inferiority, randomised controlled trial." <u>Lancet (London, England)</u> 392 (10154): 1197-1206.
Gupta-Wright, A., et al. (2018). "Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial." <u>Lancet (London, England)</u> 392 (10144): 292-301.
Hargreaves, S., et al. (2018). "Who is responsible for the vaccination of migrants in Europe?" <u>Lancet (London, England)</u> 391 (10132): 1752-1754.
Hartvigsen, J., et al. (2018). "What low back pain is and why we need to pay attention." <u>Lancet (London, England)</u> 391 (10137): 2356-2367.
Heffernan, A., et al. (2019). "Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model." <u>Lancet (London, England)</u> 393 (10178): 1319-1329.
Hocking, J. S., et al. (2018). "Population effectiveness of opportunistic chlamydia testing in primary care in Australia: a cluster-randomised controlled trial." <u>Lancet (London, England)</u> 392 (10156): 1413-1422.
Honigsbaum, M. (2018). "Spanish influenza redux: revisiting the mother of all pandemics." <u>Lancet (London, England)</u> 391 (10139): 2492-2495.
Iuliano, A. D., et al. (2018). "Estimates of global seasonal influenza-associated respiratory mortality: a modelling study." <u>Lancet (London, England)</u> 391 (10127): 1285-1300.
Jaber, S., et al. (2018). "Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial." <u>Lancet (London, England)</u> 392 (10141): 31-40.
Jourdan, P. M., et al. (2018). "Soil-transmitted helminth infections." <u>Lancet (London, England)</u> 391 (10117): 252-265.
Karthikeyan, G. and L. Guilherme (2018). "Acute rheumatic fever." <u>Lancet (London, England)</u> 392 (10142): 161-174.
Killeen, G. F. and H. Ranson (2018). "Insecticide-resistant malaria vectors must be tackled." <u>Lancet (London, England)</u> 391 (10130):

1551-1552.
Kotloff, K. L., et al. (2018). "Shigellosis." <u>Lancet (London, England)</u> 391 (10122): 801-812.
Lamontagne, F., et al. (2018). "Evidence-based guidelines for supportive care of patients with Ebola virus disease." <u>Lancet (London, England)</u> 391 (10121): 700-708.
Landier, J., et al. (2018). "Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme." <u>Lancet (London, England)</u> 391 (10133): 1916-1926.
Larson, H. J. (2018). "The state of vaccine confidence." <u>Lancet (London, England)</u> 392 (10161): 2244-2246.
Lessler, J., et al. (2018). "Mapping the burden of cholera in sub-Saharan Africa and implications for control: an analysis of data across geographical scales." <u>Lancet (London, England)</u> 391 (10133): 1908-1915.
Llibre, J. M., et al. (2018). "Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies." <u>Lancet (London, England)</u> 391 (10123): 839-849.
Marais, B. and A. Zumla (2018). "Advancing global tuberculosis control after the UNGA-HLM." <u>Lancet (London, England)</u> 392 (10153): 1096-1097.
Marques, E. T. A. and D. S. Burke (2018). "Tradition and innovation in development of a Zika vaccine." <u>Lancet (London, England)</u> 391 (10120): 516-517.
Mazure, C. M. and D. A. Fiellin (2018). "Women and opioids: something different is happening here." <u>Lancet (London, England)</u> 392 (10141): 9-11.
Mease, P., et al. (2018). "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial." <u>Lancet (London, England)</u> 392 (10162): 2367-2377.
Mehanna, H., et al. (2019). "Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial." <u>Lancet (London, England)</u> 393 (10166): 51-60.
Mesu, V. K. B. K., et al. (2018). "Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial." <u>Lancet (London, England)</u> 391 (10116): 144-154.
Miller, W. C., et al. (2018). "A scalable, integrated intervention to engage people who inject drugs in HIV care and medication-assisted treatment (HPTN 074): a randomised, controlled phase 3 feasibility and efficacy study." <u>Lancet (London, England)</u> 392 (10149): 747-759.
Mitja, O., et al. (2018). "Re-emergence of yaws after single mass azithromycin treatment followed by targeted treatment: a

longitudinal study." <u>Lancet (London, England)</u> 391 (10130): 1599-1607.
Modjarrad, K., et al. (2018). "Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials." <u>Lancet (London, England)</u> 391 (10120): 563-571.
Nakkazi, E. (2018). "DR Congo Ebola virus outbreak: responding in a conflict zone." <u>Lancet (London, England)</u> 392 (10148): 623-623.
Nakkazi, E. (2018). "Changes to dolutegravir policy in several African countries." <u>Lancet (London, England)</u> 392 (10143): 199-199.
Nkengasong, J. N. and P. Onyebujoh (2018). "Response to the Ebola virus disease outbreak in the Democratic Republic of the Congo." <u>Lancet (London, England)</u> 391 (10138): 2395-2398.
Opoku, N. O., et al. (2018). "Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial." <u>Lancet (London, England)</u> 392 (10154): 1207-1216.
Pavlakakis, G. N. and B. K. Felber (2018). "A new step towards an HIV/AIDS vaccine." <u>Lancet (London, England)</u> 392 (10143): 192-194.
Peng, X., et al. (2018). "On reducing the risk of vaccine-associated paralytic poliomyelitis in the global transition from oral to inactivated poliovirus vaccine." <u>Lancet (London, England)</u> 392 (10147): 610-612.
Perez-Molina, J. A. and I. Molina (2018). "Chagas disease." <u>Lancet (London, England)</u> 391 (10115): 82-94.
Protopopoff, N., et al. (2018). "Effectiveness of a long-lasting piperonyl butoxide-treated insecticidal net and indoor residual spray interventions, separately and together, against malaria transmitted by pyrethroid-resistant mosquitoes: a cluster, randomised controlled, two-by-two factorial design trial." <u>Lancet (London, England)</u> 391 (10130): 1577-1588.
Reid, M. J. A., et al. (2019). "Building a tuberculosis-free world: The Lancet Commission on tuberculosis." <u>Lancet (London, England)</u> 393 (10178): 1331-1384.
Reignier, J., et al. (2018). "Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2)." <u>Lancet (London, England)</u> 391 (10116): 133-143.
Reisinger, E. C., et al. (2019). "Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial." <u>Lancet (London, England)</u> 392 (10165): 2718-2727.
Saha, S. K., et al. (2018). "Causes and incidence of community-acquired serious infections among young children in south Asia (ANISA): an observational cohort study." <u>Lancet (London, England)</u> 392 (10142): 145-159.

Seto, W.-K., et al. (2018). "Chronic hepatitis B virus infection." <u>Lancet (London, England)</u> 392 (10161): 2313-2324.
Starrs, A. M., et al. (2018). "Accelerate progress-sexual and reproductive health and rights for all: report of the Guttmacher-Lancet Commission." <u>Lancet (London, England)</u> 391 (10140): 2642-2692.
Story, A., et al. (2019). "Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial." <u>Lancet (London, England)</u> 393 (10177): 1216-1224.
Subtil, D., et al. (2018). "Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial." <u>Lancet (London, England)</u> 392 (10160): 2171-2179.
Sullivan, S. (2018). "Challenges in reducing influenza-associated mortality." <u>Lancet (London, England)</u> 391 (10127): 1242-1244.
Tangcharoensathien, V., et al. (2018). "Health systems development in Thailand: a solid platform for successful implementation of universal health coverage." <u>Lancet (London, England)</u> 391 (10126): 1205-1223.
The, L. (2018). "Measles, war, and health-care reforms in Ukraine." <u>Lancet (London, England)</u> 392 (10149): 711-711.
The, L. (2018). "Dolutegravir for HIV: a lesson in pregnancy safety research." <u>Lancet (London, England)</u> 391 (10137): 2296-2296.
The, L. (2018). "Opioids and methamphetamine: a tale of two crises." <u>Lancet (London, England)</u> 391 (10122): 713-713.
The, L. (2018). "Our responsibility to protect the Rohingya." <u>Lancet (London, England)</u> 390 (10114): 2740-2740.
Thwaites, G. E., et al. (2018). "Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial." <u>Lancet (London, England)</u> 391 (10121): 668-678.
Tiono, A. B., et al. (2018). "Efficacy of Olyset Duo, a bednet containing pyriproxyfen and permethrin, versus a permethrin-only net against clinical malaria in an area with highly pyrethroid-resistant vectors in rural Burkina Faso: a cluster-randomised controlled trial." <u>Lancet (London, England)</u> 392 (10147): 569-580.
van Brunschot, S., et al. (2018). "Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial." <u>Lancet (London, England)</u> 391 (10115): 51-58.
van der Heijde, D., et al. (2018). "Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial." <u>Lancet (London, England)</u> 392 (10162): 2378-2387.
Wallace, D. J., et al. (2018). "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial." <u>Lancet (London, England)</u> 392 (10143): 222-231.
Watts, N., et al. (2018). "The Lancet Countdown on health and climate change: from 25 years of inaction to a global transformation for public health." <u>Lancet (London, England)</u> 391 (10120): 581-630.
Webster, P. (2019). "Inuit research raises concerns about tuberculosis eradication." <u>Lancet (London, England)</u> 393 (10178): 1275-

1276.
Williams, R., et al. (2018). "Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK." <u>Lancet (London, England)</u> 391 (10125): 1097-1107.
Williams, R., et al. (2018). "Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK." <u>Lancet (London, England)</u> 392 (10162): 2398-2412.
Wingfield, T., et al. (2018). "Addressing social determinants to end tuberculosis." <u>Lancet (London, England)</u> 391 (10126): 1129-1132.
Winston, D. J., et al. (2018). "Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial." <u>Lancet (London, England)</u> 391 (10135): 2116-2127.
Yen, L. M. and C. L. Thwaites (2019). "Tetanus." <u>Lancet (London, England)</u> 393 (10181): 1657-1668.
Yuan, X. (2018). "China's vaccine production scare." <u>Lancet (London, England)</u> 392 (10145): 371-371.
Zaffran, M., et al. (2018). "The polio endgame: securing a world free of all polioviruses." <u>Lancet (London, England)</u> 391 (10115): 11-13.
Althoff, K. N., et al. (2019). "Contributions of traditional and HIV-related risk factors on non-AIDS-defining cancer, myocardial infarction, and end-stage liver and renal diseases in adults with HIV in the USA and Canada: a collaboration of cohort studies." <u>The lancet. HIV</u> 6 (2): e93-e104.
Bailey, H., et al. (2018). "HIV treatment in pregnancy." <u>The lancet. HIV</u> 5 (8): e457-e467.
Bavinton, B. R., et al. (2018). "Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study." <u>The lancet. HIV</u> 5 (8): e438-e447.
Bekker, L.-G., et al. (2018). "Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial." <u>The lancet. HIV</u> 5 (7): e366-e378.
Bekker, L.-G., et al. (2018). "Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial." <u>The lancet. HIV</u> 5 (2): e68-e78.
Black, V. and S. R. Schwartz (2018). "Issues about periconception use of dolutegravir are reminiscent of early concerns about efavirenz." <u>The lancet. HIV</u> 5 (12): e732-e736.
Blanche, S., et al. (2019). "Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial." <u>The lancet. HIV</u> 6 (5): e307-e314.
Bogoch, I. I., et al. (2018). "Identifying HIV care continuum gaps with verbal autopsy." <u>The lancet. HIV</u> 5 (2): e65-e67.
Borgdorff, M. W., et al. (2018). "HIV incidence in western Kenya during scale-up of antiretroviral therapy and voluntary medical male circumcision: a population-based cohort analysis." <u>The lancet. HIV</u> 5 (5): e241-e249.

Boyd, M. A., et al. (2018). "Towards a universal second-line fixed-dose combination ART." <u>The lancet. HIV</u> 5 (1): e3-e5.
Brown, B., et al. (2018). "Crucial but understudied: incentives in HIV research." <u>The lancet. HIV</u> 5 (2): e61-e62.
Calabrese, S. K. and K. H. Mayer (2019). "Providers should discuss U=U with all patients living with HIV." <u>The lancet. HIV</u> 6 (4): e211-e213.
Cepeda, J. A., et al. (2018). "Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study." <u>The lancet. HIV</u> 5 (10): e578-e587.
Cohen, S. E., et al. (2018). "Acquisition of tenofovir-susceptible, emtricitabine-resistant HIV despite high adherence to daily pre-exposure prophylaxis: a case report." <u>The lancet. HIV</u> .
Coltart, C. E. M., et al. (2018). "Ethical considerations in global HIV phylogenetic research." <u>The lancet. HIV</u> 5 (11): e656-e666.
Cousins, S. (2018). "HIV in Serbia: stigma and a stagnant HIV response." <u>The lancet. HIV</u> 5 (7): e343-e344.
Cowan, F. M., et al. (2018). "Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPH-IRE): a cluster-randomised trial." <u>The lancet. HIV</u> 5 (8): e417-e426.
Crowell, T. A., et al. (2019). "Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial." <u>The lancet. HIV</u> 6 (5): e297-e306.
Daar, E. S., et al. (2018). "Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial." <u>The lancet. HIV</u> 5 (7): e347-e356.
Daniels, J. P. (2018). "Accion Solidaria: propping up HIV treatment in Venezuela." <u>The lancet. HIV</u> 5 (10): e549-e549.
de Vries, H. J. C. and R. D. M. Steenbergen (2018). "The effect of ART on cervical cancer precursor lesions." <u>The lancet. HIV</u> 5 (1): e6-e8.
Diaz, P. and A. Ferketich (2018). "Smoking and HIV: confronting the epidemic." <u>The lancet. HIV</u> 5 (3): e109-e110.
Dong, K. L., et al. (2018). "Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study." <u>The lancet. HIV</u> 5 (1): e35-e44.
Dorward, J., et al. (2018). "Point-of-care viral load testing and differentiated HIV care." <u>The lancet. HIV</u> 5 (1): e8-e9.
Dorward, J., et al. (2018). "Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research." <u>The lancet. HIV</u> 5 (7): e400-e404.
Esbjornsson, J., et al. (2018). "Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study." <u>The lancet. HIV</u> .

Figuerola, C., et al. (2018). "Reliability of HIV rapid diagnostic tests for self-testing compared with testing by health-care workers: a systematic review and meta-analysis." <u>The lancet. HIV</u> 5 (6): e277-e290.
Finocchiaro-Kessler, S., et al. (2018). "Evaluation of the HIV Infant Tracking System (HITSsystem) to optimise quality and efficiency of early infant diagnosis: a cluster-randomised trial in Kenya." <u>The lancet. HIV</u> 5 (12): e696-e705.
Frank, S. C., et al. (2019). "Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study." <u>The lancet. HIV</u> 6 (3): e182-e190.
Galvani, A. P., et al. (2018). "Defining control of HIV epidemics." <u>The lancet. HIV</u> 5 (11): e667-e670.
Golub, S. A. and C. U. Enemchukwu (2018). "The critical importance of retention in HIV prevention." <u>The lancet. HIV</u> 5 (9): e475-e476.
Gonsalves, G. S. and F. W. Crawford (2018). "Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study." <u>The lancet. HIV</u> 5 (10): e569-e577.
Gottlieb, G. S., et al. (2018). "90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2." <u>The lancet. HIV</u> 5 (7): e390-e399.
Grinsztejn, B., et al. (2018). "Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study." <u>The lancet. HIV</u> 5 (3): e136-e145.
group, A. s. (2018). "Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial." <u>The lancet. HIV</u> 5 (10): e553-e559.
Grulich, A. E., et al. (2018). "Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study." <u>The lancet. HIV</u> 5 (11): e629-e637.
Hamada, Y., et al. (2018). "Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: a systematic review and meta-analysis." <u>The lancet. HIV</u> 5 (9): e515-e523.
Hamers, R. L., et al. (2018). "HIV drug resistance in low-income and middle-income countries." <u>The lancet. HIV</u> 5 (10): e588-e596.
Harris, M. (2018). "What did we learn from the bictegravir switch studies?" <u>The lancet. HIV</u> 5 (7): e336-e337.
Hernandez-Ramirez, R. U., et al. (2019). "Association of immunosuppression and HIV viraemia with non-Hodgkin lymphoma risk overall and by subtype in people living with HIV in Canada and the USA: a multicentre cohort study." <u>The lancet. HIV</u> 6 (4): e240-e249.
Hessol, N. A., et al. (2018). "Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study." <u>The lancet. HIV</u> 5 (11): e647-e655.
Holt, M., et al. (2018). "Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual

men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013-17." <u>The lancet. HIV</u> 5 (8): e448-e456.
Howard, J. F. B., et al. (2019). "Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study." <u>The lancet. HIV</u> 6 (3): e173-e181.
Inzaule, S. C., et al. (2018). "Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study." <u>The lancet. HIV</u> 5 (11): e638-e646.
Iwuji, C. C., et al. (2018). "Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial." <u>The lancet. HIV</u> 5 (3): e116-e125.
Januraga, P. P., et al. (2018). "The cascade of HIV care among key populations in Indonesia: a prospective cohort study." <u>The lancet. HIV</u> 5 (10): e560-e568.
Jaworski, J. P. and P. Cahn (2018). "Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1." <u>The lancet. HIV</u> 5 (12): e723-e731.
Jose, S., et al. (2018). "A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study." <u>The lancet. HIV</u> 5 (6): e301-e308.
Kaplan, R. and R. Wood (2018). "Resistance to first-line ART and a role for dolutegravir." <u>The lancet. HIV</u> 5 (3): e112-e113.
Kelly, H., et al. (2018). "Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis." <u>The lancet. HIV</u> 5 (1): e45-e58.
Kelly, S. L., et al. (2018). "The global Optima HIV allocative efficiency model: targeting resources in efforts to end AIDS." <u>The lancet. HIV</u> 5 (4): e190-e198.
Kharsany, A. B. M., et al. (2018). "Community-based HIV prevalence in KwaZulu-Natal, South Africa: results of a cross-sectional household survey." <u>The lancet. HIV</u> 5 (8): e427-e437.
Kojima, N. and J. D. Klausner (2018). "Accelerating epidemic control: the role of HIV self-testing." <u>The lancet. HIV</u> 5 (6): e266-e267.
Kranzer, K., et al. (2018). "Economic incentives for HIV testing by adolescents in Zimbabwe: a randomised controlled trial." <u>The lancet. HIV</u> 5 (2): e79-e86.
Krupitsky, E., et al. (2019). "Slow-release naltrexone implant versus oral naltrexone for improving treatment outcomes in people with HIV who are addicted to opioids: a double-blind, placebo-controlled, randomised trial." <u>The lancet. HIV</u> 6 (4): e221-e229.
Loeliger, K. B., et al. (2018). "All-cause mortality among people with HIV released from an integrated system of jails and prisons in Connecticut, USA, 2007-14: a retrospective observational cohort study." <u>The lancet. HIV</u> 5 (11): e617-e628.
Loeliger, K. B., et al. (2018). "Predictors of linkage to HIV care and viral suppression after release from jails and prisons: a retrospective cohort study." <u>The lancet. HIV</u> 5 (2): e96-e106.

Lundgren, J. and A. Phillips (2018). "Prevention of HIV transmission by antiretroviral therapy." <u>The lancet. HIV</u> 5 (3): e108-e109.
Mallewa, J., et al. (2018). "Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial." <u>The lancet. HIV</u> 5 (5): e231-e240.
Marcy, O., et al. (2018). "Mortality and its determinants in antiretroviral treatment-naïve HIV-infected children with suspected tuberculosis: an observational cohort study." <u>The lancet. HIV</u> 5 (2): e87-e95.
Marshall, B. D. L., et al. (2018). "Potential effectiveness of long-acting injectable pre-exposure prophylaxis for HIV prevention in men who have sex with men: a modelling study." <u>The lancet. HIV</u> 5 (9): e498-e505.
McAuley, A., et al. (2019). "Re-emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross-sectional analysis." <u>The lancet. HIV</u> 6 (5): e315-e324.
McGettrick, P. M. C. and P. W. G. Mallon (2018). "HIV and cardiovascular disease: defining the unmeasured risk." <u>The lancet. HIV</u> 5 (6): e267-e269.
Mercie, P., et al. (2018). "Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial." <u>The lancet. HIV</u> 5 (3): e126-e135.
Molina, J.-M., et al. (2018). "Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial." <u>The lancet. HIV</u> 5 (4): e172-e180.
Molina, J.-M., et al. (2018). "Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial." <u>The lancet. HIV</u> 5 (5): e211-e220.
Molina, J.-M., et al. (2018). "Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial." <u>The lancet. HIV</u> 5 (7): e357-e365.
Mulubwa, C., et al. (2019). "Community based distribution of oral HIV self-testing kits in Zambia: a cluster-randomised trial nested in four HPTN 071 (PopART) intervention communities." <u>The lancet. HIV</u> 6 (2): e81-e92.
Mussini, C. and A. Cossarizza (2018). "Indications for starting ART." <u>The lancet. HIV</u> 5 (4): e157-e158.
Nachman, S., et al. (2018). "Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial." <u>The lancet. HIV</u> 5 (12): e715-e722.
Njuguna, I. N., et al. (2018). "Urgent versus post-stabilisation antiretroviral treatment in hospitalised HIV-infected children in Kenya (PUSH): a randomised controlled trial." <u>The lancet. HIV</u> 5 (1): e12-e22.
Olalla, J. (2018). "Wild-type HIV infection despite PrEP: a lot to learn from a case report." <u>The lancet. HIV</u> 5 (1): e10-e10.

Olawore, O., et al. (2018). "Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort study." <u>The lancet. HIV</u> 5 (4): e181-e189.
Orkin, C., et al. (2018). "Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial." <u>The lancet. HIV</u> 5 (1): e23-e34.
Phillips, A. N., et al. (2018). "Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study." <u>The lancet. HIV</u> 5 (3): e146-e154.
Phillips, A. N., et al. (2019). "Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study." <u>The lancet. HIV</u> 6 (2): e116-e127.
Pitman, M. C., et al. (2018). "Barriers and strategies to achieve a cure for HIV." <u>The lancet. HIV</u> 5 (6): e317-e328.
Piyaraj, P., et al. (2018). "The finding of casual sex partners on the internet, methamphetamine use for sexual pleasure, and incidence of HIV infection among men who have sex with men in Bangkok, Thailand: an observational cohort study." <u>The lancet. HIV</u> 5 (7): e379-e389.
Priddy, F. H., et al. (2019). "Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial." <u>The lancet. HIV</u> 6 (4): e230-e239.
Rabie, H., et al. (2018). "Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study." <u>The lancet. HIV</u> .
Ragonnet-Cronin, M., et al. (2019). "HIV transmission networks among transgender women in Los Angeles County, CA, USA: a phylogenetic analysis of surveillance data." <u>The lancet. HIV</u> 6 (3): e164-e172.
Ragonnet-Cronin, M., et al. (2018). "Non-disclosed men who have sex with men in UK HIV transmission networks: phylogenetic analysis of surveillance data." <u>The lancet. HIV</u> 5 (6): e309-e316.
Rasmussen, T. A., et al. (2018). "The effect of antiretroviral intensification with dolutegravir on residual virus replication in HIV-infected individuals: a randomised, placebo-controlled, double-blind trial." <u>The lancet. HIV</u> 5 (5): e221-e230.
Ryom, L., et al. (2018). "Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study." <u>The lancet. HIV</u> 5 (6): e291-e300.
Sewankambo, N. K. (2018). "HIV incidence and scale-up of prevention in western Kenya." <u>The lancet. HIV</u> 5 (5): e204-e205.
Shiau, S., et al. (2018). "Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?" <u>The lancet. HIV</u> 5 (5): e250-e258.
Solomon, S. S., et al. (2019). "Integrated HIV testing, prevention, and treatment intervention for key populations in India: a cluster-

randomised trial." <u>The lancet. HIV</u> 6 (5): e283-e296.
Sugarman, J., et al. (2018). "Development and implementation of participant safety plans for international research with stigmatised populations." <u>The lancet. HIV</u> 5 (8): e468-e472.
Sullivan, P. S. and A. M. Oster (2018). "Phylogenetic analyses of local HIV transmission." <u>The lancet. HIV</u> 5 (6): e270-e271.
Technau, K.-G., et al. (2018). "12-month outcomes of HIV-infected infants identified at birth at one maternity site in Johannesburg, South Africa: an observational cohort study." <u>The lancet. HIV</u> 5 (12): e706-e714.
Thirumurthy, H., et al. (2019). "Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial." <u>The lancet. HIV</u> 6 (3): e155-e163.
Tippett Barr, B. A., et al. (2018). "National estimates and risk factors associated with early mother-to-child transmission of HIV after implementation of option B+: a cross-sectional analysis." <u>The lancet. HIV</u> 5 (12): e688-e695.
Tonen-Wolyec, S., et al. (2018). "Insufficient education is a challenge for HIV self-testing." <u>The lancet. HIV</u> 5 (7): e341-e341.
Tucker, J. D. and K. A. Fenton (2018). "Innovation challenge contests to enhance HIV responses." <u>The lancet. HIV</u> 5 (3): e113-e115.
van Luenen, S., et al. (2018). "Guided internet-based intervention for people with HIV and depressive symptoms: a randomised controlled trial in the Netherlands." <u>The lancet. HIV</u> 5 (9): e488-e497.
Waite, C., et al. (2018). "Does U=U for breastfeeding mothers and infants? Breastfeeding by mothers on effective treatment for HIV infection in high-income settings." <u>The lancet. HIV</u> 5 (9): e531-e536.
Ward, J., et al. (2018). "HIV incidence in Indigenous and non-Indigenous populations in Australia: a population-level observational study." <u>The lancet. HIV</u> 5 (9): e506-e514.
Wieman, C., et al. (2018). "Widening the perspective on HIV among Indigenous Australians." <u>The lancet. HIV</u> 5 (9): e477-e478.
Winston, A., et al. (2018). "Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial." <u>The lancet. HIV</u> 5 (4): e162-e171.
Wohl, D. A. and D. L. Rosen (2018). "Inadequate HIV care after incarceration: case closed." <u>The lancet. HIV</u> 5 (2): e64-e65.
Abel, L., et al. (2018). "Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives." <u>The Lancet. Infectious diseases</u> 18 (3): e64-e75.
Abubakar, I., et al. (2018). "Prognostic value of interferon-gamma release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study." <u>The Lancet. Infectious diseases</u> 18 (10): 1077-1087.
Amato, R., et al. (2018). "Origins of the current outbreak of multidrug-resistant malaria in southeast Asia: a retrospective genetic

study." <u>The Lancet. Infectious diseases</u> 18 (3): 337-345.
Anderson, D. J., et al. (2018). "Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and <i>Clostridium difficile</i> : a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection)." <u>The Lancet. Infectious diseases</u> 18 (8): 845-853.
Arend, S. M. and D. van Soolingen (2018). "Performance of Xpert MTB/RIF Ultra: a matter of dead or alive." <u>The Lancet. Infectious diseases</u> 18 (1): 8-10.
Atkins, K. E., et al. (2018). "Use of mathematical modelling to assess the impact of vaccines on antibiotic resistance." <u>The Lancet. Infectious diseases</u> 18 (6): e204-e213.
Bahr, N. C., et al. (2018). "Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study." <u>The Lancet. Infectious diseases</u> 18 (1): 68-75.
Beigel, J. H., et al. (2018). "Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomal cattle: a phase 1 randomised, double-blind, single-dose-escalation study." <u>The Lancet. Infectious diseases</u> 18 (4): 410-418.
Bishnoi, A., et al. (2018). "Emergence of recalcitrant dermatophytosis in India." <u>The Lancet. Infectious diseases</u> 18 (3): 250-251.
Bryant, P. A. and N. T. Katz (2018). "Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review." <u>The Lancet. Infectious diseases</u> 18 (2): e45-e54.
Cambiano, V., et al. (2018). "Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation." <u>The Lancet. Infectious diseases</u> 18 (1): 85-94.
Cassell, J. A., et al. (2018). "Scabies outbreaks in ten care homes for elderly people: a prospective study of clinical features, epidemiology, and treatment outcomes." <u>The Lancet. Infectious diseases</u> 18 (8): 894-902.
Cassini, A., et al. (2019). "Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis." <u>The Lancet. Infectious diseases</u> 19 (1): 56-66.
Chan, X. H. S., et al. (2018). "Risk of sudden unexplained death after use of dihydroartemisinin-piperaquine for malaria: a systematic review and Bayesian meta-analysis." <u>The Lancet. Infectious diseases</u> 18 (8): 913-923.
Chatterjee, A., et al. (2018). "Quantifying drivers of antibiotic resistance in humans: a systematic review." <u>The Lancet. Infectious diseases</u> 18 (12): e368-e378.
Chen, L. and B. N. Kreiswirth (2018). "Convergence of carbapenem-resistance and hypervirulence in <i>Klebsiella pneumoniae</i> ." <u>The Lancet. Infectious diseases</u> 18 (1): 2-3.

Chesnais, C. B., et al. (2018). "The temporal relationship between onchocerciasis and epilepsy: a population-based cohort study." <u>The Lancet. Infectious diseases</u> 18 (11): 1278-1286.
Chow, N. A., et al. (2018). "Multiple introductions and subsequent transmission of multidrug-resistant <i>Candida auris</i> in the USA: a molecular epidemiological survey." <u>The Lancet. Infectious diseases</u> 18 (12): 1377-1384.
Collaborators, G. B. D. D. D. (2018). "Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016." <u>The Lancet. Infectious diseases</u> 18 (11): 1211-1228.
Collaborators, G. B. D. L. R. I. (2018). "Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016." <u>The Lancet. Infectious diseases</u> 18 (11): 1191-1210.
Collaborators, G. B. D. T. (2018). "The global burden of tuberculosis: results from the Global Burden of Disease Study 2015." <u>The Lancet. Infectious diseases</u> 18 (3): 261-284.
Collaborators, G. B. D. T. (2018). "Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study." <u>The Lancet. Infectious diseases</u> 18 (12): 1329-1349.
Cox, H., et al. (2018). "Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?" <u>The Lancet. Infectious diseases</u> 18 (9): e282-e287.
Damaso, C. R. (2018). "Revisiting Jenner's mysteries, the role of the Beaugency lymph in the evolutionary path of ancient smallpox vaccines." <u>The Lancet. Infectious diseases</u> 18 (2): e55-e63.
de Araujo, T. V. B., et al. (2018). "Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study." <u>The Lancet. Infectious diseases</u> 18 (3): 328-336.
Desai, M., et al. (2018). "Prevention of malaria in pregnancy." <u>The Lancet. Infectious diseases</u> 18 (4): e119-e132.
Desmet, S., et al. (2018). "Switch in a childhood pneumococcal vaccination programme from PCV13 to PCV10: a defensible approach?" <u>The Lancet. Infectious diseases</u> 18 (8): 830-831.
Devakumar, D., et al. (2018). "Infectious causes of microcephaly: epidemiology, pathogenesis, diagnosis, and management." <u>The Lancet. Infectious diseases</u> 18 (1): e1-e13.
Dokubo, E. K., et al. (2018). "Persistence of Ebola virus after the end of widespread transmission in Liberia: an outbreak report." <u>The Lancet. Infectious diseases</u> 18 (9): 1015-1024.
Dorman, S. E., et al. (2018). "Xpert MTB/RIF Ultra for detection of <i>Mycobacterium tuberculosis</i> and rifampicin resistance: a prospective multicentre diagnostic accuracy study." <u>The Lancet. Infectious diseases</u> 18 (1): 76-84.

Du, P., et al. (2018). "Emergence of carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> ." <u>The Lancet. Infectious diseases</u> 18 (1): 23-24.
Ferlazzo, G., et al. (2018). "Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study." <u>The Lancet. Infectious diseases</u> 18 (5): 536-544.
Fifer, H., et al. (2018). "Sustained transmission of high-level azithromycin-resistant <i>Neisseria gonorrhoeae</i> in England: an observational study." <u>The Lancet. Infectious diseases</u> 18 (5): 573-581.
Fisher, H., et al. (2018). "Continuous low-dose antibiotic prophylaxis for adults with repeated urinary tract infections (AnTIC): a randomised, open-label trial." <u>The Lancet. Infectious diseases</u> 18 (9): 957-968.
Ford, N., et al. (2018). "The WHO public health approach to HIV treatment and care: looking back and looking ahead." <u>The Lancet. Infectious diseases</u> 18 (3): e76-e86.
GlobalSurg, C. (2018). "Surgical site infection after gastrointestinal surgery in high-income, middle-income, and low-income countries: a prospective, international, multicentre cohort study." <u>The Lancet. Infectious diseases</u> 18 (5): 516-525.
Goldblatt, D., et al. (2018). "Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1 + 1) compared with two primary doses and a booster (2 + 1) in UK infants: a multicentre, parallel group randomised controlled trial." <u>The Lancet. Infectious diseases</u> 18 (2): 171-179.
Gu, D., et al. (2018). "A fatal outbreak of ST11 carbapenem-resistant hypervirulent <i>Klebsiella pneumoniae</i> in a Chinese hospital: a molecular epidemiological study." <u>The Lancet. Infectious diseases</u> 18 (1): 37-46.
Guery, B., et al. (2018). "Extended-pulsed fidaxomicin versus vancomycin for <i>Clostridium difficile</i> infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial." <u>The Lancet. Infectious diseases</u> 18 (3): 296-307.
Gupta, R. K., et al. (2018). "HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis." <u>The Lancet. Infectious diseases</u> 18 (3): 346-355.
Harris, S. R., et al. (2018). "Public health surveillance of multidrug-resistant clones of <i>Neisseria gonorrhoeae</i> in Europe: a genomic survey." <u>The Lancet. Infectious diseases</u> 18 (7): 758-768.
Hermans, L. E., et al. (2018). "Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study." <u>The Lancet. Infectious diseases</u> 18 (2): 188-197.
Hofmann, N. E., et al. (2018). "Assessment of ultra-sensitive malaria diagnosis versus standard molecular diagnostics for malaria elimination: an in-depth molecular community cross-sectional study." <u>The Lancet. Infectious diseases</u> 18 (10): 1108-1116.
Hui, D. S., et al. (2018). "Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission." <u>The Lancet. Infectious diseases</u> 18 (8): e217-e227.

Huttner, A., et al. (2018). "Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (7): 738-748.
Ismail, N. A., et al. (2018). "Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey." <u>The Lancet. Infectious diseases</u> 18 (7): 779-787.
Jault, P., et al. (2019). "Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by <i>Pseudomonas aeruginosa</i> (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial." <u>The Lancet. Infectious diseases</u> 19 (1): 35-45.
Khalil, I. A., et al. (2018). "Morbidity and mortality due to shigella and enterotoxigenic <i>Escherichia coli</i> diarrhoea: the Global Burden of Disease Study 1990-2016." <u>The Lancet. Infectious diseases</u> 18 (11): 1229-1240.
Kleinschmidt, I., et al. (2018). "Implications of insecticide resistance for malaria vector control with long-lasting insecticidal nets: a WHO-coordinated, prospective, international, observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (6): 640-649.
Ladhani, S. N., et al. (2018). "Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (4): 441-451.
Lamagni, T., et al. (2018). "Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study." <u>The Lancet. Infectious diseases</u> 18 (2): 180-187.
Lenguerrand, E., et al. (2018). "Risk factors associated with revision for prosthetic joint infection after hip replacement: a prospective observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (9): 1004-1014.
Lin, C., et al. (2018). "Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis." <u>The Lancet. Infectious diseases</u> 18 (2): 198-206.
Liu, Y., et al. (2018). "Resurgence of scarlet fever in China: a 13-year population-based surveillance study." <u>The Lancet. Infectious diseases</u> 18 (8): 903-912.
Llanos-Cuentas, A., et al. (2018). "Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated <i>Plasmodium falciparum</i> or <i>Plasmodium vivax</i> malaria infection: a proof-of-concept, open-label, phase 2a study." <u>The Lancet. Infectious diseases</u> 18 (8): 874-883.
Ma, G., et al. (2018). "Human toxocariasis." <u>The Lancet. Infectious diseases</u> 18 (1): e14-e24.
Mazur, N. I., et al. (2018). "The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates." <u>The Lancet. Infectious diseases</u> 18 (10): e295-e311.
McClelland, R. S., et al. (2018). "Evaluation of the association between the concentrations of key vaginal bacteria and the increased risk of HIV acquisition in African women from five cohorts: a nested case-control study." <u>The Lancet. Infectious diseases</u> 18 (5): 554-564.

Meis, J. F. and A. Chowdhary (2018). "Candida auris: a global fungal public health threat." <u>The Lancet. Infectious diseases</u> 18 (12): 1298-1299.
Messacar, K., et al. (2018). "Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality." <u>The Lancet. Infectious diseases</u> 18 (8): e239-e247.
Molina, J.-M., et al. (2018). "Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial." <u>The Lancet. Infectious diseases</u> 18 (3): 308-317.
Musso, D., et al. (2018). "Zika virus in French Polynesia 2013-14: anatomy of a completed outbreak." <u>The Lancet. Infectious diseases</u> 18 (5): e172-e182.
Musso, D., et al. (2018). "Unexpected outbreaks of arbovirus infections: lessons learned from the Pacific and tropical America." <u>The Lancet. Infectious diseases</u> 18 (11): e355-e361.
Nellums, L. B., et al. (2018). "Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis." <u>The Lancet. Infectious diseases</u> 18 (7): 796-811.
Nguyen, T.-N., et al. (2018). "The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study." <u>The Lancet. Infectious diseases</u> 18 (5): 565-572.
Okokhere, P., et al. (2018). "Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (6): 684-695.
Ombelet, S., et al. (2018). "Clinical bacteriology in low-resource settings: today's solutions." <u>The Lancet. Infectious diseases</u> 18 (8): e248-e258.
Paul, M., et al. (2018). "Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial." <u>The Lancet. Infectious diseases</u> 18 (4): 391-400.
Perez, F. and R. A. Bonomo (2018). "Evidence to improve the treatment of infections caused by carbapenem-resistant Gram-negative bacteria." <u>The Lancet. Infectious diseases</u> 18 (4): 358-360.
Poland, G. A., et al. (2018). "Development of vaccines against Zika virus." <u>The Lancet. Infectious diseases</u> 18 (7): e211-e219.
Portsmouth, S., et al. (2018). "Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial." <u>The Lancet. Infectious diseases</u> 18 (12): 1319-1328.
Rogerson, S. J., et al. (2018). "Burden, pathology, and costs of malaria in pregnancy: new developments for an old problem." <u>The Lancet. Infectious diseases</u> 18 (4): e107-e118.
Saez-Llorens, X., et al. (2018). "Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study."

The Lancet. Infectious diseases 18 (2): 162-170.
Sayasone, S., et al. (2018). "Efficacy and safety of tribendimidine versus praziquantel against <i>Opisthorchis viverrini</i> in Laos: an open-label, randomised, non-inferiority, phase 2 trial." <u>The Lancet. Infectious diseases</u> 18 (2): 155-161.
Schuetz, P., et al. (2018). "Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis." <u>The Lancet. Infectious diseases</u> 18 (1): 95-107.
Seedat, F., et al. (2018). "How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review." <u>The Lancet. Infectious diseases</u> 18 (9): e259-e271.
Sharland, M., et al. (2018). "Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe." <u>The Lancet. Infectious diseases</u> 18 (1): 18-20.
Signorelli, C., et al. (2018). "The imperative of vaccination put into practice." <u>The Lancet. Infectious diseases</u> 18 (1): 26-27.
Sivapalasingam, S., et al. (2018). "Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study." <u>The Lancet. Infectious diseases</u> 18 (8): 884-893.
Smit, M. R., et al. (2018). "Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial." <u>The Lancet. Infectious diseases</u> 18 (6): 615-626.
Sricharoenchai, S., et al. (2018). "A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial." <u>The Lancet. Infectious diseases</u> 18 (1): 58-67.
Tacconelli, E., et al. (2018). "Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis." <u>The Lancet. Infectious diseases</u> 18 (3): 318-327.
Tacconelli, E., et al. (2018). "Surveillance for control of antimicrobial resistance." <u>The Lancet. Infectious diseases</u> 18 (3): e99-e106.
Tagliani, E., et al. (2018). "EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU." <u>The Lancet. Infectious diseases</u> 18 (4): 377-377.
Tamarozzi, F., et al. (2018). "Prevalence of abdominal cystic echinococcosis in rural Bulgaria, Romania, and Turkey: a cross-sectional, ultrasound-based, population study from the HERACLES project." <u>The Lancet. Infectious diseases</u> 18 (7): 769-778.
Tiberi, S., et al. (2018). "Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies." <u>The Lancet. Infectious diseases</u> 18 (7): e183-e198.
Tornimbene, B., et al. (2018). "WHO Global Antimicrobial Resistance Surveillance System early implementation 2016-17." <u>The</u>

<u>Lancet. Infectious diseases</u> 18 (3): 241-242.
Torres, A., et al. (2018). "Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial." <u>The Lancet. Infectious diseases</u> 18 (3): 285-295.
Torrico, F., et al. (2018). "Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial." <u>The Lancet. Infectious diseases</u> 18 (4): 419-430.
van Beek, J., et al. (2018). "Molecular surveillance of norovirus, 2005-16: an epidemiological analysis of data collected from the NoroNet network." <u>The Lancet. Infectious diseases</u> 18 (5): 545-553.
van Duijn, P. J., et al. (2018). "The effects of antibiotic cycling and mixing on antibiotic resistance in intensive care units: a cluster-randomised crossover trial." <u>The Lancet. Infectious diseases</u> 18 (4): 401-409.
van Laarhoven, A., et al. (2018). "Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study." <u>The Lancet. Infectious diseases</u> 18 (5): 526-535.
Van Puyvelde, S., et al. (2018). "Why the antibiotic resistance crisis requires a One Health approach." <u>The Lancet. Infectious diseases</u> 18 (2): 132-134.
Vardakas, K. Z., et al. (2018). "Prolonged versus short-term intravenous infusion of antipseudomonal beta-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials." <u>The Lancet. Infectious diseases</u> 18 (1): 108-120.
Walker, T. M., et al. (2018). "A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study." <u>The Lancet. Infectious diseases</u> 18 (4): 431-440.
Walzl, G., et al. (2018). "Tuberculosis: advances and challenges in development of new diagnostics and biomarkers." <u>The Lancet. Infectious diseases</u> 18 (7): e199-e210.
Whiley, D. M., et al. (2018). "Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin." <u>The Lancet. Infectious diseases</u> 18 (7): 717-718.
Williams, P. C. M., et al. (2018). "Antimicrobial resistance among children in sub-Saharan Africa." <u>The Lancet. Infectious diseases</u> 18 (2): e33-e44.
Zelenev, A., et al. (2018). "Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study." <u>The Lancet. Infectious diseases</u> 18 (2): 215-224.
Zignol, M., et al. (2018). "Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study." <u>The Lancet. Infectious diseases</u> 18 (6): 675-683.
Allix-Beguec, C., et al. (2018). "Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing." <u>The New England journal of medicine</u> 379 (15): 1403-1415.

Andrews, J. R., et al. (2018). "Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?" <u>The New England journal of medicine</u> 379 (16): 1493-1495.
Annane, D., et al. (2018). "Hydrocortisone plus Fludrocortisone for Adults with Septic Shock." <u>The New England journal of medicine</u> 378 (9): 809-818.
Baltimore, R. S., et al. (2018). "Case 4-2018: A Newborn with Thrombocytopenia, Cataracts, and Hepatosplenomegaly." <u>The New England journal of medicine</u> 378 (6): 564-572.
Barbar, S. D., et al. (2018). "Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis." <u>The New England journal of medicine</u> 379 (15): 1431-1442.
Berend, K. (2018). "Diagnostic Use of Base Excess in Acid-Base Disorders." <u>The New England journal of medicine</u> 378 (15): 1419-1428.
Bines, J. E., et al. (2018). "Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth." <u>The New England journal of medicine</u> 378 (8): 719-730.
Blake, I. M., et al. (2018). "Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine." <u>The New England journal of medicine</u> 379 (9): 834-845.
Blendon, R. J. and J. M. Benson (2018). "The Public and the Opioid-Abuse Epidemic." <u>The New England journal of medicine</u> 378 (5): 407-411.
Bloch, E. M., et al. (2018). "Revisiting Blood Safety Practices Given Emerging Data about Zika Virus." <u>The New England journal of medicine</u> 378 (19): 1837-1841.
Bloom, B. R. (2018). "New Promise for Vaccines against Tuberculosis." <u>The New England journal of medicine</u> 379 (17): 1672-1674.
Chitnis, T., et al. (2018). "Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis." <u>The New England journal of medicine</u> 379 (11): 1017-1027.
Choi, I. J., et al. (2018). "Helicobacter pylori Therapy for the Prevention of Metachronous Gastric Cancer." <u>The New England journal of medicine</u> 378 (12): 1085-1095.
Colangeli, R., et al. (2018). "Bacterial Factors That Predict Relapse after Tuberculosis Therapy." <u>The New England journal of medicine</u> 379 (9): 823-833.
Cortese, I., et al. (2019). "Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy." <u>The New England journal of medicine</u> 380 (17): 1597-1605.
Cuervo, G., et al. (2018). "Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection." <u>The New England journal of medicine</u> 378 (26): 2540-2540.

Dalmau, J. and F. Graus (2018). "Antibody-Mediated Encephalitis." <u>The New England journal of medicine</u> 378 (9): 840-851.
Darrow, J. J., et al. (2018). "The FDA Breakthrough-Drug Designation - Four Years of Experience." <u>The New England journal of medicine</u> 378 (15): 1444-1453.
Desjardins, A., et al. (2018). "Recurrent Glioblastoma Treated with Recombinant Poliovirus." <u>The New England journal of medicine</u> 379 (2): 150-161.
Diallo, T., et al. (2018). "Safety and Side Effects of Rifampin versus Isoniazid in Children." <u>The New England journal of medicine</u> 379 (5): 454-463.
Dierickx, D. and T. M. Habermann (2018). "Post-Transplantation Lymphoproliferative Disorders in Adults." <u>The New England journal of medicine</u> 378 (6): 549-562.
Dimopoulos, M. A., et al. (2018). "Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma." <u>The New England journal of medicine</u> 379 (19): 1811-1822.
Dusheiko, G. (2018). "A Shift in Thinking to Reduce Mother-to-Infant Transmission of Hepatitis B." <u>The New England journal of medicine</u> 378 (10): 952-953.
Emu, B., et al. (2018). "Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1." <u>The New England journal of medicine</u> 379 (7): 645-654.
Eyre, D. W., et al. (2018). "A Candida auris Outbreak and Its Control in an Intensive Care Setting." <u>The New England journal of medicine</u> 379 (14): 1322-1331.
Fauci, A. S. and R. W. Eisinger (2018). "PEPFAR - 15 Years and Counting the Lives Saved." <u>The New England journal of medicine</u> 378 (4): 314-316.
Feldmann, H. (2018). "Virus in Semen and the Risk of Sexual Transmission." <u>The New England journal of medicine</u> 378 (15): 1440-1441.
Feller-Kopman, D. and R. Light (2018). "Pleural Disease." <u>The New England journal of medicine</u> 378 (8): 740-751.
Ferreras, E., et al. (2018). "Single-Dose Cholera Vaccine in Response to an Outbreak in Zambia." <u>The New England journal of medicine</u> 378 (6): 577-579.
Fox, G. J., et al. (2018). "Household-Contact Investigation for Detection of Tuberculosis in Vietnam." <u>The New England journal of medicine</u> 378 (3): 221-229.
Fremerey, C. and P. Nenoff (2018). "Tinea Capitis in a Newborn." <u>The New England journal of medicine</u> 378 (21): 2022-2022.
Fuster, D. and J. H. Samet (2018). "Alcohol Use in Patients with Chronic Liver Disease." <u>The New England journal of medicine</u> 379 (13): 1251-1261.

Gates, B. (2018). "Innovation for Pandemics." <u>The New England journal of medicine</u> 378 (22): 2057-2060.
Grosenbach, D. W., et al. (2018). "Oral Tecovirimat for the Treatment of Smallpox." <u>The New England journal of medicine</u> 379 (1): 44-53.
Hayden, F. G., et al. (2018). "Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents." <u>The New England journal of medicine</u> 379 (10): 913-923.
Hoen, B., et al. (2018). "Pregnancy Outcomes after ZIKV Infection in French Territories in the Americas." <u>The New England journal of medicine</u> 378 (11): 985-994.
Hogan, B. (2018). "Stemming Lung Disease?" <u>The New England journal of medicine</u> 378 (25): 2439-2440.
Honein, M. A. (2018). "Recognizing the Global Impact of Zika Virus Infection during Pregnancy." <u>The New England journal of medicine</u> 378 (11): 1055-1056.
Huang, D. T., et al. (2018). "Procalcitonin-Guided Use of Antibiotics for Lower Respiratory Tract Infection." <u>The New England journal of medicine</u> 379 (3): 236-249.
Huang, S. S., et al. (2019). "Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers." <u>The New England journal of medicine</u> 380 (7): 638-650.
Iversen, K., et al. (2019). "Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis." <u>The New England journal of medicine</u> 380 (5): 415-424.
Johnson, J. R. and T. A. Russo (2018). "Acute Pyelonephritis in Adults." <u>The New England journal of medicine</u> 378 (1): 48-59.
Jourdain, G., et al. (2018). "Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B." <u>The New England journal of medicine</u> 378 (10): 911-923.
Joynt Maddox, K. E., et al. (2018). "Evaluation of Medicare's Bundled Payments Initiative for Medical Conditions." <u>The New England journal of medicine</u> 379 (3): 260-269.
Justman, J. E., et al. (2018). "HIV Population Surveys - Bringing Precision to the Global Response." <u>The New England journal of medicine</u> 378 (20): 1859-1861.
Juul, F. E., et al. (2018). "Fecal Microbiota Transplantation for Primary Clostridium difficile Infection." <u>The New England journal of medicine</u> 378 (26): 2535-2536.
Keenan, J. D., et al. (2018). "Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa." <u>The New England journal of medicine</u> 378 (17): 1583-1592.
King, C. L., et al. (2018). "A Trial of a Triple-Drug Treatment for Lymphatic Filariasis." <u>The New England journal of medicine</u> 379 (19): 1801-1810.

Krag, M., et al. (2018). "Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU." <u>The New England journal of medicine</u> 379 (23): 2199-2208.
Kushel, M. (2018). "Hepatitis A Outbreak in California - Addressing the Root Cause." <u>The New England journal of medicine</u> 378 (3): 211-213.
Kwong, J. C., et al. (2018). "Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection." <u>The New England journal of medicine</u> 378 (4): 345-353.
Li, H.-K., et al. (2019). "Oral versus Intravenous Antibiotics for Bone and Joint Infection." <u>The New England journal of medicine</u> 380 (5): 425-436.
Liang, T. J. and J. W. Ward (2018). "Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic." <u>The New England journal of medicine</u> 378 (13): 1169-1171.
Lissauer, D., et al. (2019). "A Randomized Trial of Prophylactic Antibiotics for Miscarriage Surgery." <u>The New England journal of medicine</u> 380 (11): 1012-1021.
Magill, S. S., et al. (2018). "Changes in Prevalence of Health Care-Associated Infections in U.S. Hospitals." <u>The New England journal of medicine</u> 379 (18): 1732-1744.
Malfertheiner, P. (2018). "Helicobacter pylori Treatment for Gastric Cancer Prevention." <u>The New England journal of medicine</u> 378 (12): 1154-1156.
Marcus, J. L., et al. (2019). "Risk Compensation and Clinical Decision Making - The Case of HIV Preexposure Prophylaxis." <u>The New England journal of medicine</u> 380 (6): 510-512.
Marston, H. D., et al. (2018). "Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History." <u>The New England journal of medicine</u> 378 (16): 1469-1472.
Mateos, M.-V., et al. (2018). "Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma." <u>The New England journal of medicine</u> 378 (6): 518-528.
McDermott, D. H., et al. (2019). "Plerixafor for the Treatment of WHIM Syndrome." <u>The New England journal of medicine</u> 380 (2): 163-170.
McKinnell, J. A., et al. (2019). "Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae." <u>The New England journal of medicine</u> 380 (8): 791-793.
Mead, P. S. (2018). "Plague in Madagascar - A Tragic Opportunity for Improving Public Health." <u>The New England journal of medicine</u> 378 (2): 106-108.
Mead, P. S., et al. (2018). "Zika Virus Shedding in Semen of Symptomatic Infected Men." <u>The New England journal of medicine</u> 378 (15): 1377-1385.

Meintjes, G., et al. (2018). "Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS." <u>The New England journal of medicine</u> 379 (20): 1915-1925.
Menzies, D., et al. (2018). "Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults." <u>The New England journal of medicine</u> 379 (5): 440-453.
Mi, M. Y., et al. (2018). "Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome." <u>The New England journal of medicine</u> 379 (9): 884-887.
Molloy, S. F., et al. (2018). "Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa." <u>The New England journal of medicine</u> 378 (11): 1004-1017.
Muftuoglu, M., et al. (2018). "Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy." <u>The New England journal of medicine</u> 379 (15): 1443-1451.
Munster, V. J., et al. (2018). "Outbreaks in a Rapidly Changing Central Africa - Lessons from Ebola." <u>The New England journal of medicine</u> 379 (13): 1198-1201.
Myles, P. S., et al. (2018). "Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery." <u>The New England journal of medicine</u> 378 (24): 2263-2274.
Nemes, E., et al. (2018). "Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination." <u>The New England journal of medicine</u> 379 (2): 138-149.
Nunn, A. J., et al. (2019). "A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis." <u>The New England journal of medicine</u> 380 (13): 1201-1213.
O'Riordan, W., et al. (2019). "Omadacycline for Acute Bacterial Skin and Skin-Structure Infections." <u>The New England journal of medicine</u> 380 (6): 528-538.
Opel, D. J., et al. (2018). "Vaccination without Litigation - Addressing Religious Objections to Hospital Influenza-Vaccination Mandates." <u>The New England journal of medicine</u> 378 (9): 785-788.
Oshima, K., et al. (2018). "Letermovir Prophylaxis for Cytomegalovirus." <u>The New England journal of medicine</u> 378 (10): 964-964.
Paules, C. I., et al. (2018). "Tickborne Diseases - Confronting a Growing Threat." <u>The New England journal of medicine</u> 379 (8): 701-703.
Paules, C. I., et al. (2018). "Chasing Seasonal Influenza - The Need for a Universal Influenza Vaccine." <u>The New England journal of medicine</u> 378 (1): 7-9.
Paz-Bailey, G., et al. (2018). "Persistence of Zika Virus in Body Fluids - Final Report." <u>The New England journal of medicine</u> 379 (13): 1234-1243.

Rosenbaum, L. (2018). "Trolleyology and the Dengue Vaccine Dilemma." <u>The New England journal of medicine</u> 379 (4): 305-307.
Rough, K., et al. (2018). "Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine." <u>The New England journal of medicine</u> 378 (17): 1593-1603.
Saa, P., et al. (2018). "Investigational Testing for Zika Virus among U.S. Blood Donors." <u>The New England journal of medicine</u> 378 (19): 1778-1788.
Sato, T., et al. (2018). "Mogamulizumab (Anti-CCR4) in HTLV-1-Associated Myelopathy." <u>The New England journal of medicine</u> 378 (6): 529-538.
Shah, R., et al. (2018). "Circulating Extracellular Vesicles in Human Disease." <u>The New England journal of medicine</u> 379 (10): 958-966.
Shinde, V., et al. (2018). "Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine." <u>The New England journal of medicine</u> 378 (24): 2346-2348.
Siddle, K. J., et al. (2018). "Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018." <u>The New England journal of medicine</u> 379 (18): 1745-1753.
Sridhar, S., et al. (2018). "Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy." <u>The New England journal of medicine</u> 379 (4): 327-340.
Stets, R., et al. (2019). "Omadacycline for Community-Acquired Bacterial Pneumonia." <u>The New England journal of medicine</u> 380 (6): 517-527.
Suffredini, A. F. (2018). "A Role for Hydrocortisone Therapy in Septic Shock?" <u>The New England journal of medicine</u> 378 (9): 860-861.
Sullivan, K. M., et al. (2018). "Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma." <u>The New England journal of medicine</u> 378 (1): 35-47.
Swindells, S., et al. (2019). "One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis." <u>The New England journal of medicine</u> 380 (11): 1001-1011.
Tate, J. E., et al. (2018). "Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa." <u>The New England journal of medicine</u> 378 (16): 1521-1528.
Taylor, S. N., et al. (2018). "Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea." <u>The New England journal of medicine</u> 379 (19): 1835-1845.
Terrault, N. A., et al. (2018). "Tenofovir to Prevent Perinatal Transmission of Hepatitis B." <u>The New England journal of medicine</u> 378 (24): 2348-2349.

Tyler, K. L. (2018). "Acute Viral Encephalitis." <u>The New England journal of medicine</u> 379 (6): 557-566.
Van Der Meeren, O., et al. (2018). "Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis." <u>The New England journal of medicine</u> 379 (17): 1621-1634.
Venkatesh, B., et al. (2018). "Adjunctive Glucocorticoid Therapy in Patients with Septic Shock." <u>The New England journal of medicine</u> 378 (9): 797-808.
Wagenlehner, F. M. E., et al. (2019). "Once-Daily Plazomicin for Complicated Urinary Tract Infections." <u>The New England journal of medicine</u> 380 (8): 729-740.
Woolley, A. E., et al. (2019). "Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients." <u>The New England journal of medicine</u> 380 (17): 1606-1617.
Yarchoan, R. and T. S. Uldrick (2018). "HIV-Associated Cancers and Related Diseases." <u>The New England journal of medicine</u> 378 (11): 1029-1041.
Zeuzem, S., et al. (2018). "Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection." <u>The New England journal of medicine</u> 378 (4): 354-369.
Achee, N. L., et al. (2019). "Alternative strategies for mosquito-borne arbovirus control." <u>PLoS neglected tropical diseases</u> 13 (1): e0006822-e0006822.
Aktar, A., et al. (2018). "Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh." <u>PLoS neglected tropical diseases</u> 12 (4): e0006399-e0006399.
Akuffo, H., et al. (2018). "New insights into leishmaniasis in the immunosuppressed." <u>PLoS neglected tropical diseases</u> 12 (5): e0006375-e0006375.
Asad, S., et al. (2018). "Suppression of the pelo protein by Wolbachia and its effect on dengue virus in Aedes aegypti." <u>PLoS neglected tropical diseases</u> 12 (4): e0006405-e0006405.
Asbjornsdottir, K. H., et al. (2018). "Assessing the feasibility of interrupting the transmission of soil-transmitted helminths through mass drug administration: The DeWorm3 cluster randomized trial protocol." <u>PLoS neglected tropical diseases</u> 12 (1): e0006166-e0006166.
Beeres, D. T., et al. (2018). "Efficacy of ivermectin mass-drug administration to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 - March 2016." <u>PLoS neglected tropical diseases</u> 12 (5): e0006401-e0006401.
Bisanzio, D., et al. (2018). "Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico." <u>PLoS neglected tropical diseases</u> 12 (3): e0006298-e0006298.

Britto, C. D., et al. (2018). "Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy." <u>PLoS neglected tropical diseases</u> 12 (4): e0006408-e0006408.
Buonfrate, D., et al. (2018). "Accuracy of molecular biology techniques for the diagnosis of Strongyloides stercoralis infection-A systematic review and meta-analysis." <u>PLoS neglected tropical diseases</u> 12 (2): e0006229-e0006229.
Bwire, G., et al. (2018). "Molecular characterization of Vibrio cholerae responsible for cholera epidemics in Uganda by PCR, MLVA and WGS." <u>PLoS neglected tropical diseases</u> 12 (6): e0006492-e0006492.
Calvez, E., et al. (2018). "Zika virus outbreak in the Pacific: Vector competence of regional vectors." <u>PLoS neglected tropical diseases</u> 12 (7): e0006637-e0006637.
Camicia, F., et al. (2018). "Unique pharmacological properties of serotonergic G-protein coupled receptors from cestodes." <u>PLoS neglected tropical diseases</u> 12 (2): e0006267-e0006267.
Cantoni, D. and J. S. Rossman (2018). "Ebolaviruses: New roles for old proteins." <u>PLoS neglected tropical diseases</u> 12 (5): e0006349-e0006349.
Carbajosa, S., et al. (2018). "L-arginine supplementation reduces mortality and improves disease outcome in mice infected with Trypanosoma cruzi." <u>PLoS neglected tropical diseases</u> 12 (1): e0006179-e0006179.
Cardoso, C. S., et al. (2018). "Beneficial effects of benznidazole in Chagas disease: NIH SaMi-Trop cohort study." <u>PLoS neglected tropical diseases</u> 12 (11): e0006814-e0006814.
Chatterjee, M., et al. (2018). "Polymorphisms in voltage-gated sodium channel gene and susceptibility of Aedes albopictus to insecticides in three districts of northern West Bengal, India." <u>PLoS neglected tropical diseases</u> 12 (1): e0006192-e0006192.
Coffey, P. M., et al. (2018). "The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review." <u>PLoS neglected tropical diseases</u> 12 (6): e0006577-e0006577.
Colombe, S., et al. (2018). "Impact of schistosome infection on long-term HIV/AIDS outcomes." <u>PLoS neglected tropical diseases</u> 12 (7): e0006613-e0006613.
Contopoulos-Ioannidis, D., et al. (2018). "Mother-to-child transmission of Chikungunya virus: A systematic review and meta-analysis." <u>PLoS neglected tropical diseases</u> 12 (6): e0006510-e0006510.
Converse, P. J., et al. (2018). "Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer." <u>PLoS neglected tropical diseases</u> 12 (8): e0006728-e0006728.
Costa, F. C., et al. (2018). "Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping." <u>PLoS neglected tropical diseases</u> 12 (4): e0006388-e0006388.

Crispim, M., et al. (2018). "The glutamine synthetase of <i>Trypanosoma cruzi</i> is required for its resistance to ammonium accumulation and evasion of the parasitophorous vacuole during host-cell infection." <u>PLoS neglected tropical diseases</u> 12 (1): e0006170-e0006170.
da Silva, M. B., et al. (2018). "Evidence of zoonotic leprosy in Para, Brazilian Amazon, and risks associated with human contact or consumption of armadillos." <u>PLoS neglected tropical diseases</u> 12 (6): e0006532-e0006532.
Delea, M. G., et al. (2018). "Interventions to maximize facial cleanliness and achieve environmental improvement for trachoma elimination: A review of the grey literature." <u>PLoS neglected tropical diseases</u> 12 (1): e0006178-e0006178.
Deribe, K., et al. (2018). "Mapping the geographical distribution of podoconiosis in Cameroon using parasitological, serological, and clinical evidence to exclude other causes of lymphedema." <u>PLoS neglected tropical diseases</u> 12 (1): e0006126-e0006126.
Deribe, K., et al. (2018). "Global epidemiology of podoconiosis: A systematic review." <u>PLoS neglected tropical diseases</u> 12 (3): e0006324-e0006324.
Eddaikra, N., et al. (2018). "Antimony susceptibility of <i>Leishmania</i> isolates collected over a 30-year period in Algeria." <u>PLoS neglected tropical diseases</u> 12 (3): e0006310-e0006310.
El Hamzaoui, B., et al. (2018). "Detection of <i>Bartonella</i> spp. in fleas by MALDI-TOF MS." <u>PLoS neglected tropical diseases</u> 12 (2): e0006189-e0006189.
Engelman, D., et al. (2018). "Consensus criteria for the diagnosis of scabies: A Delphi study of international experts." <u>PLoS neglected tropical diseases</u> 12 (5): e0006549-e0006549.
Fornace, K. M., et al. (2018). "Exposure and infection to <i>Plasmodium knowlesi</i> in case study communities in Northern Sabah, Malaysia and Palawan, The Philippines." <u>PLoS neglected tropical diseases</u> 12 (6): e0006432-e0006432.
Francois, R., et al. (2018). "The other <i>Campylobacters</i> : Not innocent bystanders in endemic diarrhea and dysentery in children in low-income settings." <u>PLoS neglected tropical diseases</u> 12 (2): e0006200-e0006200.
Freire de Carvalho, M., et al. (2018). "Rabies in the Americas: 1998-2014." <u>PLoS neglected tropical diseases</u> 12 (3): e0006271-e0006271.
Fritzell, C., et al. (2018). "Current challenges and implications for dengue, chikungunya and Zika seroprevalence studies worldwide: A scoping review." <u>PLoS neglected tropical diseases</u> 12 (7): e0006533-e0006533.
Garcia, G. d. A., et al. (2018). "The impact of insecticide applications on the dynamics of resistance: The case of four <i>Aedes aegypti</i> populations from different Brazilian regions." <u>PLoS neglected tropical diseases</u> 12 (2): e0006227-e0006227.
Garn, J. V., et al. (2018). "Sanitation and water supply coverage thresholds associated with active trachoma: Modeling cross-sectional data from 13 countries." <u>PLoS neglected tropical diseases</u> 12 (1): e0006110-e0006110.
Gass, K. M. (2018). "Rethinking the serological threshold for onchocerciasis elimination." <u>PLoS neglected tropical diseases</u> 12 (3):

e0006249-e0006249.

Gunaratne, G. S., et al. (2018). "Activation of host transient receptor potential (TRP) channels by praziquantel stereoisomers." PLoS neglected tropical diseases **12**(4): e0006420-e0006420.

Hantrakun, V., et al. (2018). "Presence of *B. thailandensis* and *B. thailandensis* expressing *B. pseudomallei*-like capsular polysaccharide in Thailand, and their associations with serological response to *B. pseudomallei*." PLoS neglected tropical diseases **12**(1): e0006193-e0006193.

Harischandra, H., et al. (2018). "Profiling extracellular vesicle release by the filarial nematode *Brugia malayi* reveals sex-specific differences in cargo and a sensitivity to ivermectin." PLoS neglected tropical diseases **12**(4): e0006438-e0006438.

Harper, K. M., et al. (2018). "Environmental enteric dysfunction pathways and child stunting: A systematic review." PLoS neglected tropical diseases **12**(1): e0006205-e0006205.

He, J., et al. (2018). "Spatiotemporal variation of the association between climate dynamics and HFRS outbreaks in Eastern China during 2005-2016 and its geographic determinants." PLoS neglected tropical diseases **12**(6): e0006554-e0006554.

Honap, T. P., et al. (2018). "Mycobacterium leprae genomes from naturally infected nonhuman primates." PLoS neglected tropical diseases **12**(1): e0006190-e0006190.

Hotez, P. J., et al. (2018). "'Rapid impact' 10 years after: The first 'decade' (2006-2016) of integrated neglected tropical disease control." PLoS neglected tropical diseases **12**(5): e0006137-e0006137.

Huber, J. H., et al. (2018). "Seasonal temperature variation influences climate suitability for dengue, chikungunya, and Zika transmission." PLoS neglected tropical diseases **12**(5): e0006451-e0006451.

Islam, K., et al. (2018). "Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type *Vibrio cholerae* O1 El Tor Inaba in North American volunteers." PLoS neglected tropical diseases **12**(4): e0006376-e0006376.

Karasartova, D., et al. (2018). "Bacterial and protozoal pathogens found in ticks collected from humans in Corum province of Turkey." PLoS neglected tropical diseases **12**(4): e0006395-e0006395.

Koishi, A. C., et al. (2018). "Development and evaluation of a novel high-throughput image-based fluorescent neutralization test for detection of Zika virus infection." PLoS neglected tropical diseases **12**(3): e0006342-e0006342.

Krolewiecki, A. J., et al. (2018). "Transrenal DNA-based diagnosis of *Strongyloides stercoralis* (Grassi, 1879) infection: Bayesian latent class modeling of test accuracy." PLoS neglected tropical diseases **12**(6): e0006550-e0006550.

Kuo, Y.-P., et al. (2018). "Establishment of a mouse model for the complete mosquito-mediated transmission cycle of Zika virus." PLoS neglected tropical diseases **12**(4): e0006417-e0006417.

Leite, B. M. M., et al. (2018). "The mass use of deltamethrin collars to control and prevent canine visceral leishmaniasis: A field effectiveness study in a highly endemic area." <u>PLoS neglected tropical diseases</u> 12 (5): e0006496-e0006496.
Lim, M. D., et al. (2018). "Diagnostic tools for soil-transmitted helminths control and elimination programs: A pathway for diagnostic product development." <u>PLoS neglected tropical diseases</u> 12 (3): e0006213-e0006213.
Lim, W., et al. (2018). "Addressing the most neglected diseases through an open research model: The discovery of fenarimols as novel drug candidates for eumycetoma." <u>PLoS neglected tropical diseases</u> 12 (4): e0006437-e0006437.
Lima, I. D., et al. (2018). "Changing demographics of visceral leishmaniasis in northeast Brazil: Lessons for the future." <u>PLoS neglected tropical diseases</u> 12 (3): e0006164-e0006164.
Lindholz, C. G., et al. (2018). "Study of diagnostic accuracy of Helmintex, Kato-Katz, and POC-CCA methods for diagnosing intestinal schistosomiasis in Candeal, a low intensity transmission area in northeastern Brazil." <u>PLoS neglected tropical diseases</u> 12 (3): e0006274-e0006274.
Lockwood, D. N. J., et al. (2018). "Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention." <u>PLoS neglected tropical diseases</u> 12 (6): e0006403-e0006403.
Lopes-Bezerra, L. M., et al. (2018). "Cell walls of the dimorphic fungal pathogens <i>Sporothrix schenckii</i> and <i>Sporothrix brasiliensis</i> exhibit bilaminar structures and sloughing of extensive and intact layers." <u>PLoS neglected tropical diseases</u> 12 (3): e0006169-e0006169.
Lopez, L., et al. (2018). "A phase II study to evaluate the safety and efficacy of topical 3% amphotericin B cream (Anfoleish) for the treatment of uncomplicated cutaneous leishmaniasis in Colombia." <u>PLoS neglected tropical diseases</u> 12 (7): e0006653-e0006653.
Lumbala, C., et al. (2018). "Prospective evaluation of a rapid diagnostic test for <i>Trypanosoma brucei</i> gambiense infection developed using recombinant antigens." <u>PLoS neglected tropical diseases</u> 12 (3): e0006386-e0006386.
Main, B. J., et al. (2018). "Vector competence of <i>Aedes aegypti</i> , <i>Culex tarsalis</i> , and <i>Culex quinquefasciatus</i> from California for Zika virus." <u>PLoS neglected tropical diseases</u> 12 (6): e0006524-e0006524.
Martinez-Perez, A., et al. (2018). "Management of severe strongyloidiasis attended at reference centers in Spain." <u>PLoS neglected tropical diseases</u> 12 (2): e0006272-e0006272.
Martins-Melo, F. R., et al. (2018). "The burden of Neglected Tropical Diseases in Brazil, 1990-2016: A subnational analysis from the Global Burden of Disease Study 2016." <u>PLoS neglected tropical diseases</u> 12 (6): e0006559-e0006559.
Mateer, E. J., et al. (2018). "Lassa fever-induced sensorineural hearing loss: A neglected public health and social burden." <u>PLoS neglected tropical diseases</u> 12 (2): e0006187-e0006187.
McDonald, E. M., et al. (2018). "Infection of epididymal epithelial cells and leukocytes drives seminal shedding of Zika virus in a mouse model." <u>PLoS neglected tropical diseases</u> 12 (8): e0006691-e0006691.

Mehta, R., et al. (2018). "The spectrum of neurological disease associated with Zika and chikungunya viruses in adults in Rio de Janeiro, Brazil: A case series." <u>PLoS neglected tropical diseases</u> 12 (2): e0006212-e0006212.
Moretti, R., et al. (2018). "Combining Wolbachia-induced sterility and virus protection to fight Aedes albopictus-borne viruses." <u>PLoS neglected tropical diseases</u> 12 (7): e0006626-e0006626.
Mukhtar, M., et al. (2018). "Sensitive and less invasive confirmatory diagnosis of visceral leishmaniasis in Sudan using loop-mediated isothermal amplification (LAMP)." <u>PLoS neglected tropical diseases</u> 12 (2): e0006264-e0006264.
Munoz, J., et al. (2018). "Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers." <u>PLoS neglected tropical diseases</u> 12 (1): e0006020-e0006020.
Nyakarahuka, L., et al. (2018). "Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale district in Southwestern Uganda, 2016." <u>PLoS neglected tropical diseases</u> 12 (5): e0006412-e0006412.
Oladele, R. O., et al. (2018). "Histoplasmosis in Africa: An emerging or a neglected disease?" <u>PLoS neglected tropical diseases</u> 12 (1): e0006046-e0006046.
Oliveira, W. J., et al. (2018). "Evaluation of diagnostic methods for the detection of intestinal schistosomiasis in endemic areas with low parasite loads: Saline gradient, Helmintex, Kato-Katz and rapid urine test." <u>PLoS neglected tropical diseases</u> 12 (2): e0006232-e0006232.
Olliaro, P., et al. (2018). "Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation." <u>PLoS neglected tropical diseases</u> 12 (1): e0006141-e0006141.
Openshaw, J. J., et al. (2018). "Prevalence and risk factors for Taenia solium cysticercosis in school-aged children: A school based study in western Sichuan, People's Republic of China." <u>PLoS neglected tropical diseases</u> 12 (5): e0006465-e0006465.
Palmeirim, M. S., et al. (2018). "Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: A systematic review, meta-analysis and individual patient data analysis." <u>PLoS neglected tropical diseases</u> 12 (4): e0006458-e0006458.
Papaiakovou, M., et al. (2018). "A comparative analysis of preservation techniques for the optimal molecular detection of hookworm DNA in a human fecal specimen." <u>PLoS neglected tropical diseases</u> 12 (1): e0006130-e0006130.
Paquin-Proulx, D., et al. (2018). "MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection." <u>PLoS neglected tropical diseases</u> 12 (1): e0006154-e0006154.
Perez-Anton, E., et al. (2018). "Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients." <u>PLoS neglected tropical diseases</u> 12 (5): e0006480-e0006480.
Rabiee, M. H., et al. (2018). "Rodent-borne diseases and their public health importance in Iran." <u>PLoS neglected tropical diseases</u> 12 (4): e0006256-e0006256.

Rafferty, P., et al. (2018). "Establishing Ebola Virus Disease (EVD) diagnostics using GeneXpert technology at a mobile laboratory in Liberia: Impact on outbreak response, case management and laboratory systems strengthening." <u>PLoS neglected tropical diseases</u> 12 (1): e0006135-e0006135.
Ramasamy, V., et al. (2018). "A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice." <u>PLoS neglected tropical diseases</u> 12 (1): e0006191-e0006191.
Recht, J., et al. (2018). "Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries." <u>PLoS neglected tropical diseases</u> 12 (4): e0006230-e0006230.
Rezende, I. M. d., et al. (2018). "Persistence of Yellow fever virus outside the Amazon Basin, causing epidemics in Southeast Brazil, from 2016 to 2018." <u>PLoS neglected tropical diseases</u> 12 (6): e0006538-e0006538.
Rojas, L. Z., et al. (2018). "Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis." <u>PLoS neglected tropical diseases</u> 12 (6): e0006567-e0006567.
Saba Villarroel, P. M., et al. (2018). "Zika virus epidemiology in Bolivia: A seroprevalence study in volunteer blood donors." <u>PLoS neglected tropical diseases</u> 12 (3): e0006239-e0006239.
Sachetto, A. T. A., et al. (2018). "Rutin (quercetin-3-rutinoside) modulates the hemostatic disturbances and redox imbalance induced by Bothrops jararaca snake venom in mice." <u>PLoS neglected tropical diseases</u> 12 (10): e0006774-e0006774.
Salvo, M. A., et al. (2018). "Zika virus like particles elicit protective antibodies in mice." <u>PLoS neglected tropical diseases</u> 12 (2): e0006210-e0006210.
Saraswati, K., et al. (2018). "Scrub typhus point-of-care testing: A systematic review and meta-analysis." <u>PLoS neglected tropical diseases</u> 12 (3): e0006330-e0006330.
Sato, M. O., et al. (2018). "Taenia solium, Taenia saginata, Taenia asiatica, their hybrids and other helminthic infections occurring in a neglected tropical diseases' highly endemic area in Lao PDR." <u>PLoS neglected tropical diseases</u> 12 (2): e0006260-e0006260.
Schioldann, E., et al. (2018). "Why snakebite patients in Myanmar seek traditional healers despite availability of biomedical care at hospitals? Community perspectives on reasons." <u>PLoS neglected tropical diseases</u> 12 (2): e0006299-e0006299.
Sengyee, S., et al. (2018). "Comprehensive analysis of clinical Burkholderia pseudomallei isolates demonstrates conservation of unique lipid A structure and TLR4-dependent innate immune activation." <u>PLoS neglected tropical diseases</u> 12 (2): e0006287-e0006287.
Silver, Z. A., et al. (2018). "Geographical distribution of soil transmitted helminths and the effects of community type in South Asia and South East Asia - A systematic review." <u>PLoS neglected tropical diseases</u> 12 (1): e0006153-e0006153.
Specht, S., et al. (2018). "Combinations of registered drugs reduce treatment times required to deplete Wolbachia in the

Litomosoides sigmodontis mouse model." <u>PLoS neglected tropical diseases</u> 12 (1): e0006116-e0006116.
Steketee, P. C., et al. (2018). "Benzoxaborole treatment perturbs S-adenosyl-L-methionine metabolism in Trypanosoma brucei." <u>PLoS neglected tropical diseases</u> 12 (5): e0006450-e0006450.
Sun, G. G., et al. (2018). "Characterization of a Trichinella spiralis putative serine protease. Study of its potential as sero-diagnostic tool." <u>PLoS neglected tropical diseases</u> 12 (5): e0006485-e0006485.
Terhoch, C. B., et al. (2018). "Clinical findings and prognosis of patients hospitalized for acute decompensated heart failure: Analysis of the influence of Chagas etiology and ventricular function." <u>PLoS neglected tropical diseases</u> 12 (2): e0006207-e0006207.
Tsai, J.-J., et al. (2018). "Seroprevalence of dengue virus in two districts of Kaohsiung City after the largest dengue outbreak in Taiwan since World War II." <u>PLoS neglected tropical diseases</u> 12 (10): e0006879-e0006879.
Villanueva-Lizama, L. E., et al. (2018). "Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico." <u>PLoS neglected tropical diseases</u> 12 (1): e0006240-e0006240.
Wangrangsimaikul, T., et al. (2018). "Causes of acute undifferentiated fever and the utility of biomarkers in Chiangrai, northern Thailand." <u>PLoS neglected tropical diseases</u> 12 (5): e0006477-e0006477.
Watson, J., et al. (2018). "Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria." <u>PLoS neglected tropical diseases</u> 12 (4): e0006440-e0006440.
White, S. K., et al. (2018). "Detection and phylogenetic characterization of arbovirus dual-infections among persons during a chikungunya fever outbreak, Haiti 2014." <u>PLoS neglected tropical diseases</u> 12 (5): e0006505-e0006505.
Zivcec, M., et al. (2018). "Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge." <u>PLoS neglected tropical diseases</u> 12 (7): e0006628-e0006628.
Ahmed, H., et al. (2018). "Incidence and antibiotic prescribing for clinically diagnosed urinary tract infection in older adults in UK primary care, 2004-2014." <u>PLoS One</u> 13 (1): e0190521-e0190521.
Ahn, K. B., et al. (2018). "Lactobacillus plantarum lipoteichoic acid inhibits biofilm formation of Streptococcus mutans." <u>PLoS One</u> 13 (2): e0192694-e0192694.
Babii, C., et al. (2018). "A novel synthetic flavonoid with potent antibacterial properties: In vitro activity and proposed mode of action." <u>PLoS One</u> 13 (4): e0194898-e0194898.
Bamorovat, M., et al. (2018). "Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran." <u>PLoS One</u> 13 (2): e0192236-e0192236.
Bankier, C., et al. (2018). "A comparison of methods to assess the antimicrobial activity of nanoparticle combinations on bacterial cells." <u>PLoS One</u> 13 (2): e0192093-e0192093.

Bastiaens, G. J. H., et al. (2018). "Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials." <u>PLoS One</u> 13 (1): e0190272-e0190272.
Bolotin, S., et al. (2018). "Population-based estimate of hepatitis C virus prevalence in Ontario, Canada." <u>PLoS One</u> 13 (1): e0191184-e0191184.
Borges, A. L. V., et al. (2018). "Women's reproductive health knowledge, attitudes and practices in relation to the Zika virus outbreak in northeast Brazil." <u>PLoS One</u> 13 (1): e0190024-e0190024.
Bouzroud, S., et al. (2018). "Auxin Response Factors (ARFs) are potential mediators of auxin action in tomato response to biotic and abiotic stress (<i>Solanum lycopersicum</i>)." <u>PLoS One</u> 13 (2): e0193517-e0193517.
Brunello, G., et al. (2018). "Biocompatibility and antibacterial properties of zirconium nitride coating on titanium abutments: An in vitro study." <u>PLoS One</u> 13 (6): e0199591-e0199591.
Callendret, B., et al. (2018). "A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates." <u>PLoS One</u> 13 (2): e0192312-e0192312.
Campos, M. B., et al. (2018). "Toll-like receptors 2, 4, and 9 expressions over the entire clinical and immunopathological spectrum of American cutaneous leishmaniasis due to <i>Leishmania</i> (V.) <i>braziliensis</i> and <i>Leishmania</i> (L.) <i>amazonensis</i> ." <u>PLoS One</u> 13 (3): e0194383-e0194383.
Charre, C., et al. (2018). "Hepatitis C virus spread from HIV-positive to HIV-negative men who have sex with men." <u>PLoS One</u> 13 (1): e0190340-e0190340.
Chen, L., et al. (2018). "A comprehensive understanding of the biocontrol potential of <i>Bacillus velezensis</i> LM2303 against <i>Fusarium</i> head blight." <u>PLoS One</u> 13 (6): e0198560-e0198560.
Ciesinski, L., et al. (2018). "High dietary zinc feeding promotes persistence of multi-resistant <i>E. coli</i> in the swine gut." <u>PLoS One</u> 13 (1): e0191660-e0191660.
Dee, S. A., et al. (2018). "Survival of viral pathogens in animal feed ingredients under transboundary shipping models." <u>PLoS One</u> 13 (3): e0194509-e0194509.
Degli Esposti, M., et al. (2018). "iCoverT: A rich data source on the incidence of child maltreatment over time in England and Wales." <u>PLoS One</u> 13 (8): e0201223-e0201223.
Demsiss, W., et al. (2018). "Hepatitis B and C: Seroprevalence, knowledge, practice and associated factors among medicine and health science students in Northeast Ethiopia." <u>PLoS One</u> 13 (5): e0196539-e0196539.
Dowarah, R., et al. (2018). "Selection and characterization of probiotic lactic acid bacteria and its impact on growth, nutrient digestibility, health and antioxidant status in weaned piglets." <u>PLoS One</u> 13 (3): e0192978-e0192978.

Dutta, S., et al. (2018). "Amelioration of CCl4 induced liver injury in swiss albino mice by antioxidant rich leaf extract of Croton bonplandianus Baill." <u>PLoS One</u> 13 (4): e0196411-e0196411.
Farras, M., et al. (2018). "Characterizing the metabolic phenotype of intestinal villus blunting in Zambian children with severe acute malnutrition and persistent diarrhea." <u>PLoS One</u> 13 (3): e0192092-e0192092.
Ferdin, J., et al. (2018). "Viral protein Nef is detected in plasma of half of HIV-infected adults with undetectable plasma HIV RNA." <u>PLoS One</u> 13 (1): e0191613-e0191613.
Ferrer, M., et al. (2018). "Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients." <u>PLoS One</u> 13 (1): e0191721-e0191721.
Geldenhuys, M., et al. (2018). "A metagenomic viral discovery approach identifies potential zoonotic and novel mammalian viruses in Neoromicia bats within South Africa." <u>PLoS One</u> 13 (3): e0194527-e0194527.
Glasset, B., et al. (2018). "Bacillus cereus, a serious cause of nosocomial infections: Epidemiologic and genetic survey." <u>PLoS One</u> 13 (5): e0194346-e0194346.
Goethert, H. K., et al. (2018). "Zoonotic Babesia microti in the northeastern U.S.: Evidence for the expansion of a specific parasite lineage." <u>PLoS One</u> 13 (3): e0193837-e0193837.
Green, B. N., et al. (2018). "A scoping review of biopsychosocial risk factors and co-morbidities for common spinal disorders." <u>PLoS One</u> 13 (6): e0197987-e0197987.
Gruda, M. C., et al. (2018). "Broad adsorption of sepsis-related PAMP and DAMP molecules, mycotoxins, and cytokines from whole blood using CytoSorb sorbent porous polymer beads." <u>PLoS One</u> 13 (1): e0191676-e0191676.
Hall, M. T., et al. (2018). "Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: Example from Australia." <u>PLoS One</u> 13 (2): e0185332-e0185332.
Hamad, I., et al. (2018). "Metabarcoding analysis of eukaryotic microbiota in the gut of HIV-infected patients." <u>PLoS One</u> 13 (1): e0191913-e0191913.
Hamasuna, R., et al. (2018). "Mutations in ParC and GyrA of moxifloxacin-resistant and susceptible Mycoplasma genitalium strains." <u>PLoS One</u> 13 (6): e0198355-e0198355.
Han, S. S., et al. (2018). "Deep neural networks show an equivalent and often superior performance to dermatologists in onychomycosis diagnosis: Automatic construction of onychomycosis datasets by region-based convolutional deep neural network." <u>PLoS One</u> 13 (1): e0191493-e0191493.
Hassani, A., et al. (2018). "Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells." <u>PLoS One</u> 13 (2): e0192109-e0192109.
Hermansson, R. S., et al. (2018). "HPV prevalence and HPV-related dysplasia in elderly women." <u>PLoS One</u> 13 (1): e0189300-

e0189300.
Huang, T.-S., et al. (2018). "Rapid identification of mycobacteria from positive MGIT broths of primary cultures by MALDI-TOF mass spectrometry." <u>PLoS One</u> 13 (2): e0192291-e0192291.
Jajou, R., et al. (2018). "Epidemiological links between tuberculosis cases identified twice as efficiently by whole genome sequencing than conventional molecular typing: A population-based study." <u>PLoS One</u> 13 (4): e0195413-e0195413.
Jarosz-Biej, M., et al. (2018). "M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma." <u>PLoS One</u> 13 (1): e0191012-e0191012.
Jeong, J., et al. (2018). "Pathogen Box screening for hit identification against Mycobacterium abscessus." <u>PLoS One</u> 13 (4): e0195595-e0195595.
Kamminga, S., et al. (2018). "Seroprevalence of fourteen human polyomaviruses determined in blood donors." <u>PLoS One</u> 13 (10): e0206273-e0206273.
Katchanov, J., et al. (2018). "Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel beta-lactam/beta-lactamase inhibitor combinations." <u>PLoS One</u> 13 (4): e0195757-e0195757.
Kawakami, R., et al. (2018). "Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice." <u>PLoS One</u> 13 (2): e0191895-e0191895.
Khajuria, C., et al. (2018). "Development and characterization of the first dsRNA-resistant insect population from western corn rootworm, <i>Diabrotica virgifera virgifera</i> LeConte." <u>PLoS One</u> 13 (5): e0197059-e0197059.
Khan, A., et al. (2018). "Computational identification, characterization and validation of potential antigenic peptide vaccines from hrHPVs E6 proteins using immunoinformatics and computational systems biology approaches." <u>PLoS One</u> 13 (5): e0196484-e0196484.
Khan, J., et al. (2018). "The changing epidemiological pattern of Dengue in Swat, Khyber Pakhtunkhwa." <u>PLoS One</u> 13 (4): e0195706-e0195706.
Khan, Z., et al. (2018). "Increasing prevalence, molecular characterization and antifungal drug susceptibility of serial <i>Candida auris</i> isolates in Kuwait." <u>PLoS One</u> 13 (4): e0195743-e0195743.
Komaki-Yasuda, K., et al. (2018). "A novel PCR-based system for the detection of four species of human malaria parasites and <i>Plasmodium knowlesi</i> ." <u>PLoS One</u> 13 (1): e0191886-e0191886.
Krause, P. J., et al. (2018). "Human <i>Borrelia miyamotoi</i> infection in California: Serodiagnosis is complicated by multiple endemic <i>Borrelia</i> species." <u>PLoS One</u> 13 (2): e0191725-e0191725.

Kuehn, R., et al. (2018). "Identification of a piscine reovirus-related pathogen in proliferative darkening syndrome (PDS) infected brown trout (<i>Salmo trutta fario</i>) using a next-generation technology detection pipeline." <u>PLoS One</u> 13 (10): e0206164-e0206164.
Kyrklund, M., et al. (2018). "Immunization with gingipain A hemagglutinin domain of <i>Porphyromonas gingivalis</i> induces IgM antibodies binding to malondialdehyde-acetaldehyde modified low-density lipoprotein." <u>PLoS One</u> 13 (1): e0191216-e0191216.
Larpin, Y., et al. (2018). "In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria." <u>PLoS One</u> 13 (2): e0192507-e0192507.
Lee, M., et al. (2018). "Current <i>Helicobacter pylori</i> infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study." <u>PLoS One</u> 13 (3): e0193646-e0193646.
Lee, Y.-T., et al. (2018). "Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses." <u>PLoS One</u> 13 (1): e0190868-e0190868.
Liao, Y.-T., et al. (2018). "Investigation of prevalence of free Shiga toxin-producing <i>Escherichia coli</i> (STEC)-specific bacteriophages and its correlation with STEC bacterial hosts in a produce-growing area in Salinas, California." <u>PLoS One</u> 13 (1): e0190534-e0190534.
Lima, S. F., et al. (2018). "Evaluation of milk sample fractions for characterization of milk microbiota from healthy and clinical mastitis cows." <u>PLoS One</u> 13 (3): e0193671-e0193671.
Lyte, M. and D. R. Brown (2018). "Evidence for PMAT- and OCT-like biogenic amine transporters in a probiotic strain of <i>Lactobacillus</i> : Implications for interkingdom communication within the microbiota-gut-brain axis." <u>PLoS One</u> 13 (1): e0191037-e0191037.
Mashiba, T., et al. (2018). "Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group." <u>PLoS One</u> 13 (4): e0194704-e0194704.
Matveev, A. L., et al. (2018). "Novel mouse monoclonal antibodies specifically recognize <i>Aspergillus fumigatus</i> galactomannan." <u>PLoS One</u> 13 (3): e0193938-e0193938.
Mayfield, A. B., et al. (2018). "The proteomic response of the reef coral <i>Pocillopora acuta</i> to experimentally elevated temperatures." <u>PLoS One</u> 13 (1): e0192001-e0192001.
Miner, C. M., et al. (2018). "Large-scale impacts of sea star wasting disease (SSWD) on intertidal sea stars and implications for recovery." <u>PLoS One</u> 13 (3): e0192870-e0192870.
Mohr, E. L., et al. (2018). "Ocular and uteroplacental pathology in a macaque pregnancy with congenital Zika virus infection." <u>PLoS One</u> 13 (1): e0190617-e0190617.
Napolitano, F., et al. (2018). "Primary care pediatricians' attitudes and practice towards HPV vaccination: A nationwide survey in

Italy." PLoS One 13(3) : e0194920-e0194920.
Nehme, H., et al. (2018). "Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity." PLoS One 13(1) : e0189950-e0189950.
Newman, L. P., et al. (2018). "Global influenza seasonality to inform country-level vaccine programs: An analysis of WHO FluNet influenza surveillance data between 2011 and 2016." PLoS One 13(2) : e0193263-e0193263.
Noyce, R. S., et al. (2018). "Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments." PLoS One 13(1) : e0188453-e0188453.
Noyes, N., et al. (2018). "Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis." PLoS One 13(1) : e0191625-e0191625.
Oka, T., et al. (2018). "Attempts to grow human noroviruses, a sapovirus, and a bovine norovirus in vitro." PLoS One 13(2) : e0178157-e0178157.
Olech, M., et al. (2018). "Epidemiological survey in single-species flocks from Poland reveals expanded genetic and antigenic diversity of small ruminant lentiviruses." PLoS One 13(3) : e0193892-e0193892.
Papackova, Z., et al. (2018). "Silymarin prevents acetaminophen-induced hepatotoxicity in mice." PLoS One 13(1) : e0191353-e0191353.
Prieto, I., et al. (2018). "Influence of a diet enriched with virgin olive oil or butter on mouse gut microbiota and its correlation to physiological and biochemical parameters related to metabolic syndrome." PLoS One 13(1) : e0190368-e0190368.
Rajendran, M., et al. (2018). "An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations." PLoS One 13(4) : e0194830-e0194830.
Ridgeway, K., et al. (2018). "Interventions to improve antiretroviral therapy adherence among adolescents in low- and middle-income countries: A systematic review of the literature." PLoS One 13(1) : e0189770-e0189770.
Scheibenbogen, C., et al. (2018). "Immunoabsorption to remove SS2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME." PLoS One 13(3) : e0193672-e0193672.
Schmid-Hempel, P., et al. (2018). "The genomes of <i>Crithidia bombi</i> and <i>C. expoeki</i> , common parasites of bumblebees." PLoS One 13(1) : e0189738-e0189738.
Sharifi, S., et al. (2018). "Integration of machine learning and meta-analysis identifies the transcriptomic bio-signature of mastitis disease in cattle." PLoS One 13(2) : e0191227-e0191227.
Sheridan, M. A., et al. (2018). "African and Asian strains of Zika virus differ in their ability to infect and lyse primitive human placental trophoblast." PLoS One 13(7) : e0200086-e0200086.

Shrivastava, S., et al. (2018). "Co-circulation of all the four dengue virus serotypes and detection of a novel clade of DENV-4 (genotype I) virus in Pune, India during 2016 season." <u>PLoS One</u> 13 (2): e0192672-e0192672.
Sierra, L.-J., et al. (2018). "Colonization of the cervicovaginal space with <i>Gardnerella vaginalis</i> leads to local inflammation and cervical remodeling in pregnant mice." <u>PLoS One</u> 13 (1): e0191524-e0191524.
Sigauque, B., et al. (2018). "Invasive bacterial disease trends and characterization of group B streptococcal isolates among young infants in southern Mozambique, 2001-2015." <u>PLoS One</u> 13 (1): e0191193-e0191193.
Sirijatuphat, R., et al. (2018). "Implementation of global antimicrobial resistance surveillance system (GLASS) in patients with bacteremia." <u>PLoS One</u> 13 (1): e0190132-e0190132.
Tadesse, G., et al. (2018). "Molecular epidemiology of fluoroquinolone resistant <i>Salmonella</i> in Africa: A systematic review and meta-analysis." <u>PLoS One</u> 13 (2): e0192575-e0192575.
Tarigan, S., et al. (2018). "Field effectiveness of highly pathogenic avian influenza H5N1 vaccination in commercial layers in Indonesia." <u>PLoS One</u> 13 (1): e0190947-e0190947.
Taylor, R. A., et al. (2018). "Predicting urinary tract infections in the emergency department with machine learning." <u>PLoS One</u> 13 (3): e0194085-e0194085.
Tonen-Wolyec, S., et al. (2018). "Evaluation of the practicability and virological performance of finger-stick whole-blood HIV self-testing in French-speaking sub-Saharan Africa." <u>PLoS One</u> 13 (1): e0189475-e0189475.
Topp, S. M., et al. (2018). "Rethinking retention: Mapping interactions between multiple factors that influence long-term engagement in HIV care." <u>PLoS One</u> 13 (3): e0193641-e0193641.
Touzain, F., et al. (2018). "Characterization of plasmids harboring blaCTX-M and blaCMY genes in <i>E. coli</i> from French broilers." <u>PLoS One</u> 13 (1): e0188768-e0188768.
Tran, B. X., et al. (2018). "Social and structural barriers for adherence to methadone maintenance treatment among Vietnamese opioid dependence patients." <u>PLoS One</u> 13 (1): e0190941-e0190941.
Tsuchiaka, S., et al. (2018). "Genetic diversity and recombination of enterovirus G strains in Japanese pigs: High prevalence of strains carrying a papain-like cysteine protease sequence in the enterovirus G population." <u>PLoS One</u> 13 (1): e0190819-e0190819.
Vallabhajosyula, S., et al. (2018). "Clinical profile and outcomes of acute cardiorenal syndrome type-5 in sepsis: An eight-year cohort study." <u>PLoS One</u> 13 (1): e0190965-e0190965.
Valles, S. M., et al. (2018). "Prospecting for viral natural enemies of the fire ant <i>Solenopsis invicta</i> in Argentina." <u>PLoS One</u> 13 (2): e0192377-e0192377.
Varshney, A. K., et al. (2018). "A natural human monoclonal antibody targeting <i>Staphylococcus</i> Protein A protects against <i>Staphylococcus aureus</i> bacteremia." <u>PLoS One</u> 13 (1): e0190537-e0190537.

Velayutham, B., et al. (2018). "Recurrence of tuberculosis among newly diagnosed sputum positive pulmonary tuberculosis patients treated under the Revised National Tuberculosis Control Programme, India: A multi-centric prospective study." <u>PLoS One</u> 13 (7): e0200150-e0200150.
Villegas, L. E. M., et al. (2018). "Zika virus infection modulates the bacterial diversity associated with Aedes aegypti as revealed by metagenomic analysis." <u>PLoS One</u> 13 (1): e0190352-e0190352.
Visser, M., et al. (2018). "Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands." <u>PLoS One</u> 13 (3): e0194823-e0194823.
Walters, K., et al. (2018). "Are Mechanical Turk worker samples representative of health status and health behaviors in the U.S.?" <u>PLoS One</u> 13 (6): e0198835-e0198835.
Walther, B., et al. (2018). "Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Acinetobacter baumannii among horses entering a veterinary teaching hospital: The contemporary "Trojan Horse"." <u>PLoS One</u> 13 (1): e0191873-e0191873.
Wang, R., et al. (2018). "Modeling and mapping the current and future distribution of Pseudomonas syringae pv. actinidiae under climate change in China." <u>PLoS One</u> 13 (2): e0192153-e0192153.
Wang, W., et al. (2018). "Metabolomics analysis of Lactobacillus plantarum ATCC 14917 adhesion activity under initial acid and alkali stress." <u>PLoS One</u> 13 (5): e0196231-e0196231.
Wang, Z., et al. (2018). "Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China." <u>PLoS One</u> 13 (2): e0191671-e0191671.
Zhang, X., et al. (2018). "Dexmedetomidine inhibits inflammatory reaction in the hippocampus of septic rats by suppressing NF-kappaB pathway." <u>PLoS One</u> 13 (5): e0196897-e0196897.
Zuckerman, A., et al. (2018). "Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era." <u>PLoS One</u> 13 (6): e0199174-e0199174.

Supplementary table 2. Data collected, homogenized variable and grouped variables.

Variable number	Variable	Homogenized variables	Medical workflow categories	Structured variable	Direct variable
NVG2422	Non-hospital admission exacerbations in past 12months	Non-hospital admission exacerbations in past 12months	Comorbidities	1	0
NVG0665	Cause of ICU admission	Cause of ICU admission	Prognosis	1	0
NVG3176	Admissions for scarlet fever management or complications (scarlet fever, tonsilitis, respiratory tract infection)	Admissions for scarlet fever management or complications	Diagnosis	1	1
NVG3177	Admissions for scarlet fever management or complications (scarlet fever, tonsilitis, respiratory tract infection)	Admissions for scarlet fever management or complications	Diagnosis	1	1
NVG3178	Admissions for scarlet fever management or complications (scarlet fever, tonsilitis, respiratory tract infection)	Admissions for scarlet fever management or complications	Diagnosis	1	1
NVG1829	Status at diagnosis (long term, recent, acute, unknown)	Diagnosis other	Other	0	2
NVG1830	Status at diagnosis (long term, recent, acute, unknown)	Diagnosis other	Other	0	2
NVG1831	Status at diagnosis (long term, recent, acute, unknown)	Diagnosis other	Other	0	2
NVG1832	Status at diagnosis (long term, recent, acute, unknown)	Diagnosis other	Other	0	2
NVG1687	WHO stage (1-asympt, 2-oligosympt, 3-advanced)	Diagnosis other	Other	0	2

NVG1688	WHO stage (1-asympt, 2-oligosympt, 3-advanced)	Diagnosis other	Other	0	2
NVG1689	WHO stage (1-asympt, 2-oligosympt, 3-advanced)	Diagnosis other	Other	0	2
NVG0613	Admission diagnosis (ascitic decompensation)	Admission diagnosis	Diagnosis	1	1
NVG4209	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG4210	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG4211	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG4212	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG4213	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG4214	Admission diagnosis (heart failure, shock, arrhythmia, acute coronary syndrome, infections, other).	Admission diagnosis	Diagnosis	1	1
NVG0614	Admission diagnosis (hepatic encephalopathy)	Admission diagnosis	Diagnosis	1	1
NVG0615	Admission diagnosis (hepatorenal syndrome)	Admission diagnosis	Diagnosis	1	1
NVG0616	Admission diagnosis (suspected bacterial	Admission diagnosis	Diagnosis	1	1

	infection)				
NVG0984	Diagnosis: Unidentified tumour	Diagnosis	Diagnosis	1	1
NVG0985	Diagnosis: Other	Diagnosis	Diagnosis	1	1
NVG1413	Diagnosis: Other	Diagnosis	Diagnosis	1	1
NVG2004	Provisional diagnosis: Other	Diagnosis	diagnosis	1	1
NVG0697	Uncertainty of diagnosis	Diagnosis	Diagnosis	1	0
NVG1410	Diagnosis: Nongonococcal urethritis	Diagnosis	Diagnosis	1	1
NVG2879	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)	Diagnosis	Diagnosis	1	1
NVG2880	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)	Diagnosis	Diagnosis	1	1
NVG2881	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)	Diagnosis	Diagnosis	1	1
NVG2882	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)	Diagnosis	Diagnosis	1	1
NVG2883	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with	Diagnosis	Diagnosis	1	1

	pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)				
NVG2884	Clinical diagnosis at baseline (cUTI with or without pyelonephritis, cUTI with pyelonephritis, cUTI without pyelonephritis, Acute uncomplicated pyelonephritis, Pyelonephritis, any)	Diagnosis	Diagnosis	1	1
NVG1339	Clinical diagnosis: Pharyngitis	Diagnosis	Diagnosis	1	1
NVG1341	Clinical diagnosis: Pneumonia	Diagnosis	Diagnosis	1	1
NVG1340	Clinical diagnosis: Tracheobronchitis	Diagnosis	Diagnosis	1	1
NVG0981	Diagnosis: gastritis	Diagnosis	Diagnosis	1	1
NVG0982	Diagnosis: GERD	Diagnosis	Diagnosis	1	1
NVG1412	Diagnosis: Pelvic inflammatory disease	Diagnosis	Diagnosis	1	1
NVG1411	Diagnosis: Proctitis	Diagnosis	Diagnosis	1	1
NVG0983	Diagnosis: Ulcer	Diagnosis	Diagnosis	1	1
NVG2000	Provisional diagnosis (enteric fever, pneumonia, acute febrile illness, UTI, Other)	Diagnosis	diagnosis	1	1
NVG2001	Provisional diagnosis (enteric fever, pneumonia, acute febrile illness, UTI, Other)	Diagnosis	diagnosis	1	1
NVG2002	Provisional diagnosis (enteric fever, pneumonia, acute febrile illness, UTI, Other)	Diagnosis	diagnosis	1	1
NVG2003	Provisional diagnosis (enteric fever, pneumonia, acute febrile illness, UTI, Other)	Diagnosis	diagnosis	1	1

NVG0930	Disease (gastritis or duodenal ulcer)	Disease	Diagnosis	1	1
NVG0915	Previous hospitalization	Previous hospitalization	Other	1	0
NVG1039	Previous ICU admission	Previous ICU admission	Other	1	0
NVG0719	Prior hospital admission	Prior hospital admission	Other	1	0
NVG0310	Recent admission to a hospital	Recent admission to a hospital	Other	1	1
NVG4349	3 or more hospital admissions within 6 months prior to detection of MDR-GNB	3 or more hospital admissions within 6 months prior to detection of MDR-GNB	Comorbidities	1	0
NVG0010	No. of outpatient visits in past 6 mo	No. of outpatient visits in past 6 mo	Other	1	1
NVG1432	Outpatient visits from birth through 23 months (number of visits)	Outpatient visits from birth through 23 months	Other	1	0
NVG0495	Previous visits in past 90 d	Previous visits in past 90 d	Other	1	0
NVG2166	admitted at least once to nursing home	Admitted at least once to nursing home	Demographics	1	0
NVG2966	Admitted from home	Admitted from home	Demographics	1	0
NVG0527	Admission through emergency room	Admission through emergency room	Other	1	1
NVG0716	Admission to long-term care facility	Admission to long-term care facility	Other	1	0
NVG0999	number of ICU admissions	Admission to the	Other	1	0

		intensive care unit			
NVG3860	Admission to university hospital — no. (%)	Admission to university hospital	Other	1	0
NVG2064	admitted to hospital	Admitted to hospital	Other	1	1
NVG2406	Admitted to ICU	Admitted to ICU	Other	1	1
NVG3387	Admission type (medical or surgical)	Admission type	Other	1	1
NVG3387	Admission type (medical or surgical)	Admission type	Other	1	1
NVG0993	Admission type: (medical)	Admission type	Other	1	1
NVG0994	Admission type: (surgical)	Admission type	Other	1	1
NVG0597	Emergency	Emergency	Other	1	1
NVG0200	Emergency department	Emergency	Other	1	1
NVG0353	ICU	ICU admission	Other	1	1
NVG1516	ICU	ICU admission	Other	1	1
NVG0201	Intensive care unit	ICU admission	Other	1	1
NVG0812	Intensive care unit	ICU admission	Other	1	1
NVG1351	Admission to the intensive care unit	ICU admission	Other	1	1
NVG0072	ICU admission	ICU admission	Other	1	1
NVG1718	ICU admission	ICU admission	Other	1	1
NVG0228	Intensive care unit on day 1 of bacteremia	ICU admission	Other	1	0
NVG3864	ICU admission type (Medical Emergency surgery Elective surgery)	ICU admission type	Other	1	0
NVG3865	ICU admission type (Medical Emergency surgery Elective surgery)	ICU admission type	Other	1	0
NVG3866	ICU admission type (Medical Emergency surgery)	ICU admission type	Other	1	0

	Elective surgery)				
NVG1524	Type of ICU admission (Med, Surg, Trauma)	ICU admission type	Other	1	0
NVG1525	Type of ICU admission (Med, Surg, Trauma)	ICU admission type	Other	1	0
NVG1526	Type of ICU admission (Med, Surg, Trauma)	ICU admission type	Other	1	0
NVG4350	preceding stay in long term care facilities	Preceding stay in long term care facilities	Comorbidities	1	0
NVG0199	Location at time of culture	Location at time of culture	Microbiology/serology	1	0
NVG4347	preceding ICU stay within 6 months prior to detection of MDR-GNB	Preceding ICU stay within 6 months prior to detection of MDR-GNB	Microbiology/serology	1	0
NVG1528	Location before ICU admission (same hospital, Another Hosp; Home)	Location before ICU admission	Other	1	0
NVG1529	Location before ICU admission (same hospital, Another Hosp; Home)	Location before ICU admission	Other	1	0
NVG1530	Location before ICU admission (same hospital, Another Hosp; Home)	Location before ICU admission	Other	1	0
NVG3487	Location of patient (Critical care unit/ Unit housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)	Location of patient	Other	1	1
NVG3488	Location of patient (Critical care unit/ Unit housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)	Location of patient	Other	1	1
NVG3489	Location of patient (Critical care unit/ Unit	Location of patient	Other	1	1

	housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)				
NVG3490	Location of patient (Critical care unit/ Unit housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)	Location of patient	Other	1	1
NVG3491	Location of patient (Critical care unit/ Unit housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)	Location of patient	Other	1	1
NVG3492	Location of patient (Critical care unit/ Unit housing patients receiving different levels of acute care/ Newborn or special care nursery/ Specialty care area/ Step-down unit/ Ward, excluding nursery)	Location of patient	Other	1	1
NVG1982	Location of patient admission (medical, pediatric, surgical, emergency	Location of patient admission	Other	1	1
NVG1983	Location of patient admission (medical, pediatric, surgical, emergency	Location of patient admission	Other	1	1
NVG1984	Location of patient admission (medical, pediatric, surgical, emergency	Location of patient admission	Other	1	1
NVG1985	Location of patient admission (medical, pediatric, surgical, emergency	Location of patient admission	Other	1	1
NVG1986	Location of patient admission (other)	Location of patient admission	Other	1	1

NVG2334	Pediatric intensive care unit	Pediatric intensive care unit	Other	1	0
NVG1503	Transferred from other hospital	Transferred from other hospital	Other	1	0
NVG4058	Trial center (x7)	Trial center	Other	1	2
NVG1311	Unit: ICU	Unit	Other	1	1
NVG1312	Unit: Medical	Unit	Other	1	1
NVG1313	Unit: Surgical	Unit	Other	1	1
NVG1314	Unit: Transplant	Unit	Other	1	1
NVG0352	Ward submitting index culture	Ward submitting index culture	Microbiology/serology	1	1
NVG0202	Ward	Ward	Other	1	1
NVG0176	Inpatient at time of randomization	Inpatient at time of randomization	Other	1	0
NVG2171	Number of pneumonia hospitalizations	Number of pneumonia hospitalizations	comorbidities	1	0
NVG3560	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0
NVG3561	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0

NVG3562	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0
NVG3563	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0
NVG3564	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0
NVG3565	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge, discharged to nursing home)	Recruitment hospitalization	Comorbidities	1	0
NVG3566	Recruitment hospitalization (hospitalized in previous year, nursing home stay in previous year, ICU stay, surgery, MRSA infection, wound at hospital discharge, medical device at hospital discharge,	Recruitment hospitalization	Comorbidities	1	0

	discharged to nursing home)				
NVG3174	All admissions within 30 days scarlet fever onset (emergency admissions, elective admission)	All admissions within 30 days scarlet fever onset	Other	1	0
NVG3174	All admissions within 30 days scarlet fever onset (emergency admissions, elective admission)	All admissions within 30 days scarlet fever onset	Other	1	0
NVG3174	All admissions within 30 days scarlet fever onset (emergency admissions, elective admission)	All admissions within 30 days scarlet fever onset	Other	1	0
NVG0998	number of hospital admissions	Hospital admission	Other	1	0
NVG2496	Hospital admission	Hospital admission	Other	1	1
NVG2423	Hospital admissions in past 2 years	Hospital admission	Other	1	1
NVG0742	Hospitalisation	Hospital admission	Other	1	1
NVG1364	Hospitalized	Hospital admission	Other	1	1
NVG4055	Hospitalized	Hospital admission	Other	1	1
NVG1350	Hospitalized patients	Hospital admission	Other	1	1
NVG1299	No. hospitalized	No. hospitalized	Other	1	1
NVG0720	Number of admissions	Number of admissions	Other	1	1
NVG3298	Number of admissions	Number of admissions	Other	1	1
NVG3570	Number of hospitalizations according to serotype	Number of hospitalizations according to serotype	Other	1	0
NVG3567	Number of hospitalizations for Dengue	Number of hospitalizations for Dengue	Other	1	0
NVG4182	Days of hospitalization	Hospital length of stay	Other	1	1
NVG0601	Hospital length of stay	Hospital length of stay	Other	1	1

NVG1468	Hospital length of stay	Hospital length of stay	Other	1	1
NVG1169	Hospital stay	Hospital length of stay	Other	1	1
NVG3497	Hospital stay	Hospital length of stay	Other	1	1
NVG4114	Hospital stay	Hospital length of stay	Other	1	1
NVG1051	Hospital stay before treatment	Hospital length of stay	Other	1	1
NVG1788	length of hospital stay	Hospital length of stay	Other	1	0
NVG0848	Length of hospital stay	Hospital length of stay	Other	1	0
NVG1353	Length of hospital stay	Hospital length of stay	Other	1	0
NVG2946	Length of hospital stay	Hospital length of stay	Other	1	0
NVG4490	Length of hospital stay	Hospital length of stay	Other	1	0
NVG0491	Length of stay	Hospital length of stay	Other	1	0
NVG2336	Length of stay	Hospital length of stay	Other	1	0
NVG3861	Median time from ICU admission to randomization	Median time from ICU admission to randomization	Other	1	0
NVG3862	Time from hospital admission to randomization	Time from hospital admission to randomization	Other	1	0
NVG3413	Time from ICU admission	Time from ICU admission	Other	1	0
NVG1573	Time from matching entry criteria to randomization	Time from matching entry criteria to randomization	Other	1	1
NVG0997	inclusion period	inclusion period	Other	1	1
NVG0724	Length of hospital stay prior to infection	Length of hospital stay prior to infection	Other	1	0
NVG3301	Length of stay in intensive care unit	Length of stay in intensive care unit	Other	1	0

NVG0073	Mean ICU length of stay	Mean ICU length of stay	Other	1	0
NVG0071	Mean length of stay	Mean length of stay	Other	1	0
NVG1572	Capillary refill time	Clinical manifestations	Clinical manifestations	0	2
NVG3428	CSF opening pressure	Clinical manifestations	Clinical manifestations	0	2
NVG3923	Days after symptom onset	Clinical manifestations	Clinical manifestations	0	2
NVG1153	Days from tick exposure to illness onset	Clinical manifestations	Clinical manifestations	0	2
NVG2332	Days of symptoms (number)	Clinical manifestations	Clinical manifestations	0	2
NVG0441	Days post onset of symptoms when ZIKV PCR Diagnosis Made	Clinical manifestations	Clinical manifestations	0	2
NVG4181	Days with fever before admission	Clinical manifestations	Clinical manifestations	0	2
NVG1227	Duration of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG1774	Duration of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG3568	Duration of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG4215	Duration of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG1290	Duration of symptoms before diagnosis	Clinical manifestations	Clinical manifestations	0	2
NVG2046	Fraction of reporting symptomatic cases	Clinical manifestations	Clinical manifestations	0	2
NVG3032	Headache duration	Clinical manifestations	Clinical manifestations	0	2
NVG2258	Interval from illness onset to enrollment	Clinical manifestations	Clinical manifestations	0	2
NVG0786	Length of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG3744	Lesion area	Clinical manifestations	Clinical manifestations	0	2
NVG0097	Mean lesion size	Clinical manifestations	Clinical manifestations	0	2
NVG4027	Symptoms duration	Clinical manifestations	Clinical manifestations	0	2
NVG1956	Time since onset of symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG0023	Time since symptom onset	Clinical manifestations	Clinical manifestations	0	2
NVG1875	Ulceration	Clinical manifestations	Clinical manifestations	0	2
NVG2788	chills	Clinical manifestations	Clinical manifestations	0	2

NVG2813	chills	Clinical manifestations	Clinical manifestations	0	2
NVG0404	Headache only	Clinical manifestations	Clinical manifestations	0	2
NVG1288	Lesion over a joint	Clinical manifestations	Clinical manifestations	0	2
NVG3905	Presence of signs or symptoms of Zika virus infection at enrollment	Clinical manifestations	Clinical manifestations	0	2
NVG1996	Seizures	Clinical manifestations	Clinical manifestations	0	2
NVG2938	Seizures	Clinical manifestations	Clinical manifestations	0	2
NVG3420	Seizures	Clinical manifestations	Clinical manifestations	0	2
NVG1943	Symptoms (symptomatic vs asymptomatic)	Clinical manifestations	Clinical manifestations	0	2
NVG4245	> 1 episode with clinical signs	Clinical manifestations	Clinical manifestations	0	2
NVG2601	limb discomfort	Clinical manifestations	Clinical manifestations	0	2
NVG4668	Number of lesion	clinical manifestations	clinical manifestations	0	2
NVG2421	Number of lobes affected	clinical manifestations	clinical manifestations	0	2
NVG1543	Number of symptoms	clinical manifestations	clinical manifestations	0	2
NVG0123	Abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG0886	Abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG1143	Abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG1264	Abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG1989	abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG2684	abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG2743	abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG3915	Abdominal pain	Clinical manifestations	Clinical manifestations	0	2
NVG1872	Adenopathy	Clinical manifestations	Clinical manifestations	0	2
NVG1157	Anorexia	Clinical manifestations	Clinical manifestations	0	2
NVG2682	anorexia	Clinical manifestations	Clinical manifestations	0	2
NVG2221	Anxiety	Clinical manifestations	Clinical manifestations	0	2

NVG2755	Any WHO TB symptom	Clinical manifestations	Clinical manifestations	0	2
NVG1880	Areflexia	Clinical manifestations	Clinical manifestations	0	2
NVG0128	Arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG0882	Arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG1159	Arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG2600	arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG2742	arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG3912	Arthralgia	Clinical manifestations	Clinical manifestations	0	2
NVG1155	Asthenia	Clinical manifestations	Clinical manifestations	0	2
NVG1869	Asthenia	Clinical manifestations	Clinical manifestations	0	2
NVG0403	Asymptomatic	Clinical manifestations	Clinical manifestations	0	2
NVG0634	Athralgias	Clinical manifestations	Clinical manifestations	0	2
NVG0887	Back pain	Clinical manifestations	Clinical manifestations	0	2
NVG2668	bleeding gums	Clinical manifestations	Clinical manifestations	0	2
NVG0017	Body aches	Clinical manifestations	Clinical manifestations	0	2
NVG2803	bruising	Clinical manifestations	Clinical manifestations	0	2
NVG2495	Bulging fontanelle	Clinical manifestations	Clinical manifestations	0	2
NVG0885	Chest pain	Clinical manifestations	Clinical manifestations	0	2
NVG2441	Chest wall deformity Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG3028	Clinical characteristics (vaccine related arthritis)	Clinical manifestations	Clinical manifestations	0	2
NVG4236	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2
NVG4237	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2

NVG4238	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2
NVG4239	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2
NVG4240	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2
NVG4241	Clinical presentation (itch, burrows, crusted scabies, skin defects, secondary infections, missing in medical record).	Clinical manifestations	Clinical manifestations	0	2
NVG2223	Clinically overt fatigue	Clinical manifestations	Clinical manifestations	0	2
NVG2669	conjunctival injections	Clinical manifestations	Clinical manifestations	0	2
NVG1329	Conjunctival injection	Clinical manifestations	Clinical manifestations	0	2
NVG1997	Constipation	Clinical manifestations	Clinical manifestations	0	2
NVG1146	Convulsion	Clinical manifestations	Clinical manifestations	0	2
NVG2490	Convulsions	Clinical manifestations	Clinical manifestations	0	2
NVG0013	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG0125	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG0883	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG1141	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG1885	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG1934	cough	Clinical manifestations	Clinical manifestations	0	2
NVG1954	cough	Clinical manifestations	Clinical manifestations	0	2
NVG2266	cough	Clinical manifestations	Clinical manifestations	0	2
NVG2751	cough	Clinical manifestations	Clinical manifestations	0	2

NVG4559	Cough	Clinical manifestations	Clinical manifestations	0	2
NVG2439	Cough score Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG1990	cough/ difficulty to breath	Clinical manifestations	Clinical manifestations	0	2
NVG2443	Crackels Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG2940	Cranial nerve palsy	Clinical manifestations	Clinical manifestations	0	2
NVG3423	Cranial-nerve palsy	Clinical manifestations	Clinical manifestations	0	2
NVG0892	Crepitations	Clinical manifestations	Clinical manifestations	0	2
NVG1873	Cutaneous tumefaction	Clinical manifestations	Clinical manifestations	0	2
NVG4560	Difficult breathing	Clinical manifestations	Clinical manifestations	0	2
NVG2685	difficulty breathing	Clinical manifestations	Clinical manifestations	0	2
NVG2683	difficulty swallowing	Clinical manifestations	Clinical manifestations	0	2
NVG2440	Digital clubing Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG2612	dysmenorrhea	Clinical manifestations	Clinical manifestations	0	2
NVG1328	Dyspnea/tachypnea	Clinical manifestations	Clinical manifestations	0	2
NVG0884	Dyspnoea	Clinical manifestations	Clinical manifestations	0	2
NVG0410	dysuria	Clinical manifestations	Clinical manifestations	0	2
NVG3921	Dysuria	Clinical manifestations	Clinical manifestations	0	2
NVG1932	earache	Clinical manifestations	Clinical manifestations	0	2
NVG2675	ecchymoses	Clinical manifestations	Clinical manifestations	0	2
NVG2727	echymosis	Clinical manifestations	Clinical manifestations	0	2
NVG1871	Edema	Clinical manifestations	Clinical manifestations	0	2
NVG3911	Edema	Clinical manifestations	Clinical manifestations	0	2
NVG2007	Encephalopathy	Clinical manifestations	Clinical manifestations	0	2
NVG2670	epistaxis	Clinical manifestations	Clinical manifestations	0	2
NVG2726	Erythema	Clinical manifestations	Clinical manifestations	0	2
NVG1162	Eschar	Clinical manifestations	Clinical manifestations	0	2

NVG4187	Eschar	Clinical manifestations	Clinical manifestations	0	2
NVG3094	Examination (vaginal discharge, ulceration or cervical mucopus)	Clinical manifestations	Clinical manifestations	0	2
NVG3095	Examination (vaginal discharge, ulceration or cervical mucopus)	Clinical manifestations	Clinical manifestations	0	2
NVG3096	Examination (vaginal discharge, ulceration or cervical mucopus)	Clinical manifestations	Clinical manifestations	0	2
NVG0129	Examination findings on enrollment	Clinical manifestations	Clinical manifestations	0	2
NVG2227	Fatigue	Clinical manifestations	Clinical manifestations	0	2
NVG2596	Fatigue	Clinical manifestations	Clinical manifestations	0	2
NVG2740	fatigue	Clinical manifestations	Clinical manifestations	0	2
NVG0019	Fatigue/run down	Clinical manifestations	Clinical manifestations	0	2
NVG0968	fever without source	Clinical manifestations	Clinical manifestations	0	2
NVG2739	feverishness	Clinical manifestations	Clinical manifestations	0	2
NVG2599	flue like symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG2666	General Health-altered	Clinical manifestations	Clinical manifestations	0	2
NVG1993	general weakness	Clinical manifestations	Clinical manifestations	0	2
NVG2672	haematemesis	Clinical manifestations	Clinical manifestations	0	2
NVG0121	Headache	Clinical manifestations	Clinical manifestations	0	2
NVG0633	Headache	Clinical manifestations	Clinical manifestations	0	2
NVG1144	Headache	Clinical manifestations	Clinical manifestations	0	2
NVG1156	Headache	Clinical manifestations	Clinical manifestations	0	2
NVG1937	headache	Clinical manifestations	Clinical manifestations	0	2
NVG1994	headache	Clinical manifestations	Clinical manifestations	0	2
NVG2603	headache	Clinical manifestations	Clinical manifestations	0	2
NVG2680	headache	Clinical manifestations	Clinical manifestations	0	2
NVG2787	headache	Clinical manifestations	Clinical manifestations	0	2

NVG2809	headache	Clinical manifestations	Clinical manifestations	0	2
NVG3914	Headache	Clinical manifestations	Clinical manifestations	0	2
NVG3419	Headache (and duration)	Clinical manifestations	Clinical manifestations	0	2
NVG0016	Headaches	Clinical manifestations	Clinical manifestations	0	2
NVG2738	headhache	Clinical manifestations	Clinical manifestations	0	2
NVG3571	Hemorrhage	Clinical manifestations	Clinical manifestations	0	2
NVG1876	Hepatic pain	Clinical manifestations	Clinical manifestations	0	2
NVG0895	Hepatomegaly	Clinical manifestations	Clinical manifestations	0	2
NVG1877	Hepatomegaly	Clinical manifestations	Clinical manifestations	0	2
NVG2687	hiccups	Clinical manifestations	Clinical manifestations	0	2
NVG1870	Icterus	Clinical manifestations	Clinical manifestations	0	2
NVG2728	induration	Clinical manifestations	Clinical manifestations	0	2
NVG1777	inflammatory edema	Clinical manifestations	Clinical manifestations	0	2
NVG3082	Inhalation injury	Clinical manifestations	Clinical manifestations	0	2
NVG2607	injection site erithema	Clinical manifestations	Clinical manifestations	0	2
NVG2605	injection site induration	Clinical manifestations	Clinical manifestations	0	2
NVG2606	injection site oedema	Clinical manifestations	Clinical manifestations	0	2
NVG2610	injection site pain	Clinical manifestations	Clinical manifestations	0	2
NVG2608	injection site pruritus	Clinical manifestations	Clinical manifestations	0	2
NVG2609	injection site tenderness	Clinical manifestations	Clinical manifestations	0	2
NVG2228	Inluenza-like symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG2224	Insomnioa	Clinical manifestations	Clinical manifestations	0	2
NVG0018	Irritability	Clinical manifestations	Clinical manifestations	0	2
NVG2729	itching	Clinical manifestations	Clinical manifestations	0	2
NVG2790	joint pain	Clinical manifestations	Clinical manifestations	0	2
NVG2810	joint pain	Clinical manifestations	Clinical manifestations	0	2

NVG1936	joint/muscle ache	Clinical manifestations	Clinical manifestations	0	2
NVG0096	Lesion type	Clinical manifestations	Clinical manifestations	0	2
NVG4659	Location of lesion (Hands Face Legs Other)	Clinical manifestations	Clinical manifestations	0	2
NVG4660	Location of lesion (Hands Face Legs Other)	Clinical manifestations	Clinical manifestations	0	2
NVG4661	Location of lesion (Hands Face Legs Other)	Clinical manifestations	Clinical manifestations	0	2
NVG4662	Location of lesion (Hands Face Legs Other)	Clinical manifestations	Clinical manifestations	0	2
NVG1992	loss of appetite	Clinical manifestations	Clinical manifestations	0	2
NVG0904	Lymph	Clinical manifestations	Clinical manifestations	0	2
NVG0894	Lymphadenopathy	Clinical manifestations	Clinical manifestations	0	2
NVG1160	Lymphadenopathy	Clinical manifestations	Clinical manifestations	0	2
NVG3916	Lymphadenopathy	Clinical manifestations	Clinical manifestations	0	2
NVG1874	Maculae, papulae	Clinical manifestations	Clinical manifestations	0	2
NVG0880	Malaise	Clinical manifestations	Clinical manifestations	0	2
NVG1933	malaise	Clinical manifestations	Clinical manifestations	0	2
NVG2737	malaise	Clinical manifestations	Clinical manifestations	0	2
NVG2785	malaise	Clinical manifestations	Clinical manifestations	0	2

NVG2807	malaise	Clinical manifestations	Clinical manifestations	0	2
NVG1016	Mass lesions in liver	Clinical manifestations	Clinical manifestations	0	2
NVG0478	Mastitis	Clinical manifestations	Clinical manifestations	0	2
NVG2602	mialgia	Clinical manifestations	Clinical manifestations	0	2
NVG1270	Morphologic features	Clinical manifestations	Clinical manifestations	0	2
NVG2939	Motor abnormalities	clinical manifestations	clinical manifestations	0	2
NVG2489	Movement only whet stimulated or no movement	clinical manifestations	clinical manifestations	0	2
NVG1271	Multiple abscesses	clinical manifestations	clinical manifestations	0	2
NVG2689	muscle or joint pain	Clinical manifestations	Clinical manifestations	0	2
NVG1879	Muscle weakness	Clinical manifestations	Clinical manifestations	0	2
NVG2230	Musculoskeletal disorders	Clinical manifestations	Clinical manifestations	0	2
NVG0127	Myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG1158	Myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG2736	myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG2786	myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG2808	myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG3913	Myalgia	Clinical manifestations	Clinical manifestations	0	2
NVG0636	Myalgias	Clinical manifestations	Clinical manifestations	0	2
NVG2493	Nappy rash or skin pustules	Clinical manifestations	Clinical manifestations	0	2
NVG2611	nasopharyngitis	Clinical manifestations	Clinical manifestations	0	2
NVG0020	Nausea	Clinical manifestations	Clinical manifestations	0	2
NVG2598	nausea	Clinical manifestations	Clinical manifestations	0	2
NVG2735	nausea	Clinical manifestations	Clinical manifestations	0	2
NVG2789	Nausea	Clinical manifestations	Clinical manifestations	0	2
NVG2812	nausea	Clinical manifestations	Clinical manifestations	0	2

NVG3918	Nausea	Clinical manifestations	Clinical manifestations	0	2
NVG4184	Neurological findings	Clinical manifestations	Clinical manifestations	0	2
NVG0700	Neurological symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG2158	neurological/musculoskeletal	Clinical manifestations	Clinical manifestations	0	2
NVG0889	New cardiac murmur	clinical manifestations	clinical manifestations	0	2
NVG2753	night sweats	Clinical manifestations	Clinical manifestations	0	2
NVG1006	Not first onset	clinical manifestations	clinical manifestations	0	2
NVG0891	Oedema	clinical manifestations	clinical manifestations	0	2
NVG2613	oropharyngeal pain	clinical manifestations	clinical manifestations	0	2
NVG1868	Pallor	clinical manifestations	clinical manifestations	0	2
NVG0136	Palpable liver	clinical manifestations	clinical manifestations	0	2
NVG0137	Palpable spleen	clinical manifestations	clinical manifestations	0	2
NVG0473	Parotid pain	clinical manifestations	clinical manifestations	0	2
NVG0472	Parotid swelling	clinical manifestations	clinical manifestations	0	2
NVG3920	Pelvic pain	clinical manifestations	clinical manifestations	0	2
NVG0411	penile/rectal discharge	clinical manifestations	clinical manifestations	0	2
NVG2674	petechiae	clinical manifestations	clinical manifestations	0	2
NVG3910	Photophobia	clinical manifestations	clinical manifestations	0	2
NVG3573	Plasma Leakage	Clinical manifestations	Clinical manifestations	0	2
NVG2453	Poor Nutritional Status (mid- upper-arm circumference < 21,5cm)	Clinical manifestations	Clinical manifestations	0	2
NVG0632	Pruritus	Clinical manifestations	Clinical manifestations	0	2
NVG2806	pruritus	Clinical manifestations	Clinical manifestations	0	2
NVG3909	Pruritus	Clinical manifestations	Clinical manifestations	0	2
NVG0138	Rash	Clinical manifestations	Clinical manifestations	0	2
NVG0631	Rash	Clinical manifestations	Clinical manifestations	0	2

NVG1161	Rash	Clinical manifestations	Clinical manifestations	0	2
NVG2576	rash	Clinical manifestations	Clinical manifestations	0	2
NVG2734	rash	Clinical manifestations	Clinical manifestations	0	2
NVG3908	Rash	Clinical manifestations	Clinical manifestations	0	2
NVG2867	Rash during pregnancy	Clinical manifestations	Clinical manifestations	0	2
NVG3907	Red eyes or eye pain	Clinical manifestations	Clinical manifestations	0	2
NVG2784	redness	Clinical manifestations	Clinical manifestations	0	2
NVG2805	redness	Clinical manifestations	Clinical manifestations	0	2
NVG1952	reported fever	Clinical manifestations	Clinical manifestations	0	2
NVG4185	Respiratory findings	Clinical manifestations	Clinical manifestations	0	2
NVG0637	Respiratory symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG4039	Rhonchi	Clinical manifestations	Clinical manifestations	0	2
NVG0120	Rigors	Clinical manifestations	Clinical manifestations	0	2
NVG2614	rinitis	Clinical manifestations	Clinical manifestations	0	2
NVG1928	runny nose	Clinical manifestations	Clinical manifestations	0	2
NVG1955	runny nose	Clinical manifestations	Clinical manifestations	0	2
NVG0015	Runny or stuffy nose	Clinical manifestations	Clinical manifestations	0	2
NVG2487	Severe chest in-drawing	Clinical manifestations	Clinical manifestations	0	2
NVG2681	severe fatigue	Clinical manifestations	Clinical manifestations	0	2
NVG0126	Shortness of breath	Clinical manifestations	Clinical manifestations	0	2
NVG1935	shortness of breath	Clinical manifestations	Clinical manifestations	0	2
NVG1226	Signs and symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG0734	Signs of hypo perfusion	Clinical manifestations	Clinical manifestations	0	2
NVG3922	Signs or symptoms at enrollment: Other§	Clinical manifestations	Clinical manifestations	0	2
NVG0898	Skin lesion	Clinical manifestations	Clinical manifestations	0	2
NVG3324	Skin snip	Clinical manifestations	Clinical manifestations	0	2

NVG2769	skin ulcer	Clinical manifestations	Clinical manifestations	0	2
NVG1930	sneezing	Clinical manifestations	Clinical manifestations	0	2
NVG1931	sore thorat	Clinical manifestations	Clinical manifestations	0	2
NVG0014	Sore throat	Clinical manifestations	Clinical manifestations	0	2
NVG1953	sore throat	Clinical manifestations	Clinical manifestations	0	2
NVG1995	sore throat	Clinical manifestations	Clinical manifestations	0	2
NVG0890	Splinter haemorrhages	Clinical manifestations	Clinical manifestations	0	2
NVG0897	Sternal Wound	Clinical manifestations	Clinical manifestations	0	2
NVG1929	stuffed nose	Clinical manifestations	Clinical manifestations	0	2
NVG2264	subjective general state status	Clinical manifestations	Clinical manifestations	0	2
NVG2783	Swelling	Clinical manifestations	Clinical manifestations	0	2
NVG2804	swelling	Clinical manifestations	Clinical manifestations	0	2
NVG4132	Symptom of initial illness (rash, fever, joint pain, conjunctivitis, bloody semen)	Clinical manifestations	Clinical manifestations	0	2
NVG4134	Symptom of initial illness (rash, fever, joint pain, conjunctivitis, bloody semen)	Clinical manifestations	Clinical manifestations	0	2
NVG4135	Symptom of initial illness (rash, fever, joint pain, conjunctivitis, bloody semen)	Clinical manifestations	Clinical manifestations	0	2
NVG4136	Symptom of initial illness (rash, fever, joint pain, conjunctivitis, bloody semen)	Clinical manifestations	Clinical manifestations	0	2
NVG3755	Symptomatic asthma with wheezing	Clinical manifestations	Clinical manifestations	0	2
NVG0011	Symptoms	Clinical manifestations	Clinical manifestations	0	2
NVG4029	Symptoms (Cough Dyspnea Sputum production Chest discomfort Chills)	Clinical manifestations	Clinical manifestations	0	2
NVG4030	Symptoms (Cough	Clinical manifestations	Clinical manifestations	0	2

	Dyspnea Sputum production Chest discomfort Chills)				
NVG4031	Symptoms (Cough Dyspnea Sputum production Chest discomfort Chills)	Clinical manifestations	Clinical manifestations	0	2
NVG4032	Symptoms (Cough Dyspnea Sputum production Chest discomfort Chills)	Clinical manifestations	Clinical manifestations	0	2
NVG4033	Symptoms (Cough Dyspnea Sputum production Chest discomfort Chills)	Clinical manifestations	Clinical manifestations	0	2
NVG3664	Symptoms at presentation	Clinical manifestations	Clinical manifestations	0	2
NVG4520	Symptoms of respiratory tract infection; AOM, acute otitis media.	Clinical manifestations	Clinical manifestations	0	2
NVG0119	Symptoms on enrollment	Clinical manifestations	Clinical manifestations	0	2
NVG2233	Symptoms: None	Clinical manifestations	Clinical manifestations	0	2
NVG1998	Symptoms: other	Clinical manifestations	Clinical manifestations	0	2
NVG2234	Symptoms: Other	Clinical manifestations	Clinical manifestations	0	2
NVG2434	Syndromic Cause of bronchiectasies:	Clinical manifestations	Clinical manifestations	0	2
NVG2731	tenderness	Clinical manifestations	Clinical manifestations	0	2

NVG2782	Tenderness	Clinical manifestations	Clinical manifestations	0	2
NVG0413	testicular pain/swelling	Clinical manifestations	Clinical manifestations	0	2
NVG1152	Tick bite location	Clinical manifestations	Clinical manifestations	0	2
NVG0477	Transient hearing loss	Clinical manifestations	Clinical manifestations	0	2
NVG1860	Type of Wound (Bite, scratch, don't remember)	Clinical manifestations	Clinical manifestations	0	2
NVG1861	Type of Wound (Bite, scratch, don't remember)	Clinical manifestations	Clinical manifestations	0	2
NVG1862	Type of Wound (Bite, scratch, don't remember)	Clinical manifestations	Clinical manifestations	0	2
NVG0835	Type/severity of infection	Clinical manifestations	Clinical manifestations	0	2
NVG4146	Ulcer location (Head and neck Thorax Upper limbs Lower limbs)	Clinical manifestations	Clinical manifestations	0	2
NVG4147	Ulcer location (Head and neck Thorax Upper limbs Lower limbs)	Clinical manifestations	Clinical manifestations	0	2
NVG4148	Ulcer location (Head and neck Thorax Upper limbs Lower limbs)	Clinical manifestations	Clinical manifestations	0	2
NVG4149	Ulcer location (Head and neck Thorax Upper limbs Lower limbs)	Clinical manifestations	Clinical manifestations	0	2
NVG4144	Ulcer size	Clinical manifestations	Clinical manifestations	0	2
NVG2492	Umbilical flare or infection	Clinical manifestations	Clinical manifestations	0	2

NVG4561	Unable to drink or breastfeed	Clinical manifestations	Clinical manifestations	0	2
NVG2679	Unexplained bleeding	Clinical manifestations	Clinical manifestations	0	2
NVG2678	Unexplained death	Clinical manifestations	Clinical manifestations	0	2
NVG3102	Unformed bowel movements	Clinical manifestations	Clinical manifestations	0	2
NVG3289	Urgency	Clinical manifestations	Clinical manifestations	0	2
NVG2673	vaginal bleeding outside of menstruation	Clinical manifestations	Clinical manifestations	0	2
NVG3572	Visceral manifestation	Clinical manifestations	Clinical manifestations	0	2
NVG3422	Vision loss	Clinical manifestations	Clinical manifestations	0	2
NVG2437	Weight Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG2442	Wheeze Examination findings:	Clinical manifestations	Clinical manifestations	0	2
NVG4040	Wheezing	Clinical manifestations	Clinical manifestations	0	2
NVG2759	WHO danger signs	Clinical manifestations	Clinical manifestations	0	2
NVG0209	Wound	Clinical manifestations	Clinical manifestations	0	2
NVG0599	Wound class	Clinical manifestations	Clinical manifestations	0	2
NVG0797	NYHA class 3 or 4	Clinical manifestations	Clinical manifestations	0	2
NVG3730	Osame Motor Disability Score	Clinical manifestations	Clinical manifestations	0	2
NVG0035	Duration of exposure	Clinical manifestations	Other	0	2
NVG4667	Duration of lesion (months)	Clinical manifestations	Other	0	2
NVG4138	Time from illness onset to first sample	Clinical manifestations	Other	0	2
NVG2667	bleeding at or from injection points	Clinical manifestations	Other	0	2
NVG4133	Symptom of initial illness (rash, fever, joint pain, conjunctivitis, bloody semen)	Clinical manifestations	Clinical manifestations	0	2
NVG0798	Symptomatic CNS complication	Clinical manifestations	Clinical manifestations	0	2
NVG0795	Symptomatic peripheral embolism (other than CNS)	Clinical manifestations	Clinical manifestations	0	2
NVG0501	Weight loss	Weight loss	Clinical manifestations	1	1
NVG0881	Weight loss	Weight loss	Clinical manifestations	1	1

NVG2754	weight loss	Weight loss	Clinical manifestations	1	1
NVG0022	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG0124	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG1145	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG1327	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG1988	diarrhea	Diarrhea	Clinical manifestations	1	1
NVG2741	diarrhea	Diarrhea	Clinical manifestations	1	1
NVG3917	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG4562	Diarrhea	Diarrhea	Clinical manifestations	1	1
NVG2688	diarrhoea	Diarrhea	Clinical manifestations	1	1
NVG2671	melaena	Melaena	Clinical manifestations	1	1
NVG1326	Nausea/vomiting	Vomiting	Clinical manifestations	1	1
NVG1991	nausea/vomiting	Vomiting	Clinical manifestations	1	1
NVG0021	Vomiting	Vomiting	Clinical manifestations	1	1
NVG0122	Vomiting	Vomiting	Clinical manifestations	1	1
NVG1142	Vomiting	Vomiting	Clinical manifestations	1	1
NVG2686	vomiting	Vomiting	Clinical manifestations	1	1
NVG3919	Vomiting	Vomiting	Clinical manifestations	1	1
NVG4563	Vomiting	Vomiting	Clinical manifestations	1	1
NVG2597	vomiting	Vomiting	Clinical manifestations	1	1
NVG2732	vomiting	Vomiting	Clinical manifestations	1	1
NVG3426	Abnormal mental status	Abnormal mental status	Clinical manifestations	1	1
NVG0405	Confusion	Abnormal mental status	Clinical manifestations	1	1
NVG4739	Confusion/disorientation	Abnormal mental status	Clinical manifestations	1	1

NVG2979	Consciousness	Abnormal mental status	Clinical manifestations	1	1
NVG1451	Altered mental status	Altered mental status	Diagnosis	1	0
NVG1510	Altered mental status	Altered mental status	Diagnosis	1	0
NVG2730	pain	Pain	clinical manifestations	1	1
NVG2781	Pain	Pain	clinical manifestations	1	1
NVG2802	pain/tenderness	Pain	clinical manifestations	1	1
NVG1882	Paresthesia	Paresthesia	clinical manifestations	1	1
NVG4558	History of convulsions	Seizures	Clinical manifestations	1	1
NVG0502	Hemiplegia	Focal Weakness	Clinical manifestations	1	1
NVG0757	Hemiplegia	Focal Weakness	Clinical manifestations	1	1
NVG1881	Paralysis	Focal Weakness	clinical manifestations	1	1
NVG3203	Paraplegia and hemiplegia	Focal Weakness	clinical manifestations	1	1
NVG4742	Pleural effusion	Pleural effusion	Images/EKG	1	0
NVG0118	Days of fever	Duration of fever	Clinical manifestations	1	0
NVG3569	Duration of fever	Duration of fever	Clinical manifestations	1	0
NVG2054	Fever duration	Duration of fever	Clinical manifestations	1	0
NVG1325	Fever >5 d	Duration of fever	Clinical manifestations	1	0
NVG0595	Total number of other allergies	Allergies	Comorbidities	1	0
NVG0593	Cephalosporin allergy	Cephalosporin allergy	Comorbidities	1	1
NVG0592	Drug allergies	Drug allergies	Comorbidities	1	1
NVG0594	Vancomycin allergy	Vancomycin allergy	Comorbidities	1	1
NVG0800	New conduction abnormality	Arrhythmia	clinical manifestations	1	1
NVG0505	Arrhythmia	Arrhythmia	Clinical manifestations	1	1
NVG1883	Arrhythmia	Arrhythmia	Clinical manifestations	1	1
NVG0522	Ventricular fibrillation	Arrhythmia	Clinical manifestations	1	1

NVG0521	Atrial fibrillation	Atrial fibrillation	Comorbidities	1	1
NVG1884	Cardiac insufficiency	Cardiovascular disease	Comorbidities	1	1
NVG0342	Cardiovascular disease	Cardiovascular disease	Comorbidities	1	1
NVG0585	Cardiovascular disease	Cardiovascular disease	Comorbidities	1	1
NVG0755	Cardiovascular disease	Cardiovascular disease	Comorbidities	1	1
NVG0816	Cardiovascular disease	Cardiovascular disease	Comorbidities	1	1
NVG1078	Cardiovascular disease or Hypertension	Cardiovascular disease	Comorbidities	1	1
NVG2155	Chronic cardiac disease	Cardiovascular disease	Comorbidities	1	1
NVG4717	Chronic cardiovascular disease	Cardiovascular disease	Comorbidities	1	1
NVG1067	Chronic heart disease	Cardiovascular disease	Comorbidities	1	1
NVG4258	Heart damage	Cardiovascular disease	Comorbidities	1	0
NVG0197	Heart disease	Cardiovascular disease	Comorbidities	1	0
NVG2117	Heart disease	Cardiovascular disease	Comorbidities	1	0
NVG1260	Heart failure	Cardiovascular disease	Comorbidities	1	0
NVG1011	cerebrovascular disease	Cerebrovascular disease	Comorbidities	1	1

NVG3201	Cerebrovascular disease	Cerebrovascular disease	Comorbidities	1	1
NVG0343	Cerebrovascular disease or dementia	Cerebrovascular disease	Comorbidities	1	1
NVG2274	congenital heart disease	Congenital heart disease	Comorbidities	1	1
NVG1591	Congenital heart disease	Congenital heart disease	Comorbidities	1	1
NVG3891	Prosthetic heart valve	Prosthetic heart valve	Comorbidities	1	0
NVG4367	congestive heart disease	Congestive heart failure	Comorbidities	1	1
NVG0498	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG0796	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG1009	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG1099	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG2973	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG3198	Congestive heart failure	Congestive heart failure	Comorbidities	1	1
NVG4202	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease, chugs heart disease, hypertension, valvular heart disease, other)	Heart failure etiology	Comorbidities	1	1
NVG4203	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease,	Heart failure etiology	Comorbidities	1	1

	chugs heart disease, hypertension, valvular heart disease, other)				
NVG4204	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease, chugs heart disease, hypertension, valvular heart disease, other)	Heart failure etiology	Comorbidities	1	1
NVG4205	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease, chugs heart disease, hypertension, valvular heart disease, other)	Heart failure etiology	Comorbidities	1	1
NVG4206	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease, chugs heart disease, hypertension, valvular heart disease, other)	Heart failure etiology	Comorbidities	1	1
NVG4207	Heart failure etiology (dilated cardiomyopathy, ischemic heart disease, chugs heart disease, hypertension, valvular heart disease, other)	Heart failure etiology	Comorbidities	1	1
NVG2116	HTA	Hypertension	Comorbidities	1	1
NVG0516	Hypertension	Hypertension	Comorbidities	1	1
NVG1070	Hypertension	Hypertension	Comorbidities	1	1
NVG1563	Hypertension	Hypertension	Comorbidities	1	1
NVG2350	Hypertension	Hypertension	Comorbidities	1	1
NVG4164	Hypertension	Hypertension	Comorbidities	1	1
NVG4264	Hypertension	Hypertension	Comorbidities	1	1
NVG4377	Hypertension	Hypertension	Comorbidities	1	1
NVG1590	Hypertrophic cardiomyopathy	Hypertrophic cardiomyopathy	Comorbidities	1	1

NVG4379	Coronary artery disease	Ischemic heart disease	Comorbidities	1	1
NVG0520	Ischemic heart disease	Ischemic heart disease	Comorbidities	1	1
NVG3202	Myocardial infarction	Myocardial infarction	Comorbidities	1	1
NVG4380	Prior myocardial infarction	Prior myocardial infarction	Comorbidities	1	1
NVG3205	Peripheral vascular disease	Peripheral vascular disease	comorbidities	1	1
NVG0512	Peripheral vascular disorder	Peripheral vascular disease	comorbidities	1	1
NVG3893	Other known valve disease	Other known valve disease	comorbidities	1	0
NVG1587	Preexisting valvular heart disease	Preexisting valvular heart disease	Comorbidities	1	0
NVG2232	Skin and subcutaneous disorders	Skin and subcutaneous disorders	Comorbidities	1	0
NVG1183	Decubitus ulcers	Decubitus ulcers	Clinical manifestations	1	1
NVG4150	Number of ulcers	Number of ulcers	clinical manifestations	1	0
NVG0030	Diabetes	Diabetes	Comorbidities	1	1
NVG0234	Diabetes	Diabetes	Comorbidities	1	1
NVG0584	Diabetes	Diabetes	Comorbidities	1	1
NVG0756	Diabetes	Diabetes	Comorbidities	1	1
NVG0778	Diabetes	Diabetes	Comorbidities	1	1
NVG0814	Diabetes	Diabetes	Comorbidities	1	1
NVG0946	Diabetes	Diabetes	Comorbidities	1	1
NVG1007	Diabetes	Diabetes	Comorbidities	1	1
NVG1041	Diabetes	Diabetes	Comorbidities	1	1

NVG1069	Diabetes	Diabetes	Comorbidities	1	1
NVG1177	Diabetes	Diabetes	Comorbidities	1	1
NVG1255	Diabetes	Diabetes	Comorbidities	1	1
NVG1445	Diabetes	Diabetes	Comorbidities	1	1
NVG1727	Diabetes	Diabetes	Comorbidities	1	1
NVG1961	Diabetes	Diabetes	Comorbidities	1	1
NVG2114	diabetes	Diabetes	Comorbidities	1	1
NVG2157	diabetes	Diabetes	Comorbidities	1	1
NVG2312	Diabetes	Diabetes	Comorbidities	1	1
NVG2970	Diabetes	Diabetes	Comorbidities	1	1
NVG3147	Diabetes	Diabetes	Comorbidities	1	1
NVG3195	Diabetes	Diabetes	Comorbidities	1	1
NVG3272	Diabetes	Diabetes	Comorbidities	1	1
NVG3447	Diabetes	Diabetes	Comorbidities	1	1
NVG3929	Diabetes	Diabetes	Comorbidities	1	1
NVG4165	Diabetes	Diabetes	Comorbidities	1	1
NVG0099	Diabetes	Diabetes	Comorbidities	1	1
NVG0191	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG0349	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG0706	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG0725	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG0855	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG1081	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG1291	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG1582	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG1658	Diabetes mellitus	Diabetes	Comorbidities	1	1

NVG4360	diabetes mellitus	Diabetes	Comorbidities	1	1
NVG4378	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG4614	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG4718	Diabetes mellitus	Diabetes	Comorbidities	1	1
NVG2214	Type 2 diabetes	Diabetes	Comorbidities	1	1
NVG0508	Complicated diabetes	Complicated diabetes	Diagnosis	1	0
NVG2118	Hypercholesterolemia	Hypercholesterolemia	Laboratory	1	0
NVG0518	Hyperlipidemia	Hyperlipidemia	Laboratory	1	0
NVG2120	Thyroid disease	Thyroid disease	Comorbidities	1	0
NVG4262	Alcohol (cantidad)	Comorbidities	Comorbidities	0	2
NVG2341	Alcohol consumption (units)	Comorbidities	Comorbidities	0	2
NVG2249	Alcohol consumption in last six monts	Comorbidities	Comorbidities	0	2
NVG1400	Self-reported chikungunya infection	Comorbidities	Comorbidities	0	2
NVG1401	Self-reported chronic form	Comorbidities	Comorbidities	0	2
NVG2070	Frequency of drug use in the last month	Comorbidities	Comorbidities	0	2
NVG2352	current smoking status	Comorbidities	Comorbidities	0	2
NVG4197	Nutritional status	Comorbidities	comorbidities	0	2
NVG0116	Previous malaria (self-reported)	Comorbidities	Comorbidities	0	2
NVG2143	Household member with acute illness in past 3 mo	Comorbidities	Demographics	0	2
NVG3019	Duration of need for clean catheterization	Comorbidities	Other	0	2
NVG1429	Estimated cumulative vaccine antigen exposure from birth through 23 mo, No. of antigens	Comorbidities	Other	0	2
NVG1430	Estimated maximum single-day antigen exposure from birth through 23 mo, No. of	Comorbidities	Other	0	2

	antigens				
NVG0308	Bedridden patients	Comorbidities	Other	0	2
NVG2047	Relative infectiousness of long-term carriers	Comorbidities	Other	0	2
NVG3023	Frequency of clean intermittent self-catheterization over 24h	Comorbidities	Other	0	2
NVG1300	No. fetal losses	Comorbidities	Other	0	2
NVG3552	Bathing assistance needed	Comorbidities	Other	0	2
NVG4003	Lifestyle practices during this pregnancy (alcohol, drug use, smoker, use of mosquito repellents, use of larvicides).	Comorbidities	Other	0	2
NVG4004	Lifestyle practices during this pregnancy (alcohol, drug use, smoker, use of mosquito repellents, use of larvicides).	Comorbidities	Other	0	2
NVG2113	Acute illness in the past 6 months	Acute illness in the past 6 months	Comorbidities	1	1
NVG0701	Any chronic disease	Any chronic disease	Comorbidities	1	1
NVG1426	Chronic condition status (crónico no-complejo)	Chronic condition status	Comorbidities	1	0
NVG1427	Chronic condition status (crónico y complejo)	Chronic condition status	Comorbidities	1	0
NVG1428	Chronic condition status (no-crónico)	Chronic condition status	Comorbidities	1	0
NVG0496	Chronic conditions	Chronic conditions	Comorbidities	1	0
NVG3875	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD)	Comorbidities	Comorbidities	1	1

	Liver disease Cancer Intravenous drug use)				
NVG3876	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)	Comorbidities	Comorbidities	1	1
NVG3877	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)	Comorbidities	Comorbidities	1	1
NVG3878	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)	Comorbidities	Comorbidities	1	1
NVG3879	Coexisting condition or risk factor (Diabetes	Comorbidities	Comorbidities	1	1

	Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)				
NVG3880	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)	Comorbidities	Comorbidities	1	1
NVG3881	Coexisting condition or risk factor (Diabetes Renal failure Dialysis COPD Liver disease Cancer Intravenous drug use)	Comorbidities	Comorbidities	1	1
NVG3852	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9	Comorbidities	Comorbidities	1	1

	Coagulopathy++				
NVG3853	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy++	Comorbidities	Comorbidities	1	1
NVG3854	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy++	Comorbidities	Comorbidities	1	1
NVG3855	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy++	Comorbidities	Comorbidities	1	1
NVG3856	Coexisting conditions (Chronic lung	Comorbidities	Comorbidities	1	1

	disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy††				
NVG3857	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy††	Comorbidities	Comorbidities	1	1
NVG3858	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡ Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy††	Comorbidities	Comorbidities	1	1
NVG3859	Coexisting conditions (Chronic lung disease† Previous myocardial infarction Chronic heart failure‡	Comorbidities	Comorbidities	1	1

	Use of glucocorticoids§ Hematologic cancer¶ Metastatic cancer AIDS**9 Coagulopathy††				
NVG4107	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4108	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4109	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4110	Coexisting conditions (Chronic renal failure Hypertension Diabetes	Comorbidities	Comorbidities	1	1

	Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)				
NVG4111	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4112	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4113	Coexisting conditions (Chronic renal failure Hypertension Diabetes Congestive heart failure‡ Chronic respiratory failure Chronic liver disease Immunosuppression)	Comorbidities	Comorbidities	1	1
NVG4017	Coexisting conditions and risk factors (Charlson comorbidity score‡ Current smoker — no./total no. (%) COPD — no./total no. (%)	Comorbidities	Comorbidities	1	1

	Asthma — no./total no. (%))				
NVG4018	Coexisting conditions and risk factors (Charlson comorbidity score‡ Current smoker — no./total no. (%) COPD — no./total no. (%) Asthma — no./total no. (%))	Comorbidities	Comorbidities	1	1
NVG4019	Coexisting conditions and risk factors (Charlson comorbidity score‡ Current smoker — no./total no. (%) COPD — no./total no. (%) Asthma — no./total no. (%))	Comorbidities	Comorbidities	1	1
NVG4020	Coexisting conditions and risk factors (Charlson comorbidity score‡ Current smoker — no./total no. (%) COPD — no./total no. (%) Asthma — no./total no. (%))	Comorbidities	Comorbidities	1	1
NVG0098	Comorbidities	Comorbidities	Comorbidities	1	1
NVG0340	Comorbidities	Comorbidities	Comorbidities	1	1
NVG3546	Comorbilities (diabetes, chronic obstructive pulmonary disease, congestive heart failure, renal disease, Charlson score)	Comorbidities	Comorbidities	1	1
NVG3547	Comorbilities (diabetes, chronic obstructive pulmonary disease, congestive heart failure, renal disease, Charlson score)	Comorbidities	Comorbidities	1	1
NVG3548	Comorbilities (diabetes, chronic obstructive pulmonary disease, congestive heart failure, renal disease, Charlson score)	Comorbidities	Comorbidities	1	1
NVG3549	Comorbilities (diabetes, chronic obstructive pulmonary disease, congestive	Comorbidities	Comorbidities	1	1

	heart failure, renal disease, Charlson score)				
NVG3550	Comorbidities (diabetes, chronic obstructive pulmonary disease, congestive heart failure, renal disease, Charlson score)	Comorbidities	Comorbidities	1	1
NVG1257	Concurrent condition	Coexisting condition	Comorbidities	1	1
NVG0117	History of chronic disease	History of chronic disease	Comorbidities	1	0
NVG4666	History of chronic disease	History of chronic disease	Comorbidities	1	0
NVG1962	Major comorbidity (any cardiovasc, gastrointestinal, pulmonary or malignant disease)	Major comorbidity	Comorbidities	1	0
NVG1962	Major comorbidity (any cardiovasc, gastrointestinal, pulmonary or malignant disease)	Major comorbidity	Comorbidities	1	0
NVG1962	Major comorbidity (any cardiovasc, gastrointestinal, pulmonary or malignant disease)	Major comorbidity	Comorbidities	1	0
NVG1962	Major comorbidity (any cardiovasc, gastrointestinal, pulmonary or malignant disease)	Major comorbidity	Comorbidities	1	0
NVG3993	Medical history (HBP, Diabetes, sickle cell disease)	Medical history	Comorbidities	1	1
NVG3994	Medical history (HBP, Diabetes, sickle cell disease)	Medical history	Comorbidities	1	1
NVG3995	Medical history (HBP, Diabetes, sickle cell disease)	Medical history	Comorbidities	1	1
NVG1446	No comorbidity	No comorbidity	comorbidities	1	0
NVG0677	Pre-existing conditions (cardiovascular)	Pre-existing	Comorbidities	1	1

		conditions			
NVG0678	Pre-existing conditions (Immunocompromise)	Pre-existing conditions	Comorbidities	1	1
NVG0679	Pre-existing conditions (neurological)	Pre-existing conditions	Comorbidities	1	1
NVG0680	Pre-existing conditions (None)	Pre-existing conditions	Comorbidities	1	0
NVG0681	Pre-existing conditions (Other)	Pre-existing conditions	Comorbidities	1	1
NVG0683	Pre-existing conditions (respiratory)	Pre-existing conditions	Comorbidities	1	1
NVG0684	Pre-existing conditions (Trauma)	Pre-existing conditions	Comorbidities	1	1
NVG0854	Pre-transplant conditions	Pre-transplant conditions	Comorbidities	1	0
NVG0229	Preexisting medical conditions	Preexisting medical conditions	Comorbidities	1	0
NVG2124	Previous condition: Chronic	Previous condition	Comorbidities	1	0
NVG2123	Previous condition: None	Previous condition	Comorbidities	1	0
NVG2122	Previous condition: Other	Previous condition	Comorbidities	1	0
NVG4217	Previous history (hypertension, diabetes, atrial fibrillation, previous VT/VF)	Previous history	Comorbidities	1	1
NVG4218	Previous history (hypertension, diabetes, atrial fibrillation, previous VT/VF)	Previous history	Comorbidities	1	1
NVG4219	Previous history (hypertension, diabetes, atrial fibrillation, previous VT/VF)	Previous history	Comorbidities	1	1
NVG4220	Previous history (hypertension, diabetes, atrial fibrillation, previous VT/VF)	Previous history	Comorbidities	1	1
NVG0629	Prior medical history	Prior medical history	Comorbidities	1	1

NVG2618	underlying diseases (Non-Hodgkin lymphoma Hodgkin's lymphoma Multiple myeloma Acute leukaemia Others)	Underlying disease	Comorbidities	1	1
NVG2619	underlying diseases (Non-Hodgkin lymphoma Hodgkin's lymphoma Multiple myeloma Acute leukaemia Others)	Underlying disease	Comorbidities	1	1
NVG2621	underlying diseases (Non-Hodgkin lymphoma Hodgkin's lymphoma Multiple myeloma Acute leukaemia Others)	Underlying disease	Comorbidities	1	1
NVG2622	underlying diseases (Non-Hodgkin lymphoma Hodgkin's lymphoma Multiple myeloma Acute leukaemia Others)	Underlying disease	Comorbidities	1	1
NVG0813	Underlying disease	Underlying disease	Comorbidities	1	1
NVG3643	Underlying disease (Restrictive lung disease, Obstructive lung disease, Cystic fibrosis, Ischemic cardiomyopathy, Nonischemic cardiomyopathy)	Underlying disease	Comorbidities	1	1
NVG3644	Underlying disease (Restrictive lung disease, Obstructive lung disease, Cystic fibrosis, Ischemic cardiomyopathy, Nonischemic cardiomyopathy)	Underlying disease	Comorbidities	1	1
NVG3645	Underlying disease (Restrictive lung disease, Obstructive lung disease, Cystic fibrosis, Ischemic cardiomyopathy, Nonischemic cardiomyopathy)	Underlying disease	Comorbidities	1	1
NVG3647	Underlying disease (Restrictive lung disease, Obstructive lung disease, Cystic fibrosis, Ischemic cardiomyopathy, Nonischemic cardiomyopathy)	Underlying disease	Comorbidities	1	1

NVG2859	Good health	Good health	Comorbidities	1	0
NVG0969	Non-infectious fever	Non-infectious fever	Diagnosis	1	1
NVG0147	G6PD deficiency present	G6PD deficiency present	Laboratory	1	1
NVG2275	chromosomal disorder	Chromosomal disorder	Diagnosis	1	1
NVG0329	Baseline polymorphisms	Baseline polymorphisms	Other	1	1
NVG4688	CYP2D6 inferred intermediate metabolizer phenotype, %	CYP2D6 inferred metabolizer phenotype	Other	1	1
NVG4687	CYP2D6 inferred poor metabolizer phenotype, %	CYP2D6 inferred metabolizer phenotype	Other	1	1
NVG2203	SNP genotype	SNP genotype	Diagnosis	1	1
NVG3612	Non-CC IL28B genotype	Non-CC IL28B genotype	Laboratory	1	1
NVG1976	HLA , B, DR mismatch	HLA , B, DR mismatch	Laboratory	1	0
NVG3016	Cause of bladder dysfunction	Cause of bladder dysfunction	Diagnosis	1	0
NVG2284	circumcised	Circumcised	Comorbidities	1	0
NVG3246	Continence (Continent, Urinary incontinence, Faecal incontinence, Urinary and faecal incontinence)	Continence	Comorbidities	1	0
NVG3247	Continence (Continent, Urinary incontinence, Faecal incontinence, Urinary and faecal incontinence)	Continence	Comorbidities	1	0
NVG3248	Continence (Continent, Urinary incontinence, Faecal incontinence, Urinary	Continence	Comorbidities	1	0

	and faecal incontinence)				
NVG3249	Continence (Continent, Urinary incontinence, Faecal incontinence, Urinary and faecal incontinence)	Continence	Comorbidities	1	0
NVG0731	Urological patient	Urological patient	Other	1	1
NVG4137	History of vasectomy	History of vasectomy	Comorbidities	1	1
NVG1393	Biliary anastomotic stricture	Biliary anastomotic stricture	Comorbidities	1	1
NVG1008	Congenital biliary disease	Congenital biliary disease	Comorbidities	1	1
NVG2229	Gastrointestinal disorders	Gastrointestinal disorders	Comorbidities	1	0
NVG1785	incisional hernia	Incisional hernia	Treatment	1	0
NVG0714	Inflammatory bowel disease	Inflammatory bowel disease	Comorbidities	1	1
NVG0819	Inflammatory bowel disease	Inflammatory bowel disease	Comorbidities	1	1
NVG3204	Peptic ulcer disease	Peptic ulcer disease	Comorbidities	1	0
NVG0979	Anaemia	Anemia	Diagnosis	1	0
NVG0509	Anemia	Anemia	Diagnosis	1	0
NVG2226	Anemia	Anemia	Diagnosis	1	0
NVG0146	Anemia (baseline)	Anemia	Diagnosis	1	0
NVG0507	Coagulopathy	Coagulopathy	Diagnosis	1	0
NVG1722	Immune compromise	Immunosuppression	Comorbidities	1	0
NVG1292	Immune suppression	Immunosuppression	Comorbidities	1	0
NVG1043	Immunesupressed	Immunosuppression	Comorbidities	1	0
NVG0175	Immunocompromised	Immunosuppression	Comorbidities	1	0
NVG0235	Immunocompromised	Immunosuppression	Comorbidities	1	0

NVG0729	Immunocompromised	Immunosuppression	Comorbidities	1	0
NVG1363	Immunocompromised	Immunosuppression	Comorbidities	1	0
NVG0713	Immunocompromising condition	Immunosuppression	Comorbidities	1	0
NVG0194	Immunosuppressed	Immunosuppression	Comorbidities	1	0
NVG1442	Immunosuppressed	Immunosuppression	Comorbidities	1	0
NVG1581	Immunosuppressed conditiond	Immunosuppression	Comorbidities	1	0
NVG0056	Immunosuppression	Immunosuppression	Comorbidities	1	0
NVG1253	Immunosuppression	Immunosuppression	Comorbidities	1	0
NVG2156	Inmunosupression	Immunosuppression	Comorbidities	1	0
NVG0379	Immunosuppression at month 1	Immunosuppression	Comorbidities	1	0
NVG0380	Immunosuppression at month 3	Immunosuppression	Comorbidities	1	0
NVG0381	Immunosuppression at month 6	Immunosuppression	Comorbidities	1	0
NVG2163	Other metabolic or inmunity disorder	Other metabolic or inmunity disorder	comorbidities	1	0
NVG1010	Chornic Kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG1045	Chornic Kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG0754	Chronic kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG1100	Chronic kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG2971	Chronic kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG4361	chronic kidney disease	Chronic Kidney disease	Comorbidities	1	1
NVG2159	chronic renal disease	Chronic Kidney disease	Comorbidities	1	1

NVG4720	Chronic renal disease	Chronic Kidney disease	Comorbidities	1	1
NVG0348	Chronic renal failure	Chronic Kidney disease	Comorbidities	1	1
NVG0710	Chronic renal failure	Chronic Kidney disease	Comorbidities	1	1
NVG0779	Chronic renal failure	Chronic Kidney disease	Comorbidities	1	1
NVG0818	Chronic renal failure	Chronic Kidney disease	Comorbidities	1	1
NVG0588	Chronic renal impairment	Chronic Kidney disease	Comorbidities	1	1
NVG1588	Chronic renal insufficiency	Chronic Kidney disease	Comorbidities	1	1
NVG4399	Chronic renal replacement therapy use	Chronic Kidney disease	Comorbidities	1	1
NVG1444	Chronic renal failure or liver disease	Chronic Kidney disease	Comorbidities	1	1
NVG0728	Renal disease	Kidney disease	Comorbidities	1	0
NVG3206	Renal disease	Kidney disease	Comorbidities	1	0
NVG2910	Renal status	Renal status	Comorbidities	1	0
NVG0865	Underlying end-stage renal disease: Chronic interstitial nephropathy	Underlying end-stage renal disease	Comorbidities	1	1
NVG0866	Underlying end-stage renal disease: Congenital nephropathy	Underlying end-stage renal disease	Comorbidities	1	1
NVG0862	Underlying end-stage renal disease: Diabetic nephropathy	Underlying end-stage renal disease	Comorbidities	1	1
NVG0861	Underlying end-stage renal disease: Glomerulonephritis	Underlying end-stage renal disease	Comorbidities	1	1

NVG0863	Underlying end-stage renal disease: Nephroangiosclerosis	Underlying end-stage renal disease	Comorbidities	1	1
NVG0870	Underlying end-stage renal disease: Other	Underlying end-stage renal disease	Comorbidities	1	1
NVG0864	Underlying end-stage renal disease: Polycystic kidney disease	Underlying end-stage renal disease	Comorbidities	1	1
NVG0868	Underlying end-stage renal disease: Reflux nephropathy	Underlying end-stage renal disease	Comorbidities	1	1
NVG0869	Underlying end-stage renal disease: Unknown	Underlying end-stage renal disease	Comorbidities	1	1
NVG0181	Hepatic impairment	Hepatic impairment	Clinical manifestations	1	0
NVG1583	Chronic liver disease	Chronic liver disease	Comorbidities	1	1
NVG4721	Chronic liver disease	Chronic liver disease	Comorbidities	1	1
NVG0817	Chronic liver failure	Chronic liver disease	Comorbidities	1	1
NVG0711	Cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG1258	Cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG2216	Cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG4535	Cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG1044	Live cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG0761	Liver cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG4371	liver cirrhosis	Chronic liver disease	Comorbidities	1	1
NVG1084	Liver failure	Chronic liver disease	Comorbidities	1	0
NVG0346	Liver disease	Liver disease	Comorbidities	1	0
NVG0511	Liver disease	Liver disease	Comorbidities	1	0
NVG1012	Liver disease	Liver disease	Comorbidities	1	0
NVG3197	Liver disease	Liver disease	Comorbidities	1	0
NVG1728	Liver disease	Liver disease	Comorbidities	1	0

NVG0604	Liver disease (alcoholic)	Liver disease	Comorbidities	1	1
NVG0605	Liver disease (cryptogenic)	Liver disease	Comorbidities	1	1
NVG0606	Liver disease (Hepatitis B)	Liver disease	Comorbidities	1	1
NVG0608	Liver disease (hepatitis C)	Liver disease	Comorbidities	1	1
NVG0609	Liver disease (hepatocellular carcinoma).	Liver disease	Comorbidities	1	1
NVG0610	Liver disease (nonalcoholic fatty liver disease)	Liver disease	Comorbidities	1	1
NVG2162	liver diseases	Liver disease	Comorbidities	1	0
NVG1180	End-stage renal disease	End-stage renal disease	Comorbidities	1	1
NVG2072	FibroScan liver disease stage	Fibrosis stage	Images/EKG	1	1
NVG0328	Fibrosis stage	Fibrosis stage	Images/EKG	1	1
NVG3614	Fibrosis stage (F0 or F1, F2, F3)	Fibrosis stage	Images/EKG	1	1
NVG3615	Fibrosis stage (F0 or F1, F2, F3)	Fibrosis stage	Images/EKG	1	1
NVG3616	Fibrosis stage (F0 or F1, F2, F3)	Fibrosis stage	Images/EKG	1	1
NVG3617	Fibrosis stage (F0 or F1, F2, F3)	Fibrosis stage	Images/EKG	1	1
NVG2314	Fibrosis stage (F0, F1...)	Fibrosis stage	Images/EKG	1	1
NVG0399	Fibrosis-4 index	Fibrosis stage	Images/EKG	1	1
NVG0426	Liver fibrosis score F3 or higher	Liver fibrosis score	Images/EKG	1	1
NVG1391	Nonalcoholic fatty liver disease	Nonalcoholic fatty liver disease	Comorbidities	1	1
NVG1634	Acute myeloid leukemiaa	Acute myeloid leukemiaa	Diagnosis	1	1
NVG0707	Active malignancy	Active malignancy	Comorbidities	1	1
NVG0504	Any tumor	Cancer	Comorbidities	1	0
NVG1254	Cancer	Cancer	Comorbidities	1	1
NVG2121	cancer	Cancer	Comorbidities	1	1

NVG3200	Cancer	Cancer	Comorbidities	1	1
NVG3105	Cancer status	Cancer	Comorbidities	1	1
NVG1179	Colon cancer	Cancer	Comorbidities	1	1
NVG0726	Solid malignancy	Cancer	Comorbidities	1	0
NVG1079	Solid malignancy	Cancer	Comorbidities	1	0
NVG1015	Solid organ malignancy	Cancer	Comorbidities	1	0
NVG1104	Solid organ tumor	Cancer	Comorbidities	1	0
NVG0344	Solid tumor	Cancer	Comorbidities	1	0
NVG4358	solid tumor	Cancer	Comorbidities	1	0
NVG0193	History of malignancy	History of malignancy	Comorbidities	1	0
NVG3678	initial synchronous tumor	Initial synchronous tumor	Comorbidities	1	0
NVG1178	Malignancies	Malignancy	Comorbidities	1	0
NVG2160	malignancies	Malignancy	Comorbidities	1	0
NVG0586	Malignancy	Malignancy	Comorbidities	1	0
NVG0780	Malignancy	Malignancy	Comorbidities	1	0
NVG0947	Malignancy	Malignancy	Comorbidities	1	0
NVG1071	Malignancy	Malignancy	Comorbidities	1	0
NVG1441	Malignancy	Malignancy	Comorbidities	1	0
NVG2972	Malignancy	Malignancy	Comorbidities	1	0
NVG0762	Neoplasia	Malignancy	Comorbidities	1	0
NVG0497	Metastatic disease	Metastatic disease	Comorbidities	1	1
NVG1199	Invasive disease (Candida auris infection)	Invasive disease	Diagnosis	1	0
NVG2164	Haematological	Haematological	Comorbidities	1	0
NVG0727	Haematological malignancy	Haematological malignancy	Comorbidities	1	0
NVG1014	Haematological malignancy	Haematological	Comorbidities	1	0

		malignancy			
NVG1080	Haematological malignancy	Haematological malignancy	Comorbidities	1	0
NVG3148	Haematological malignancy	Haematological malignancy	Comorbidities	1	0
NVG0345	Hematologic malignancy	Hematologic malignancy	Comorbidities	1	0
NVG4357	hematologic malignancy	Hematologic malignancy	Comorbidities	1	0
NVG1394	Liver malignancies	Liver malignancies	Comorbidities	1	0
NVG3676	Tumor depth (Mucosa, Submucosa)	Tumor depth	Other	1	0
NVG3677	Tumor depth (Mucosa, Submucosa)	Tumor depth	Other	1	0
NVG3667	Tumor location (Upper, Middle, Lower)	Tumor location	Other	1	0
NVG3668	Tumor location (Upper, Middle, Lower)	Tumor location	Other	1	0
NVG3669	Tumor location (Upper, Middle, Lower)	Tumor location	Other	1	0
NVG3210	Avascular necrosis	Avascular necrosis	Diagnosis	1	1
NVG3211	Dysplasia or congenital dislocation	Dysplasia or congenital dislocation	Diagnosis	1	1
NVG1102	End stage Liver disease	End-stage liver disease	Comorbidities	1	1
NVG0230	End-stage liver disease	End-stage liver disease	Comorbidities	1	1
NVG2167	fracture	Fracture	Clinical manifestations	1	1
NVG3208	Fractures neck of femur	Fracture	Clinical manifestations	1	1
NVG2119	Joint disease	Joint disease	Diagnosis	1	1
NVG4719	Chronic neurological disease	Chronic neurological disease	Comorbidities	1	1
NVG0715	Cognitive impairment	Chronic neurological	Comorbidities	1	1

		disease			
NVG2231	Nervous system disorders	Chronic neurological disease	Comorbidities	1	0
NVG1176	Neurologic disease	Chronic neurological disease	Comorbidities	1	0
NVG2273	Neurologic disorder	Chronic neurological disease	Comorbidities	1	0
NVG1072	Neurological or psychiatric disorder	Chronic neurological disease	Comorbidities	1	0
NVG0499	Dementia	Dementia	Comorbidities	1	1
NVG2969	Dementia	Dementia	Comorbidities	1	1
NVG3196	Dementia	Dementia	Comorbidities	1	1
NVG3244	Dementia	Dementia	Comorbidities	1	1
NVG0307	Patients with dementia	Dementia	comorbidities	1	1
NVG3251	Mobility (Mobile, Transfer with help, Bedbound, Other)	Mobility	Other	1	0
NVG3252	Mobility (Mobile, Transfer with help, Bedbound, Other)	Mobility	Other	1	0
NVG3253	Mobility (Mobile, Transfer with help, Bedbound, Other)	Mobility	Other	1	0
NVG3254	Mobility (Mobile, Transfer with help, Bedbound, Other)	Mobility	Other	1	0
NVG1261	Malnutrition	Malnutrition	Comorbidities	1	1
NVG0517	Obesity	Obesity	comorbidities	1	1
NVG4094	Cesarean section before labor onset	Cesarean section before labor onset	Other	1	0
NVG2183	Mode of delivery	Mode of delivery	Other	1	1
NVG4092	Type of delivery (Vaginal	Type of delivery	Treatment	1	1

	Cesarean section)				
NVG4093	Type of delivery (Vaginal Cesarean section)	Type of delivery	Treatment	1	1
NVG2514	History of induced preterm labour	History of induced preterm labour	Comorbidities	1	1
NVG2454	Received full antenatal package	Received full antenatal package	Treatment	1	0
NVG2513	History of miscarriage <16 weeks	History of miscarriage <16 weeks	Comorbidities	1	1
NVG2452	Miscarriages	Miscarriages	Diagnosis	1	1
NVG3344	Type of miscarriage	Type of miscarriage	Diagnosis	1	0
NVG2511	Nulliparous	Nulliparous	comorbidities	1	1
NVG3998	Previous adverse pregnancy outcomes (Congenital abnormalities Stillbirth Termination of pregnancy for medical reasons)	Previous adverse pregnancy outcomes	diagnosis	1	1
NVG3999	Previous adverse pregnancy outcomes (Congenital abnormalities Stillbirth Termination of pregnancy for medical reasons)	Previous adverse pregnancy outcomes	diagnosis	1	1
NVG4000	Previous adverse pregnancy outcomes (Congenital abnormalities Stillbirth Termination of pregnancy for medical reasons)	Previous adverse pregnancy outcomes	diagnosis	1	1
NVG2515	History of perinatal death	History of perinatal death	Comorbidities	1	1

NVG0753	Current pregnancy	Current pregnancy	Comorbidities	1	1
NVG1303	No. (%) pregnancy associated	No. pregnancy associated	comorbidities	1	0
NVG2516	Multiple pregnancy	Pregnancy	Comorbidities	1	1
NVG2577	pregnancy	Pregnancy	Comorbidities	1	1
NVG3904	Pregnancy	Pregnancy	Comorbidities	1	1
NVG3089	Pregnancy and contraception status	Pregnancy	Comorbidities	1	1
NVG0443	Pregnancy Status	Pregnancy	Comorbidities	1	1
NVG2105	pregnant	Pregnancy	Comorbidities	1	1
NVG3996	Previous pregnancies	Pregnancy	Comorbidities	1	1
NVG2455	At least one antenatal care visit with a skilled provider	At least one antenatal care visit with a skilled provider	Other	1	0
NVG2328	Breastfeeding	Breastfeeding	Other	1	0
NVG2418	Breastfeeding	Breastfeeding	Other	1	0
NVG4321	Breastfeeding status (Breastfed or Not breastfed)	Breastfeeding	Other	1	0
NVG2814	Total number fo participants	Other comorbidities	Other	0	2
NVG2222	Depression	Depression	Comorbidities	1	1
NVG2832	Mental Health Problem	Mental Health Problem	Comorbidities	1	0
NVG4545	Psychiatric Disorderc	Psychiatric Disorderc	Comorbidities	1	0
NVG0513	Psychosis	Psychosis	diagnosis	1	1
NVG0587	Asthma	Asthma	Comorbidities	1	1
NVG2115	asthma	Asthma	Comorbidities	1	1
NVG2271	Asthma	Asthma	Comorbidities	1	1
NVG4043	Asthma	Asthma	Comorbidities	1	1

NVG2435	Asthma Cause of bronchiectasies:	Cause of bronchiectasies	Diagnosis	1	0
NVG2432	Other Cause of bronchiectasies:	Cause of bronchiectasies	diagnosis	1	1
NVG2427	Post-infectious Cause of bronchiectasies:	Cause of bronchiectasies	diagnosis	1	1
NVG2431	primary culiary dyskinesia Cause of bronchiectasies:	Cause of bronchiectasies	diagnosis	1	1
NVG2433	TracheomalaciaCause of bronchiectasies:	Cause of bronchiectasies	Diagnosis	1	1
NVG2430	Aspiration Cause of bronchiectasies:	Cause of bronchiectasies	Diagnosis	1	0
NVG0759	Chronic airways disease	Chronic airways disease	Comorbidities	1	1
NVG1068	Chrinc lung disease	Chronic lung disease	Comorbidities	1	1
NVG1013	Chronic lung disease	Chronic lung disease	Comorbidities	1	1
NVG2974	Chronic pulmonary disease	Chronic lung disease	Comorbidities	1	1
NVG3194	Chronic pulmonary disease	Chronic lung disease	Comorbidities	1	1
NVG1083	Chronic respiratory disease	Chronic lung disease	Comorbidities	1	1
NVG4716	Chronic respiratory disease	Chronic lung disease	Comorbidities	1	1
NVG0232	Structural lung diseasea	Chronic lung disease	Comorbidities	1	1
NVG1042	Chronic obstructive lung disease	Chronic obstructive lung disease	Comorbidities	1	1
NVG0815	Chronic obstructive pulmonary disease	Chronic obstructive lung disease	Comorbidities	1	1
NVG0856	Chronic obstructive pulmonary disease	Chronic obstructive lung disease	Comorbidities	1	1
NVG1101	Chronic obstructive Pulmonary disease	Chronic obstructive	Comorbidities	1	1

		lung disease			
NVG4373	chronic obstructive pulmonary disease	Chronic obstructive lung disease	Comorbidities	1	1
NVG0192	COPD	Chronic obstructive lung disease	Comorbidities	1	1
NVG0341	COPD	Chronic obstructive lung disease	Comorbidities	1	1
NVG4044	COPD	Chronic obstructive lung disease	Comorbidities	1	1
NVG2161	chronic pulmonary	Chronic obstructive lung disease	Comorbidities	1	1
NVG0506	Pulmonary disease	Lung disease	Comorbidities	1	0
NVG4369	cystic fibrosis	Cystic fibrosis	Comorbidities	1	1
NVG2428	idiopathic Cause of bronchiectasies:	Idiopathic cause of bronchiectasies	Comorbidities	1	0
NVG2429	Immunodeficiency Cause of bronchiectasies:	Immunodeficiency cause of bronchiectasies	Comorbidities	1	0
NVG0514	Pulmonary circulatory disorders	Pulmonary circulatory disorders	Comorbidities	1	0
NVG0760	Autoimmune disease	Autoimmune disease	Comorbidities	1	1
NVG3212	Inflammatory arthropathy	Inflammatory arthropathy	Comorbidities	1	1
NVG3199	Connective tissue and rheumatic disease	Connective tissue and rheumatic disease	Comorbidities	1	0
NVG1073	Rheumatic disease	Rheumatic disease	Comorbidities	1	0
NVG0758	Chronic skin condition	Chronic skin condition	Comorbidities	1	0
NVG4368	chronic wounds	Chronic wounds	Comorbidities	1	0

NVG1207	Excess alcohol user	Alcohol abuse	Clinical manifestations	1	1
NVG4546	Active alcohol abused	Alcohol abuse	Comorbidities	1	1
NVG0503	Alcohol abuse	Alcohol abuse	Comorbidities	1	1
NVG0641	Alcohol drinker	Alcohol abuse	Comorbidities	1	1
NVG3662	Alcohol drinker	Alcohol abuse	Comorbidities	1	1
NVG2836	Alcohol problem	Alcohol abuse	Comorbidities	1	1
NVG4612	Alcohol use	Alcohol abuse	Comorbidities	1	1
NVG3482	Alcohol use during pregnancy	Alcohol abuse	Comorbidities	1	1
NVG4709	Current or former alcohol abuse	Alcohol abuse	Comorbidities	1	1
NVG4547	History of alcohol abused	Alcohol abuse	Comorbidities	1	1
NVG4548	Active illicit substance use	Active illicit substance use	Comorbidities	1	1
NVG3154	Drug or alcohol misuse	Drug or alcohol misuse	Comorbidities	1	1
NVG3657	Illicit drug use within 6 mo of death	Illicit drug use within 6 mo of death	Comorbidities	1	0
NVG2069	Injecting drug use in the last month	Injection drug use	Comorbidities	1	0
NVG2068	History of ever injectin drugs	Injection drug use	Comorbidities	1	1
NVG4550	History of injection drug use	Injection drug use	Comorbidities	1	1
NVG3484	Illicit-drug use at pregnancy	Injection drug use	Comorbidities	1	1
NVG3623	Injection drug	Injection drug use	Comorbidities	1	1
NVG1586	Injection drug use	Injection drug use	Comorbidities	1	1
NVG1208	Injection drug user	Injection drug use	Comorbidities	1	1
NVG4710	Intravenous drug abuse	Injection drug use	Comorbidities	1	1
NVG0088	Intravenous drug use	Injection drug use	Comorbidities	1	1
NVG0101	Intravenous drug use	Injection drug use	Comorbidities	1	1
NVG4450	Intravenous drug use/ChemSex	Injection drug use	Comorbidities	1	1

NVG0034	IVDA (intravenous drug abuse)	Injection drug use	Comorbidities	1	1
NVG2410	Active injecting Drug use	Injection drug use	Comorbidities	1	1
NVG0336	Injection drug use >12 months prior to screening	Injection drug use	Comorbidities	1	0
NVG0335	Injection drug use within 12 months	Injection drug use	Comorbidities	1	0
NVG4549	Ongoing injection drug use	Ongoing injection drug use	comorbidities	1	1
NVG1482	Use of intravenous injected drugs	Drug Use	Other	1	0
NVG1922	farmaco (si Vs no)	Drug	Treatment	1	1
NVG0033	Medical history relevant to substance abuse	Substance abuse	Comorbidities	1	1
NVG3752	Past smoker	Past smoker	comorbidities	1	0
NVG2329	Second hand smoke	Second hand smoke	Comorbidities	1	0
NVG4524	Smoke exposure in house	Second hand smoke	Comorbidities	1	0
NVG2259	Exposure to smoke	Tobacco exposure	Comorbidities	1	1
NVG1743	Tabaco	Tobacco exposure	Comorbidities	1	1
NVG3483	Tobacco at pregnancy	Tobacco exposure	Comorbidities	1	1
NVG0300	Tobacco exposure	Tobacco exposure	Comorbidities	1	1
NVG2419	Tobacco smoke exposure	Tobacco exposure	Comorbidities	1	1
NVG4708	Current or former smoking	Tobacco exposure	Comorbidities	1	1
NVG0642	Current smoker	Tobacco exposure	Comorbidities	1	1
NVG3274	Current smoker	Tobacco exposure	Comorbidities	1	1
NVG3751	Current smoker	Tobacco exposure	Comorbidities	1	1
NVG3932	Current smoker	Tobacco exposure	Comorbidities	1	1
NVG3658	History of cigarette use	Tobacco exposure	Comorbidities	1	1
NVG3464	Smoker	Tobacco exposure	Comorbidities	1	1
NVG3663	Smoker	Tobacco exposure	Comorbidities	1	1

NVG2248	Smoking	Tobacco exposure	Comorbidities	1	1
NVG4261	Smoking	Tobacco exposure	Comorbidities	1	1
NVG4611	Smoking	Tobacco exposure	Comorbidities	1	1
NVG2512	Smoking at the beggining of pregnancy	Tobacco exposure	Comorbidities	1	1
NVG0766	Smoking status	Tobacco exposure	Comorbidities	1	1
NVG3150	Smoking status	Tobacco exposure	Comorbidities	1	1
NVG2041	Duration of carriage	Duration of carriage	Clinical manifestations	1	0
NVG3471	Year of delivery	Year of delivery	Other	1	1
NVG2384	Time since HIV diagnosis	Time since HIV diagnosis	Diagnosis	1	1
NVG2237	Years since HIV diagnosis	Time since HIV diagnosis	Diagnosis	1	0
NVG3938	Years since HIV diagnosis	Time since HIV diagnosis	Diagnosis	1	0
NVG2358	Years since HIV diagnosis	Time since HIV diagnosis	Diagnosis	1	0
NVG1969	donor after circulatory death	Donor after circulatory death	Other	1	0
NVG1968	Living donor	Living donor	Other	1	1
NVG4366	heart transplantation	Heart transplantation	Clinical manifestations	1	1
NVG1106	Hematopoietic stem cell transplantation	Hematopoietic stem cell transplantation	Comorbidities	1	1
NVG0548	Prior HSCT	Prior HSCT	Comorbidities	1	0
NVG0550	Allogeneic	Allogeneic transplant	Treatment	1	1
NVG1637	Allogeneic transplant	Allogeneic transplant	Treatment	1	1
NVG2629	Auto-HSCT	Auto-HSCT	Treatment	1	1
NVG0549	Autologous	Autologous transplant	Treatment	1	1

NVG1636	Autologous transplant	Autologous transplant	Treatment	1	1
NVG0708	Haematopoietic stem cell transplantation	Haematopoietic stem cell transplantation	Treatment	1	1
NVG4362	stem cell transplantation	Stem cell transplantation	Treatment	1	1
NVG1392	Liver graft rejection	Liver graft rejection	Diagnosis	1	1
NVG1380	Organ transplanted: Combined kidney and liver	Organ transplanted	comorbidities	1	1
NVG1378	Organ transplanted: Heart	Organ transplanted	comorbidities	1	1
NVG1376	Organ transplanted: Kidney	Organ transplanted	comorbidities	1	1
NVG1377	Organ transplanted: Liver	Organ transplanted	comorbidities	1	1
NVG1379	Organ transplanted: Lung	Organ transplanted	comorbidities	1	1
NVG1973	Retransplantation	Retransplantation	Comorbidities	1	0
NVG0347	Solid organ transplantation	Transplant	Comorbidities	1	0
NVG0709	Solid organ transplantation	Transplant	Comorbidities	1	0
NVG0377	Transplant organ	Transplant	Comorbidities	1	0
NVG0730	Transplant	Transplant	Comorbidities	1	0
NVG0055	Type of transplant	Type of transplant	Diagnosis	1	0
NVG1974	ABO incompatible transplantation	ABO incompatible transplantation	Other	1	0
NVG3649	Bilateral transplantation	Bilateral transplantation	Treatment	1	1
NVG1182	Kidney transplant	kidney transplantation	Comorbidities	1	1
NVG4365	kidney transplantation	kidney transplantation	Comorbidities	1	1
NVG0859	Previous kidney transplantation	Previous kidney transplantation	Comorbidities	1	0

NVG0054	Previous rejection	Previous rejection	Comorbidities	1	0
NVG3151	Previous solid organ transplant	Previous solid organ transplant	Comorbidities	1	0
NVG4364	liver transplantation	Liver transplantation	Treatment	1	1
NVG0598	Trauma	Trauma	Diagnosis	1	1
NVG1585	Trauma within previous 30 d	Trauma within previous 30 d	Other	1	0
NVG2902	Obstructive uropathy	Obstructive uropathy	comorbidities	1	0
NVG2889	Medical history associated with renal stones	Medical history associated with renal stones	Comorbidities	1	1
NVG0661	Prior tracheostomy	Prior tracheostomy	Comorbidities	1	1
NVG3580	Patients younger than 12month with intussusception	Patients younger than 12month with intussusception	comorbidities	1	0
NVG2824	Adolescets (12-17y)	Age	Demographics	1	1
NVG0002	Age	Age	Demographics	1	1
NVG0024	Age	Age	Demographics	1	1
NVG0038	Age	Age	Demographics	1	1
NVG0047	Age	Age	Demographics	1	1
NVG0057	Age	Age	Demographics	1	1
NVG0067	Age	Age	Demographics	1	1
NVG0113	Age	Age	Demographics	1	1
NVG0166	Age	Age	Demographics	1	1
NVG0188	Age	Age	Demographics	1	1
NVG0216	Age	Age	Demographics	1	1
NVG0240	Age	Age	Demographics	1	1

NVG0244	Age	Age	Demographics	1	1
NVG0282	Age	Age	Demographics	1	1
NVG0288	Age	Age	Demographics	1	1
NVG0296	Age	Age	Demographics	1	1
NVG0303	Age	Age	Demographics	1	1
NVG0321	Age	Age	Demographics	1	1
NVG0339	Age	Age	Demographics	1	1
NVG0375	Age	Age	Demographics	1	1
NVG0382	Age	Age	Demographics	1	1
NVG0389	Age	Age	Demographics	1	1
NVG0400	Age	Age	Demographics	1	1
NVG0407	Age	Age	Demographics	1	1
NVG0419	Age	Age	Demographics	1	1
NVG0430	Age	Age	Demographics	1	1
NVG0436	Age	Age	Demographics	1	1
NVG0444	Age	Age	Demographics	1	1
NVG0452	Age	Age	Demographics	1	1
NVG0464	Age	Age	Demographics	1	1
NVG0482	Age	Age	Demographics	1	1
NVG0490	Age	Age	Demographics	1	1
NVG0535	Age	Age	Demographics	1	1
NVG0540	Age	Age	Demographics	1	1
NVG0579	Age	Age	Demographics	1	1
NVG0602	Age	Age	Demographics	1	1
NVG0626	Age	Age	Demographics	1	1
NVG0651	Age	Age	Demographics	1	1

NVG0653	Age	Age	Demographics	1	1
NVG0674	Age	Age	Demographics	1	1
NVG0695	Age	Age	Demographics	1	1
NVG0704	Age	Age	Demographics	1	1
NVG0722	Age	Age	Demographics	1	1
NVG0739	Age	Age	Demographics	1	1
NVG0763	Age	Age	Demographics	1	1
NVG0775	Age	Age	Demographics	1	1
NVG0807	Age	Age	Demographics	1	1
NVG0852	Age	Age	Demographics	1	1
NVG0927	Age	Age	Demographics	1	1
NVG0939	Age	Age	Demographics	1	1
NVG0987	Age	Age	Demographics	1	1
NVG1003	Age	Age	Demographics	1	1
NVG1036	Age	Age	Demographics	1	1
NVG1058	Age	Age	Demographics	1	1
NVG1074	Age	Age	Demographics	1	1
NVG1097	Age	Age	Demographics	1	1
NVG1129	Age	Age	Demographics	1	1
NVG1139	Age	Age	Demographics	1	1
NVG1149	Age	Age	Demographics	1	1
NVG1171	Age	Age	Demographics	1	1
NVG1195	Age	Age	Demographics	1	1
NVG1201	Age	Age	Demographics	1	1
NVG1223	Age	Age	Demographics	1	1
NVG1232	Age	Age	Demographics	1	1

NVG1235	Age	Age	Demographics	1	1
NVG1249	Age	Age	Demographics	1	1
NVG1285	Age	Age	Demographics	1	1
NVG1306	Age	Age	Demographics	1	1
NVG1322	Age	Age	Demographics	1	1
NVG1381	Age	Age	Demographics	1	1
NVG1397	Age	Age	Demographics	1	1
NVG1407	Age	Age	Demographics	1	1
NVG1417	Age	Age	Demographics	1	1
NVG1420	Age	Age	Demographics	1	1
NVG1437	Age	Age	Demographics	1	1
NVG1477	Age	Age	Demographics	1	1
NVG1495	Age	Age	Demographics	1	1
NVG1519	Age	Age	Demographics	1	1
NVG1542	Age	Age	Demographics	1	1
NVG1558	Age	Age	Demographics	1	1
NVG1576	Age	Age	Demographics	1	1
NVG1614	Age	Age	Demographics	1	1
NVG1638	Age	Age	Demographics	1	1
NVG1653	Age	Age	Demographics	1	1
NVG1674	Age	Age	Demographics	1	1
NVG1701	Age	Age	Demographics	1	1
NVG1736	Age	Age	Demographics	1	1
NVG1749	Age	Age	Demographics	1	1
NVG1768	Age	Age	Demographics	1	1
NVG1796	Age	Age	Demographics	1	1

NVG1811	Age	Age	Demographics	1	1
NVG1840	Age	Age	Demographics	1	1
NVG1857	Age	Age	Demographics	1	1
NVG1914	Age	Age	Demographics	1	1
NVG1926	age	Age	Demographics	1	1
NVG1979	Age	Age	Demographics	1	1
NVG2052	Age	Age	Demographics	1	1
NVG2066	Age	Age	Demographics	1	1
NVG2075	Age	Age	Demographics	1	1
NVG2106	age	Age	Demographics	1	1
NVG2152	age	Age	Demographics	1	1
NVG2194	Age	Age	Demographics	1	1
NVG2206	Age	Age	Demographics	1	1
NVG2236	Age	Age	Demographics	1	1
NVG2254	Age	Age	Demographics	1	1
NVG2268	Age	Age	Demographics	1	1
NVG2281	Age	Age	Demographics	1	1
NVG2298	Age	Age	Demographics	1	1
NVG2308	Age	Age	Demographics	1	1
NVG2325	Age	Age	Demographics	1	1
NVG2339	age	Age	Demographics	1	1
NVG2361	Age	Age	Demographics	1	1
NVG2389	Age	Age	Demographics	1	1
NVG2414	Age	Age	Demographics	1	1
NVG2498	Age	Age	Demographics	1	1
NVG2547	Age	Age	Demographics	1	1

NVG2557	Age	Age	Demographics	1	1
NVG2583	Age	Age	Demographics	1	1
NVG2590	Age	Age	Demographics	1	1
NVG2615	Age	Age	Demographics	1	1
NVG2652	Age	Age	Demographics	1	1
NVG2700	Age	Age	Demographics	1	1
NVG2710	Age	Age	Demographics	1	1
NVG2774	Age	Age	Demographics	1	1
NVG2793	Age	Age	Demographics	1	1
NVG2820	Age	Age	Demographics	1	1
NVG2827	Age	Age	Demographics	1	1
NVG2848	Age	Age	Demographics	1	1
NVG2856	Age	Age	Demographics	1	1
NVG2860	Age	Age	Demographics	1	1
NVG2865	Age	Age	Demographics	1	1
NVG2874	Age	Age	Demographics	1	1
NVG2905	Age	Age	Demographics	1	1
NVG2933	Age	Age	Demographics	1	1
NVG2949	Age	Age	Demographics	1	1
NVG2963	Age	Age	Demographics	1	1
NVG3012	Age	Age	Demographics	1	1
NVG3026	Age	Age	Demographics	1	1
NVG3030	Age	Age	Demographics	1	1
NVG3042	Age	Age	Demographics	1	1
NVG3073	Age	Age	Demographics	1	1
NVG3079	Age	Age	Demographics	1	1

NVG3084	Age	Age	Demographics	1	1
NVG3101	Age	Age	Demographics	1	1
NVG3111	Age	Age	Demographics	1	1
NVG3120	Age	Age	Demographics	1	1
NVG3131	Age	Age	Demographics	1	1
NVG3142	Age	Age	Demographics	1	1
NVG3168	Age	Age	Demographics	1	1
NVG3190	Age	Age	Demographics	1	1
NVG3222	Age	Age	Demographics	1	1
NVG3231	Age	Age	Demographics	1	1
NVG3238	Age	Age	Demographics	1	1
NVG3243	Age	Age	Demographics	1	1
NVG3267	Age	Age	Demographics	1	1
NVG3300	Age	Age	Demographics	1	1
NVG3315	Age	Age	Demographics	1	1
NVG3320	Age	Age	Demographics	1	1
NVG3326	Age	Age	Demographics	1	1
NVG3342	Age	Age	Demographics	1	1
NVG3371	Age	Age	Demographics	1	1
NVG3378	Age	Age	Demographics	1	1
NVG3384	Age	Age	Demographics	1	1
NVG3416	Age	Age	Demographics	1	1
NVG3439	Age	Age	Demographics	1	1
NVG3442	Age	Age	Demographics	1	1
NVG3459	Age	Age	Demographics	1	1
NVG3543	Age	Age	Demographics	1	1

NVG3583	Age	Age	Demographics	1	1
NVG3606	Age	Age	Demographics	1	1
NVG3633	Age	Age	Demographics	1	1
NVG3655	Age	Age	Demographics	1	1
NVG3659	Age	Age	Demographics	1	1
NVG3689	Age	Age	Demographics	1	1
NVG3699	Age	Age	Demographics	1	1
NVG3706	Age	Age	Demographics	1	1
NVG3727	Age	Age	Demographics	1	1
NVG3737	Age	Age	Demographics	1	1
NVG3745	Age	Age	Demographics	1	1
NVG3782	Age	Age	Demographics	1	1
NVG3805	Age	Age	Demographics	1	1
NVG3819	Age	Age	Demographics	1	1
NVG3849	Age	Age	Demographics	1	1
NVG3872	Age	Age	Demographics	1	1
NVG3902	Age	Age	Demographics	1	1
NVG3933	Age	Age	Demographics	1	1
NVG3935	Age	Age	Demographics	1	1
NVG3965	Age	Age	Demographics	1	1
NVG3983	Age	Age	Demographics	1	1
NVG4009	Age	Age	Demographics	1	1
NVG4013	Age	Age	Demographics	1	1
NVG4056	Age	Age	Demographics	1	1
NVG4074	Age	Age	Demographics	1	1
NVG4082	Age	Age	Demographics	1	1

NVG4103	Age	Age	Demographics	1	1
NVG4140	Age	Age	Demographics	1	1
NVG4152	Age	Age	Demographics	1	1
NVG4155	Age	Age	Demographics	1	1
NVG4159	Age	Age	Demographics	1	1
NVG4177	Age	Age	Demographics	1	1
NVG4196	Age	Age	Demographics	1	1
NVG4199	Age	Age	Demographics	1	1
NVG4248	Age	Age	Demographics	1	1
NVG4260	Age	Age	Demographics	1	1
NVG4276	Age	Age	Demographics	1	1
NVG4283	Age	Age	Demographics	1	1
NVG4289	Age	Age	Demographics	1	1
NVG4310	Age	Age	Demographics	1	1
NVG4314	Age	Age	Demographics	1	1
NVG4320	Age	Age	Demographics	1	1
NVG4329	Age	Age	Demographics	1	1
NVG4374	Age	Age	Demographics	1	1
NVG4426	Age	Age	Demographics	1	1
NVG4441	Age	Age	Demographics	1	1
NVG4459	Age	Age	Demographics	1	1
NVG4526	Age	Age	Demographics	1	1
NVG4609	Age	Age	Demographics	1	1
NVG4669	Age	Age	Demographics	1	1
NVG4682	Age	Age	Demographics	1	1
NVG4690	Age	Age	Demographics	1	1

NVG4745	Age	Age	Demographics	1	1
NVG0090	Age	Age	Demographics	1	1
NVG0107	Age	Age	Demographics	1	1
NVG0563	Age	Age	Demographics	1	1
NVG0572	Age	Age	Demographics	1	1
NVG1431	Age	Age	Demographics	1	1
NVG4586	Age	Age	Demographics	1	1
NVG4706	Age	Age	Demographics	1	1
NVG0169	Age ≥65 ya	Age	Demographics	1	1
NVG2524	Age of children	Age	Demographics	1	1
NVG0114	Age, y	Age	Demographics	1	1
NVG4516	Mean age in months	Age	Demographics	1	0
NVG4512	Median age at end of follow-up	Age	Demographics	1	0
NVG4511	Median age at start of follow-up	Age	Demographics	1	0
NVG4552	Median age in days	Age	Demographics	1	0
NVG3118	Age at booster	Age	Demographics	1	0
NVG2476	Age at breastmilk supplementation (days)	Age	Demographics	1	0
NVG2449	Age at delivery	Age	Demographics	1	1
NVG3472	Age at delivery	Age	Demographics	1	1
NVG1834	Age at diagnosis	Age	Demographics	1	1
NVG2420	Age at diagnosis	Age	Demographics	1	1
NVG0767	Age at first intercourse	Age	Demographics	1	0
NVG3116	Age at first PCV (pneumococcal conjugate vaccine) dose	Age	Demographics	1	1
NVG2468	Age at registration	Age	Demographics	1	1
NVG3117	Age at second PCV dose	Age	Demographics	1	0

NVG3057	Age at start of ART	Age	Demographics	1	1
NVG1970	donor age	Age	Demographics	1	1
NVG1470	Maternal Age	Age	Demographics	1	1
NVG2509	Maternal age	Age	Demographics	1	1
NVG2703	Population age distribution	Age	Demographics	1	0
NVG1957	Recipient Age	Age	Demographics	1	1
NVG2172	Mean age at vaccine dose 1,	Mean age at vaccine dose	Other	1	0
NVG1473	Gestation Week	Gestational age	Clinical manifestations	1	1
NVG2181	gestational age	Gestational age	Clinical manifestations	1	1
NVG2508	Gestational age	Gestational age	Clinical manifestations	1	1
NVG2870	Gestational age	Gestational age	Clinical manifestations	1	1
NVG3343	Gestational age	Gestational age	Clinical manifestations	1	1
NVG4083	Gestational age	Gestational age	Clinical manifestations	1	1
NVG3702	Gestational age (weeks)	Gestational age	Clinical manifestations	1	1
NVG2471	Preterm	Preterm birth	diagnosis	1	1
NVG2272	Preterm birth	Preterm birth	diagnosis	1	1
NVG2417	Preterm birth	Preterm birth	diagnosis	1	1
NVG2450	First birth	First birth	Other	1	1
NVG4253	Distance to forest edge	Distance to forest edge	Other	1	0
NVG2646	distance to nearest coastline	Distance to nearest coastline	Other	1	0
NVG2647	distance to nearest major waterbody	Distance to nearest major waterbody	Other	1	0
NVG2108	Annual household income	Economic or Work demographics	Demographics	0	2

NVG2373	Unemployment past 3 months (yes/no)	Economic or Work demographics	Demographics	0	2
NVG4751	Basic Pay Scale (BPS: 1±20) wise distribution of Patients	Economic or Work demographics	Demographics	0	2
NVG2209	Employed	Economic or Work demographics	Demographics	0	2
NVG3122	Employed	Economic or Work demographics	Demographics	0	2
NVG0471	Employment	Economic or Work demographics	Demographics	0	2
NVG1679	Employment	Economic or Work demographics	Demographics	0	2
NVG4595	Employment status (Full-time Part-time / unemployed / retired / student)	Economic or Work demographics	Demographics	0	2
NVG4596	Employment status (Full-time Part-time / unemployed / retired / student)	Economic or Work demographics	Demographics	0	2
NVG2375	Employment status (full-time, part-time, seeking work, not seeking work, retired)	Economic or Work demographics	Demographics	0	2
NVG2376	Employment status (full-time, part-time, seeking work, not seeking work, retired)	Economic or Work demographics	Demographics	0	2
NVG2377	Employment status (full-time, part-time, seeking work, not seeking work, retired)	Economic or Work demographics	Demographics	0	2
NVG2378	Employment status (full-time, part-time, seeking work, not seeking work, retired)	Economic or Work demographics	Demographics	0	2
NVG0039	Occupation	Economic or Work demographics	demographics	0	2
NVG3158	Occupation (Health-care sector, Social or	Economic or Work	demographics	0	2

	prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	demographics			
NVG3159	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3160	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3161	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3162	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3163	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3164	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3165	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology	Economic or Work demographics	demographics	0	2

	worker, Agricultural or animal care, Education, None, Other, Unknown)				
NVG3166	Occupation (Health-care sector, Social or prison sector, Laboratory or pathology worker, Agricultural or animal care, Education, None, Other, Unknown)	Economic or Work demographics	demographics	0	2
NVG3985	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG3986	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG3987	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG3988	Occupation (Student Artisan, merchant, or business owner	Economic or Work demographics	demographics	0	2

	Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)				
NVG3989	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG3990	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG3991	Occupation (Student Artisan, merchant, or business owner Professional Employee Laborer, factory worker, or farmer Unemployed Missing data or declined to respond)	Economic or Work demographics	demographics	0	2
NVG2078	Primary occupation (Nurse	Economic or Work demographics	Demographics	0	2
NVG2079	Primary occupation Allied health	Economic or Work	Demographics	0	2

	professionals	demographics			
NVG2082	Primary occupation Community health worker	Economic or Work demographics	Demographics	0	2
NVG2080	Primary occupation Doctor	Economic or Work demographics	Demographics	0	2
NVG2084	Primary occupation Frontline Ebola response worker	Economic or Work demographics	Demographics	0	2
NVG2083	Primary occupation Laboratory worker	Economic or Work demographics	Demographics	0	2
NVG2087	Primary occupation Not currently working in a health facility	Economic or Work demographics	Demographics	0	2
NVG2086	Primary occupation Other/Not reported	Economic or Work demographics	Demographics	0	2
NVG2081	Primary occupation Pharmacist	Economic or Work demographics	Demographics	0	2
NVG2085	Primary occupation Surveillance worker	Economic or Work demographics	Demographics	0	2
NVG4156	Socio-economic status	Economic or Work demographics	Demographics	0	2
NVG4752	Socioeconomic status	Economic or Work demographics	Demographics	0	2
NVG2701	Socioeconomic status cluster	Economic or Work demographics	Demographics	0	2
NVG4162	Family monthly income	Economic or Work demographics	Other	0	2
NVG4288	Shoe wearing during the interview	Economic or Work demographics	Other	0	2
NVG4754	Departmental wise distribution (Education Administration	Economic or Work demographics	Other	0	2

	Health Public)				
NVG4755	Departmental wise distribution (Education Administration Health Public)	Economic or Work demographics	Other	0	2
NVG4756	Departmental wise distribution (Education Administration Health Public)	Economic or Work demographics	Other	0	2
NVG4757	Departmental wise distribution (Education Administration Health Public)	Economic or Work demographics	Other	0	2
NVG0749	Farm animal contact	Economic or Work demographics	Other	0	2
NVG4249	Farming or plantation work	Economic or Work demographics	Other	0	2
NVG1323	Military rank: Active-duty soldiers	Economic or Work demographics	Other	0	2
NVG1324	Military rank: New recruits	Economic or Work demographics	Other	0	2
NVG2579	Income level	Economic or Work demographics	Other	0	2
NVG2457	Mobile phone ownership	Mobile phone ownership	Other	1	2
NVG4266	>7 years of education	Education demographics	Demographics	0	2
NVG2282	education duration	Education	Demographics	0	2

		demographics			
NVG2866	Years in education	Education demographics	Demographics	0	2
NVG3086	Years of education	Education demographics	Demographics	0	2
NVG2797	Education	Education demographics	Demographics	0	2
NVG4285	Education	Education demographics	Demographics	0	2
NVG4671	Education (Illiterate Primary and Secondary education High school and university education)	Education demographics	Demographics	0	2
NVG3354	Education (No formal education, Did not complete primary education, Completed primary education, Completed secondary education, Completed tertiary education)	Education demographics	Demographics	0	2
NVG3473	Education (Not a high school graduate, High school graduate, College or more, Missing data)	Education demographics	Demographics	0	2
NVG1737	Education level (high school, collage, some University)	Education demographics	Demographics	0	2
NVG2362	Education Level (no schooling, primary school. secondary...)	Education demographics	Demographics	0	2
NVG4591	Education level (Secondary or below College or above)	Education demographics	Demographics	0	2
NVG2094	Education: None	Education demographics	Demographics	0	2
NVG2093	Education: None Primary	Education demographics	Demographics	0	2

	Secondary Tertiary Other/Not reported				
NVG0628	Educational level	Education demographics	Demographics	0	2
NVG2510	Educational level	Education demographics	Demographics	0	2
NVG2109	Educational level (Less than high school degree, High school degree or equivalent, Some college, associate's degree or technical school	Education demographics	Demographics	0	2
NVG4746	Educational profile (Primary Middle Bachelor Higher)	Education demographics	Demographics	0	2
NVG2544	educational status	Education demographics	Demographics	0	2
NVG2465	Ever attended school/madrasa	Education demographics	Demographics	0	2
NVG2239	High school graduate	Education demographics	Demographics	0	2
NVG0465	Level of study	Education demographics	Demographics	0	2
NVG3124	Post-secondary education	Education demographics	Demographics	0	2
NVG0469	University activities	Education demographics	Demographics	0	2
NVG1678	Completed school years	Education demographics	Other	0	2

NVG0466	College	Education demographics	Other	0	2
NVG4161	Illiterate	Education demographics	Other	0	2
NVG0301	Maternal education level	Education demographics	Other	0	2
NVG4518	Presence of siblings <5y	Family demographics	Demographics	0	2
NVG2459	Household members	Family demographics	Demographics	0	2
NVG2466	Household members	Family demographics	Demographics	0	2
NVG2142	Household members participating.	Family demographics	Demographics	0	2
NVG1677	Number of children	Family demographics	demographics	0	2
NVG3436	Number of children	Family demographics	demographics	0	2
NVG3437	Number of children per community	Family demographics	demographics	0	2
NVG4087	Number of infants	Family demographics	demographics	0	2
NVG2295	living together	Family demographics	Demographics	0	2
NVG2331	Siblings	Family demographics	Demographics	0	2
NVG4555	Caregiver previously sought care for child's condition	Family demographics	Other	0	2
NVG4554	Child is breastfed	Family demographics	Other	0	2
NVG4072	Children with > 1sibling in trial	Family demographics	Other	0	2
NVG1971	donor sex	Gender	Demographics	1	0
NVG1416	Female	Gender	Demographics	1	1
NVG0061	Gender	Gender	Demographics	1	1
NVG0091	Gender	Gender	Demographics	1	1
NVG0437	Gender	Gender	Demographics	1	1
NVG0928	Gender	Gender	Demographics	1	1
NVG1478	Gender	Gender	Demographics	1	1

NVG1496	Gender	Gender	Demographics	1	1
NVG3112	Gender	Gender	Demographics	1	1
NVG4139	Gender	Gender	Demographics	1	1
NVG4151	Gender	Gender	Demographics	1	1
NVG4309	Gender	Gender	Demographics	1	1
NVG4328	Gender	Gender	Demographics	1	1
NVG4427	Gender	Gender	Demographics	1	1
NVG0853	Gender	Gender	Demographics	1	1
NVG1958	Recipient Sex	Gender	Demographics	1	1
NVG0003	Sex	Gender	Demographics	1	1
NVG0025	Sex	Gender	Demographics	1	1
NVG0037	Sex	Gender	Demographics	1	1
NVG0048	Sex	Gender	Demographics	1	1
NVG0068	Sex	Gender	Demographics	1	1
NVG0115	Sex	Gender	Demographics	1	1
NVG0167	Sex	Gender	Demographics	1	1
NVG0187	Sex	Gender	Demographics	1	1
NVG0217	Sex	Gender	Demographics	1	1
NVG0245	Sex	Gender	Demographics	1	1
NVG0297	Sex	Gender	Demographics	1	1
NVG0304	Sex	Gender	Demographics	1	1
NVG0320	Sex	Gender	Demographics	1	1
NVG0338	Sex	Gender	Demographics	1	1
NVG0376	Sex	Gender	Demographics	1	1
NVG0383	Sex	Gender	Demographics	1	1
NVG0388	Sex	Gender	Demographics	1	1

NVG0401	Sex	Gender	Demographics	1	1
NVG0420	Sex	Gender	Demographics	1	1
NVG0445	Sex	Gender	Demographics	1	1
NVG0453	Sex	Gender	Demographics	1	1
NVG0462	Sex	Gender	Demographics	1	1
NVG0489	Sex	Gender	Demographics	1	1
NVG0536	Sex	Gender	Demographics	1	1
NVG0541	Sex	Gender	Demographics	1	1
NVG0564	Sex	Gender	Demographics	1	1
NVG0573	Sex	Gender	Demographics	1	1
NVG0580	Sex	Gender	Demographics	1	1
NVG0603	Sex	Gender	Demographics	1	1
NVG0652	Sex	Gender	Demographics	1	1
NVG0654	Sex	Gender	Demographics	1	1
NVG0675	Sex	Gender	Demographics	1	1
NVG0696	Sex	Gender	Demographics	1	1
NVG0703	Sex	Gender	Demographics	1	1
NVG0740	Sex	Gender	Demographics	1	1
NVG0808	Sex	Gender	Demographics	1	1
NVG0924	Sex	Gender	Demographics	1	1
NVG0940	Sex	Gender	Demographics	1	1
NVG0972	Sex	Gender	Demographics	1	1
NVG0986	Sex	Gender	Demographics	1	1
NVG1004	Sex	Gender	Demographics	1	1
NVG1037	sex	Gender	Demographics	1	1
NVG1059	sex	Gender	Demographics	1	1

NVG1075	Sex	Gender	Demographics	1	1
NVG1098	Sex	Gender	Demographics	1	1
NVG1130	Sex	Gender	Demographics	1	1
NVG1138	Sex	Gender	Demographics	1	1
NVG1148	Sex	Gender	Demographics	1	1
NVG1172	Sex	Gender	Demographics	1	1
NVG1196	Sex	Gender	Demographics	1	1
NVG1202	Sex	Gender	Demographics	1	1
NVG1224	Sex	Gender	Demographics	1	1
NVG1231	Sex	Gender	Demographics	1	1
NVG1236	Sex	Gender	Demographics	1	1
NVG1250	Sex	Gender	Demographics	1	1
NVG1286	Sex	Gender	Demographics	1	1
NVG1307	Sex	Gender	Demographics	1	1
NVG1356	Sex	Gender	Demographics	1	1
NVG1382	Sex	Gender	Demographics	1	1
NVG1398	Sex	Gender	Demographics	1	1
NVG1418	Sex	Gender	Demographics	1	1
NVG1425	Sex	Gender	Demographics	1	1
NVG1438	Sex	Gender	Demographics	1	1
NVG1520	Sex	Gender	Demographics	1	1
NVG1559	Sex	Gender	Demographics	1	1
NVG1577	Sex	Gender	Demographics	1	1
NVG1615	Sex	Gender	Demographics	1	1
NVG1639	Sex	Gender	Demographics	1	1
NVG1654	Sex	Gender	Demographics	1	1

NVG1675	Sex	Gender	Demographics	1	1
NVG1702	Sex	Gender	Demographics	1	1
NVG1750	Sex	Gender	Demographics	1	1
NVG1767	Sex	Gender	Demographics	1	1
NVG1797	Sex	Gender	Demographics	1	1
NVG1812	Sex	Gender	Demographics	1	1
NVG1841	Sex	Gender	Demographics	1	1
NVG1916	Sex	Gender	Demographics	1	1
NVG1927	sex	Gender	Demographics	1	1
NVG1980	Sex	Gender	Demographics	1	1
NVG2053	sex	Gender	Demographics	1	1
NVG2067	sex	Gender	Demographics	1	1
NVG2076	Sex	Gender	Demographics	1	1
NVG2104	sex	Gender	Demographics	1	1
NVG2151	sex	Gender	Demographics	1	1
NVG2173	Sex	Gender	Demographics	1	1
NVG2180	sex	Gender	Demographics	1	1
NVG2195	sex	Gender	Demographics	1	1
NVG2207	Sex	Gender	Demographics	1	1
NVG2255	Sex	Gender	Demographics	1	1
NVG2269	sex	Gender	Demographics	1	1
NVG2309	sex	Gender	Demographics	1	1
NVG2326	Sex	Gender	Demographics	1	1
NVG2338	Sex	Gender	Demographics	1	1
NVG2360	Sex	Gender	Demographics	1	1
NVG2388	Sex	Gender	Demographics	1	1

NVG2415	Sex	Gender	Demographics	1	1
NVG2470	Sex	Gender	Demographics	1	1
NVG2499	Sex	Gender	Demographics	1	1
NVG2546	Sex	Gender	Demographics	1	1
NVG2558	Sex	Gender	Demographics	1	1
NVG2589	Sex	Gender	Demographics	1	1
NVG2616	Sex	Gender	Demographics	1	1
NVG2651	Sex	Gender	Demographics	1	1
NVG2699	Sex	Gender	Demographics	1	1
NVG2707	Sex	Gender	Demographics	1	1
NVG2744	Sex	Gender	Demographics	1	1
NVG2773	Sex	Gender	Demographics	1	1
NVG2792	Sex	Gender	Demographics	1	1
NVG2823	Sex	Gender	Demographics	1	1
NVG2828	Sex	Gender	Demographics	1	1
NVG2847	Sex	Gender	Demographics	1	1
NVG2861	Sex	Gender	Demographics	1	1
NVG2873	Sex	Gender	Demographics	1	1
NVG2906	Sex	Gender	Demographics	1	1
NVG2934	Sex	Gender	Demographics	1	1
NVG3013	Sex	Gender	Demographics	1	1
NVG3025	Sex	Gender	Demographics	1	1
NVG3031	Sex	Gender	Demographics	1	1
NVG3043	Sex	Gender	Demographics	1	1
NVG3056	Sex	Gender	Demographics	1	1
NVG3072	Sex	Gender	Demographics	1	1

NVG3080	Sex	Gender	Demographics	1	1
NVG3099	Sex	Gender	Demographics	1	1
NVG3114	Sex	Gender	Demographics	1	1
NVG3132	Sex	Gender	Demographics	1	1
NVG3140	Sex	Gender	Demographics	1	1
NVG3224	Sex	Gender	Demographics	1	1
NVG3232	Sex	Gender	Demographics	1	1
NVG3239	Sex	Gender	Demographics	1	1
NVG3242	Sex	Gender	Demographics	1	1
NVG3268	Sex	Gender	Demographics	1	1
NVG3299	Sex	Gender	Demographics	1	1
NVG3318	Sex	Gender	Demographics	1	1
NVG3321	Sex	Gender	Demographics	1	1
NVG3327	Sex	Gender	Demographics	1	1
NVG3370	Sex	Gender	Demographics	1	1
NVG3379	Sex	Gender	Demographics	1	1
NVG3385	Sex	Gender	Demographics	1	1
NVG3415	Sex	Gender	Demographics	1	1
NVG3438	Sex	Gender	Demographics	1	1
NVG3443	Sex	Gender	Demographics	1	1
NVG3461	Sex	Gender	Demographics	1	1
NVG3544	Sex	Gender	Demographics	1	1
NVG3584	Sex	Gender	Demographics	1	1
NVG3604	Sex	Gender	Demographics	1	1
NVG3634	Sex	Gender	Demographics	1	1
NVG3660	Sex	Gender	Demographics	1	1

NVG3690	Sex	Gender	Demographics	1	1
NVG3700	Sex	Gender	Demographics	1	1
NVG3705	Sex	Gender	Demographics	1	1
NVG3728	Sex	Gender	Demographics	1	1
NVG3738	Sex	Gender	Demographics	1	1
NVG3746	Sex	Gender	Demographics	1	1
NVG3783	Sex	Gender	Demographics	1	1
NVG3806	Sex	Gender	Demographics	1	1
NVG3820	Sex	Gender	Demographics	1	1
NVG3850	Sex	Gender	Demographics	1	1
NVG3873	Sex	Gender	Demographics	1	1
NVG3903	Sex	Gender	Demographics	1	1
NVG3930	Sex	Gender	Demographics	1	1
NVG3936	Sex	Gender	Demographics	1	1
NVG3966	Sex	Gender	Demographics	1	1
NVG4011	Sex	Gender	Demographics	1	1
NVG4014	Sex	Gender	Demographics	1	1
NVG4057	Sex	Gender	Demographics	1	1
NVG4075	Sex	Gender	Demographics	1	1
NVG4104	Sex	Gender	Demographics	1	1
NVG4160	Sex	Gender	Demographics	1	1
NVG4178	Sex	Gender	Demographics	1	1
NVG4195	Sex	Gender	Demographics	1	1
NVG4200	Sex	Gender	Demographics	1	1
NVG4233	Sex	Gender	Demographics	1	1
NVG4247	Sex	Gender	Demographics	1	1

NVG4259	Sex	Gender	Demographics	1	1
NVG4281	Sex	Gender	Demographics	1	1
NVG4291	Sex	Gender	Demographics	1	1
NVG4319	Sex	Gender	Demographics	1	1
NVG4375	Sex	Gender	Demographics	1	1
NVG4460	Sex	Gender	Demographics	1	1
NVG4510	Sex	Gender	Demographics	1	1
NVG4527	Sex	Gender	Demographics	1	1
NVG4551	Sex	Gender	Demographics	1	1
NVG4583	Sex	Gender	Demographics	1	1
NVG4608	Sex	Gender	Demographics	1	1
NVG4670	Sex	Gender	Demographics	1	1
NVG4689	Sex	Gender	Demographics	1	1
NVG4707	Sex	Gender	Demographics	1	1
NVG4777	Sex	Gender	Demographics	1	1
NVG0108	Sex	Gender	Demographics	1	1
NVG0483	Sex	Gender	Demographics	1	1
NVG3189	Sex	Gender	Demographics	1	1
NVG4095	Sex	Gender	Demographics	1	1
NVG4515	Sex	Gender	Demographics	1	1
NVG2869	Sex of neonates	Gender	Demographics	1	1
NVG2964	Women	Gender	Demographics	1	1
NVG2704	Population sex distribution	Gender	Demographics	1	0
NVG1479	Trans or gender diverse	Trans or gender diverse	Other	1	1
NVG2698	Number of clinics	Health demographics	demographics	0	2

NVG2697	Number of clusters	Healt demographics	demographics	0	2
NVG2531	Cumulative number of villages equipped with malaria posts at the end of the period	Healt demographics	Other	0	2
NVG3312	Number of student nurses per patient	Healt demographics	Other	0	2
NVG0774	Number of visits/woman	Healt demographics	other	0	2
NVG0531	Blue Cross	Healt demographics	Other	0	2
NVG0044	Coverage among population present and eligible during mass drug administration	Healt demographics	Other	0	2
NVG0809	Department	Healt demographics	Other	0	2
NVG1193	Equipment in room	Healt demographics	Other	0	2
NVG1194	Equipment outside of room	Healt demographics	Other	0	2
NVG3066	Exposed admissions	Healt demographics	Other	0	2
NVG2461	Health facility	Healt demographics	Other	0	2
NVG1197	Health sector	Healt demographics	Other	0	2
NVG2765	Massive Drug Adminstration treated non-travelling resident	Healt demographics	Other	0	2
NVG3485	Hospital size	Hospital size	Other	1	1
NVG1467	Hospital with pediatric intensive care	Hospital with pediatric intensive care	Other	1	0
NVG3311	Number of nurses per patient	Number of nurses per patient	treatment	1	0
NVG0996	number of hospitals	Number of hospitals	demographics	1	0
NVG2089	Facility type (Ebola Facility)	Facility type	Other	1	1
NVG2090	Facility type (Hospital	Facility type	Other	1	1
NVG2091	Facility type Community/field/clinic	Facility type	Other	1	1
NVG2092	Facility type Other/Not reported	Facility type	Other	1	1

NVG2034	Sentinel Healthcare facility	Sentinel Healthcare facility	Other	1	1
NVG3579	Sentinel hospitals	Sentinel hospitals	Other	1	1
NVG0467	Household size	House situation demographics	Demographics	0	2
NVG2548	sleeps under net	House situation demographics	Demographics	0	2
NVG2128	Slept under mosquito net in past month	House situation demographics	Demographics	0	2
NVG4251	Stay overnight outside village	House situation demographics	Demographics	0	2
NVG4763	Building type (Double/Multiple Storey, Single Storey)	House situation demographics	Demographics	0	2
NVG4764	Building type (Double/Multiple Storey, Single Storey)	House situation demographics	Demographics	0	2
NVG2458	Piped water	House situation demographics	demographics	0	2
NVG2147	Residence type (1 story house, 2-story house, apartment)	House situation demographics	Demographics	0	2
NVG0919	roomate.	House situation demographics	Demographics	0	2
NVG4179	Rural occupation	House situation demographics	Demographics	0	2
NVG4293	Household asset score	House situation demographics	Demographics	0	2
NVG0042	Bed net use	House situation demographics	Other	0	2
NVG4645	Door and window Net	House situation demographics	Other	0	2

NVG4649	Dwelling hygienic condition	House situation demographics	Other	0	2
NVG4294	Family currently owns pigs	House situation demographics	Other	0	2
NVG4647	Out of building toilet	House situation demographics	other	0	2
NVG4655	Presence of dog in region	House situation demographics	Other	0	2
NVG4653	Presence of manure in home	House situation demographics	Other	0	2
NVG4650	Presence of palm and orange trees in home	House situation demographics	Other	0	2
NVG2148	Presence of screens on doors and windows	House situation demographics	Other	0	2
NVG4648	Presence of small garden	House situation demographics	Other	0	2
NVG4652	Presenceof dog in home	House situation demographics	Other	0	2
NVG4651	Presenceof domestic animal	House situation demographics	Other	0	2
NVG0751	Raw meat preparation	House situation demographics	Other	0	2
NVG4158	Urban/rural designation of clusters	House situation demographics	Other	0	2
NVG2144	Vacant houses in cluster	House situation demographics	Other	0	2
NVG4308	Child who doesn't defecate in bathroom	House situation demographics	Other	0	2
NVG4656	Number of room	House situation	other	0	2

		demographics			
NVG4254	Cleared areas around house	House situation demographics	Other	0	2
NVG0748	Companion animal contact	House situation demographics	Other	0	2
NVG4256	Forest around house	House situation demographics	Other	0	2
NVG2462	Home	House situation demographics	Other	0	2
NVG3361	Latrine (No latrine, Nonventilated pit latrine, Ventilated improved pit latrine, Flush toilet)	House situation demographics	Other	0	2
NVG3362	Latrine (No latrine, Nonventilated pit latrine, Ventilated improved pit latrine, Flush toilet)	House situation demographics	Other	0	2
NVG3363	Latrine (No latrine, Nonventilated pit latrine, Ventilated improved pit latrine, Flush toilet)	House situation demographics	Other	0	2
NVG3364	Latrine (No latrine, Nonventilated pit latrine, Ventilated improved pit latrine, Flush toilet)	House situation demographics	Other	0	2
NVG1192	Other surfaces and objects in rooms	House situation demographics	other	0	2
NVG4295	Pigs are allowed to freely forage in households	House situation demographics	Other	0	2
NVG4296	Pigs-owning households reporting human feces in household fed to pigs	House situation demographics	Other	0	2
NVG2833	Prison	House situation demographics	Other	0	2

NVG3366	Water to wash in (Piped and tapped water, Shared tap or pump, Open water well/ River, pond, or lake)	House situation demographics	Other	0	2
NVG3367	Water to wash in (Piped and tapped water, Shared tap or pump, Open water well/ River, pond, or lake)	House situation demographics	Other	0	2
NVG3368	Water to wash in (Piped and tapped water, Shared tap or pump, Open water well/ River, pond, or lake)	House situation demographics	Other	0	2
NVG3369	Water to wash in (Piped and tapped water, Shared tap or pump, Open water well/ River, pond, or lake)	House situation demographics	Other	0	2
NVG4657	Number of window	House situation demographics	other	0	2
NVG2456	Electricity	Electricity	Demographics	1	0
NVG4252	Elevation (meters above sea level)	Elevation (meters above sea level)	Demographics	1	0
NVG4317	Household-level (sanitation, water coverage)	Household-level	Demographics	1	0
NVG4318	Household-level (sanitation, water coverage)	Household-level	Demographics	1	0
NVG4530	Insurance (Medicaid, Other Medicare/Medicaid dual Private)	Insurance	Other	1	1
NVG4531	Insurance (Medicaid, Other Medicare/Medicaid dual	Insurance	Other	1	1

	Private)				
NVG4532	Insurance (Medicaid, Other Medicare Medicare/Medicaid dual Private)	Insurance	Other	1	1
NVG4533	Insurance (Medicaid, Other Medicare Medicare/Medicaid dual Private)	Insurance	Other	1	1
NVG4534	Insurance (Medicaid, Other Medicare Medicare/Medicaid dual Private)	Insurance	Other	1	1
NVG0530	Medicaid	Insurance	Other	1	1
NVG0524	Medical	Insurance	Other	1	1
NVG0810	Medical	Insurance	Other	1	1
NVG0529	Medicare	Insurance	Other	1	1
NVG1440	Medicare Medicaid Private or HMO Self-pay	Insurance	Other	1	1
NVG0008	Privately insured	Insurance	Other	1	0
NVG0532	Other Insurance	Other Insurance	other	1	1
NVG0528	Primary payer	Primary payer	Other	1	0
NVG0302	Public insurance (Medicaid)	Public insurance	Other	1	1
NVG2520	Altitude of the households selected	Altitude of the	Other	1	0

		households selected			
NVG0931	Area of China	Area of China	Demographics	1	1
NVG4759	Area wise distribution (Rural /Urban)	Area wise distribution	Demographics	1	0
NVG4760	Area wise distribution (Rural /Urban)	Area wise distribution	Demographics	1	0
NVG3143	UK born	Country	Demographics	1	1
NVG1132	Country	Country	Demographics	1	1
NVG1513	Country	Country	Demographics	1	1
NVG1795	Country	Country	Demographics	1	1
NVG2263	Country	Country	Demographics	1	1
NVG2578	Country	Country	Demographics	1	1
NVG2648	Country	Country	Demographics	1	1
NVG2965	Country	Country	Demographics	1	1
NVG3085	Country	Country	Demographics	1	1
NVG3346	Country	Country	Demographics	1	1
NVG3463	Country	Country	Demographics	1	1
NVG3576	Country	Country	Demographics	1	1
NVG3582	Country	Country	Demographics	1	1
NVG3931	Country	Country	Demographics	1	1
NVG2024	Country	Country	Demographics	1	1
NVG1809	Country (Origin)	Country	Demographics	1	1
NVG1801	Country income	Country	Demographics	1	0
NVG0384	Country income level	Country	Demographics	1	0
NVG2841	Country income level	Country	Demographics	1	0
NVG1833	Country of birth	Country	Demographics	1	1
NVG3957	Country x 16	Country	Demographics	1	1
NVG1800	Country-level of education (from US	Country	Demographics	1	0

	Census)				
NVG4234	Country(x7 + missing)	Country	Demographics	1	1
NVG2829	Born in UK	Country	Demographics	1	1
NVG1234	Location	Location	Demographics	1	1
NVG1287	Location	Location	Demographics	1	1
NVG2460	Birth location	Birth location	Other	1	1
NVG3804	Continent of residence	Continent of residence	Other	1	0
NVG4435	Department (Medical laboratory Medicine Midwifery Nursing Pharmacy)	Department	Other	1	1
NVG4436	Department (Medical laboratory Medicine Midwifery Nursing Pharmacy)	Department	Other	1	1
NVG4437	Department (Medical laboratory Medicine Midwifery Nursing Pharmacy)	Department	Other	1	1
NVG4438	Department (Medical laboratory Medicine Midwifery Nursing Pharmacy)	Department	Other	1	1
NVG4439	Department (Medical laboratory	Department	Other	1	1

	Medicine Midwifery Nursing Pharmacy)				
NVG2016	Destination (other).	Destination	Other	1	1
NVG2013	Destination (sent home, referred to another hospital, left against medical advice).	Destination	Other	1	1
NVG2014	Destination (sent home, referred to another hospital, left against medical advice).	Destination	Other	1	1
NVG2015	Destination (sent home, referred to another hospital, left against medical advice).	Destination	Other	1	1
NVG3578	Enrollment period	Enrollment period	Other	1	1
NVG2211	Enrolled in US	Enrollment site	Other	1	1
NVG0005	Enrollment site	Enrollment site	Other	1	1
NVG0094	Geographic region	Region	Demographics	1	0
NVG0576	Geographic region	Region	Demographics	1	0
NVG1225	Location/Region	Region	Demographics	1	1
NVG1198	Province	Region	Demographics	1	0
NVG1421	Province	Region	Demographics	1	0
NVG3055	Province	Region	Demographics	1	0
NVG0028	Region	Region	Demographics	1	1
NVG0290	Region	Region	Demographics	1	1
NVG0386	Region	Region	Demographics	1	1
NVG0624	Region	Region	Demographics	1	1
NVG3110	Region	Region	Demographics	1	1

NVG3133	Region	Region	Demographics	1	1
NVG3137	Region	Region	Demographics	1	1
NVG3171	Region	Region	Demographics	1	1
NVG3440	Region	Region	Demographics	1	1
NVG3697	Region	Region	Demographics	1	1
NVG3748	Region	Region	Demographics	1	1
NVG3785	Region	Region	Demographics	1	1
NVG4315	Region	Region	Demographics	1	1
NVG4154	Region (x3)	Region	Demographics	1	1
NVG4335	Region (x5)	Region	Demographics	1	1
NVG4425	Region (x7)	Region	Demographics	1	1
NVG4584	Region (x7)	Region	Demographics	1	1
NVG2306	region in England	Region	Demographics	1	1
NVG0421	Region of origin	Region	Demographics	1	1
NVG0971	Region of origin	Region	Demographics	1	1
NVG0922	United States Region	Region	Demographics	1	1
NVG2154	US region	Region	Demographics	1	1
NVG1296	State	State	Demographics	1	1
NVG2253	US State	State	Demographics	1	1
NVG1402	Urban area	Urban area	Demographics	1	0
NVG3319	Village	Village	Demographics	1	1
NVG3323	Village	Village	Demographics	1	1
NVG4008	Site (x2)	Site	Other	1	1
NVG3348	Current residence (rural or urban)	Residence	Demographics	1	0
NVG2074	District	Residence	Demographics	1	0
NVG1243	Residence	Residence	Demographics	1	1

NVG4428	Residence (Urban Vs Rural)	Residence	Demographics	1	0
NVG3982	Residence x 3	Residence	Demographics	1	0
NVG1835	Residency at diagnosis (Manhatt, Brookl, Bronx)	Residence	Demographics	1	1
NVG1237	Rural residence	Residence	Demographics	1	0
NVG0041	Residency status	Residence	Demographics	1	0
NVG0040	Residency duration	Residence	Demographics	1	0
NVG0664	Resident in long term care system	Residence	Demographics	1	0
NVG1205	Resident of long-term care facility	Residence	Demographics	1	0
NVG1131	Setting	Setting	Demographics	1	0
NVG1514	Setting	Setting	Demographics	1	0
NVG3698	Setting (urban or rural)	Setting	Demographics	1	0
NVG1447	Protcol initiation site (Emergency Dept)	Protocol initiation site	Other	1	1
NVG1448	Protcol initiation site (ICU)	Protocol initiation site	Other	1	1
NVG1449	Protcol initiation site (Ward)	Protocol initiation site	Other	1	1
NVG2165	nursing home resident	nursing home resident	demographics	1	0
NVG1406	Years in French Polynesia	Place of residency demographics	Demographics	0	2
NVG2107	years lived in Puerto Rico	Place of residency demographics	Demographics	0	2
NVG4255	Agriculture around house	Place of residency demographics	Demographics	0	2
NVG2141	Air conditioner use	Place of residency demographics	Demographics	0	2
NVG4643	Building Condition	Place of residency demographics	Demographics	0	2
NVG2521	households with adequate long-lasting insecticidal nets	Place of residency demographics	Demographics	0	2

NVG4646	Interior housing condition	Place of residency demographics	Demographics	0	2
NVG3435	Number of communities	Place of residency demographics	demographics	0	2
NVG2529	number of vectors found indoors per house per night	Place of residency demographics	demographics	0	2
NVG1206	Homeless	Place of residency demographics	Demographics	0	2
NVG3155	Homeless status	Place of residency demographics	Demographics	0	2
NVG2835	Homless	Place of residency demographics	Demographics	0	2
NVG2542	House structure	Place of residency demographics	Demographics	0	2
NVG2145	House within 50m of index case	Place of residency demographics	Demographics	0	2
NVG2522	households with > 1 long-lasting insecticidal net	Place of residency demographics	Demographics	0	2
NVG2541	household assets	Place of residency demographics	Demographics	0	2
NVG4250	Household farm activities	Place of residency demographics	Demographics	0	2
NVG0468	Housing type	Place of residency demographics	Demographics	0	2
NVG4307	No toilet at family home	Place of residency demographics	demographics	0	2
NVG4431	Place of work (Hospital, Health center, Private clinic/ laboratories	Place of work	Other	1	1
NVG4432	Place of work (Hospital, Health center,	Place of work	Other	1	1

	Private clinic/ laboratories				
NVG4433	Place of work (Hospital, Health center, Private clinic/ laboratories)	Place of work	Other	1	1
NVG3087	Married	Martial status	Demographics	0	2
NVG0575	Marital status	Martial status	Demographics	0	2
NVG0765	Marital status	Martial status	Demographics	0	2
NVG1676	Marital status	Martial status	Demographics	0	2
NVG1748	Marital status	Martial status	Demographics	0	2
NVG4286	Marital status	Martial status	Demographics	0	2
NVG4588	Marital status (Currently single, Cohabitate / married with men, Cohabitate / married with women)	Martial status	Demographics	0	2
NVG4589	Marital status (Currently single, Cohabitate / married with men, Cohabitate / married with women)	Martial status	Demographics	0	2
NVG4590	Marital status (Currently single, Cohabitate / married with men, Cohabitate / married with women)	Martial status	Demographics	0	2
NVG4429	Marital status (Married Vs Single)	Martial status	Demographics	0	2
NVG2240	Marital/partner status	Martial status	Demographics	0	2
NVG4680	Marital status (Single or Married)	Martial status	Demographics	0	2
NVG4681	Marital status (Single or Married)	Martial status	Demographics	0	2
NVG2294	married to study partner	Martial status	Demographics	0	2
NVG3123	Not in a relationship	Martial status	Demographics	0	2
NVG2369	Relationship status (married, living with sexual partner)	Martial status	Demographics	0	2
NVG2370	Relationship status (married, living with sexual partner)	Martial status	Demographics	0	2

NVG2371	Relationship status (married, living with sexual partner)	Marital status	Demographics	0	2
NVG2372	Relationship status (married, living with sexual partner)	Marital status	Demographics	0	2
NVG1902	CI level	CI level	Other	1	0
NVG2534	Number of hotspots identified	Other demographics	demographics	0	2
NVG3307	Number of patients included in point-prevalence measurements	Other demographics	demographics	0	2
NVG2764	Newly arrived migrant	Other demographics	Demographics	0	2
NVG2146	Occupied houses inc luster	Other demographics	demographics	0	2
NVG1362	Outbreak-associated illness	Other demographics	demographics	0	2
NVG2702	Remoteness area of clusters	Other demographics	Demographics	0	2
NVG3256	Resident type (Not collected, Permanent, Respite, Other	Other demographics	Demographics	0	2
NVG3257	Resident type (Not collected, Permanent, Respite, Other	Other demographics	Demographics	0	2
NVG3258	Resident type (Not collected, Permanent, Respite, Other	Other demographics	Demographics	0	2
NVG3259	Resident type (Not collected, Permanent, Respite, Other	Other demographics	Demographics	0	2
NVG3107	Residential setting	Other demographics	Demographics	0	2
NVG3297	Safety checklist	Other demographics	Demographics	0	2
NVG2300	Sample collection venue (General practise, family planning...)	Other demographics	Demographics	0	2
NVG0746	Social exposures	Other demographics	Demographics	0	2
NVG3733	Patient global assessment VAS score	Other demographics	demographics	0	2
NVG2532	Total area covered	Other demographics	Other	0	2
NVG1405	Place	Other demographics	Other	0	2

NVG3125	Site of enrolment	Other demographics	Other	0	2
NVG1683	Travel method to health facility	Other demographics	Other	0	2
NVG0923	VHA Medical Facility Complexity Level	Other demographics	Other	0	2
NVG2469	Child-days observed (in 10 000 days)	Population demographics	Other	0	2
NVG2818	Participants in Lofa	Population demographics	demographics	0	2
NVG2817	Participants in Nkwanta	Population demographics	demographics	0	2
NVG2816	participants in Nord Ituri	Population demographics	demographics	0	2
NVG2815	Participants in Nord Kivu	Population demographics	demographics	0	2
NVG2518	Total population in core and buffer areas	Population demographics	Demographics	0	2
NVG0036	Population	Population	Demographics	1	0
NVG1794	Population	Population	Demographics	1	0
NVG2519	population in core area	Population	Demographics	1	0
NVG2036	Population size	Population	Demographics	1	0
NVG2643	proportion of the population with access to drinking water	Population	Demographics	1	0
NVG2644	proportion of the population with access to sanitation	Population	Demographics	1	0
NVG2543	Number of residents	Number of residents	Other	1	0
NVG1204	Foreign-born	Foreign-born	Other	1	1
NVG1302	No. (%) Hispanic	Race demographics	Demographics	0	2
NVG1656	White race	Race demographics	Demographics	0	2
NVG2819	African origin	Race demographics	Demographics	0	2

NVG1251	Ethnic group	Race demographics	Demographics	0	2
NVG3027	Ethnic origin	Race demographics	Demographics	0	2
NVG3121	Ethnic origin	Race demographics	Demographics	0	2
NVG0027	Ethnicity	Race demographics	Demographics	0	2
NVG0062	Ethnicity	Race demographics	Demographics	0	2
NVG0537	Ethnicity	Race demographics	Demographics	0	2
NVG0574	Ethnicity	Race demographics	Demographics	0	2
NVG0627	Ethnicity	Race demographics	Demographics	0	2
NVG0764	Ethnicity	Race demographics	Demographics	0	2
NVG1358	Ethnicity	Race demographics	Demographics	0	2
NVG1741	Ethnicity	Race demographics	Demographics	0	2
NVG1856	Ethnicity	Race demographics	Demographics	0	2
NVG2416	Ethnicity	Race demographics	Demographics	0	2
NVG2500	Ethnicity	Race demographics	Demographics	0	2
NVG2591	Ethnicity	Race demographics	Demographics	0	2
NVG2708	Ethnicity	Race demographics	Demographics	0	2
NVG2776	Ethnicity	Race demographics	Demographics	0	2
NVG2795	Ethnicity	Race demographics	Demographics	0	2
NVG3141	Ethnicity	Race demographics	Demographics	0	2
NVG3191	Ethnicity	Race demographics	Demographics	0	2
NVG3701	Ethnicity	Race demographics	Demographics	0	2
NVG2559	Ethnicity	Race demographics	Demographics	0	2
NVG4077	Ethnicity (x2)	Race demographics	Demographics	0	2
NVG4292	Ethnicity (x5 + Other)	Race demographics	Demographics	0	2
NVG0004	Race	Race demographics	Demographics	0	2
NVG0026	Race	Race demographics	Demographics	0	2

NVG0063	Race	Race demographics	Demographics	0	2
NVG0092	Race	Race demographics	Demographics	0	2
NVG0246	Race	Race demographics	Demographics	0	2
NVG0289	Race	Race demographics	Demographics	0	2
NVG0298	Race	Race demographics	Demographics	0	2
NVG0323	Race	Race demographics	Demographics	0	2
NVG0454	Race	Race demographics	Demographics	0	2
NVG0463	Race	Race demographics	Demographics	0	2
NVG0538	Race	Race demographics	Demographics	0	2
NVG0581	Race	Race demographics	Demographics	0	2
NVG1203	Race	Race demographics	Demographics	0	2
NVG1357	Race	Race demographics	Demographics	0	2
NVG1436	Race	Race demographics	Demographics	0	2
NVG1439	Race	Race demographics	Demographics	0	2
NVG1471	Race	Race demographics	Demographics	0	2
NVG1481	Race	Race demographics	Demographics	0	2
NVG1578	Race	Race demographics	Demographics	0	2
NVG1616	Race	Race demographics	Demographics	0	2
NVG1640	Race	Race demographics	Demographics	0	2
NVG1655	Race	Race demographics	Demographics	0	2
NVG1751	Race	Race demographics	Demographics	0	2
NVG1802	Race	Race demographics	Demographics	0	2
NVG1810	Race	Race demographics	Demographics	0	2
NVG1827	Race	Race demographics	Demographics	0	2
NVG1842	Race	Race demographics	Demographics	0	2
NVG1917	Race	Race demographics	Demographics	0	2

NVG2153	race	Race demographics	Demographics	0	2
NVG2174	race	Race demographics	Demographics	0	2
NVG2177	Race	Race demographics	Demographics	0	2
NVG2208	Race	Race demographics	Demographics	0	2
NVG2238	Race	Race demographics	Demographics	0	2
NVG2256	Race	Race demographics	Demographics	0	2
NVG2270	race	Race demographics	Demographics	0	2
NVG2299	Race	Race demographics	Demographics	0	2
NVG2310	Race	Race demographics	Demographics	0	2
NVG2327	Race	Race demographics	Demographics	0	2
NVG2340	race	Race demographics	Demographics	0	2
NVG2501	Race	Race demographics	Demographics	0	2
NVG2560	Race	Race demographics	Demographics	0	2
NVG2709	Race	Race demographics	Demographics	0	2
NVG2775	Race	Race demographics	Demographics	0	2
NVG2794	Race	Race demographics	Demographics	0	2
NVG2875	Race	Race demographics	Demographics	0	2
NVG2908	Race	Race demographics	Demographics	0	2
NVG3100	Race	Race demographics	Demographics	0	2
NVG3240	Race	Race demographics	Demographics	0	2
NVG3444	Race	Race demographics	Demographics	0	2
NVG3478	Race	Race demographics	Demographics	0	2
NVG3605	Race	Race demographics	Demographics	0	2
NVG3635	Race	Race demographics	Demographics	0	2
NVG3747	Race	Race demographics	Demographics	0	2
NVG3784	Race	Race demographics	Demographics	0	2

NVG3807	Race	Race demographics	Demographics	0	2
NVG3937	Race	Race demographics	Demographics	0	2
NVG4528	Race (x2 + Other)	Race demographics	Demographics	0	2
NVG4015	Race (x3)	Race demographics	Demographics	0	2
NVG4076	Race (x3)	Race demographics	Demographics	0	2
NVG4010	Race (x4)	Race demographics	Demographics	0	2
NVG0189	Race/ethnicity	Race demographics	Demographics	0	2
NVG0218	Race/ethnicity	Race demographics	Demographics	0	2
NVG0109	Race/Ethnicity	Race demographics	Demographics	0	2
NVG0769	Sex partners in the last month	Sexual behavior demographics	Demographics	0	2
NVG4598	Sexual orientation (Homosexual Bisexual)	Sexual behavior demographics	Demographics	0	2
NVG4599	Sexual orientation (Homosexual Bisexual)	Sexual behavior demographics	Demographics	0	2
NVG4079	Sexual partner of male (Women only Men only Men and women)	Sexual behavior demographics	Demographics	0	2
NVG4080	Sexual partner of male (Women only Men only Men and women)	Sexual behavior demographics	Demographics	0	2
NVG4081	Sexual partner of male (Women only Men only Men and women)	Sexual behavior demographics	Demographics	0	2
NVG2706	Number of partners in past 12 months	Sexual behavior demographics	demographics	0	2
NVG3090	Recent sexual partners	Sexual behavior demographics	Demographics	0	2

NVG2342	Man sex with man	Sexual behavior demographics	Demographics	0	2
NVG1485	Regular partner	Sexual behavior demographics	Demographics	0	2
NVG0416	condom use in the past 30 days	Sexual behavior demographics	Other	0	2
NVG4605	Condomless anal sex with men	Sexual behavior demographics	Other	0	2
NVG4603	Had had anal intercourse with non-regular male sex partner	Sexual behavior demographics	Other	0	2
NVG4602	Had had anal intercourse with regular male sex partner	Sexual behavior demographics	Other	0	2
NVG4604	Multiple male sex partnerships	Sexual behavior demographics	Other	0	2
NVG3092	Recent unprotected sex	Sexual behavior demographics	Other	0	2
NVG2252	Receptive anal sex ever	Sexual behavior demographics	Other	0	2
NVG2251	Receptive anal sex in last 6 months	Sexual behavior demographics	Other	0	2
NVG0408	reported receptive anal intercourse in the past 30 days	Sexual behavior demographics	Other	0	2
NVG4606	Use of illicit substances before / during sexual intercourse (Chemsex)	Sexual behavior demographics	Other	0	2
NVG4607	Use of sexual potency drugs before / during sexual intercourse	Sexual behavior demographics	Other	0	2
NVG3091	Frequency of sex	Sexual behavior demographics	Other	0	2
NVG0768	Lifetime sex partners	Sexual behavior	Other	0	2

		demographics			
NVG1742	Lifetime sexual partners	Sexual behavior demographics	Other	0	2
NVG0415	number of sex partners	Sexual behavior demographics	Other	0	2
NVG2250	Number of sexual partners in last 6 months	Sexual behavior demographics	Other	0	2
NVG2290	Any act with additional partner	Sexual behavior demographics	Other	0	2
NVG2289	Any sex act condomless	Sexual behavior demographics	Other	0	2
NVG2288	any sex act with condom	Sexual behavior demographics	Other	0	2
NVG2287	Any sex act with study partner	Sexual behavior demographics	Other	0	2
NVG3236	Forms of contraception	Sexual behavior demographics	Other	0	2
NVG1415	Heterosexual men	Sexual behavior demographics	Other	0	2
NVG1486	HIV status of partner	Sexual behavior demographics	Other	0	2
NVG1681	HIV status of partner	Sexual behavior demographics	Other	0	2
NVG1414	Men who have sex with men	Sexual behavior demographics	Other	0	2
NVG4601	Other HIV-related prevention services	Sexual behavior demographics	Other	0	2
NVG2293	partnership duration	Sexual behavior demographics	Other	0	2

NVG4451	Rough sex	Sexual behavior demographics	Other	0	2
NVG0577	Route of HIV infection	Sexual behavior demographics	Other	0	2
NVG3127	Sexual risk factors (number of partners, of sexual acts, circumcised or STIs diagnosed at screening).	Sexual behavior demographics	Other	0	2
NVG3128	Sexual risk factors (number of partners, of sexual acts, circumcised or STIs diagnosed at screening).	Sexual behavior demographics	Other	0	2
NVG3129	Sexual risk factors (number of partners, of sexual acts, circumcised or STIs diagnosed at screening).	Sexual behavior demographics	Other	0	2
NVG3130	Sexual risk factors (number of partners, of sexual acts, circumcised or STIs diagnosed at screening).	Sexual behavior demographics	Other	0	2
NVG1480	Sexuality	Sexual behavior demographics	Other	0	2
NVG2540	Month of the year	Month	Demographics	1	1
NVG2580	Seasons or years with estimates available	Seasons	Demographics	1	0
NVG4522	Summer	Summer	Demographics	1	1
NVG4523	Winter	Winter	Demographics	1	1
NVG0438	Country visited	Travel demographics	Demographics	0	2
NVG2763	Travelling residents	Travel demographics	Demographics	0	2
NVG2129	time spent in community	Travel demographics	Other	0	2
NVG1684	Travel time to health facility	Travel demographics	Other	0	2
NVG2766	Absent from initian MDA non-travelling resident	Travel demographics	Other	0	2

NVG0747	High risk travel	Travel demographics	Other	0	2
NVG4775	Travel history	Travel history	Demographics	1	1
NVG3167	Travel in previous 2 years	Travel in previous 2 years	Demographics	1	0
NVG3376	Cavitation	Chest radiograph result	Images/EKG	1	0
NVG2850	Cavitation on Chest X-ray	Chest radiograph result	Images/EKG	1	0
NVG1211	Chest radiograph result: Consistent with TB	Chest radiograph result	Images/EKG	1	0
NVG1210	Chest radiograph result: Normal	Chest radiograph result	Images/EKG	1	0
NVG1212	Chest radiograph result: Unknown/Not done	Chest radiograph result	Images/EKG	1	0
NVG3596	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3597	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3598	Chest radiography (Normal, Apical or	Chest radiograph	Images/EKG	1	0

	upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	result			
NVG3599	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3600	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3601	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2 cm ² <2 cm ² , Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3602	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥ 2	Chest radiograph result	Images/EKG	1	0

	cm2 <2 cm2, Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)				
NVG3603	Chest radiography (Normal, Apical or upper-lobe fibronodular abnormality, ≥2 cm2 <2 cm2, Granuloma, Costophrenic angle blunting, Hilar lymph-node enlargement, Other possible tuberculosis-related abnormality, Abnormal result but not tuberculosis-related)	Chest radiograph result	Images/EKG	1	0
NVG3375	Radiographic extent of disease	Chest radiograph result	Images/EKG	1	0
NVG1334	Radiographic findings: Bilateral involvement	Chest radiograph result	Images/EKG	1	0
NVG1335	Radiographic findings: Consolidation	Chest radiograph result	Images/EKG	1	0
NVG1337	Radiographic findings: Effusion	Chest radiograph result	Images/EKG	1	0
NVG1336	Radiographic findings: Patchy infiltration	Chest radiograph result	Images/EKG	1	0
NVG3448	Radiography (Chest cavitation or Bilateral disease)	Chest radiograph result	Images/EKG	1	0
NVG3449	Radiography (Chest cavitation or Bilateral disease)	Chest radiograph result	Images/EKG	1	0
NVG4064	Result on chest radiography (Normal Abnormality not related to tuberculosis Hilar lymph node	Chest radiograph result	Images/EKG	1	0

	Other possible tuberculosis-related abnormality¶)				
NVG4065	Result on chest radiography (Normal Abnormality not related to tuberculosis Hilar lymph node Other possible tuberculosis-related abnormality¶)	Chest radiograph result	Images/EKG	1	0
NVG4066	Result on chest radiography (Normal Abnormality not related to tuberculosis Hilar lymph node Other possible tuberculosis-related abnormality¶)	Chest radiograph result	Images/EKG	1	0
NVG4067	Result on chest radiography (Normal Abnormality not related to tuberculosis Hilar lymph node Other possible tuberculosis-related abnormality¶)	Chest radiograph result	Images/EKG	1	0
NVG1017	Anatomical abnormality in biliary tract	Anatomical abnormality in biliary tract	Diagnosis	1	1
NVG1776	abnormal contrast enhancement of appendix wall	Abnormal contrast enhancement of appendix wall	Images/EKG	1	0
NVG0650	Abnormal fetal MRI	Abnormal fetal MRI	Images/EKG	1	0
NVG0649	Abnormal pre-natal US exam	Abnormal pre-natal US exam	Images/EKG	1	0
NVG1778	fluid collections around appendix	Fluid collections around appendix	Images/EKG	1	0
NVG4741	Multilobar infiltration	Multilobar infiltration	clinical manifestations	1	1

NVG1775	diameter of appendix	Diameter of appendix	Other	1	0
NVG3665	Tumor size	Tumor size	Other	1	1
NVG0450	Spleen size	Spleen size	Images/EKG	1	0
NVG0896	Splenomegaly	Spleen size	Images/EKG	1	1
NVG1878	Splenomegaly	Spleen size	Images/EKG	1	1
NVG0648	Number of prenatal US exams	Number of prenatal US exams	Images/EKG	1	0
NVG4413	Estimated right atrial pressure (mm Hg)	Estimated right atrial pressure	Clinical manifestations	1	1
NVG1602	Echocardiogram performed	Echocardiographic characteristics	Images/EKG	1	1
NVG0074	Received TTE	Echocardiographic characteristics	Images/EKG	1	1
NVG4404	Echocardiographic characteristics	Echocardiographic characteristics	Images/EKG	1	0
NVG4408	Mitral E/A ratio	Mitral E/A ratio	Images/EKG	1	1
NVG4410	Mitral E/e' ratio (lateral)	Mitral E/A ratio	Images/EKG	1	1
NVG4409	Mitral E/e' ratio (medial)	Mitral E/A ratio	Images/EKG	1	1
NVG4411	TR jet velocity (m/s)	TR jet velocity	Images/EKG	1	1
NVG0075	Received TEE	Transesophageal echocardiogram	Images/EKG	1	1
NVG1603	Transesophageal echocardiogram	Transesophageal echocardiogram	Images/EKG	1	1
NVG4221	Left ventricle ejection fraction	Left ventricular ejection fraction	Images/EKG	1	1
NVG4405	Left ventricular ejection fraction	Left ventricular ejection fraction	Images/EKG	1	1
NVG0791	Ejection fraction of the left ventricle	Left ventricular	Images/EKG	1	1

		ejection fraction			
NVG4407	Mitral E velocity	Mitral E velocity	Images/EKG	1	1
NVG0790	Maximum diameter of vegetation	Diameter of vegetation	Images/EKG	1	0
NVG3899	Vegetation size >9 mm	Diameter of vegetation	Images/EKG	1	1
NVG0357	Endoscopy	Endoscopy	Images/EKG	1	1
NVG3671	Tumor histologic classification (High-grade adenoma, Papillary adenocarcinoma, Well-differentiated tubular adenocarcinoma, Moderately differentiated tubular adenocarcinoma)	Tumor histologic classification	Other	1	0
NVG3672	Tumor histologic classification (High-grade adenoma, Papillary adenocarcinoma, Well-differentiated tubular adenocarcinoma, Moderately differentiated tubular adenocarcinoma)	Tumor histologic classification	Other	1	0
NVG3673	Tumor histologic classification (High-grade adenoma, Papillary adenocarcinoma, Well-differentiated tubular adenocarcinoma, Moderately differentiated tubular adenocarcinoma)	Tumor histologic classification	Other	1	0
NVG3674	Tumor histologic classification (High-grade adenoma, Papillary adenocarcinoma, Well-differentiated tubular adenocarcinoma, Moderately differentiated tubular adenocarcinoma)	Tumor histologic classification	Other	1	0
NVG1744	CIN grade	CIN grade	Diagnosis	1	0
NVG3831	Deep-tissue histologic result (Infected,	Histologic result	Diagnosis	1	0

	Equivocal, Uninfected, Not done or missing)				
NVG3832	Deep-tissue histologic result (Infected, Equivocal, Uninfected, Not done or missing)	Histologic result	Diagnosis	1	0
NVG3833	Deep-tissue histologic result (Infected, Equivocal, Uninfected, Not done or missing)	Histologic result	Diagnosis	1	0
NVG3834	Deep-tissue histologic result (Infected, Equivocal, Uninfected, Not done or missing)	Histologic result	Diagnosis	1	0
NVG3276	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3277	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3278	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3279	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma	Histologic result	diagnosis	1	0

	or injury, Complication of previous procedure, Other, No disease, Missing				
NVG3280	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3281	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3282	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3283	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3284	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3285	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut	Histologic result	diagnosis	1	0

	or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing				
NVG3286	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3287	Pathology (Appendicitis, Gallstone disease, Malignancy, Benign foregut, Benign midgut or hindgut, Infection, Congenital, Trauma or injury, Complication of previous procedure, Other, No disease, Missing	Histologic result	diagnosis	1	0
NVG3685	Intestinal metaplasia at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Intestinal metaplasia at corpus lesser curvature	Other	1	0
NVG3686	Intestinal metaplasia at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Intestinal metaplasia at corpus lesser curvature	Other	1	0
NVG3687	Intestinal metaplasia at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Intestinal metaplasia at corpus lesser curvature	Other	1	0
NVG3688	Intestinal metaplasia at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Intestinal metaplasia at corpus lesser curvature	Other	1	0
NVG3322	Community microfilarial load	Other diagnosis	Diagnosis	0	2
NVG3336	Median stay before diagnosis (days)	Other diagnosis	Diagnosis	0	2
NVG1245	Onset to diagnose interval	Other diagnosis	Diagnosis	0	2
NVG1422	Suspected Zika virus seropositive	Other diagnosis	Diagnosis	0	2

NVG4280	Enteric fever suspicion on admission	Other diagnosis	Diagnosis	0	2
NVG2444	FEV1% preicted	FEV1 predicted	Clinical manifestations	1	1
NVG4331	ECG findings (Normal: 13/17 LVH: 2/17 IRBBB: 1/17 Bradichardy: 1/17)	ECG findings	Images/EKG	1	0
NVG4332	ECG findings (Normal: 13/17 LVH: 2/17 IRBBB: 1/17 Bradichardy: 1/17)	ECG findings	Images/EKG	1	0
NVG4333	ECG findings (Normal: 13/17 LVH: 2/17 IRBBB: 1/17 Bradichardy: 1/17)	ECG findings	Images/EKG	1	0
NVG4334	ECG findings (Normal: 13/17 LVH: 2/17 IRBBB: 1/17 Bradichardy: 1/17)	ECG findings	Images/EKG	1	0
NVG4173	ECG typical Chagas disease	ECG findings	Images/EKG	1	0
NVG3048	Baseline QTcF	QT interval	Images/EKG	1	0
NVG3334	QT interval	QT interval	Images/EKG	1	0
NVG3377	QT interval	QT interval	Images/EKG	1	0
NVG2575	QTc Bazett	QT interval	Images/EKG	1	0
NVG3226	QTcF interval	QT interval	Images/EKG	1	0
NVG1360	Case status: Confirmed (Histoplasmosis)	Case status	Diagnosis	1	1
NVG1361	Case status: Probable (Histoplasmosis)	Case status	Diagnosis	1	1
NVG0914	Case vs contact	Case vs contact	Other	1	1
NVG1433	Case/control	Case/control	Other	1	0

NVG3172	Cases	Cases	Other	1	1
NVG1238	Frequency of episodes	Frequency of episodes	Other	1	0
NVG2048	Rate of immunological waning	Rate of immunological waning	Microbiology/serology	1	0
NVG3069	Incidence (per 10000 patient days)	Incidence	Other	1	0
NVG2650	incidence of cholera	Incidence	Other	1	1
NVG2770	incidence of yaws	Incidence	Other	1	1
NVG3067	Incident cases	Incidence	Other	1	1
NVG2482	Mean early onset of infection per 1000 livebirths (95% CI)	Mean early onset of infection per 1000 livebirths	Other	1	0
NVG3736	Number of patients	Number of patients	demographics	1	1
NVG2042	Case-fatality rate	Case-fatality rate	Prognosis	1	0
NVG2484	Mean mortality among babies younger than 60 days per 1000 livebirths (95% CI)	Mean mortality among babies younger than 60 days per 1000 livebirths	Other	1	0
NVG2585	age-especific respiratory deaths	Age-especific respiratory deaths	Prognosis	1	0
NVG2584	age-specific influenza mortality	Age-specific influenza mortality	Prognosis	1	0
NVG1512	Hospital mortality	Hospital mortality	Prognosis	1	1
NVG3306	Mortality	Mortality	Prognosis	1	0
NVG4176	Mortality in 2 years follow up	Mortality	Prognosis	1	0
NVG2037	Mortality rate	Mortality	prognosis	1	0
NVG0851	Mortality: At 30 days	Mortality	Prognosis	1	0
NVG0850	Mortality: At 7 days	Mortality	Prognosis	1	0
NVG3008	48h mortality	Mortality	Prognosis	1	1

NVG1301	No. deaths	Number of deaths	Prognosis	1	1
NVG2038	Annual birth rate	Annual birth rate	Other	1	0
NVG2451	Stillbirths	Stillbirths	Comorbidities	1	0
NVG0095	Severe infections	Stillbirth ante part+C4203:O4203m	Prognosis	1	0
NVG0918	Cluster (hospital, community)	Cluster	Other	1	0
NVG3088	Enrolment cohort	Enrolment cohort	Other	1	1
NVG4069	Reasons for eligibility (HIV infection, > 15 mm on tuberculin skin test, household contact of patient with TB).	Reasons for eligibility	Diagnosis	1	1
NVG4070	Reasons for eligibility (HIV infection, > 15 mm on tuberculin skin test, household contact of patient with TB).	Reasons for eligibility	Diagnosis	1	1
NVG4071	Reasons for eligibility (HIV infection, > 15 mm on tuberculin skin test, household contact of patient with TB).	Reasons for eligibility	Diagnosis	1	1
NVG1515	Number of patients	Number of patients	Other	1	0
NVG3068	Patient days	Patient days	Other	1	0
NVG1696	Stratification (E1, E2, K1, K2) E: E. coli K: Klebsiella, 1: less severe inf; 2: more severe infection	Stratification	Other	1	0
NVG1697	Stratification (E1, E2, K1, K2) E: E. coli K: Klebsiella, 1: less severe inf; 2: more severe infection	Stratification	Other	1	0
NVG1698	Stratification (E1, E2, K1, K2) E: E. coli K: Klebsiella, 1: less severe inf; 2: more severe infection	Stratification	Other	1	0
NVG1699	Stratification (E1, E2, K1, K2) E: E. coli K:	Stratification	Other	1	0

	Klebsiella, 1: less severe inf; 2: more severe infection				
NVG1002	Diseño de estudio (metanálisis)	Metanalysis	Other	1	1
NVG2527	Anaemia prevalence in children <5 years	Anaemia prevalence in children <5 years	Other	1	1
NVG3135	Crude prevalence.	Prevalence	Demographics	1	1
NVG0913	ST131 E. col Prevalence at baseline	ST131 E. col Prevalence at baseline	Demographics	1	1
NVG3136	Standardised prevalence (reference European population)	Standardised prevalence (reference European population)	Demographics	1	1
NVG1383	Prevalence of persistent biochemical hepatitis	Prevalence of persistent biochemical hepatitis	Laboratory	1	0
NVG0925	Prevalence of C. difficile positivity in stools	Prevalence of C. difficile positivity in stools	Microbiology/serology	1	0
NVG2526	Malaria infection prevalence	Malaria infection prevalence	Other	1	0
NVG2536	Malaria Prevalence	Malaria infection prevalence	Other	1	0
NVG2858	Birth control measures	Birth control measures	Other	1	1
NVG1647	Chlorhexidine bathing	Chlorhexidine bathing	Other	1	1
NVG3313	Hand hygiene compliance	Hand hygiene compliance	Other	1	0
NVG3308	Patients in contact isolation	Patients in contact isolation	Other	1	1
NVG3309	Patients in droplet isolation	Patients in droplet	Other	1	1

		isolation			
NVG3310	Patients in respiratory isolation	Patients in respiratory isolation	Other	1	1
NVG0354	Preinfection healthcare interventions	Preinfection healthcare interventions	Other	1	0
NVG0673	Anti-CRAB strategies (Tigecycline, colistin).	Anti-CRAB strategies	Treatment	1	1
NVG2535	Number of Mass Drug Administrations done	Number of Mass Drug Administrations done	treatment	1	0
NVG2445	PC-QoL score (parent cough specific quality of life)	Quality of life	Prognosis	0	2
NVG3071	Relative risk (95% CI)	Relative risk	Prognosis	1	1
NVG4298	Use of a commercial butcher to slaughter pigs	Risk factor demographics	Other	0	2
NVG4305	Use of crops as pig feed	Risk factor demographics	Other	0	2
NVG4306	Use of human feces as a fertilizer	Risk factor demographics	Other	0	2
NVG2691	contact with a suspected Ebola	Risk factor demographics	Other	0	2
NVG2690	Contact with dead or sick animal	Risk factor demographics	Other	0	2
NVG0470	Contact with person with mumps	Risk factor demographics	Other	0	2
NVG2140	Mosquito control activities	Risk factor demographics	Other	0	2
NVG1151	Place of exposure to ticks	Risk factor demographics	Other	0	2
NVG2149	practices with doors or windows (never	Risk factor	Other	0	2

	leaves them open; leaves regularly open)	demographics			
NVG2133	Time of mosquito bite (morining, night, day)	Risk factor demographics	Other	0	2
NVG2134	Time of mosquito bite (morining, night, day)	Risk factor demographics	Other	0	2
NVG2135	Time of mosquito bite (morining, night, day)	Risk factor demographics	Other	0	2
NVG2137	Where mosquito bite (home, school/work)	Risk factor demographics	Other	0	2
NVG2138	Where mosquito bite (home, school/work)	Risk factor demographics	Other	0	2
NVG2139	Where mosquito bite (home, school/work)	Risk factor demographics	Other	0	2
NVG0007	High-risk conditions for influenza	High-risk conditions for influenza	Comorbidities	1	0
NVG0186	No. of prespecified risk factors	No. of prespecified risk factors	comorbidities	1	0
NVG2257	risk conditions	Risk factor	Comorbidities	1	0
NVG0821	Risk factor	Risk factor	Comorbidities	1	0
NVG3590	Risk factor as indication for treatment (HIV infection, Confirmed active tuberculosis in close contact, Confirmed active tuberculosis in casual contact,, Other immunosuppressive condition or therapy, Upper-lobe fibronodular disease with area ≥ 2 cm ²)	Risk factor	Comorbidities	1	1
NVG3592	Risk factor as indication for treatment (HIV infection, Confirmed active tuberculosis in close contact, Confirmed active	Risk factor	Comorbidities	1	1

	tuberculosis in casual contact,, Other immunosuppressive condition or therapy, Upper-lobe fibronodular disease with area ≥ 2 cm ²)				
NVG1823	Transmission risk (hetero, HSH, ADVP; Other, Unknown)	Transmission risk	Comorbidities	1	0
NVG3656	increased-risk donor has characteristics that could increase the risk of disease transmission to potential transplant recipients.	Increased-risk donor has characteristics that could increase the risk of disease transmission to potential transplant recipients.	Other	1	0
NVG2100	Perceived risk of Evola Infection (High	Perceived risk of Evola Infection	Other	1	0
NVG2101	Perceived risk of Evola Infection Average	Perceived risk of Evola Infection	Other	1	0
NVG2102	Perceived risk of Evola Infection Low	Perceived risk of Evola Infection	Other	1	0
NVG2103	Perceived risk of Evola Infection: Not Reported	Perceived risk of Evola Infection	Other	1	0
NVG1822	Transmission risk (hetero, HSH, ADVP; Other, Unknown)	Transmission risk	Other	1	0
NVG1824	Transmission risk (hetero, HSH, ADVP; Other, Unknown)	Transmission risk	Other	1	0
NVG1825	Transmission risk (hetero, HSH, ADVP; Other, Unknown)	Transmission risk	Other	1	0
NVG1826	Transmission risk (hetero, HSH, ADVP; Other, Unknown)	Transmission risk	Other	1	0

NVG3070	Risk difference	Risk difference	Prognosis	1	0
NVG4422	Influenza activity pattern (One peak Two peaks Year-round activity)	Influenza activity pattern	Other	1	1
NVG4423	Influenza activity pattern (One peak Two peaks Year-round activity)	Influenza activity pattern	Other	1	1
NVG4424	Influenza activity pattern (One peak Two peaks Year-round activity)	Influenza activity pattern	Other	1	1
NVG0006	Enrollment period	Enrollment period	Other	1	1
NVG2265	Calendar time (every two weeks)	Time	Other	1	1
NVG1747	Time	Time	Other	1	1
NVG1779	Time	Time	Other	1	1
NVG1923	time	Time	Other	1	1
NVG2569	Time	Time	Other	1	1
NVG2594	time	Time	Other	1	1
NVG2649	time	Time	Other	1	1
NVG2714	time	Time	Other	1	1
NVG2771	time	Time	Other	1	1
NVG2779	time	Time	Other	1	1
NVG3441	Time	Time	Other	1	1
NVG0916	Time	Time	Other	1	1
NVG2537	Time (years)	Time	Other	1	1
NVG1289	Time period	Time	Other	1	1
NVG2581	Time series (monthly, weekly)	Time series	Other	1	0
NVG3498	Days from admission to survey	Days from admission	Other	1	0

		to survey			
NVG3170	Period (years)	Period	Other	1	0
NVG3173	Period (years)	Period	Other	1	0
NVG2033	Study period	Study period	Other	1	0
NVG0242	Year	Year	Demographics	1	1
NVG0486	Year	Year	Demographics	1	1
NVG0921	Year	Year	Demographics	1	1
NVG1295	Year	Year	Demographics	1	1
NVG1372	Year	Year	Demographics	1	1
NVG1798	Year	Year	Demographics	1	1
NVG4440	Year of study	Year of study	Other	1	1
NVG4582	Year-band (period)	Year-band	Other	1	0
NVG2260	Influenza season (2010-2011; 2011-2012...)	Influenza season	Other	1	1
NVG1734	Time to randomization (h)	Time to randomization	Other	1	1
NVG2045	long-cycle transmission coefficient	Long-cycle transmission coefficient	Microbiology/serology	1	0
NVG1109	Community acquired	Community-acquire infection	Diagnosis	1	0
NVG3709	Community-acquire infection	Community-acquire infection	Diagnosis	1	0
NVG4496	Community-acquired infection	Community-acquire infection	Diagnosis	1	0
NVG1595	Community-acquired endocarditis	Community-acquired endocarditis	Diagnosis	1	0
NVG4046	Community-acquired pneumonia	Community-acquired pneumonia	Diagnosis	1	0

NVG1005	Nosocomial onset	Hospital-acquired	clinical manifestations	1	0
NVG0741	Healthcare exposures in previous 12 months	Healthcare exposures in previous 12 months	Comorbidities	1	0
NVG0481	Healthcare utilization related to mumps diagnosis	Healthcare utilization	Comorbidities	1	0
NVG1252	Healthcare related	Healthcare-associated	Comorbidities	1	0
NVG0366	Healthcare-associated	Healthcare-associated	Comorbidities	1	0
NVG0781	Healthcare-associated IE acquisition	Healthcare-associated	Comorbidities	1	0
NVG0723	Healthcare-associated infection	Healthcare-associated	Comorbidities	1	0
NVG1704	Acquisition (Hospital, Health Care-associated, Community)	Acquisition	Diagnosis	1	1
NVG1705	Acquisition (Hospital, Health Care-associated, Community)	Acquisition	Diagnosis	1	1
NVG1706	Acquisition (Hospital, Health Care-associated, Community)	Acquisition	Diagnosis	1	1
NVG1594	Health care–associated endocarditis	Health care–associated endocarditis	Diagnosis	1	1
NVG1593	Nosocomial acquired endocarditis	Hospital-acquired infection	diagnosis	1	1
NVG1038	Hospital-acquired infection	Hospital-acquired infection	Diagnosis	1	1
NVG4497	Hospital-acquired infection	Hospital-acquired infection	Diagnosis	1	1
NVG0836	In-hospital infection	Hospital-acquired infection	Diagnosis	1	0
NVG0312	Hospital/retirement homeacquired CDI	Hospital/retirement homeacquired CDI	Diagnosis	1	1
NVG1110	Healthcare associated	Healthcare associated	Other	1	0

NVG0367	Hospital-acquired	Hospital-acquired	Other	1	0
NVG1685	Last visit to a health facility	Last visit to a health facility	Other	1	0
NVG2992	Acquisition of infection in the intensive care unit	Acquisition of infection in the intensive care unit	Treatment	1	0
NVG4348	first isolation of carbapenem-resistant MDR-GNB during ICU stay	First isolation of carbapenem-resistant MDR-GNB during ICU stay	Microbiology/serology	1	0
NVG2912	Type of nosocomial pneumonia (Ventilator-associated pneumonia Non-ventilator-associated pneumonia)	Type of nosocomial pneumonia	Diagnosis	1	0
NVG2913	Type of nosocomial pneumonia (Ventilator-associated pneumonia Non-ventilator-associated pneumonia)	Type of nosocomial pneumonia	Diagnosis	1	0
NVG2915	Type of ventilator-associated pneumonia infection (early vs late)	Type of ventilator-associated pneumonia infection	Diagnosis	1	0
NVG2916	Type of ventilator-associated pneumonia infection (early vs late)	Type of ventilator-associated pneumonia infection	Diagnosis	1	0
NVG1055	Ventilator associated pneumoniae	Ventilator-associated pneumonia	Diagnosis	1	0
NVG0658	Ventilator-associated pneumonia	Ventilator-associated pneumonia	Diagnosis	1	0
NVG3500	Ventilator-associated pneumonia	Ventilator-associated pneumonia	Diagnosis	1	0
NVG0964	Abdominal infection	Abdominal infection	Diagnosis	1	0

NVG0663	Prior A. baumannii infection	A. baumannii infection	diagnosis	1	0
NVG1783	no appendicitis recurrence in 1 year.	No appendicitis recurrence in 1 year.	diagnosis	1	0
NVG3511	Other primary bloodstream infection	Other primary bloodstream infection	comorbidities	1	0
NVG2920	Bacteraemic	Bacteremia	Diagnosis	1	1
NVG3763	Bacteremia	Bacteremia	Diagnosis	1	1
NVG4740	Bacteremia	Bacteremia	Diagnosis	1	1
NVG3792	Bacteremia (%)	Bacteremia	Diagnosis	1	1
NVG0838	Bacteria in incident blood culture	Bacteremia	Diagnosis	1	1
NVG0961	Bacteriemia	Bacteremia	Diagnosis	1	1
NVG0206	Bloodstream	Bacteremia	Diagnosis	1	1
NVG3508	Bloodstream infection	Bacteremia	Diagnosis	1	1
NVG4484	Primary bacteremia	Bacteremia	diagnosis	1	1
NVG1054	Primary bacteriemia	Bacteremia	diagnosis	1	1
NVG1114	Primary bacteriemia	Bacteremia	diagnosis	1	1
NVG0076	Uncomplicated bacteremia	Uncomplicated bacteremia	Diagnosis	1	1
NVG4485	Secondary bacteremia	Secondary bacteremia	Microbiology/serology	1	0
NVG0559	Bacterial	Bacterial	Diagnosis	1	1
NVG0956	Confirmed bacterial infection	Confirmed bacterial infection	Diagnosis	1	1
NVG4556	Possible serious bacterial infection present upon admission	Possible serious bacterial infection present upon admission	diagnosis	1	1
NVG1115	Biliary tract infection	Biliary tract infection	Diagnosis	1	0

NVG4045	Acute bronchitis	Acute bronchitis	Diagnosis	1	1
NVG0966	Central nervous system infection	Central nervous system infection	Diagnosis	1	0
NVG4257	Diagnosed with Chagas disease	Diagnosed with Chagas disease	Comorbidities	1	1
NVG0899	Choroiditis	Choroiditis	Diagnosis	1	1
NVG0170	Primary C. difficile infection (CDI)	C. difficile infection	diagnosis	1	1
NVG3503	Clostridium difficile infection†	Clostridium difficile infection	Diagnosis	1	0
NVG0833	Clostridium difficile-associated diarrhoea	Clostridium difficile infection	Diagnosis	1	0
NVG1388	CMV reactivation	CMV reactivation	Diagnosis	1	0
NVG1599	Complicated Coag-Neg Staph.	Complicated Coag-Neg Staph.	Diagnosis	1	0
NVG2494	Conjunctivities	Conjunctivitis	Diagnosis	1	1
NVG0638	Conjunctivitis	Conjunctivitis	Diagnosis	1	1
NVG3506	Deep incisional or organ-space infection	Deep incisional or organ-space infection	Diagnosis	1	1
NVG2400	<i>Deep tissue infection or abscess (foci)</i>	<i>Deep tissue infection or abscess</i>	Diagnosis	1	1
NVG4771	DF with Bronchial asthma	DF with Bronchial asthma	Diagnosis	1	0
NVG4773	DF with left arm cellulites	DF with left arm cellulites	Diagnosis	1	0
NVG4772	DHF with pleural effusion	DHF with pleural effusion	Diagnosis	1	0
NVG0519	Uncomplicated diabetes	Diabetes	Diagnosis	1	0
NVG3778	Atypical bacteria, conservative definition	Atypical bacteria,	Microbiology/serology	1	1

	of positivity	conservative definition of positivity			
NVG3774	Atypical bacteria, SAP definition of positivity	Atypical bacteria, SAP definition of positivity	Microbiology/serology	1	1
NVG1604	Diagnosed with endocarditis	Diagnosed with endocarditis	Comorbidities	1	1
NVG3895	Aortic-valve endocarditis	Aortic-valve endocarditis	Diagnosis	1	1
NVG0087	Definite endocarditis	Definite endocarditis	Diagnosis	1	1
NVG3897	Endocarditis in other locationsÅò	Endocarditis in other locations	Diagnosis	1	1
NVG0784	Intracardiac device related IE	Intracardiac device related IE	Diagnosis	1	1
NVG0785	Left-sided IE	Left-sided IE	Diagnosis	1	1
NVG3896	Mitral-valve and aortic-valve endocarditis	Mitral-valve and aortic-valve endocarditis	Diagnosis	1	1
NVG3894	Mitral-valve endocarditis	Mitral-valve endocarditis	Diagnosis	1	1
NVG0782	Native valve only IE	Native valve only IE	Diagnosis	1	1
NVG3898	Pacemaker endocarditis	Pacemaker endocarditis	diagnosis	1	0
NVG0783	Prosthetic valve IE	Prosthetic valve endocarditis	diagnosis	1	1
NVG0799	Paravalvular septic complication (by echocardiography or by surgery)	Paravalvular septic complication	Images/EKG	1	0
NVG2058	Enteric fever	Enteric fever	Diagnosis	1	1
NVG0958	Confirmed fungal infection	Confirmed fungal infection	Diagnosis	1	1

NVG3502	Gastrointestinal infection	Gastrointestinal infection	Diagnosis	1	0
NVG3504	Other gastrointestinal infection	Other gastrointestinal infection	diagnosis	1	0
NVG1490	Gonorrhea at enrollment	Gonorrhea	Comorbidities	1	1
NVG2507	hepatitis C virus infection	HCV infection	Microbiology/serology	1	1
NVG1805	hepatitis	Hepatitis	Clinical manifestations	1	0
NVG1384	Viral hepatitis	Viral hepatitis	Diagnosis	1	1
NVG1283	Cryptogenic liver abscess	Cryptogenic liver abscess	Diagnosis	1	1
NVG3507	Superficial incisional infection	Surgical site infection	Diagnosis	1	1
NVG1784	surgical site infections	Surgical site infection	Diagnosis	1	1
NVG2403	<i>Surgical wound (foci)</i>	Surgical site infection	Diagnosis	1	1
NVG3505	Surgical-site infection	Surgical site infection	Diagnosis	1	1
NVG3271	Malaria	Malaria	Diagnosis	1	1
NVG0476	Meningitis	Meningitis	Diagnosis	1	1
NVG1806	meningitis	Meningitis	Diagnosis	1	1
NVG2246	rectal N. gonorrheae	Rectal N. gonorrheae	Microbiology/serology	1	1
NVG1284	Noncryptogenic liver abscess	Noncryptogenic liver abscess	Diagnosis	1	1
NVG0475	Orchitis	Orchitis	diagnosis	1	0
NVG3207	Osteoarthritis	Osteoarthritis	clinical manifestations	1	1
NVG1184	Otitis with complications	Otitis with complications	diagnosis	1	1
NVG0959	Confirmed parasite infection	Confirmed parasite infection	Diagnosis	1	1
NVG3501	Other pneumonia	Other pneumonia	comorbidities	1	0

NVG0657	Acquired pneumonia	Acquired pneumonia	Diagnosis	1	1
NVG0207	Pneumonia	Pneumonia	diagnosis	1	1
NVG3499	Pneumonia	Pneumonia	diagnosis	1	1
NVG0435	Pneumonia and influenza	Pneumonia	diagnosis	1	1
NVG0412	proctitis	Proctitis	diagnosis	1	1
NVG2060	upper respiratory tract infection	Upper respiratory tract infection	Clinical manifestations	1	1
NVG4053	Other lower respiratory tract infection	Other lower respiratory tract infection	comorbidities	1	0
NVG1803	Lower resp tract infection	Lower respiratory tract	Diagnosis	1	1
NVG2059	lower respiratory tract infection	Lower respiratory tract	Diagnosis	1	1
NVG1117	Lower respiratory tract	Lower respiratory tract	Diagnosis	1	1
NVG4054	Non–lower respiratory tract infection	Non–lower respiratory tract infection	Diagnosis	1	1
NVG0963	Respiratory tract	Respiratory tract	Microbiology/serology	1	1
NVG4246	Developed scabies despite earlier preventive treatment	Developed scabies despite earlier preventive treatment	Treatment	1	0
NVG3237	Scabies	Scabies	Microbiology/serology	1	1
NVG0962	Skin and Soft tissiue	Skin and soft tissue	Microbiology/serology	1	1
NVG1119	Skin and soft tissue	Skin and soft tissue	Microbiology/serology	1	1
NVG1601	Nonstaphylococcal infection	Nonstaphylococcal infection	Diagnosis	1	0

NVG1597	Uncomplicated coag-neg Staph.	Uncomplicated coag-neg Staph.	Diagnosis	1	1
NVG1596	Simple Coag-neg Staph.	Simple Coag-neg Staph.	Microbiology/serology	1	1
NVG1608	Not simple C-N Staph. and intravenous catheter not removed	Not simple C-N Staph. and intravenous catheter not removed	Treatment	1	0
NVG1600	Complicated S. aureus	Complicated S. aureus	Diagnosis	1	0
NVG1598	Uncomplicated S. aureus	Uncomplicated S. aureus	Diagnosis	1	1
NVG1088	toxic megacolon	Toxic megacolon	Diagnosis	1	0
NVG3514	Other urinary tract infection	Other urinary tract infection	comorbidities	1	0
NVG3513	Catheter-associated urinary tract infection	Catheter-associated urinary tract infection	Diagnosis	1	1
NVG1651	Complicated UTI with removable site of infection	Complicated UTI with removable site of infection	Diagnosis	1	1
NVG1652	Complicated UTI without removable site of infection	Complicated UTI without removable site of infection	Diagnosis	1	1
NVG0208	Urinary tract	Urinary tract infection	Diagnosis	1	0
NVG0744	Urinary tract infection	Urinary tract infection	Diagnosis	1	0
NVG1113	Urinary tract infection	Urinary tract infection	Diagnosis	1	0
NVG2061	Urinary Tract infection	Urinary tract infection	Diagnosis	1	0
NVG3512	Urinary tract infection	Urinary tract infection	Diagnosis	1	0
NVG0965	Urogenital infection	Urogenital infection	Diagnosis	1	0
NVG3791	Urosepsis (%)	Urosepsis	Other	1	0

NVG0957	Confirmed viral infection	Confirmed viral infection	Diagnosis	1	1
NVG1389	Nonviral causes	Nonviral causes	diagnosis	1	1
NVG0571	Virologic status in those with a gap in care	Virologic status in those with a gap in care	Microbiology/serology	1	1
NVG0630	Zika infection during pregnancy (trimester)	Zika infection during pregnancy	Diagnosis	1	0
NVG4336	Zika	Zika	Microbiology/serology	1	1
NVG1298	No. infections	Number of infections	Diagnosis	1	0
NVG0364	Infection variables	Infection variables	Other	1	0
NVG1026	Infectious diseases consultation	Infectious diseases consultation	Other	1	0
NVG1613	Infectious diseases consultation for S aureus bacteremia	Infectious diseases consultation	Other	1	0
NVG1087	Site of concomitant infection	Site of concomitant infection	Diagnosis	1	1
NVG3407	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0
NVG3408	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0
NVG3409	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0
NVG3410	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0
NVG3411	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0
NVG3412	Site of infection (Pulmonary, Abdominal, Blood, Skin or soft tissue, Urinary, Other)	Site of infection	Diagnosis	1	0

NVG3711	Site of infection (Unknown, Lung, Abdomen, Urinary tract)	Site of infection	Diagnosis	1	0
NVG3712	Site of infection (Unknown, Lung, Abdomen, Urinary tract)	Site of infection	Diagnosis	1	0
NVG3713	Site of infection (Unknown, Lung, Abdomen, Urinary tract)	Site of infection	Diagnosis	1	0
NVG3714	Site of infection (Unknown, Lung, Abdomen, Urinary tract)	Site of infection	Diagnosis	1	0
NVG1456	Site of infection Central nervous system Other Unknown	Site of infection	Diagnosis	1	0
NVG1457	Site of infection Gastrointestinal Skin Central nervous system Other Unknown	Site of infection	Diagnosis	1	0
NVG1458	Site of infection Other	Site of infection	Diagnosis	1	0
NVG1459	Site of infection Respiratory Gastrointestinal Skin Central nervous system Other Unknown	Site of infection	Diagnosis	1	0
NVG1460	Site of infection Skin Central nervous system Other Unknown	Site of infection	Diagnosis	1	0
NVG1461	Site of infection Unknown	Site of infection	Diagnosis	1	0
NVG1462	Site of infection Urinary	Site of infection	Diagnosis	1	0

	Respiratory Gastrointestinal Skin Central nervous system Other Unknown				
NVG1491	Site of infection: Pharyngeal	Site of infection	Diagnosis	1	0
NVG1492	Site of infection: Rectal	Site of infection	Diagnosis	1	0
NVG1493	Site of infection: Urethral	Site of infection	Diagnosis	1	0
NVG0618	Site of infection acquisition	Site of infection	Diagnosis	1	1
NVG3049	Site of tuberculosis	Site of tuberculosis	Diagnosis	1	0
NVG1272	Right liver localization	Right liver localization	Images/EKG	1	1
NVG1216	TB site: Both	TB site	Diagnosis	1	0
NVG1215	TB site: Extrapulmonary	TB site	Diagnosis	1	0
NVG1214	TB site: Pulmonary	TB site	Diagnosis	1	0
NVG2831	Pulmonary TBC	Tuberculosis type	Diagnosis	1	0
NVG3445	Tuberculosis type	Tuberculosis type	Diagnosis	1	1
NVG1545	At risk for resistant organisms	At risk for resistant organisms	Prognosis	1	0
NVG0738	At risk of 3GCR-E-Bacteraemia according to two-predictor model	At risk of 3GCR-E-Bacteraemia according to two-predictor model	Prognosis	1	0
NVG0293	History of AIDS	History of AIDS	Diagnosis	1	0
NVG2359	History of clinical AIDS	History of AIDS	Diagnosis	1	0
NVG1837	AIDS status (HIV Non-AIDS or AIDS)	AIDS status	Diagnosis	1	0
NVG1838	AIDS status (HIV Non-AIDS or AIDS)	AIDS status	Diagnosis	1	0

NVG0461	Clinical AIDS	Clinical AIDS	Diagnosis	1	0
NVG3108	HIV negative	HIV status	Microbiology/serology	1	0
NVG4544	HIV positive	HIV status	Microbiology/serology	1	0
NVG4458	HIV-negative	HIV status	Microbiology/serology	1	0
NVG3044	HIV-positive	HIV status	Microbiology/serology	1	0
NVG2311	HIV+	HIV status	Microbiology/serology	1	1
NVG1386	Chronic HCV infection	Chronic HCV infection	Comorbidities	1	1
NVG1387	Chronic HEV infection	Chronic HEV infection	Comorbidities	1	1
NVG4443	CDC (A, B, C)	CDC category	Diagnosis	1	0
NVG4444	CDC (A, B, C)	CDC category	Diagnosis	1	0
NVG4445	CDC (A, B, C)	CDC category	Diagnosis	1	0
NVG2566	CDC category (A, B, C)	CDC category	Diagnosis	1	0
NVG2567	CDC category (A, B, C)	CDC category	Diagnosis	1	0
NVG2568	CDC category (A, B, C)	CDC category	Diagnosis	1	0
NVG0173	≥2 previous C. difficile infection episodes ever	Number of previous C. difficile infection	Comorbidities	1	0
NVG0172	1 previous C. difficile infection episode ever	Number of previous C. difficile infection	Comorbidities	1	0
NVG3104	Number of previous C. difficile infection	Number of previous C. difficile infection	comorbidities	1	1
NVG2976	Known colonization by pathogen before infection	Known colonization by pathogen before infection	Microbiology/serology	1	0
NVG3314	Patients colonised with antibiotic-resistant Gram negative bacteria	Patients colonised with antibiotic-resistant Gram negative bacteria	microbiology/serology	1	0
NVG4517	Pneumococcal carriage	Pneumococcal	Other	1	0

		carriage			
NVG1592	Previous infective endocarditis	Previous infective endocarditis	Comorbidities	1	1
NVG0440	Reported Previous Flavivirus Exposure	Reported Previous Flavivirus Exposure	Comorbidities	1	0
NVG1355	HAdV-55 infection status	HAdV-55 infection status	Microbiology/serology	1	0
NVG0294	Hepatitis B and/or C	Hepatitis B and/or C	Microbiology/serology	1	1
NVG2212	Coinfection HIV	Coinfection HIV	Comorbidities	1	1
NVG4267	HIV	HIV	Comorbidities	1	0
NVG0236	HIV	HIV	Comorbidities	1	1
NVG0948	HIV	HIV	Comorbidities	1	1
NVG1086	HIV	HIV	Comorbidities	1	1
NVG1497	HIV	HIV	Comorbidities	1	1
NVG1967	HIV	HIV	Comorbidities	1	1
NVG3270	HIV	HIV	Comorbidities	1	1
NVG3373	HIV	HIV	Comorbidities	1	1
NVG3139	HIV coinfection	HIV	Comorbidities	1	1
NVG0820	HIV infection	HIV	Comorbidities	1	1
NVG1918	HIV infection	HIV	Comorbidities	1	1
NVG2505	HIV infection category category (stage 0-3)	HIV	Comorbidities	1	0
NVG0515	HIV/AIDS	HIV	Comorbidities	1	1
NVG1804	HIVS/AIDS	HIV	Comorbidities	1	1
NVG3928	HIV	HIV	Comorbidities	1	1
NVG0455	HIV risk group	HIV	Comorbidities	1	0
NVG4457	HIV-infected	HIV	Comorbidities	1	1

NVG1680	Newly diagnosed HIV	HIV	Comorbidities	1	0
NVG1107	Uncontrolled HIV	Uncontrolled HIV	Diagnosis	1	0
NVG3628	HIV-1 coinfection	HIV-1 coinfection	Microbiology/serology	1	1
NVG2745	New HIV at diagnosis	New HIV at diagnosis	Microbiology/serology	1	1
NVG1217	HIV status	HIV status	Other	1	0
NVG3149	HIV status	HIV status	Other	1	0
NVG3345	HIV status	HIV status	Other	1	0
NVG3691	HIV status	HIV status	Other	1	0
NVG4613	HIV status	HIV status	Other	1	0
NVG2838	HIV status (positive with ART, positive without ART, negative)	HIV status	Other	1	0
NVG2839	HIV status (positive with ART, positive without ART, negative)	HIV status	Other	1	0
NVG2840	HIV status (positive with ART, positive without ART, negative)	HIV status	Other	1	0
NVG1488	ST Infection at enrollment	ST Infection at enrollment	Microbiology/serology	1	1
NVG2891	Previous infection history (N,o, cUTI, Other infection)	Previous infection history	Comorbidities	1	0
NVG2892	Previous infection history (N,o, cUTI, Other infection)	Previous infection history	Comorbidities	1	0
NVG2893	Previous infection history (N,o, cUTI, Other infection)	Previous infection history	Comorbidities	1	0
NVG3753	Previous lung infection	Previous lung infection	Comorbidities	1	0
NVG3816	Previous diagnosis of tuberculosis	Previous tuberculosis	Comorbidities	1	1
NVG2830	Previous tuberculosis	Previous tuberculosis	Comorbidities	1	0
NVG3145	Previous tuberculosis diagnosis	Previous tuberculosis	Comorbidities	1	0

NVG3144	Previous tuberculosis contact before recent exposure	Previous tuberculosis contact	Comorbidities	1	0
NVG1547	Previous UTI	Previous UTI	Comorbidities	1	0
NVG0052	History of documented influenza	History of documented influenza	Comorbidities	1	0
NVG0171	≥1 C. difficile infection episodes in past 6 mo	≥1 C. difficile infection episodes in past 6 mo	Comorbidities	1	0
NVG0699	Any tick-borne disease	Any tick-borne disease	Comorbidities	1	0
NVG1589	History of S aureus infection within the past year	History of S aureus infection within the past year	Comorbidities	1	0
NVG1494	Syphilis at enrollment	Syphilis at enrollment	Microbiology/serology	1	1
NVG3424	History of tuberculosis	History of tuberculosis	Comorbidities	1	0
NVG3696	Patient-reported history of tuberculosis	Patient-reported history of tuberculosis	comorbidities	1	0
NVG3039	Prior tuberculosis diagnosis	Prior tuberculosis diagnosis	Comorbidities	1	1
NVG1807	tuberculosis	Tuberculosis	Comorbidities	1	1
NVG2063	Tuberculosis	Tuberculosis	Comorbidities	1	1
NVG4265	Tuberculosis	Tuberculosis	Comorbidities	1	1
NVG3040	Physician tuberculous meningitis diagnosis	Physician tuberculous meningitis diagnosis	diagnosis	1	1
NVG2756	Clinically suspected TB	Suspected TB	Diagnosis	1	1
NVG3015	Number of urinary tract infections in 12 months before randomization	Number of urinary tract infections in 12 months before randomization	comorbidities	1	0

NVG1385	Reactivation of chronic HBV infection	Reactivation of chronic HBV infection	Comorbidities	1	1
NVG0446	Visceral leishmaniasis relapse prior to enrollment	Visceral leishmaniasis relapse	Comorbidities	1	0
NVG1125	Relapse	Relapse	Diagnosis	1	0
NVG2641	Relapse after auto-HSCT.	Relapse	Diagnosis	1	0
NVG0249	Relapse after HSCT	Relapse	Diagnosis	1	0
NVG1635	Relapsed acute lymphoblastic leukemia	Relapse	Diagnosis	1	1
NVG0315	Recurrences	Recurrences	Comorbidities	1	1
NVG1241	Recurrent disease	Recurrent disease	Comorbidities	1	1
NVG1396	Recurrent pyogenic cholangitis	Recurrent pyogenic cholangitis	Comorbidities	1	1
NVG4455	Reinfection	Reinfection	Diagnosis	1	0
NVG1240	Reinfection	Reinfection	Diagnosis	1	0
NVG4449	Current sexually transmitted infection	Sexually transmitted infection	Comorbidities	1	0
NVG2285	sexually transmitted infection	Sexually transmitted infection	Comorbidities	1	0
NVG4263	Sexually transmitted infection	Sexually transmitted infection	Comorbidities	1	0
NVG3098	Sexually transmitted infections at visits	Sexually transmitted infection at visits	Comorbidities	1	0
NVG0414	sexually transmitted infection history	Sexually transmitted infection history	Comorbidities	1	0
NVG0422	HIV transmission route	HIV transmission route	Microbiology/serology	1	1
NVG0225	Catheter-Source of bacteremia: associated	Catheter-Source of bacteremia	Diagnosis	1	1

NVG3509	Central catheter–associated bloodstream	Central catheter–associated bloodstream	Diagnosis	1	0
NVG2401	<i>Central or preipheral iv catheter (foci)</i>	<i>Central or preipheral iv catheter (foci)</i>	Treatment	1	1
NVG2398	<i>Prosthetic valve or joint (foci)</i>	<i>Prosthetic valve or joint (foci)</i>	diagnosis	1	1
NVG0223	Source of bacteremia: Biliary	Source of bacteremia	Diagnosis	1	0
NVG0224	Source of bacteremia: Gastrointestinal	Source of bacteremia	Diagnosis	1	0
NVG0220	Source of bacteremia: Pneumonia	Source of bacteremia	Diagnosis	1	0
NVG0221	Source of bacteremia: Skin and soft tissue	Source of bacteremia	Diagnosis	1	0
NVG0222	Source of bacteremia: Urinary tract	Source of bacteremia	Diagnosis	1	0
NVG1708	Source of bacteriemia: Intra-abdominal infection	Source of bacteremia	Diagnosis	1	0
NVG1712	Source of bacteriemia: Mucositis/neutropenia	Source of bacteremia	Diagnosis	1	0
NVG1713	Source of bacteriemia: Musculoskeletal	Source of bacteremia	Diagnosis	1	0
NVG1711	Source of bacteriemia: Pneumonia	Source of bacteremia	Diagnosis	1	0
NVG1714	Source of bacteriemia: Skin and soft tissue	Source of bacteremia	Diagnosis	1	0
NVG1710	Source of bacteriemia: Surgical site infection	Source of bacteremia	Diagnosis	1	0
NVG1707	Source of bacteriemia: Urinary tract infection	Source of bacteremia	Diagnosis	1	0
NVG1709	Source of bacteriemia: Vascular catheter–related infection	Source of bacteremia	Diagnosis	1	0
NVG1715	Source of bacteriemia: Unknown	Source of bacteremia	Diagnosis	1	0
NVG1565	Septic Shock source (intraabdomina, Pneumonia, UTI...)	Source of infection	Diagnosis	1	0

NVG0842	Source of infection: Abdomen	Source of infection	Diagnosis	1	0
NVG0840	Source of infection: CVC	Source of infection	Diagnosis	1	0
NVG0844	Source of infection: Other	Source of infection	Diagnosis	1	0
NVG0841	Source of infection: Primary	Source of infection	Diagnosis	1	0
NVG0843	Source of infection: Urine	Source of infection	Diagnosis	1	0
NVG0735	Suspected source of infection	Suspected source of infection	Diagnosis	1	0
NVG3554	MRSA source (nares, wound, respiratory, blood, other)	MRSA source	Microbiology/serology	1	0
NVG3555	MRSA source (nares, wound, respiratory, blood, other)	MRSA source	Microbiology/serology	1	0
NVG3556	MRSA source (nares, wound, respiratory, blood, other)	MRSA source	Microbiology/serology	1	0
NVG3557	MRSA source (nares, wound, respiratory, blood, other)	MRSA source	Microbiology/serology	1	0
NVG0831	Multifocal Candida colonization	Multifocal Candida colonization	microbiology/serology	1	0
NVG2396	<i>Native heart valve (foci)</i>	<i>Native heart valve (foci)</i>	Microbiology/serology	1	1
NVG2397	<i>Native joint (foci)</i>	<i>Native joint (foci)</i>	Microbiology/serology	1	1
NVG0204	Origin	Origin	other	1	1
NVG2399	<i>Implanted vascular device (foci)</i>	<i>Implanted vascular device (foci)</i>	Treatment	1	1
NVG1116	Intraabdominal	Intraabdominal	Other	1	1
NVG3294	Intraoperative contamination (Clean–contaminated, Contaminated, Dirty)	Intraoperative contamination	Other	1	0
NVG3295	Intraoperative contamination (Clean–contaminated, Contaminated, Dirty)	Intraoperative contamination	Other	1	0

NVG3296	Intraoperative contamination (Clean-contaminated, Contaminated, Dirty)	Intraoperative contamination	Other	1	0
NVG1056	Other foci (infection/bacteriemia)	Focus	diagnosis	1	1
NVG0086	Focus: Abdominal	Focus	Diagnosis	1	0
NVG0082	Focus: Cardiac device/vascular device	Focus	Diagnosis	1	0
NVG0081	Focus: Central venous line	Focus	Diagnosis	1	0
NVG0083	Focus: Osteoarticular	Focus	Diagnosis	1	0
NVG0085	Focus: Respiratory	Focus	Diagnosis	1	0
NVG0084	Focus: Skin/soft tissue	Focus	Diagnosis	1	0
NVG2404	<i>Pneumonia or Urinary Tract Infection (foci)</i>	Focus	diagnosis	1	1
NVG2405	<i>Pneumonia or Urinary Tract Infection (foci)</i>	Focus	diagnosis	1	1
NVG2402	<i>Skin or soft tissue (foci)</i>	<i>Skin or soft tissue (foci)</i>	Microbiology/serology	1	0
NVG1085	Concomitant infection	Concomitant infection	Diagnosis	1	1
NVG0671	Concomitant infection other than pneumonia	Concomitant infection other than pneumonia	Diagnosis	1	1
NVG4493	Superimposed infection	Superimposed infection	Diagnosis	1	0
NVG2485	Early onset (age<3days)	Early onset	Clinical manifestations	1	0
NVG1077	length of C. difficile infection	Duration of illness	Clinical manifestations	1	0
NVG2039	Duration of infectiousness	Duration of infectiousness	Clinical manifestations	1	0
NVG4163	Duration of Chagas disease	Duration of disease	Diagnosis	1	1
NVG4282	Duration of podocniosis	Duration of disease	Diagnosis	1	1
NVG3729	Disease duration (years)	Duration of disease	Diagnosis	1	0
NVG0479	Duration of illness	Duration of illness	Diagnosis	1	0

NVG1858	Duration of infection	Duration of illness	Diagnosis	1	0
NVG0233	CHF with an ejection fraction <45%	Ejection fraction <45%	Diagnosis	1	1
NVG0834	Time between hospitalization and onset of fungaemia	Time between hospitalization and onset of fungaemia	Diagnosis	1	0
NVG1064	Time between surgery and infection	Time between surgery and infection	Diagnosis	1	0
NVG1219	Days from diagnosis to treatment	Days from diagnosis to treatment	Treatment	1	0
NVG0050	Within 1 year of transplantation	Within 1 year of transplantation	Comorbidities	1	1
NVG0789	Length of demonstrated bacteremia after starting active treatment	Length of demonstrated bacteremia after starting active treatment	Microbiology/serology	1	0
NVG1246	Interval between succesives episodes	Interval between succesives episodes	Other	1	0
NVG2205	Relapse time	Relapse time	Diagnosis	1	0
NVG0205	Type of infection	Type of infection	Diagnosis	1	1
NVG2391	Community-acquired vs Nosocomial vs Health-care associated	Type of infection	Diagnosis	1	0
NVG2392	Community-acquired vs Nosocomial vs Health-care associated	Type of infection	Diagnosis	1	0
NVG2393	Community-acquired vs Nosocomial vs Health-care associated	Type of infection	Diagnosis	1	0
NVG2999	Type of infection (Bacteraemia, Ventilator-associated or hospital-acquired pneumonia, Probable ventilator-associated	Type of infection	Diagnosis	1	0

	pneumonia, Urinary tract infection				
NVG3000	Type of infection (Bacteraemia, Ventilator-associated or hospital-acquired pneumonia, Probable ventilator-associated pneumonia, Urinary tract infection	Type of infection	Diagnosis	1	0
NVG3001	Type of infection (Bacteraemia, Ventilator-associated or hospital-acquired pneumonia, Probable ventilator-associated pneumonia, Urinary tract infection	Type of infection	Diagnosis	1	0
NVG3002	Type of infection (Bacteraemia, Ventilator-associated or hospital-acquired pneumonia, Probable ventilator-associated pneumonia, Urinary tract infection	Type of infection	Diagnosis	1	0
NVG0967	Other infection source	Infection type	diagnosis	1	1
NVG3515	Other infection	Infection type	diagnosis	1	1
NVG0558	Infection	Infection type	Diagnosis	1	0
NVG3510	infection	Infection type	Diagnosis	1	0
NVG3516	Any infection	Infection type	Diagnosis	1	1
NVG3788	Infection type (Complicated urinary tract infection, Acute pyelonephritis)	Infection type	Diagnosis	1	1
NVG3789	Infection type (Complicated urinary tract infection, Acute pyelonephritis)	Infection type	Diagnosis	1	1
NVG3741	Infection type (Wound infection‡, Cellulitis or erysipelas, Major abscess)	Infection type	Diagnosis	1	1
NVG3742	Infection type (Wound infection‡, Cellulitis or erysipelas, Major abscess)	Infection type	Diagnosis	1	1
NVG3743	Infection type (Wound infection‡, Cellulitis or erysipelas, Major abscess)	Infection type	Diagnosis	1	1

NVG1501	Infection type: Pneumonia	Infection type	Diagnosis	1	1
NVG1499	Infection type: Dengue	Infection type	Diagnosis	1	0
NVG1500	Infection type: Malaria	Infection type	Diagnosis	1	0
NVG1502	Infection type: Tuberculosis	Infection type	Diagnosis	1	0
NVG2922	Infection type (Monomicrobial Polymicrobial No study-qualifying pathogen identified)	Infection type	Microbiology/serology	1	0
NVG2923	Infection type (Monomicrobial Polymicrobial No study-qualifying pathogen identified)	Infection type	Microbiology/serology	1	0
NVG2924	Infection type (Monomicrobial Polymicrobial No study-qualifying pathogen identified)	Infection type	Microbiology/serology	1	0
NVG1443	Cardiopulmonary dysfunction	Cardiopulmonary dysfunction	Diagnosis	1	0
<u>NVG4414</u>	Cardiorenal syndrome type-5	Cardiorenal syndrome	Diagnosis	1	1
NVG4400	Cardiorenal syndrome	Cardiorenal syndrome	Diagnosis	1	0
NVG4401	No cardiorenal syndrome	No cardiorenal syndrome	diagnosis	1	0
NVG4769	Dengue hemorrhagic fever (DHF)	Dengue hemorrhagic fever	Diagnosis	1	1
NVG0198	Critical illness at time of cultured	Critical illness at time of cultured	Microbiology/serology	1	0
NVG0494	Critical care duration	Critical care duration	Other	1	1
NVG4765	Dengue fever (DF) with intestinal obstruction	Dengue fever with intestinal obstruction	Diagnosis	1	0
NVG2009	intestinal perforation	Intestinal perforation	Diagnosis	1	1
NVG4242	Complications related to scabies	Complications	Diagnosis	1	1

NVG2011	Complications: Others	Complications	Diagnosis	1	1
NVG3180	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3181	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3182	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3183	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3184	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3185	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis,	Potential complications	diagnosis	1	1

	encephalitis, convulsions, streptococcal toxic shock).				
NVG3186	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3187	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG3188	Potential complications (otitis media, peritonsillar abscess, pneumonia, mastoiditis, cellulitis, sepsis, arthritis, encephalitis, convulsions, streptococcal toxic shock).	Potential complications	diagnosis	1	1
NVG0500	Renal failure	Renal failure	Clinical manifestations	1	0
NVG1082	Renal failure	Renal failure	Clinical manifestations	1	0
NVG0180	Renal impairment	Renal failure	Clinical manifestations	1	0
NVG2010	Renal impairment	Renal failure	Clinical manifestations	1	0
NVG0100	Renal impairment	Renal failure	Clinical manifestations	1	0
NVG1259	Renal insufficiency	Renal failure	Clinical manifestations	1	0
NVG0195	Renal failure at admission	Renal failure	Clinical manifestations	1	0
NVG0196	Renal failure at time of culture	Renal failure	Clinical manifestations	1	0
NVG4766	Renal failure with Dengue hemorrhagic fever	Renal failure	Clinical manifestations	1	0
NVG0164	Acute kidney injury	Acute kidney injury	Diagnosis	1	0

NVG1090	Acute renal failure	Acute kidney injury	Diagnosis	1	0
NVG4743	Acute renal failure	Acute kidney injury	Diagnosis	1	0
NVG4770	Glomerulo Nephritis & Pulmonary Edema With DHF	Glomerulo Nephritis & Pulmonary Edema With DHF	Diagnosis	1	1
NVG0510	Fluid and electrolyte disorders	Fluid and electrolyte disorders	Diagnosis	1	0
NVG1532	Sites of organ failure (renal, hepatic, metabolic, hematologic, and/or other)	Sites of organ failure	Clinical manifestations	1	0
NVG1533	Sites of organ failure (renal, hepatic, metabolic, hematologic, and/or other)	Sites of organ failure	Clinical manifestations	1	0
NVG1534	Sites of organ failure (renal, hepatic, metabolic, hematologic, and/or other)	Sites of organ failure	Clinical manifestations	1	0
NVG1535	Sites of organ failure (renal, hepatic, metabolic, hematologic, and/or other)	Sites of organ failure	Clinical manifestations	1	0
NVG1536	Sites of organ failure (renal, hepatic, metabolic, hematologic, and/or other)	Sites of organ failure	Clinical manifestations	1	0
NVG1537	Sites of organ failure (Resp, Cardio, NRL)	Sites of organ failure	Clinical manifestations	1	0
NVG1538	Sites of organ failure (Resp, Cardio, NRL)	Sites of organ failure	Clinical manifestations	1	0
NVG1539	Sites of organ failure (Resp, Cardio, NRL)	Sites of organ failure	Clinical manifestations	1	0
NVG4385	ARDS	ARDS	Diagnosis	1	1
NVG1174	Respiratory insufficiency requiring support	Respiratory failure	Clinical manifestations	1	0
NVG4768	Dengue shock syndrome	Dengue shock syndrome	Diagnosis	1	1
NVG4767	Dengue shock syndrome with aspiration	Dengue shock syndrome with aspiration	Diagnosis	1	1
NVG2008	Hemodynamic shock	Hemodynamic shock	Diagnosis	1	1

NVG0487	Severe sepsis/septic shock	Septic shock	Prognosis	1	0
NVG0794	Severe sepsis/septic shock	Septic shock	Prognosis	1	0
NVG1265	Severe sepsis	Severe sepsis	Prognosis	1	0
NVG1659	Systemic inflammatory response syndrome	SIRS	Prognosis	1	0
NVG0488	Sepsis	Sepsis	Diagnosis	1	0
NVG1089	Sepsis	Sepsis	Diagnosis	1	0
NVG4486	Sepsis	Sepsis	Diagnosis	1	0
NVG1395	Septic cholestasis	Sepsis	Diagnosis	1	0
NVG1266	Septic metastasis	Sepsis	Diagnosis	1	0
NVG3575	Shock	Shock	Clinical manifestations	1	0
NVG0368	Septic shock	Septic shock	Diagnosis	1	0
NVG0837	Septic shock	Septic shock	Diagnosis	1	0
NVG1112	Septic shock	Septic shock	Diagnosis	1	0
NVG1453	Septic shock	Septic shock	Diagnosis	1	0
NVG4384	Septic shock	Septic shock	Diagnosis	1	0
NVG4744	Septic shock	Septic shock	Diagnosis	1	0
NVG1057	Septic shock	Septic shock	Diagnosis	1	0
NVG3414	Time from shock onset	Time from shock onset	Diagnosis	1	0
NVG1571	Venous-arterial PCO2 gradient	Venous-arterial PCO2 gradient	Laboratory	1	0
NVG0160	Albumin	Albumin	Laboratory	1	1
NVG0182	Albumin	Albumin	Laboratory	1	1
NVG0318	Albumin	Albumin	Laboratory	1	1
NVG0906	Albumin	Albumin	Laboratory	1	1
NVG1093	Albumin	Albumin	Laboratory	1	1
NVG2986	Albumin	Albumin	Laboratory	1	1

NVG3047	Albumin	Albumin	Laboratory	1	1
NVG1906	Albumin level	Albumin	Laboratory	1	1
NVG0392	Serum albumin	Albumin	Laboratory	1	1
NVG3978	Alkaline phosphatase	Alkaline phosphatase	Laboratory	1	1
NVG0909	ALP	ALP	Laboratory	1	1
NVG0397	Alpha fetoprotein (ng/mL)	Alpha fetoprotein	Laboratory	1	1
NVG1908	Amylase level	Amylase level	Laboratory	1	1
NVG3152	Anti-TNF alpha	Anti-TNF alpha	Treatment	1	1
NVG4733	Arterial pH	Arterial pH	Laboratory	1	1
NVG0163	Bicarbonate	Bicarbonate	Laboratory	1	1
NVG4129	Bicarbonate	Bicarbonate	Laboratory	1	1
NVG1942	Bilirubin	Bilirubin	Laboratory	1	1
NVG3626	Bilirubina	Bilirubin	Laboratory	1	1
NVG3402	Bilirubina level	Bilirubin	Laboratory	1	1
NVG0158	Bilirubin	Bilirubin	Laboratory	1	1
NVG1269	Bilirubin	Bilirubin	Laboratory	1	1
NVG2720	Total Bilirubin	Bilirubin	Laboratory	1	1
NVG3976	Total bilirubin	Bilirubin	Laboratory	1	1
NVG1033	Total bilirubin	Bilirubin	Laboratory	1	1
NVG0396	Total bilirubin (mg/dL)	Bilirubin	Laboratory	1	1
NVG1909	Total Br level	Bilirubin	Laboratory	1	1
NVG2721	BUN	Blood urea nitrogen	Laboratory	1	1
NVG2956	BUN	Blood urea nitrogen	Laboratory	1	1
NVG0156	Urea	Blood urea nitrogen	Laboratory	1	1
NVG1904	Urea level	Blood urea nitrogen	Laboratory	1	1
NVG4127	Blood urea nitrogen	Blood urea nitrogen	Laboratory	1	1

NVG4231	Brain natriuretic peptide (pg/dL)	Brain natriuretic peptide	Laboratory	1	1
NVG4174	High age-adjusted NT-ProBNP	NT-ProBNP	Laboratory	1	0
NVG0954	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG1031	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG1268	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG1332	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG1770	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG2407	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG2447	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG3979	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG3889	C-reactive protein	C-reactive protein	Laboratory	1	1
NVG4727	C-reactive protein (mg/dL)	C-reactive protein	Laboratory	1	1
NVG0912	CRP	C-reactive protein	Laboratory	1	1
NVG4189	CRP levels	C-reactive protein	Laboratory	1	1
NVG3335	PCR	C-reactive protein	Laboratory	1	1
NVG3034	Serum C-reactive protein	C-reactive protein	Laboratory	1	1
NVG2960	Calcium	Calcium	Laboratory	1	1
NVG2318	Cholesterol	Cholesterol	Laboratory	1	1
NVG2356	Cholesterol level	Cholesterol	Laboratory	1	1
NVG4393	Admission creatinine	Creatinine	Laboratory	1	1
NVG4392	Baseline creatinine	Creatinine	Laboratory	1	1
NVG1580	Creat Clearanc	Creatinine	Laboratory	1	1
NVG0155	Creatinine	Creatinine	Laboratory	1	1
NVG1773	Creatinine	Creatinine	Laboratory	1	1
NVG2574	creatinine	Creatinine	Laboratory	1	1

NVG2717	creatinine	Creatinine	Laboratory	1	1
NVG2958	Creatinine	Creatinine	Laboratory	1	1
NVG2985	Creatinine	Creatinine	Laboratory	1	1
NVG3975	Creatinine	Creatinine	Laboratory	1	1
NVG4126	Creatinine	Creatinine	Laboratory	1	1
NVG3890	Creatinine	Creatinine	Laboratory	1	1
NVG4230	Creatinine (mg/dL)	Creatinine	Laboratory	1	1
NVG4726	Creatinine (mg/dL)	Creatinine	Laboratory	1	1
NVG0284	creatinine clearance	Creatinine	Laboratory	1	1
NVG1657	Creatinine clearance	Creatinine	Laboratory	1	1
NVG2877	Creatinine clearance	Creatinine	Laboratory	1	1
NVG3017	Creatinine clearance	Creatinine	Laboratory	1	1
NVG3234	Creatinine clearance	Creatinine	Laboratory	1	1
NVG3750	Creatinine clearance	Creatinine	Laboratory	1	1
NVG3790	Creatinine clearance	Creatinine	Laboratory	1	1
NVG3403	Creatinine level	Creatinine	Laboratory	1	1
NVG3433	Creatinine level	Creatinine	Laboratory	1	1
NVG1630	Endogenous creatinine clearance	Creatinine	Laboratory	1	0
NVG0319	Serum creatinine	Creatinine	Laboratory	1	1
NVG1633	Serum creatinine	Creatinine	Laboratory	1	1
NVG1907	CPK level	Creatinine kinase	Laboratory	1	1
NVG2724	Creatinine Klnase Serum	Creatinine kinase	Laboratory	1	1
NVG2941	Cerebrospinal fluid features	Cerebrospinal fluid features	Laboratory	1	1
NVG3430	CSF Glucose level	CSF Glucose level	Laboratory	1	1
NVG3431	CSF protein level	CSF protein level	Laboratory	1	1

NVG2659	Cerebrospinal fluid presence of trypanosomes:	Cerebrospinal fluid presence of trypanosomes	Microbiology/serology	1	1
NVG3332	GGT	GGT	Laboratory	1	1
NVG0395	γ -Glutamyl transpeptidase (IU/L)	GGT	Laboratory	1	1
NVG2169	GFR <45ml/min	GFR <45ml/min	Laboratory	1	0
NVG0911	eGFR	Glomerular filtration rate	Laboratory	1	1
NVG1629	estimated Glom Filtration Rate	Glomerular filtration rate	Laboratory	1	1
NVG2504	Glomerular Filtration Rate	Glomerular filtration rate	Laboratory	1	1
NVG0159	Glucose	Glucose	Laboratory	1	1
NVG2317	Glucose	Glucose	Laboratory	1	1
NVG3038	Glucose	Glucose	Laboratory	1	1
NVG1903	Glycemia	Glucose	Laboratory	1	1
NVG2316	HbA1c basal	HbA1c	Laboratory	1	1
NVG2170	HbA1c>9%	HbA1c	Laboratory	1	0
NVG2319	HDL	HDL	Laboratory	1	1
NVG4390	Highest lactate	Lactate	Laboratory	1	0
NVG1454	Lactate	Lactate	Laboratory	1	1
NVG3401	Lactate level	Lactate	Laboratory	1	1
NVG1570	Serum lactate	Lactate	Laboratory	1	1
NVG1910	LDH	LDH	Laboratory	1	1
NVG2320	LDL	LDL	Laboratory	1	1
NVG3977	Alanine aminotransferase	Alanine aminotransferase	Laboratory	1	1

NVG0394	Alanine-2-oxoglutarate aminotransferase (IU/L)	Alanine aminotransferase	Laboratory	1	1
NVG0162	ALT	Alanine aminotransferase	Laboratory	1	1
NVG0907	ALT	Alanine aminotransferase	Laboratory	1	1
NVG1168	ALT	Alanine aminotransferase	Laboratory	1	1
NVG1941	ALT	Alanine aminotransferase	Laboratory	1	1
NVG2323	ALT	Alanine aminotransferase	Laboratory	1	1
NVG2719	ALT	Alanine aminotransferase	Laboratory	1	1
NVG3229	ALT	Alanine aminotransferase	Laboratory	1	1
NVG3331	ALT	Alanine aminotransferase	Laboratory	1	1
NVG3625	ALT	Alanine aminotransferase	Laboratory	1	1
NVG1912	ALT	Alanine aminotransferase	Laboratory	1	1
NVG2197	ALT level	Alanine aminotransferase	Laboratory	1	1
NVG2218	ALT level	Alanine aminotransferase	Laboratory	1	1
NVG0393	Asparate-2-oxoglutarate aminotransferase (IU/L)	Aspartate aminotransferase	Laboratory	1	1
NVG0161	AST	Aspartate	Laboratory	1	1

		aminotransferase			
NVG1167	AST	Aspartate aminotransferase	Laboratory	1	1
NVG1940	AST	Aspartate aminotransferase	Laboratory	1	1
NVG2322	AST	Aspartate aminotransferase	Laboratory	1	1
NVG2718	AST	Aspartate aminotransferase	Laboratory	1	1
NVG3228	AST	Aspartate aminotransferase	Laboratory	1	1
NVG3330	AST	Aspartate aminotransferase	Laboratory	1	1
NVG1911	AST level	Aspartate aminotransferase	Laboratory	1	1
NVG0165	Blood culture positive	Bacteremia	Laboratory	1	1
NVG2573	liver enzymes	Liver enzymes	Laboratory	1	1
NVG2962	Liver function tests	Liver enzymes	Laboratory	1	1
NVG2346	Neuronal damage biomarkers	Neuronal damage biomarkers	laboratory	1	1
NVG0398	Protein induced by vitamin K absence or antagonist-II (mAU/mL)	Protein induced by vitamin K absence or antagonist-II	Other	1	1
NVG4419	PaCO2 (mm Hg)	PaCO2	laboratory	1	1
NVG4732	PaCO2 (mmHg)	PaCO2	laboratory	1	1
NVG4416	PaO2 (mm Hg)	PaCO2	laboratory	1	1
NVG3404	PaO2:FiO2	PaO2:FiO2	laboratory	1	1
NVG4731	PaO2/FiO2 (mmHg)	PaO2:FiO2	laboratory	1	1

NVG1901	K level	Potassium	Laboratory	1	1
NVG2957	Potassium	Potassium	Laboratory	1	1
NVG4128	Potassium	Potassium	Laboratory	1	1
NVG4735	Serum K+ (mEq/L)	Potassium	Laboratory	1	1
NVG4190	Procalcitonin	Procalcitonin	Laboratory	1	1
NVG4042	Procalcitonin level	Procalcitonin	Laboratory	1	1
NVG0953	Procalcitonine	Procalcitonin	Laboratory	1	1
NVG1905	Protein level	Protein	Laboratory	1	1
NVG3037	Total protein	Protein	Laboratory	1	1
NVG0910	Na	Sodium	laboratory	1	1
NVG1900	Na level	Sodium	laboratory	1	1
NVG4734	Serum Na+ (mEq/L)	Sodium	Laboratory	1	1
NVG0157	Sodium	Sodium	Laboratory	1	1
NVG2959	Sodium	Sodium	Laboratory	1	1
NVG3338	Sodium	Sodium	Laboratory	1	1
NVG3974	Sodium	Sodium	Laboratory	1	1
NVG2321	Triglycerids	Triglycerids	Laboratory	1	1
NVG4391	Admission troponin-T	Troponin-T	Laboratory	1	1
NVG2723	Urinary porteins	Urinary porteins	Laboratory	1	1
NVG1897	Basophils	Basophils	Laboratory	1	1
NVG2635	CD34 cells in grafts	CD34 cells in grafts	Laboratory	1	1
NVG0447	Baseline CD4 count	CD4 count	Laboratory	1	1
NVG2564	Baseline CD4 count	CD4 count	Laboratory	1	1
NVG3434	Baseline CD4+ cell count	CD4 count	Laboratory	1	1
NVG0110	CD4	CD4 count	Laboratory	1	1
NVG0456	CD4	CD4 count	Laboratory	1	1

NVG4268	CD4 < 350 cells/uL	CD4 count	Laboratory	1	1
NVG0460	CD4 at ART initiation	CD4 count	Laboratory	1	0
NVG0387	CD4 cell count	CD4 count	Laboratory	1	1
NVG0402	CD4 cell count	CD4 count	Laboratory	1	1
NVG0417	CD4 cell count	CD4 count	Laboratory	1	1
NVG1691	CD4 cell count	CD4 count	Laboratory	1	1
NVG2503	CD4 cell count	CD4 count	Laboratory	1	1
NVG2761	CD4 cell count	CD4 count	Laboratory	1	1
NVG3374	CD4 cell count	CD4 count	Laboratory	1	1
NVG4447	CD4 cells count	CD4 count	Laboratory	1	1
NVG2244	CD4 count	CD4 count	Laboratory	1	1
NVG2292	CD4 count	CD4 count	Laboratory	1	1
NVG2387	CD4 count	CD4 count	Laboratory	1	1
NVG3045	CD4 count	CD4 count	Laboratory	1	1
NVG3941	CD4 count	CD4 count	Laboratory	1	1
NVG3968	CD4 count	CD4 count	Laboratory	1	1
NVG3061	CD4 count at start	CD4 count	Laboratory	1	0
NVG3062	CD4 count nadir	CD4 count	Laboratory	1	1
NVG3063	CD4 count recovery	CD4 count	Laboratory	1	1
NVG2245	CD4 nadir	CD4 count	Laboratory	1	1
NVG2347	CD4 nadir	CD4 count	Laboratory	1	1
NVG3033	CD4 T-cell count	CD4 count	Laboratory	1	1
NVG0565	CD4 testing and ART history	CD4 count	Laboratory	1	1
NVG0330	CD4+ cell count	CD4 count	Laboratory	1	1
NVG3809	CD4+ count	CD4 count	Laboratory	1	1
NVG0291	CD4+ T-cell count	CD4 count	Laboratory	1	1

NVG2348	Current CD4	CD4 count	Laboratory	1	1
NVG3479	First CD4 count in pregnancy	CD4 count	Laboratory	1	0
NVG0484	First CD4 count test 0-99 cells/uL	CD4 count	Laboratory	1	0
NVG0485	First CD4 count test 0-99 cells/uL	CD4 count	Laboratory	1	0
NVG3632	Median CD4+ cell count per cubic millimeter (range)	CD4 count	Laboratory	1	0
NVG0562	Unique patients with CD4 counts <50	CD4 counts <50	Laboratory	1	0
NVG2178	median CD4 frequency	CD4 frequency	Laboratory	1	0
NVG2961	Complete blood count	Complete blood count	Laboratory	1	1
NVG1895	Eosinophils	Eosinophils	Laboratory	1	1
NVG1888	Erythrocyte count	Erythrocyte count	Laboratory	1	1
NVG2556	Haemoglobin	Haemoglobin	Laboratory	1	1
NVG2716	haemoglobin	Haemoglobin	Laboratory	1	1
NVG2762	Haemoglobin	Haemoglobin	Laboratory	1	1
NVG3227	Haemoglobin	Haemoglobin	Laboratory	1	1
NVG4191	Haemoglobin	Haemoglobin	Laboratory	1	1
NVG2528	Haemoglobin	Haemoglobin	Laboratory	1	1
NVG0901	Hb	Haemoglobin	Laboratory	1	1
NVG1889	Hemoglobil level	Haemoglobin	Laboratory	1	1
NVG0145	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG1771	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG2213	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG2943	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG3380	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG3887	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG3971	Hemoglobin	Haemoglobin	Laboratory	1	1

NVG4683	Hemoglobin	Haemoglobin	Laboratory	1	1
NVG4417	Hemoglobin (g/dL)	Haemoglobin	Laboratory	1	1
NVG3432	Hemoglobin level	Haemoglobin	Laboratory	1	1
NVG1890	hematocrit	Hematocrit	Laboratory	1	1
NVG3926	hematocrit	Hematocrit	Laboratory	1	1
NVG4729	Hematocrite (%)	Hematocrit	Laboratory	1	1
NVG0955	Leucocyte count	White blood cell count	Laboratory	1	1
NVG0102	Leucocytes	White blood cell count	Laboratory	1	1
NVG2944	Leucocytes	White blood cell count	Laboratory	1	1
NVG0317	Leukocyte count	White blood cell count	Laboratory	1	1
NVG1330	Leukocyte count	White blood cell count	Laboratory	1	1
NVG1772	Leukocyte count	White blood cell count	Laboratory	1	1
NVG1893	Leukocyte count	White blood cell count	Laboratory	1	1
NVG4418	Leukocyte count (x109 /L)	White blood cell count	Laboratory	1	1
NVG1163	Leukocytes	White blood cell count	Laboratory	1	1
NVG3888	Leukocytes	White blood cell count	Laboratory	1	1
NVG2006	Leukopenia	White blood cell count	Laboratory	1	0

NVG0902	WBC	White blood cell count	Laboratory	1	1
NVG3035	Whit blood cells	White blood cell count	Laboratory	1	1
NVG1507	White blood cell	White blood cell count	Laboratory	1	1
NVG0148	White blood cell count	White blood cell count	Laboratory	1	1
NVG1032	White blood cell count	White blood cell count	Laboratory	1	1
NVG1092	White blood cell count	White blood cell count	Laboratory	1	1
NVG2446	White blood cell count	White blood cell count	Laboratory	1	1
NVG2987	White blood cells	White blood cell count	Laboratory	1	1
NVG3329	White blood cells	White blood cell count	Laboratory	1	1
NVG4192	White blood cells	White blood cell count	Laboratory	1	1
NVG4728	White blood cells (109 cell/L)	White blood cell count	Laboratory	1	1
NVG2660	white blood cells in CS fluid	White blood cell count	Laboratory	1	1
NVG3405	White cell count	White blood cell count	Laboratory	1	1
NVG3429	White cell count	White blood cell count	Laboratory	1	1
NVG3924	white-cell count	White blood cell	Laboratory	1	1

		count			
NVG3972	White-cell count	White blood cell count	Laboratory	1	1
NVG4041	White-cell count	White blood cell count	Laboratory	1	1
NVG0251	Hematologic parameters before CTI: ALC <300 cells/ μ L	ALC <300 cells/ μ L	Laboratory	1	0
NVG0256	Hematologic parameters on day of CTI: ALC <300 cells/ μ L	ALC <300 cells/ μ L	Laboratory	1	0
NVG0150	Lymphocyte count	Lymphocytes	Laboratory	1	1
NVG1164	Lymphocytes	Lymphocytes	Laboratory	1	1
NVG1896	Lymphocytes	Lymphocytes	Laboratory	1	1
NVG3036	Lymphocytes	Lymphocytes	Laboratory	1	1
NVG4194	Lymphocytes	Lymphocytes	Laboratory	1	1
NVG0553	Lymphopenia	Lymphopenia	Laboratory	1	0
NVG0151	Monocyte count	Monocytes	Laboratory	1	1
NVG1898	Monocytes	Monocytes	Laboratory	1	1
NVG0903	Neut	Neut	Other	1	0
NVG1643	Absolute Neutroph count never <500	Absolute neutrophil count	Laboratory	1	0
NVG0238	Absolute neutrophil count \leq 100 cells/ μ L	Absolute neutrophil count	Laboratory	1	0
NVG1644	Absolute neutrophil count never >200 μ L post nadir	Absolute neutrophil count	Laboratory	1	0
NVG0253	Hematologic parameters before CTI: ANC <500 cells/ μ L	ANC <500 cells/ μ L	Laboratory	1	0
NVG0257	Hematologic parameters on day of CTI: ANC <500 cells/ μ L	ANC <500 cells/ μ L	Laboratory	1	0

NVG0350	Neutropenia	Neutrophils	laboratory	1	0
NVG0552	Neutropenia	Neutrophils	laboratory	1	0
NVG1103	neutropenia	Neutrophils	laboratory	1	0
NVG1641	Neutropenia	Neutrophils	laboratory	1	0
NVG1723	Neutropenia	Neutrophils	laboratory	1	0
NVG0832	Neutropenia (<500 cells/mm3)	Neutrophils	laboratory	1	0
NVG0149	Neutrophil count	Neutrophils	laboratory	1	1
NVG3339	Neutrophil count	Neutrophils	laboratory	1	1
NVG1165	Neutrophils	Neutrophils	laboratory	1	1
NVG4193	Neutrophils	Neutrophils	laboratory	1	1
NVG1894	Polynuclear cells	Polynuclear cells	Laboratory	1	1
NVG0905	Plat	Platelet count	Laboratory	1	1
NVG1450	Platelet	Platelet count	Laboratory	1	1
NVG0152	Platelet count	Platelet count	Laboratory	1	1
NVG1331	Platelet count	Platelet count	Laboratory	1	1
NVG2715	platelet count	Platelet count	Laboratory	1	1
NVG3627	Platelet count	Platelet count	Laboratory	1	1
NVG3925	platelet count	Platelet count	Laboratory	1	1
NVG3973	Platelet count	Platelet count	Laboratory	1	1
NVG0390	Platelet count	Platelet count	Laboratory	1	1
NVG1166	Platelets	Platelet count	Laboratory	1	1
NVG4730	Platelets (109 cell/L)	Platelet count	Laboratory	1	1
NVG4774	Platelets counts	Platelet count	Laboratory	1	1
NVG2945	Thrombocytes	Platelet count	Laboratory	1	1
NVG1899	Thromocyte count	Platelet count	Laboratory	1	1
NVG0153	Platelet nadir	Platelet count	Laboratory	1	0

NVG2005	Thrombocytopenia	Platelet count	Laboratory	1	0
NVG3574	Thrombocytopenia	Platelet count	Laboratory	1	0
NVG0154	Thrombocytopenia	Platelet count	Laboratory	1	0
NVG4153	Blood group O	Blood type	Laboratory	1	1
NVG3651	Blood type (A, B, AB y O)	Blood type	Laboratory	1	1
NVG3652	Blood type (A, B, AB y O)	Blood type	Laboratory	1	1
NVG3653	Blood type (A, B, AB y O)	Blood type	Laboratory	1	1
NVG3654	Blood type (A, B, AB y O)	Blood type	Laboratory	1	1
NVG1939	activated thromboplastine tissue time	Activated thromboplastine tissue time	Laboratory	1	1
NVG0391	Prothrombin time	Prothrombin time	Laboratory	1	1
NVG1938	prothrombine time	Prothrombin time	Laboratory	1	1
NVG2343	Biomarkers of monocyte activation in plasma and CSF	Biomarkers of monocyte activation in plasma and CSF	Laboratory	1	1
NVG2175	anti-gE-antibody	anti-gE-antibody	Microbiology/serology	1	1
NVG2725	Antibody levels	Antibody levels	Microbiology/serology	1	1
NVG3328	ELISA	ELISA	Laboratory	1	1
NVG0875	Pre-transplant positive serostatus: CMV	Pre-transplant positive serostatus	Comorbidities	1	0
NVG0874	Pre-transplant positive serostatus: Epstein-Barr virus (anti-EBNA)	Pre-transplant positive serostatus	Comorbidities	1	0
NVG0873	Pre-transplant positive serostatus: Hepatitis B virus (surface antigen)	Pre-transplant positive serostatus	Comorbidities	1	0
NVG0872	Pre-transplant positive serostatus: Hepatitis C virus	Pre-transplant positive serostatus	Comorbidities	1	0
NVG2624	Pre-trial VVZ IgG seropositivity	Pre-trial VVZ IgG	Comorbidities	1	0

		seropositivity			
NVG1963	CMV IgG	CMV IgG	Microbiology/serology	1	1
NVG0645	CMV IgM	CMV IgM	Microbiology/serology	1	1
NVG1972	donor CMV IgG	Donor CMV IgG	Microbiology/serology	1	0
NVG1975	DOnor specific antibody	Donor specific antibody	Microbiology/serology	1	0
NVG1964	EBV IgG	EBV IgG	Microbiology/serology	1	1
NVG1424	Flavivirus seropositive	Flavivirus seropositive	Microbiology/serology	1	1
NVG2711	Flavivirus status	Flavivirus status	Microbiology/serology	1	1
NVG1966	HBV antibody	HBV antibody	Microbiology/serology	1	1
NVG4600	HIV testing	HIV testing	Microbiology/serology	1	1
NVG1745	Screening at baseline (HPV positivity)	HPV positivity	Microbiology/serology	1	1
NVG2286	HSV2 seropotivie	HSV2 seropotivie	Microbiology/serology	1	1
NVG2595	neutralising antibodies	Neutralising antibodies	Microbiology/serology	1	0
NVG0702	Positive Borrelia IgG antibody test at time of diagnosis	Positive Borrelia IgG antibody test at time of diagnosis	Microbiology/serology	1	1
NVG0646	Rubella IgM	Rubella IgM	Microbiology/serology	1	1
NVG2772	Serologic positivity	Serologic positivity	Microbiology/serology	1	1
NVG1399	Serologic results	Serologic results	Microbiology/serology	1	1
NVG3113	Seropositive at baseline	Seropositive at baseline	Microbiology/serology	1	1
NVG1404	Seropositivity for Chikungunya	Seropositivity for Chikungunya	Microbiology/serology	1	1
NVG1403	Seropositivity for Dengue	Seropositivity for Dengue	Microbiology/serology	1	1
NVG0644	Toxoplasmosis IgM	Toxoplasmosis IgM	Microbiology/serology	1	1

NVG0647	VDRL	VDRL	Microbiology/serology	1	1
NVG2780	Zika virus specific antibodies	Zika virus specific antibodies	Microbiology/serology	1	1
NVG1423	Confirmed Zika virus seropositive	Confirmed Zika virus seropositive	Microbiology/serology	1	1
NVG0252	Hematologic parameters before CTI: Lymphopenia duration	Lymphopenia duration	Laboratory	1	0
NVG0254	Hematologic parameters before CTI: Neutropenia duration	Neutropenia duration	Laboratory	1	0
NVG1642	Days to absolute neutrophil count >200/ul	Days to absolute neutrophil count >200/ul	Laboratory	1	0
NVG0566	Days since last CD4	Days since last CD4	Laboratory	1	0
NVG0287	no known integrase resistance mutations	No known integrase resistance mutations	Microbiology/serology	1	0
NVG0286	pretreatment genotype documenting no nucleos(t)ide reverse-transcriptase resistance mutations	Pretreatment genotype documenting no nucleos(t)ide reverse-transcriptase resistance mutations	Microbiology/serology	1	0
NVG1813	Resistance-Associated Substitution NS3	Resistance-Associated Substitution NS3	Microbiology/serology	1	1
NVG1814	Resistance-Associated Substitution NS5A	Resistance-Associated Substitution NS5A	Microbiology/serology	1	1
NVG1815	Resistance-Associated Substitution NS5B	Resistance-Associated Substitution NS5B	Microbiology/serology	1	1
NVG2842	No second line drug susceptibility testing	No second line drug susceptibility testing	treatment	1	0

NVG2572	genotypic and phenotypic resistance for integrase	Genotypic and phenotypic resistance for integrase	Microbiology/serology	1	0
NVG2571	genotypic and phenotypic resistance for reverse protease inhibitor	Genotypic and phenotypic resistance for reverse protease inhibitor	Microbiology/serology	1	0
NVG2570	genotypic and phenotypic resistance for reverse transcriptase	Genotypic and phenotypic resistance for reverse transcriptase	Microbiology/serology	1	0
NVG0406	CrAg positive	CrAg positive	Microbiology/serology	1	1
NVG3383	Filarial antigen test-strip score	Filarial antigen test-strip score	Microbiology/serology	1	1
NVG2199	HBeAg positive	HBeAg positive	Microbiology/serology	1	1
NVG2344	HBsAg +	HBsAg +	Microbiology/serology	1	1
NVG0241	Serogroup	Serogroup	Microbiology/serology	1	1
NVG1305	Serotype	Serotype	Microbiology/serology	1	1
NVG1373	Serotype	Serotype	Microbiology/serology	1	1
NVG3169	Serotypes	Serotype	Microbiology/serology	1	1
NVG2552	Positive rapid diagnostic test	Positive rapid diagnostic test	Microbiology/serology	1	1
NVG2997	Meropenem MIC distribution	MIC	Microbiology/serology	1	1
NVG0932	MIC for Amoxicillin	MIC	Microbiology/serology	1	1
NVG0935	MIC for Azithromycin	MIC	Microbiology/serology	1	1
NVG0934	MIC for chloramphenicol	MIC	Microbiology/serology	1	1
NVG0933	MIC for levofloxacin	MIC	Microbiology/serology	1	1
NVG0937	MIC for moxifloxacin	MIC	Microbiology/serology	1	1

NVG0936	MIC for rifampycin	MIC	Microbiology/serology	1	1
NVG0938	MIC for tetracyclin	MIC	Microbiology/serology	1	1
NVG0078	Vancomycin MIC	MIC	Microbiology/serology	1	1
NVG1605	Vancomycin minimum inhibitory concentration	MIC	Microbiology/serology	1	1
NVG1278	Extended-spectrum β -lactamase	Extended-spectrum β -lactamase	Microbiology/serology	1	0
NVG1218	Multidrug resistance	Multidrug resistant organisms	microbiology/serology	1	0
NVG0620	Multidrug resistant organisms.	Multidrug resistant organisms	microbiology/serology	1	0
NVG3051	Multidrug-resistant tuberculosis	Multidrug-resistant tuberculosis	microbiology/serology	1	0
NVG0591	VRE flag	VRE flag	Comorbidities	1	1
NVG2029	Amoxi/Ampi R	Amoxicilin/ampicilin resistance	Microbiology/serology	1	1
NVG2017	Resistencia a ampicilina	Ampicilin resistance	Microbiology/serology	1	0
NVG2032	Azitro R	Azitromicin resistance	Microbiology/serology	1	1
NVG2019	Resisyencia a Cefepime	Cefepime resistance	Microbiology/serology	1	0
NVG2020	R a cftriaxona	Ceftriaxona resistance	Microbiology/serology	1	0
NVG2018	Resistencia a cloramfenicol	Chloramphenicol resistance	Microbiology/serology	1	0
NVG2021	R a ciprofloxacino	Ciprofloxacino resistance	Microbiology/serology	1	0
NVG2022	R a cotrimoxazol	Cotrimoxazol resistance	Microbiology/serology	1	0
NVG1321	Antimicrobial drug resistance profile of non- β -lactams	Drug susceptibility	Microbiology/serology	1	0

NVG1277	Antimicrobial drug-resistance phenotype	Drug susceptibility	Microbiology/serology	1	0
NVG4499	Antibiotic susceptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4500	Antibiotic susceptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4501	Antibiotic susceptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4502	Antibiotic susceptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4503	Antibiotic susceptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem	Drug susceptibility	Microbiology/serology	1	0

	Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)				
NVG4504	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4505	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4506	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4507	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG4508	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime	Drug susceptibility	Microbiology/serology	1	0

	Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)				
NVG4509	Antibiotic suseptibility 8Amoxicillin/clavulanate Piperacillin/tazobactam Ceftazidime Ceftriaxone Cefepime Meropenem Amikacin Ciprofloxacin Colistin Oxacillin Vancomycin)	Drug susceptibility	Microbiology/serology	1	0
NVG3960	Susceptible to drugs (Isoniazid Rifampin Ethambutol Pyrazinamide)	Drug susceptibility	Microbiology/serology	1	0
NVG3961	Susceptible to drugs (Isoniazid Rifampin Ethambutol Pyrazinamide)	Drug susceptibility	Microbiology/serology	1	0
NVG3962	Susceptible to drugs (Isoniazid Rifampin Ethambutol Pyrazinamide)	Drug susceptibility	Microbiology/serology	1	0
NVG3963	Susceptible to drugs (Isoniazid Rifampin Ethambutol Pyrazinamide)	Drug susceptibility	Microbiology/serology	1	0
NVG2031	Ceftri R	Drug susceptibility	Microbiology/serology	1	1
NVG2027	Chloramphenicol R	Drug susceptibility	Microbiology/serology	1	0
NVG2030	Cipro R	Drug susceptibility	Microbiology/serology	1	0
NVG4626	Drug susceptibility profile (Susceptible to	Drug susceptibility	Microbiology/serology	1	0

	H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)				
NVG4627	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0
NVG4628	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0

NVG4629	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0
NVG4630	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0
NVG4631	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0

NVG4632	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0
NVG4633	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0
NVG4634	Drug susceptibility profile (Susceptible to H, R, E Resistant to any drug Resistant to H Resistant to R Resistant to E Resistant to HR Resistant to HE Resistant to ER Resistant to HRE)	Drug susceptibility	Microbiology/serology	1	0

NVG1279	Drug susceptible	Drug susceptibility	Microbiology/serology	1	0
NVG3794	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3795	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3796	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype,	Drug susceptibility	Microbiology/serology	1	0

	Not susceptible to carbapenem, Multidrug resistant)				
NVG3797	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3798	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3799	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype,	Drug susceptibility	Microbiology/serology	1	0

	Not susceptible to carbapenem, Multidrug resistant)				
NVG3800	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3801	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3802	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype,	Drug susceptibility	Microbiology/serology	1	0

	Not susceptible to carbapenem, Multidrug resistant)				
NVG3803	Enterobacteriaceae uropathogens (Not susceptible to levofloxacin, Not susceptible to at least one aminoglycoside, Not susceptible to amikacin, Not susceptible to gentamicin, Not susceptible to tobramycin, Not susceptible to any two aminoglycosides, Not susceptible to all three aminoglycosides, ESBL phenotype, Not susceptible to carbapenem, Multidrug resistant)	Drug susceptibility	Microbiology/serology	1	0
NVG3109	Drug-resistant tuberculosis	Drug susceptibility	Microbiology/serology	1	0
NVG3138	Drug-resistant tuberculosis	Drug susceptibility	Microbiology/serology	1	0
NVG3964	Drug-resistant tuberculosis	Drug susceptibility	Microbiology/serology	1	0
NVG1668	E coli Meropenem R	Drug susceptibility	Microbiology/serology	1	0
NVG1669	E. coli PiperTazo R	Drug susceptibility	Microbiology/serology	1	0
NVG1120	ESBL-producing E. coli	Drug susceptibility	Microbiology/serology	1	0
NVG2854	Ethambutol Resistace	Ethambutol resistace	Microbiology/serology	1	0
NVG1670	K. pneumoniae Mero R	Klebsiella pneumoniae meropenem resistance	Microbiology/serology	1	0
NVG1671	K pneumoniae PiperTazo R	Klebsiella pneumoniae piperacilin/tazobactam resistance	Microbiology/serology	1	0
NVG2767	Macrolide-resistant Mutation	Macrolide-resistant mutation	Microbiology/serology	1	0

NVG2023	MDR	MDR	Microbiology/serology	1	0
NVG1136	No. isolates resistant	No. isolates resistant	microbiology/serology	1	0
NVG2900	Number of antimicrobials pathogens had resistance to	Number of antimicrobials pathogens had resistance to	microbiology/serology	1	1
NVG0736	Prior identification of 3GCR-E (3th generation cephalosporin-resistant Enterobacteriaceae)	Prior identification of 3GCR-E (3th generation cephalosporin-resistant Enterobacteriaceae)	Microbiology/serology	1	0
NVG2855	Pyrazinamide resistance	Pyrazinamide resistance	Microbiology/serology	1	0
NVG2545	Pyrethroids resistance	Pyrethroids resistance	Microbiology/serology	1	0
NVG3944	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to >1 drug in class	Microbiology/serology	1	0
NVG3945	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor	Resistance to >1 drug in class	Microbiology/serology	1	0

	Coreceptor antagonist‡ Fusion inhibitor‡)				
NVG3946	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to >1 drug in class	Microbiology/serology	1	0
NVG3947	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to >1 drug in class	Microbiology/serology	1	0
NVG3948	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to >1 drug in class	Microbiology/serology	1	0
NVG3949	Resistance to >1 drug in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase	Resistance to >1 drug in class	Microbiology/serology	1	0

	inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)				
NVG3951	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0
NVG3952	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0
NVG3953	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0

NVG3954	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0
NVG3955	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0
NVG3956	Resistance to all drugs in class (Nucleoside reverse-transcriptase inhibitor Non-nucleoside reverse-transcriptase inhibitor Protease inhibitor Integrase inhibitor Coreceptor antagonist‡ Fusion inhibitor‡)	Resistance to all drugs in class	Microbiology/serology	1	0
NVG0589	Resistant organism colonization	Resistant organism colonization	Microbiology/serology	1	0
NVG2845	Resistant to fluororquinolones	Resistant to fluororquinolones	Microbiology/serology	1	0
NVG2844	Resistant to second line injectable drugs	Resistant to second	Microbiology/serology	1	0

		line injectable drugs			
NVG2846	Resistant to second line injectable drugs and fluoroquinolones	Resistant to second line injectable drugs and fluoroquinolones	Microbiology/serology	1	0
NVG2413	Rifampicin-resistant infection at randomisation	Rifampicin-resistant infection at randomisation	Microbiology/serology	1	0
NVG2843	Sensitive to second line injectable drugs and fluororquinolones	Sensitive to second line injectable drugs and fluororquinolones	Microbiology/serology	1	0
NVG3767	Streptococcus pneumoniae Macrolide-resistant	Streptococcus pneumoniae macrolide-resistant	Microbiology/serology	1	0
NVG3766	Streptococcus pneumoniae Penicillin-susceptible	Streptococcus pneumoniae penicillin-susceptible	Microbiology/serology	1	0
NVG3768	Streptococcus pneumoniae Tetracycline-resistant	Streptococcus pneumoniae tetracycline resistant	Microbiology/serology	1	0
NVG0215	Susceptibility Ceftazidime-avibactam	Susceptibility Ceftazidime-avibactam	Microbiology/serology	1	0
NVG0214	Susceptibility Colistin	Susceptibility Colistin	Microbiology/serology	1	0
NVG2028	TMP-Sulphamethoxazole R	TMP-Sulphamethoxazole resistance	Microbiology/serology	1	0
NVG0211	Type of carbapenem-resistant Enterobacteriaceae	Type of carbapenem-resistant Enterobacteriaceae	Microbiology/serology	1	0

NVG2853	Fluoroquinolone- resistance	Fluoroquinolone-resistance	Treatment	1	0
NVG1370	Positive for <i>S. pneumoniae</i>	Positive for <i>S. pneumoniae</i>	Microbiology/serology	1	1
NVG3531	<i>Acinetobacter baumannii</i>	<i>Acinetobacter baumannii</i>	Microbiology/serology	1	1
NVG4346	<i>Acinetobacter baumannii</i>	<i>Acinetobacter baumannii</i>	Microbiology/serology	1	1
NVG4465	<i>Acinetobacter baumannii</i>	<i>Acinetobacter baumannii</i>	Microbiology/serology	1	1
NVG4474	<i>Aeromonas</i> spp.	<i>Aeromonas</i> spp.	Microbiology/serology	1	1
NVG1024	Anaerobes isolation	Anaerobes isolation	Microbiology/serology	1	1
NVG4480	<i>Bacillus</i> spp.	<i>Bacillus</i> spp.	Microbiology/serology	1	1
NVG1275	Positive blood culture	Bacteremia	Microbiology/serology	1	0
NVG3715	Positive Blood culture	Bacteremia	Microbiology/serology	1	0
NVG3532	<i>Bacteroides</i> species	<i>Bacteroides</i> species	Microbiology/serology	1	1
NVG2247	Rectal <i>C. trachomatis</i>	Rectal <i>C. trachomatis</i>	Microbiology/serology	1	1
NVG4322	<i>C. coli/jejuni</i> (all)	<i>C. coli/jejuni</i>	Microbiology/serology	1	1
NVG4323	<i>C. coli/jejuni</i> & <i>Shigella</i>	<i>C. coli/jejuni</i> and <i>Shigella</i>	Microbiology/serology	1	1
NVG4327	Non-Campylobacter & non- <i>Shigella</i>	Non-Campylobacter & non- <i>Shigella</i>	microbiology/serology	1	1
NVG4324	Other Campylobacter (all)	Other Campylobacter	microbiology/serology	1	0
NVG4325	Other Campylobacter & <i>Shigella</i>	Other Campylobacter and <i>Shigella</i>	microbiology/serology	1	0
NVG3520	<i>Candida</i> species	<i>Candida</i> species	Microbiology/serology	1	1
NVG1200	Colonization (<i>Candida auris</i> infection)	Colonization (<i>Candida auris</i> infection)	Microbiology/serology	1	1

NVG3781	C. pneumoniae	C. pneumoniae	Microbiology/serology	1	1
NVG1489	Chlamydia at enrollment	Chlamydia	Microbiology/serology	1	1
NVG3777	Chlamydia pneumoniae	Chlamydia	Microbiology/serology	1	1
NVG2301	Chlamydia positivity	Chlamydia	Microbiology/serology	1	1
NVG2705	Chlamydia testing in the past 12 months	Chlamydia	Microbiology/serology	1	0
NVG3534	Citrobacter freundii	Citrobacter freundii	Microbiology/serology	1	1
NVG0926	BI/NAP1/027 C. difficile + (subtype).	BI/NAP1/027 C. difficile + (subtype).	Microbiology/serology	1	1
NVG3517	C. difficile	C. difficile	Microbiology/serology	1	1
NVG0183	Clostridium difficile straining	Clostridium difficile straining	Microbiology/serology	1	1
NVG4477	Coryneform bacteria	Coryneform bacteria	Microbiology/serology	1	1
NVG4338	Dengue	Dengue	Diagnosis	1	1
NVG0920	ST131 E. coli pulsotype.	ST131 E. coli pulsotype	Microbiology/serology	1	1
NVG4273	Total number of enteric fever pathogens	Total number of enteric fever pathogens	Microbiology/serology	1	0
NVG4343	Enterobacter aerogenes	Enterobacter aerogenes	Microbiology/serology	1	1
NVG4342	Enterobacter cloacae complex	Enterobacter cloacae complex	Microbiology/serology	1	1
NVG1666	Enterobacter cloacae species complex	Enterobacter cloacae species complex	Microbiology/serology	1	1
NVG1555	Enterobacter spp	Enterobacter spp	Microbiology/serology	1	1
NVG0213	Enterobacter sp.	Enterobacter spp	Microbiology/serology	1	1
NVG3522	Enterobacter species††	Enterobacter spp	Microbiology/serology	1	1
NVG4469	Enterobacter spp.	Enterobacter spp	Microbiology/serology	1	1

NVG1664	Enterococcus faecalis	Enterococcus faecalis	Microbiology/serology	1	1
NVG4471	Enterococcus faecalis	Enterococcus faecalis	Microbiology/serology	1	1
NVG4470	Enterococcus faecium	Enterococcus faecium	Microbiology/serology	1	1
NVG3521	Enterococcus species	Enterococcus spp	Microbiology/serology	1	1
NVG1553	Enterococcus spp	Enterococcus spp	Microbiology/serology	1	1
NVG1550	Escherichia coli	Escherichia coli	Microbiology/serology	1	1
NVG1662	Escherichia coli	Escherichia coli	Microbiology/serology	1	1
NVG3519	Escherichia coli	Escherichia coli	Microbiology/serology	1	1
NVG4462	Escherichia coli	Escherichia coli	Microbiology/serology	1	1
NVG4341	Escherichia coli	Escherichia coli	Microbiology/serology	1	1
NVG1554	Group B Streptococcus	Group B Streptococcus	Microbiology/serology	1	1
NVG3771	Haemophilus influenzae	Haemophilus influenzae	Microbiology/serology	1	1
NVG3539	Haemophilus influenzae, type not specified	Haemophilus influenzae	Microbiology/serology	1	1
NVG3772	H. parainfluenzae	Haemophilus parainfluenzae	Microbiology/serology	1	1
NVG4344	Hafnia alvei	Hafnia alvei	Microbiology/serology	1	1
NVG4340	Klebsiella oxytoca	Klebsiella oxytoca	Microbiology/serology	1	1
NVG0212	Klebsiella pneumoniae	Klebsiella pneumoniae	Microbiology/serology	1	1
NVG1663	Klebsiella pneumoniae	Klebsiella pneumoniae	Microbiology/serology	1	1
NVG3773	Klebsiella pneumoniae	Klebsiella pneumoniae	Microbiology/serology	1	1
NVG4463	Klebsiella pneumoniae	Klebsiella pneumoniae	Microbiology/serology	1	1

NVG4339	Klebsiella pneumoniae	Klebsiella pneumoniae	Microbiology/serology	1	1
NVG3524	Klebsiella pneumoniae or K. oxytoca	Klebsiella pneumoniae	Microbiology/serology	1	1
NVG1551	Klebsiella spp	Klebsiella spp	Microbiology/serology	1	0
NVG3540	Lactobacillus species	Lactobacillus species	Microbiology/serology	1	1
NVG3780	L. pneumophil	Legionella pneumophila	Microbiology/serology	1	1
NVG3776	Legionella pneumophila	Legionella pneumophila	Microbiology/serology	1	1
NVG2942	Micobacterium tuberculosis culture positive	Micobacterium tuberculosis culture positive	Microbiology/serology	1	1
NVG3970	Microbiologically confirmed tuberculosis	Microbiologically confirmed tuberculosis	Microbiology/serology	1	0
NVG1564	Confirmed microbiology	Confirmed microbiology	Diagnosis	1	1
NVG4481	Micrococcus spp.	Micrococcus spp.	Microbiology/serology	1	1
NVG1066	Pathogen causing prosthetic joint infection	Pathogen causing prosthetic joint infection	diagnosis	1	0
NVG1065	Pathogen found in urine	Pathogen found in urine	diagnosis	1	0
NVG1757	Microorganisms (no growth, GN, GP, Other, mixed)	Microorganisms	Microbiology/serology	1	0
NVG1758	Microorganisms (no growth, GN, GP, Other, mixed)	Microorganisms	Microbiology/serology	1	0
NVG1759	Microorganisms (no growth, GN, GP,	Microorganisms	Microbiology/serology	1	0

	Other, mixed)				
NVG1760	Microorganisms (no growth, GN, GP, Other, mixed)	Microorganisms	Microbiology/serology	1	0
NVG1761	Microorganisms (no growth, GN, GP, Other, mixed)	Microorganisms	Microbiology/serology	1	0
NVG1693	Organism (E. coli vs K. pneumoniae)	Microorganisms	microbiology/serology	1	1
NVG1694	Organism (E. coli vs K. pneumoniae)	Microorganisms	microbiology/serology	1	1
NVG3843	Organisms identified (Staphylococcus aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)	Microorganisms	microbiology/serology	1	1
NVG3844	Organisms identified (Staphylococcus aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)	Microorganisms	microbiology/serology	1	1
NVG3845	Organisms identified (Staphylococcus aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)	Microorganisms	microbiology/serology	1	1
NVG3846	Organisms identified (Staphylococcus	Microorganisms	microbiology/serology	1	1

	aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)				
NVG3847	Organisms identified (Staphylococcus aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)	Microorganisms	microbiology/serology	1	1
NVG3848	Organisms identified (Staphylococcus aureus Coagulase-negative staphylococcus Streptococcus species Pseudomonas species Other gram-negative organisms Culture negative)	Microorganisms	microbiology/serology	1	1
NVG2994	Pathogen (Acinetobacter baumannii, Enterobacteriaceae, Pseudomonas/other)	Microorganisms	microbiology/serology	1	1
NVG2995	Pathogen (Acinetobacter baumannii, Enterobacteriaceae, Pseudomonas/other)	Microorganisms	microbiology/serology	1	1
NVG2996	Pathogen (Acinetobacter baumannii, Enterobacteriaceae, Pseudomonas/other)	Microorganisms	microbiology/serology	1	1
NVG3883	Pathogen (Streptococcus Enterococcus faecalis Staphylococcus aureus‡	Microorganisms	microbiology/serology	1	1

	Coagulase-negative staphylococci)				
NVG3884	Pathogen (Streptococcus Enterococcus faecalis Staphylococcus aureus‡ Coagulase-negative staphylococci)	Microorganisms	microbiology/serology	1	1
NVG3885	Pathogen (Streptococcus Enterococcus faecalis Staphylococcus aureus‡ Coagulase-negative staphylococci)	Microorganisms	microbiology/serology	1	1
NVG3886	Pathogen (Streptococcus Enterococcus faecalis Staphylococcus aureus‡ Coagulase-negative staphylococci)	Microorganisms	microbiology/serology	1	1
NVG1135	Pathogen resistance type	Microorganisms	microbiology/serology	1	0
NVG0625	Type of microorganism	Microorganisms	Microbiology/serology	1	0
NVG1464	Type of pathogen (GP, GN, other, unreported)	Microorganisms	Microbiology/serology	1	0
NVG1465	Type of pathogen (GP, GN, other, unreported)	Microorganisms	Microbiology/serology	1	0
NVG1466	Type of pathogen (GP, GN, other, unreported)	Microorganisms	Microbiology/serology	1	0
NVG3716	Pathogen	Organisms identified	microbiology/serology	1	1
NVG3541	Other pathogen+++	Other pathogen	Microbiology/serology	1	0
NVG0365	Polymicrobial	Polymicrobial	Microbiology/serology	1	0
NVG1274	Polymicrobial	Polymicrobial	Microbiology/serology	1	0
NVG1025	Polymicrobials	Polymicrobial	Microbiology/serology	1	0
NVG1556	Mixed flora	Mixed flora	Microbiology/serology	1	0
NVG0104	Mixed gram positive and gram negative	Mixed flora	Microbiology/serology	1	0

NVG0077	MRSA	MRSA	Microbiology/serology	1	0
NVG2394	MRSA	MRSA	Microbiology/serology	1	0
NVG0590	MRSA flag	MRSA flag	Microbiology/serology	1	0
NVG3779	M. pneumoniae	Mycoplasma pneumoniae	Microbiology/serology	1	1
NVG1344	Mycoplasma pneumoniae	Mycoplasma pneumoniae	microbiology/serology	1	1
NVG3775	Mycoplasma pneumoniae	Mycoplasma pneumoniae	microbiology/serology	1	1
NVG3542	No pathogen reported	No pathogen reported	Microbiology/serology	1	0
NVG3535	Prevotella species	Prevotella species	Microbiology/serology	1	0
NVG1665	Proteus mirabilis	Proteus mirabilis	Microbiology/serology	1	1
NVG3528	Proteus mirabilis	Proteus mirabilis	Microbiology/serology	1	1
NVG4468	Proteus mirabilis	Proteus mirabilis	Microbiology/serology	1	1
NVG1552	Proteus spp	Proteus mirabilis	Microbiology/serology	1	0
NVG3523	Pseudomonas aeruginosa	Pseudomonas aeruginosa	Microbiology/serology	1	1
NVG4466	Pseudomonas aeruginosa	Pseudomonas aeruginosa	Microbiology/serology	1	1
NVG4345	Pseudomonas aeruginosa	Pseudomonas aeruginosa	Microbiology/serology	1	1
NVG4275	S. Paratyphi A	S. Paratyphi A	Microbiology/serology	1	1
NVG4274	S. Typhi	S. Typhi	Microbiology/serology	1	1
NVG4472	Salmonella spp.	Salmonella spp.	Microbiology/serology	1	1
NVG2025	type of Salmonella	Type of Salmonella	Microbiology/serology	1	0
NVG3536	Serratia species	Serratia species	Microbiology/serology	1	1
NVG4326	Shigella	Shigella	Microbiology/serology	1	1

NVG3526	Coagulase-negative staphylococcus	Coagulase-negative staphylococcus	Microbiology/serology	1	1
NVG4461	Coagulase-negative Staphylococcus spp.	Coagulase-negative Staphylococcus	Microbiology/serology	1	1
NVG3518	Staphylococcus aureus	Staphylococcus aureus	Microbiology/serology	1	1
NVG3769	Staphylococcus aureus	Staphylococcus aureus	Microbiology/serology	1	1
NVG4464	Staphylococcus aureus	Staphylococcus aureus	Microbiology/serology	1	1
NVG4473	Stenotrophomonas maltophilia	Stenotrophomonas maltophilia	Microbiology/serology	1	1
NVG3530	Stenotrophomonas species	Stenotrophomonas species	Microbiology/serology	1	1
NVG4479	Streptococci, alpha-hemolytic	Streptococci, alpha-hemolytic	Microbiology/serology	1	1
NVG4478	Streptococci, beta-hemolytic	Streptococci, beta-hemolytic	Microbiology/serology	1	1
NVG4476	Streptococci, group D	Streptococci, group D	Microbiology/serology	1	1
NVG3525	Streptococcus species##	Streptococcus species	Microbiology/serology	1	0
NVG1371	Negative for S. pneumoniae	Negative for S. pneumoniae	microbiology/serology	1	1
NVG1343	Streptococcus pneumoniae	Streptococcus pneumoniae	Microbiology/serology	1	1
NVG3765	Streptococcus pneumoniae	Streptococcus pneumoniae	Microbiology/serology	1	1
NVG2768	Molecular type of T. pallidum pertenue	Molecular type of T. pallidum pertenue	Microbiology/serology	1	0
NVG0560	Fungal	Fungal	Microbiology/serology	1	0

NVG3427	CSF Fungal count	CSF Fungal count	Microbiology/serology	1	1
NVG3537	Mold	Mold	Microbiology/serology	1	0
NVG2849	Acid-fast bacili smear	Acid-fast bacili smear	Microbiology/serology	1	1
NVG3456	Positive results on first acid-fast bacillus smear	Positive results on first acid-fast bacillus smear	Microbiology/serology	1	1
NVG2645	population density	Density	Demographics	1	0
NVG3077	Egg count	Egg count	Microbiology/serology	1	1
NVG0144	Gametocytes present	Gametocytes present	Microbiology/serology	1	1
NVG3097	Vaginal GRAM stain	Vaginal GRAM stain	Microbiology/serology	1	0
NVG3770	Gram-negative aerobic bacteria	Gram-negative aerobic bacteria	Microbiology/serology	1	0
NVG3718	Gram-negative bacteria	Gram-negative bacteria	Microbiology/serology	1	0
NVG1023	Gram-negative isolation	Gram-negative isolation	Microbiology/serology	1	0
NVG4475	Gram-negative rods, NF	Gram-negative rods	Microbiology/serology	1	0
NVG2903	Number of Gram-negative uropathogens	Number of Gram-negative uropathogens	microbiology/serology	1	0
NVG4482	Other Gram-negative bacteriac	Other Gram-negative bacteria	microbiology/serology	1	0
NVG3527	Other gram-negative bacterium	Other Gram-negative bacteria	microbiology/serology	1	0
NVG0103	Exclusively gram positive	Exclusively gram positive	Microbiology/serology	1	0
NVG1022	Gram-positive isolation	Gram-positive isolation	Microbiology/serology	1	0

NVG3764	Gram-positive aerobic bacteria	Gram-positive aerobic bacteria	Microbiology/serology	1	0
NVG3717	Gram-positive bacteria	Gram-positive bacteria	Microbiology/serology	1	0
NVG4483	Other Gram-positive bacteriad	Other Gram-positive bacteria	microbiology/serology	1	0
NVG3529	Other gram-positive bacteriumÅ~Å~	Other Gram-positive bacteria	microbiology/serology	1	0
NVG2655	Human African Trypanosomiasis examination performed	Human African Trypanosomiasis examination performed	Microbiology/serology	1	1
NVG2658	in blood presence of trypanosomes:	In blood presence of trypanosomes:	Microbiology/serology	1	0
NVG2657	in lymph nodes presence of trypanosomes:	In lymph nodes presence of trypanosomes:	Microbiology/serology	1	1
NVG3538	Yeast, not otherwise specified	Yeast	Microbiology/serology	1	0
NVG4467	Yeastsb	Yeast	Microbiology/serology	1	0
NVG0112	Baseline HIV-1 RNA Category	Baseline HIV-1 RNA Category	Laboratory	1	1
NVG3458	Beijing genotype	Beijing genotype	Microbiology/serology	1	1
NVG1134	Genome type	Genome type	Microbiology/serology	1	1
NVG0324	Genotype	Genotype	Microbiology/serology	1	1
NVG4537	Genotype (1a 1b 2 3 4	Genotype	Microbiology/serology	1	1

	6)				
NVG4538	Genotype (1a 1b 2 3 4 6)	Genotype	Microbiology/serology	1	1
NVG4539	Genotype (1a 1b 2 3 4 6)	Genotype	Microbiology/serology	1	1
NVG4540	Genotype (1a 1b 2 3 4 6)	Genotype	Microbiology/serology	1	1
NVG4541	Genotype (1a 1b 2 3 4 6)	Genotype	Microbiology/serology	1	1
NVG4542	Genotype (1a 1b 2 3	Genotype	Microbiology/serology	1	1

	4 6)				
NVG2196	HBV genotype B infection	HBV genotype B infection	Microbiology/serology	1	1
NVG0425	HCV genotype	HCV genotype	Microbiology/serology	1	1
NVG2219	HCV genotype	HCV genotype	Microbiology/serology	1	1
NVG4453	HCV Genotype (1a, 4d)	HCV genotype	Microbiology/serology	1	1
NVG4454	HCV Genotype (1a, 4d)	HCV genotype	Microbiology/serology	1	1
NVG3610	HCV subtype 1 or 3	HCV subtype	Microbiology/serology	1	1
NVG3611	HCV subtype 1 or 3	HCV subtype	Microbiology/serology	1	1
NVG2506	HIV subtype	HIV subtype	Microbiology/serology	1	1
NVG0295	HIV-1 subtype B	HIV-1 subtype B	Microbiology/serology	1	1
NVG2587	Influenza subtype	Influenza subtype	Microbiology/serology	1	1
NVG1949	Influenza virus A subtype	Influenza virus A subtype	Microbiology/serology	1	1
NVG1950	Influenza virus A subtype	Influenza virus A subtype	Microbiology/serology	1	1
NVG2582	influenza type	Influenza virus type	Microbiology/serology	1	1
NVG3468	Influenza type	Influenza virus type	Microbiology/serology	1	1
NVG1946	Influenza virus type (A, B)	Influenza virus type	Microbiology/serology	1	1
NVG1947	Influenza virus type (A, B)	Influenza virus type	Microbiology/serology	1	1
NVG4692	Polyomavirus type (BKPyV JCPyV KIPyV WUPyV MCPyV HPyV6 HPyV7)	Polyomavirus type	Microbiology/serology	1	1

	TSPyV❓ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)				
NVG4693	Polyomavirus type (BKPyV JCPyV KIPyV❓❓ WUPyV MCPyV❓ HPyV6❓❓ HPyV7❓❓ TSPyV❓ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4694	Polyomavirus type (BKPyV JCPyV KIPyV❓❓ WUPyV MCPyV❓ HPyV6❓❓ HPyV7❓❓ TSPyV❓	Polyomavirus type	Microbiology/serology	1	1

	HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)				
NVG4695	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4696	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9	Polyomavirus type	Microbiology/serology	1	1

	MWPyV STLPyV HPyV12 NJPyV LIPyV)				
NVG4697	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4698	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV	Polyomavirus type	Microbiology/serology	1	1

	STLPyV HPyV12 NJPyV LIPyV)				
NVG4699	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4700	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV	Polyomavirus type	Microbiology/serology	1	1

	HPyV12 NJPyV LIPyV)				
NVG4701	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4702	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12	Polyomavirus type	Microbiology/serology	1	1

	NJPyV LIPyV)				
NVG4703	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG4704	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV	Polyomavirus type	Microbiology/serology	1	1

	LIPyV)				
NVG4705	Polyomavirus type (BKPyV JCPyV KIPyV❖❖ WUPyV MCPyV❖ HPyV6❖❖ HPyV7❖❖ TSPyV❖ HPyV9 MWPyV STLPyV HPyV12 NJPyV LIPyV)	Polyomavirus type	Microbiology/serology	1	1
NVG0185	Ribotype	Ribotype	Microbiology/serology	1	1
NVG0314	Ribotype O27	Ribotype O27	Microbiology/serology	1	1
NVG2262	virus subtype	virus subtype	Microbiology/serology	1	1
NVG3818	Interferon-γ release assay for tuberculosis	Interferon-γ release assay for tuberculosis	Microbiology/serology	1	1
NVG1222	Negative IGRA	Negative IGRA	microbiology/serology	1	1
NVG1221	Positive IGRA	Positive IGRA	Microbiology/serology	1	1
NVG4175	PCR positivity	PCR positivity	laboratory	1	0
NVG0698	Positive Borrelia PCR in punch biopsy	Positive Borrelia PCR in punch biopsy	Microbiology/serology	1	1
NVG2217	RNA level	RNA	Microbiology/serology	1	1
NVG2676	RNA virus in blood	RNA virus in blood	Microbiology/serology	1	1
NVG2677	RNA virus in fluids	RNA virus in fluids	Microbiology/serology	1	1

NVG0001	RT-PCR influenza status	RT-PCR influenza status	Microbiology/serology	1	1
NVG0640	Urine ZIKA PCR	Urine ZIKA PCR	Microbiology/serology	1	1
NVG1308	Multilocus sequence type	Multilocus sequence type	Microbiology/serology	1	0
NVG2349	CSF HIV RNA	CSF HIV RNA	Laboratory	1	1
NVG3480	First viral RNA level in pregnancy	First viral RNA level in pregnancy	Laboratory	1	0
NVG4086	HBV DNA	HBV DNA	Microbiology/serology	1	1
NVG2200	HBV DNA level	HBV DNA	Microbiology/serology	1	1
NVG4585	HCV antibody status	HCV antibody	Microbiology/serology	1	1
NVG1965	HCV antibody	HCV antibody	Microbiology/serology	1	1
NVG0325	HCV RNA	HCV RNA	Microbiology/serology	1	1
NVG3608	HCV RNA	HCV RNA	Microbiology/serology	1	1
NVG0418	HIV load	HIV load	Microbiology/serology	1	1
NVG0111	HIV RNA (copies/mL)	HIV load	Microbiology/serology	1	1
NVG2345	HIV RNA detectable (<200/ml)	HIV load	Microbiology/serology	1	1
NVG2291	HIV RNA plasam levels	HIV load	Microbiology/serology	1	1
NVG2243	HIV RNA viral load	HIV load	Microbiology/serology	1	1
NVG3969	HIV-1 RNA viral load	HIV load	Microbiology/serology	1	1
NVG2386	HIV-1 viral load	HIV load	Microbiology/serology	1	1
NVG2502	HIV-1 viral load	HIV load	Microbiology/serology	1	1
NVG0283	HIV-RNA	HIV load	Microbiology/serology	1	1
NVG0292	Plasma HIV-1 RNA	HIV load	Microbiology/serology	1	1
NVG3815	Viral load of HIV	HIV load	Microbiology/serology	1	1
NVG4448	HIV-RNA <50 copies/mL	HIV load	Microbiology/serology	1	1
NVG0770	HPV DNA status	HPV DNA status	Microbiology/serology	1	1

NVG3469	Influenza viral load	Influenza viral load	Microbiology/serology	1	0
NVG3064	Low level viraemia	Low level viraemia	Microbiology/serology	1	0
NVG1808	Viral load	Viral load	Microbiology/serology	1	1
NVG1924	viral load	Viral load	Microbiology/serology	1	1
NVG3939	Viral load	Viral load	Microbiology/serology	1	1
NVG2337	Viral loads	Viral load	Microbiology/serology	1	1
NVG3940	Viral load of > 100,000 copies/ml	Viral load	Microbiology/serology	1	1
NVG3059	Viral load test during follow-up	Viral load test during follow-up	Microbiology/serology	1	1
NVG0639	Serum ZIKA PCR	Serum ZIKA PCR	Microbiology/serology	1	1
NVG2150	Female A. aegypti mosquitoes captured (number)	Other microbiology	Other	0	2
NVG2538	Anopheles type	Other microbiology	Other	0	2
NVG3134	Abdominal cystic echinococcosis detected/participants screened.	Other microbiology	Microbiology/serology	0	2
NVG2043	Duration of Salmonella infectusness in environment	Other microbiology	Microbiology/serology	0	2
NVG4685	Gametocyte prevalence by microscopy, %	Other microbiology	Microbiology/serology	0	2
NVG4686	Gametocyte prevalence by QT-NASBA, %	Other microbiology	Microbiology/serology	0	2
NVG3325	Individual microfilarial density	Other microbiology	Microbiology/serology	0	2
NVG2530	Sporozite rate	Other microbiology	Microbiology/serology	0	2
NVG2044	Shirt cicle transmission coeficient	Other microbiology	Microbiology/serology	0	2
NVG4684	Asexual parasite density by microscopy parasites/μL	Other microbiology	Microbiology/serology	0	2
NVG2825	Skin microfilariae density across all participants	Other microbiology	Microbiology/serology	0	2
NVG1487	Partner's Viral load	Other microbiology	microbiology/serology	0	2

NVG2868	Plaque reduction neutralisation test for Zika virus	Other microbiology	Microbiology/serology	0	2
NVG0442	Flavivirus Exposure Category	Other microbiology	Microbiology/serology	0	2
NVG2517	Nugent score 9 or 10.	Other microbiology	Microbiology/serology	0	2
NVG4142	Leishmania species (L. braziliensis (Lb) (%) L. panamensis (Lp) (%))	Leishmania species	Microbiology/serology	1	1
NVG4143	Leishmania species (L. braziliensis (Lb) (%) L. panamensis (Lp) (%))	Leishmania species	Microbiology/serology	1	1
NVG0142	Schizont proportion >10%	Schizont proportion >10%	Microbiology/serology	1	0
NVG0141	Schizont proportion mean	Schizont proportion mean	Microbiology/serology	1	0
NVG2826	>10 Microfilariae in the antherior chamber	>10 Microfilariae in the antherior chamber	Microbiology/serology	1	0
NVG3382	Microfilarial count	Microfilarial count	Microbiology/serology	1	1
NVG0143	Parasite count >20 000/μL	Parasite count	microbiology/serology	1	1
NVG0139	Parasite count/μL	Parasite count	microbiology/serology	1	1
NVG0140	Parasite count/μL, range	Parasite count	microbiology/serology	1	1
NVG2554	P falciparum density (/uL)	Parasite density	microbiology/serology	1	0
NVG3230	Parasite density	Parasite density	microbiology/serology	1	0
NVG0451	Parasite grading at latest VL episode before PSP of 6+	Parasite grading at latest VL episode before PSP of 6+	microbiology/serology	1	0
NVG1147	Day 0 parasitemia, median (IQR) %	Day 0 parasitemia, median %	Microbiology/serology	1	1
NVG2553	Presence of P falciparum parasites by microscopy	Presence of P falciparum parasites	Microbiology/serology	1	1

		by microscopy			
NVG2555	Presence of P. falciparum gametocytes	Presence of P. falciparum gametocytes	Microbiology/serology	1	1
NVG2026	Blood cultures performed	Blood cultures performed	Laboratory	1	1
NVG1548	Baseline cultures obtained	Baseline cultures obtained	Microbiology/serology	1	1
NVG2065	Culture positivity	Culture positivity	Microbiology/serology	1	0
NVG3054	Culture status	Culture status	Microbiology/serology	1	0
NVG2904	Number of Gram-negative pathogens isolated from both urine culture ($>1 \times 10^5$ CFU/mL) and blood culture at baseline	Number of Gram-negative pathogens isolated from both urine culture ($>1 \times 10^5$ CFU/mL) and blood culture at baseline	microbiology/serology	1	0
NVG1549	Positive cultures	Positive cultures	Microbiology/serology	1	0
NVG1276	Positive pus culture	Positive pus culture	Microbiology/serology	1	1
NVG3451	Results on 8-week sputum culture (No growth, Mycobacterium tuberculosis, Other mycobacteria)	Results on 8-week sputum culture	Microbiology/serology	1	0
NVG3452	Results on 8-week sputum culture (No growth, Mycobacterium tuberculosis, Other mycobacteria)	Results on 8-week sputum culture	Microbiology/serology	1	0
NVG3453	Results on 8-week sputum culture (No growth, Mycobacterium tuberculosis, Other mycobacteria)	Results on 8-week sputum culture	Microbiology/serology	1	0
NVG4620	Sputum culture status (Any one culture Mtb positive	Sputum culture status	Microbiology/serology	1	0

	Culture negative Non-Tuberculous mycobacteria Contaminated Sample insufficient)				
NVG4621	Sputum culture status (Any one culture Mtb positive Culture negative Non-Tuberculous mycobacteria Contaminated Sample insufficient)	Sputum culture status	Microbiology/serology	1	0
NVG4622	Sputum culture status (Any one culture Mtb positive Culture negative Non-Tuberculous mycobacteria Contaminated Sample insufficient)	Sputum culture status	Microbiology/serology	1	0
NVG4623	Sputum culture status (Any one culture Mtb positive Culture negative Non-Tuberculous mycobacteria Contaminated Sample insufficient)	Sputum culture status	Microbiology/serology	1	0
NVG4624	Sputum culture status (Any one culture Mtb positive Culture negative Non-Tuberculous mycobacteria Contaminated Sample insufficient)	Sputum culture status	Microbiology/serology	1	0
NVG4616	Sputum smear maximum grade (Scanty	Sputum smear	Microbiology/serology	1	1

	positive 1+ 2+ 3+)	maximum grade			
NVG4617	Sputum smear maximum grade (Scanty positive 1+ 2+ 3+)	Sputum smear maximum grade	Microbiology/serology	1	1
NVG4618	Sputum smear maximum grade (Scanty positive 1+ 2+ 3+)	Sputum smear maximum grade	Microbiology/serology	1	1
NVG4271	Total blood cultures performed	Total blood cultures performed	Microbiology/serology	1	0
NVG4272	Total number of significant cultures	Total number of significant cultures	Microbiology/serology	1	0
NVG2297	Number of samples by laboratory	Number of samples by laboratory	Laboratory	1	0
NVG3836	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one	Microbiologic diagnostic sampling	Microbiology/serology	1	0

	positive for a given nonpathogenic organism Sampling undertaken but no organisms identified Not done or missing‡)				
NVG3837	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one positive for a given nonpathogenic organism Sampling undertaken but no organisms identified Not done or missing‡)	Microbiologic diagnostic sampling	Microbiology/serology	1	0
NVG3838	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one positive for a given nonpathogenic organism	Microbiologic diagnostic sampling	Microbiology/serology	1	0

	Sampling undertaken but no organisms identified Not done or missing†)				
NVG3839	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one positive for a given nonpathogenic organism Sampling undertaken but no organisms identified Not done or missing†)	Microbiologic diagnostic sampling	Microbiology/serology	1	0
NVG3840	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one positive for a given nonpathogenic organism Sampling undertaken but no organisms identified	Microbiologic diagnostic sampling	Microbiology/serology	1	0

	Not done or missing‡)				
NVG3841	Microbiologic diagnostic sampling (Two or more samples positive for same organism Two or more samples taken but only one positive for a given pathogenic organism Only one sample taken, which was found to be positive for a pathogenic organism by closed biopsy Two or more samples taken but only one positive for a given nonpathogenic organism Sampling undertaken but no organisms identified Not done or missing‡)	Microbiologic diagnostic sampling	Microbiology/serology	1	0
NVG1408	Sample	Sample	Microbiology/serology	1	1
NVG1127	Specimen collection place	Specimen collection place	Microbiology/serology	1	1
NVG1128	Specimen	Specimen type	Microbiology/serology	1	1
NVG1316	Specimen type: Blood	Specimen type	Microbiology/serology	1	1
NVG1317	Specimen type: Peritoneal fluid	Specimen type	Microbiology/serology	1	1
NVG1318	Specimen type: Pus	Specimen type	Microbiology/serology	1	1
NVG1319	Specimen type: Rectal swap	Specimen type	Microbiology/serology	1	1
NVG1320	Specimen type: Urine	Specimen type	Microbiology/serology	1	1
NVG4565	Type of specimen (Blood only Blood and CSF Meets criteria for CSF culture CSF collected among those who have indications for collection9	Type of specimen	Microbiology/serology	1	1

	CSF culture positive)				
NVG4566	Type of specimen (Blood only Blood and CSF Meets criteria for CSF culture CSF collected among those who have indications for collection9 CSF culture positive)	Type of specimen	Microbiology/serology	1	1
NVG4567	Type of specimen (Blood only Blood and CSF Meets criteria for CSF culture CSF collected among those who have indications for collection9 CSF culture positive)	Type of specimen	Microbiology/serology	1	1
NVG4568	Type of specimen (Blood only Blood and CSF Meets criteria for CSF culture CSF collected among those who have indications for collection9 CSF culture positive)	Type of specimen	Microbiology/serology	1	1
NVG4569	Type of specimen (Blood only Blood and CSF Meets criteria for CSF culture CSF collected among those who have indications for collection9 CSF culture positive)	Type of specimen	Microbiology/serology	1	1
NVG3024	Urinary culture	Urinary culture	Microbiology/serology	1	1
NVG1544	Urine culture positive at inclusion	Urine culture positive at inclusion	Microbiology/serology	1	1
NVG2722	Urinary glucose	Urinary glucose	Laboratory	1	1

NVG1309	Date of isolation	Date of isolation	Other	1	1
NVG1419	Date of specimen collection	Date of specimen collection	Microbiology/serology	1	1
NVG2411	Days between drawing of first positive blood culture and randomisation	Days between drawing of first positive blood culture and randomisation	Other	1	0
NVG2191	Time from randomization to blood collection	Time from randomization to blood collection	Other	1	0
NVG0079	Mean culture days until GPCs observed	Mean culture days until GPCs observed	Microbiology/serology	1	0
NVG3119	Interval from last primary PCV dose to blood sample	Interval from last primary PCV dose to blood sample	Other	1	0
NVG1126	Specimen collection year	Specimen collection year	Microbiology/serology	1	1
NVG0929	Year of isolation	Year of isolation	Microbiology/serology	1	1
NVG1137	Year of isolation	Year of isolation	Microbiology/serology	1	1
NVG1919	Baseline time to positivity	Baseline time to positivity	Microbiology/serology	1	1
NVG0203	Time to culture	Time to culture	Microbiology/serology	1	0
NVG1766	Endotoxin activity assay levels	Endotoxin activity assay levels	Laboratory	1	1
NVG1476	pertussis toxin antibody concentrations	Pertussis toxin antibody concentrations	laboratory	1	1
NVG0313	Binary toxin	Binary toxin	Microbiology/serology	1	1
NVG3588	Reaction size on tuberculin skin test	Reaction size on	Microbiology/serology	1	1

		tuberculin skin test			
NVG4062	Reaction size on tuberculin skin test	Reaction size on tuberculin skin test	Microbiology/serology	1	1
NVG3817	Tuberculin skin test	Tuberculin skin test	Microbiology/serology	1	0
NVG4337	Chikungunya	Chikungunya	Microbiology/serology	1	1
NVG1347	Coronavirus	Coronavirus	Microbiology/serology	1	1
NVG1242	Enterovirus serotype	Enterovirus serotype	Microbiology/serology	1	1
NVG2357	HCV infection	HCV	Comorbidities	1	1
NVG1349	Metapneumovirus	Metapneumovirus	Microbiology/serology	1	1
NVG1348	Parainfluenza virus	Parainfluenza virus	microbiology/serology	1	1
NVG1346	Rhinovirus	Rhinovirus	Microbiology/serology	1	1
NVG2588	Syncitial respiratory virus positivity	Syncitial respiratory virus positivity	Microbiology/serology	1	1
NVG0561	Viral	Viral	Diagnosis	1	1
NVG3533	Virus***	Virus	Microbiology/serology	1	0
NVG2981	Haemodynamic support	Haemodynamic support	Treatment	1	0
NVG4229	Inotropes	Inotropes	Treatment	1	1
NVG4120	Inotropic support with dobutamine	Inotropes	Treatment	1	1
NVG3722	Epinephrine number patients	Epinephrine number patients	Treatment	1	0
NVG3720	Norepinephrine number patients	Norepinephrine number patients	treatment	1	1
NVG4394	Total norepinephrine	Total norepinephrine	Treatment	1	1
NVG3724	Vasopressor administration	Vasopressor administration	Treatment	1	0
NVG4119	Vasopressor support with norepinephrine or epinephrine	Vasopressor administration	Treatment	1	0

NVG0668	Vasopressor use	Vasopressor administration	Treatment	1	0
NVG1624	Vasopressor/inotropic therapy	Vasopressor administration	Treatment	1	0
NVG1518	Vasopressors	Vasopressor administration	Treatment	1	0
NVG3868	Vasopressors or inotropes	Vasopressor administration	Treatment	1	0
NVG1762	Cumulative vasopressor index	Cumulative vasopressor index	Treatment	1	0
NVG3723	Epinephrine dose	Epinephrine dose	Treatment	1	1
NVG1568	Norepinephrine dose	Norepinephrine dose	treatment	1	1
NVG1763	Norepinephrine dose	Norepinephrine dose	treatment	1	1
NVG3721	Norepinephrine dose	Norepinephrine dose	treatment	1	1
NVG2186	Feeding (breast, formula, combination)	Feeding	Other	1	0
NVG2187	Feeding (breast, formula, combination)	Feeding	Other	1	0
NVG2188	Feeding (breast, formula, combination)	Feeding	Other	1	0
NVG1050	parental nutrition	Parental nutrition	treatment	1	1
NVG0823	Total parenteral nutrition	Total parenteral nutrition	Treatment	1	1
NVG0876	Pre-transplant maintenance dialysis	Pre-transplant maintenance dialysis	Comorbidities	1	0
NVG0669	Acute renal replacement therapy	Acute renal replacement therapy	Treatment	1	1
NVG1049	Continuous renal replacement therapy	Continuous renal replacement therapy	Treatment	1	1
NVG0356	Dialysis	Dialysis	Treatment	1	1
NVG1765	Renal replacement therapy	Renal replacement	Treatment	1	1

		therapy			
NVG0231	ESRD requiring dialysis	Renal replacement therapy	Treatment	1	1
NVG2983	Haemodialysis	Renal replacement therapy	Treatment	1	1
NVG1181	Hemodialysis	Renal replacement therapy	Treatment	1	1
NVG1186	Hemodialysis	Renal replacement therapy	Treatment	1	1
NVG1960	Renal Replacement Therapy	Renal replacement therapy	Treatment	1	1
NVG3869	Renal replacement therapy	Renal replacement therapy	Treatment	1	1
NVG3726	Renal-replacement therapy	Renal replacement therapy	Treatment	1	1
NVG4121	Extracorporeal membrane oxygenation	Extracorporeal membrane oxygenation	Treatment	1	1
NVG1452	Acute respiratory failure requiring mechanical ventilation	Mechanical ventilation	Diagnosis	1	0
NVG3867	Invasive mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG4118	Invasive mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG0358	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG0667	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG0825	Mechanical ventilation	Mechanical	Treatment	1	1

		ventilation			
NVG0991	mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG1623	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG1755	Mechanical Ventilation	Mechanical ventilation	Treatment	1	1
NVG2982	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG3725	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG4397	Mechanical ventilation	Mechanical ventilation	Treatment	1	1
NVG2918	Mechanical ventilation at baseline (Ventilated Not ventilated)	Mechanical ventilation	Treatment	1	0
NVG2919	Mechanical ventilation at baseline (Ventilated Not ventilated)	Mechanical ventilation	Treatment	1	0
NVG1175	Mechanical ventilation at time of diagnosis	Mechanical ventilation	Treatment	1	0
NVG1517	Mechanical ventilators	Mechanical ventilation	Treatment	1	0
NVG3495	Ventilator	Mechanical ventilation	Treatment	1	1
NVG0660	Prior mechanical ventilation	Prior mechanical ventilation	Treatment	1	0
NVG0693	Prolonged mechanical ventilation	Prolonged mechanical ventilation	Treatment	1	0
NVG2333	O2 administration	O2 administration	treatment	1	1
NVG0694	Mechanical ventilation duration	Mechanical	Treatment	1	0

		ventilation duration			
NVG4398	Ventilator-free days	Ventilator-free days	Treatment	1	1
NVG1434	ICD code (international Classification Disease) code	ICD codes	Diagnosis	1	1
NVG2586	ICD codes	ICD codes	Diagnosis	1	1
NVG3661	Family history of gastric cancer	Other	Other	0	2
NVG4287	Family history of leg swelling	Other	Other	0	2
NVG2696	Having been breastfed by a case	Other	Other	0	2
NVG2694	Having direct physical contact during illness or with body of a deceased	Other	Other	0	2
NVG2693	Having shared transport vehicle during illness	Other	Other	0	2
NVG2695	Having touched any body fluids of a case during illness	Other	Other	0	2
NVG2525	Long lasting insecticidal net use in selected children	Other	Other	0	2
NVG2523	Long lasting insecticidal nets use in all age groups	Other	Other	0	2
NVG2040	Long term carriage (age stratified)	Other	Other	0	2
NVG2463	Skilled birth attendant	Other	Other	0	2
NVG2056	Sought prior care during episode	Other	Other	0	2
NVG2474	Washed after birth	Other	Other	0	2
NVG2130	frequency of mosquito-repellent use	Other	Other	0	2
NVG4301	Frequency of pork consumption	Other	Other	0	2
NVG2533	Number of surveys done	Other	other	0	2
NVG3958	Period isolated	Other	Other	0	2
NVG0480	Period of self-isolation	Other	Other	0	2

NVG0043	Away and excluded	Other	Other	0	2
NVG3551	Bathe daily	Other	Other	0	2
NVG2131	bitten by mosquito	Other	Other	0	2
NVG2464	Clean delivery kit	Other	Other	0	2
NVG4304	Consumed crops that family grow	Other	Other	0	2
NVG4299	Consumed pork from family's home raised pigs	Other	Other	0	2
NVG4302	Consuming raw pork in last year	Other	Other	0	2
NVG4300	Cysts in pork in last 5 years	Other	Other	0	2
NVG4303	Growing crops	Other	Other	0	2
NVG0533	HMO	Other	Other	0	2
NVG1297	Implicated cheese	Other	Other	0	2
NVG4005	Lifestyle practices during this pregnancy (alcohol, drug use, smoker, use of mosquito repellents, use of larvicides).	Other	Other	0	2
NVG4006	Lifestyle practices during this pregnancy (alcohol, drug use, smoker, use of mosquito repellents, use of larvicides).	Other	Other	0	2
NVG4007	Lifestyle practices during this pregnancy (alcohol, drug use, smoker, use of mosquito repellents, use of larvicides).	Other	Other	0	2
NVG2296	living children with study partner.	Other	Other	0	2
NVG1304	Made from pasteurized milk	Other	Other	0	2
NVG2475	Massage after birth	Other	Other	0	2
NVG1892	MCH	Other	Other	0	2
NVG1891	MCV	Other	Other	0	2
NVG1191	Near-patient surfaces and objects in rooms	Other	other	0	2

NVG1789	obstruction (addhesional problems)	Other	other	0	2
NVG3290	Operative approach	Other	other	0	2
NVG2491	Poor feeding (confirmed by observation)	Other	Other	0	2
NVG0570	Presentation in hospital in those LTF	Other	Other	0	2
NVG0439	Reason	Other	Other	0	2
NVG4492	Response	Other	Other	0	2
NVG0750	Vegetarian	Other	Other	0	2
NVG3305	TISS-28 score	Other	Other	0	2
NVG0306	WHO performance status,	Other	Other	0	2
NVG3636	Lung allocation score	Other	Prognosis	0	2
NVG2472	Proper cord care at birth	Proper cord care at birth	Other	1	0
NVG2631	Source of Stem cells (Peripheral blood Bone marrow Cord blood Peripheral blood plus bone marrow or cord blood)	Source of Stem cells	Treatment	1	1
NVG2632	Source of Stem cells (Peripheral blood Bone marrow Cord blood Peripheral blood plus bone marrow or cord blood)	Source of Stem cells	Treatment	1	1
NVG2633	Source of Stem cells (Peripheral blood Bone marrow Cord blood Peripheral blood plus bone marrow or cord blood)	Source of Stem cells	Treatment	1	1
NVG2634	Source of Stem cells (Peripheral blood Bone marrow Cord blood Peripheral blood plus bone marrow or cord blood)	Source of Stem cells	Treatment	1	1
NVG0299	Attends day care	Attends day care	Other	1	0
NVG4519	Day care attendance	Daycare	Other	1	0
NVG2330	Daycare	Daycare	Other	1	0
NVG4098	Birth length	Birth length	Other	1	1

NVG2947	Alive at discharge	Alive at discharge	Prognosis	1	1
NVG3041	Alive at discharge	Alive at discharge	Prognosis	1	1
NVG1799	Cause of death	Cause of death	Prognosis	1	0
NVG0432	Cause of death : all-cause	Cause of death	Prognosis	1	0
NVG0434	Cause of death : all-circulatory	Cause of death	Prognosis	1	0
NVG0433	Cause of death: all-respiratory	Cause of death	Prognosis	1	0
NVG1239	Death	Death	Prognosis	1	1
NVG1354	Death	Death	Prognosis	1	1
NVG2497	Death	Death	Prognosis	1	1
NVG4269	Death	Death	Prognosis	1	1
NVG4494	Death	Death	Prognosis	1	1
NVG1793	Deaths (number)	Death	Prognosis	1	1
NVG1365	Died	Death	Prognosis	1	1
NVG4638	Died	Death	Prognosis	1	1
NVG1220	Died within 1 year of TB diagnosis	Died within 1 year of TB diagnosis	Prognosis	1	0
NVG4089	Delivery outcome (Live birth Stillbirth ante partum)	Outcome	Prognosis	1	0
NVG4090	Delivery outcome (Live birth Stillbirth ante partum)	Outcome	Prognosis	1	0
NVG1469	In-hospital death	Outcome	Prognosis	1	1
NVG4495	In-hospital mortality	Outcome	Prognosis	1	1
NVG4402	In-hospital mortality	Outcome	Prognosis	1	1
NVG4403	One-year survival	Outcome	prognosis	1	0
NVG2948	Outcome at day 180	Outcome	prognosis	1	0
NVG4579	Outcome of hospital stay (Discharged, Died, Others)	Outcome	prognosis	1	0

NVG4580	Outcome of hospital stay (Discharged, Died, Others)	Outcome	prognosis	1	0
NVG4581	Outcome of hospital stay (Discharged, Died, Others)	Outcome	prognosis	1	0
NVG1281	Outcome: Death	Outcome	prognosis	1	0
NVG1282	Outcome: Relapse	Outcome	prognosis	1	0
NVG1229	Outcomes: Death	Outcome	prognosis	1	0
NVG1230	Outcomes: Survived	Outcome	prognosis	1	0
NVG3302	Patients discharged before day 3	Outcome	Prognosis	1	1
NVG1781	discharge from hospital	Discharge from hospital	Other	1	1
NVG0457	Viral suppression	Viral suppression	Microbiology/serology	1	1
NVG4635	Cured	Cured	Other	1	0
NVG3065	Virological outcome	Virological outcome	Other	1	0
NVG1780	Rate of late recurrence of appendicitis	Rate of late recurrence of appendicitis	Prognosis	1	1
NVG2324	Sustained viral Response	Sustained viral Response	Treatment	1	0
NVG2235	Sustained Viral response 12 weeks.	Sustained viral Response	Treatment	1	0
NVG1820	Sustained virologic response at 12 months	Sustained viral Response	Treatment	1	0
NVG4637	Treatment failure	Treatment failure	Treatment	1	1
NVG1124	Clinical cure at day 7	Clinical cure at day 7	Other	1	0
NVG0285	no history of virologic failure after 1 year of therapy	No history of virologic failure after 1 year of therapy	treatment	1	0

NVG0773	Follow-up time	Follow-up time	Other	1	1
NVG0029	BMI	BMI	Other	1	1
NVG0060	BMI	BMI	Other	1	1
NVG0322	BMI	BMI	Other	1	1
NVG0655	BMI	BMI	Other	1	1
NVG1619	BMI	BMI	Other	1	1
NVG1690	BMI	BMI	Other	1	1
NVG1925	BMI	BMI	Other	1	1
NVG1944	BMI	BMI	Other	1	1
NVG2210	BMI	BMI	Other	1	1
NVG2276	BMI	BMI	Other	1	1
NVG2313	BMI	BMI	Other	1	1
NVG2355	BMI	BMI	Other	1	1
NVG2654	BMI	BMI	Other	1	1
NVG2967	BMI	BMI	Other	1	1
NVG3046	BMI	BMI	Other	1	1
NVG3156	BMI	BMI	Other	1	1
NVG3192	BMI	BMI	Other	1	1
NVG3223	BMI	BMI	Other	1	1
NVG3233	BMI	BMI	Other	1	1
NVG3241	BMI	BMI	Other	1	1
NVG4312	BMI	BMI	Other	1	1
NVG0449	BMI	BMI	Other	1	1
NVG0858	BMI at transplantation	BMI	Other	1	1
NVG4001	BMI before pregnancy	BMI	Other	1	1
NVG0582	Body mass index	BMI	Other	1	1

NVG1579	Body mass index	BMI	Other	1	1
NVG1915	Body mass index	BMI	Other	1	1
NVG2757	Body mass index	BMI	Other	1	1
NVG2796	Body mass index	BMI	Other	1	1
NVG2876	Body mass index	BMI	Other	1	1
NVG3462	Body mass index	BMI	Other	1	1
NVG3607	Body mass index	BMI	Other	1	1
NVG3739	Body mass index	BMI	Other	1	1
NVG4376	Body mass index	BMI	Other	1	1
NVG4610	Body mass index	BMI	Other	1	1
NVG3074	Body weight	BMI	Other	1	1
NVG2777	Body-Mass Index	BMI	Other	1	1
NVG2907	Body-mass index	BMI	Other	1	1
NVG3749	Body-mass index	BMI	Other	1	1
NVG3786	Body-mass index	BMI	Other	1	1
NVG3808	Body-mass index	BMI	Other	1	1
NVG3967	Body-mass index	BMI	Other	1	1
NVG4012	Body-mass index	BMI	Other	1	1
NVG4061	Body-mass index	BMI	Other	1	1
NVG4105	Body-mass index	BMI	Other	1	1
NVG2863	Body-mass-index	BMI	Other	1	1
NVG3587	Median body-mass index	Median BMI	Other	1	0
NVG1959	Recipient BMI	Recipient BMI	Other	1	1
NVG4099	Head circumference	Head circumference	Other	1	1
NVG0058	Height	Height	Other	1	1
NVG1618	Height	Height	Other	1	1

NVG2822	height	Height	Other	1	1
NVG3075	Height	Height	Other	1	1
NVG3317	Height	Height	Other	1	1
NVG3585	Height	Height	Other	1	1
NVG4059	Height	Height	Other	1	1
NVG4084	Height	Height	Other	1	1
NVG4311	Height	Height	Other	1	1
NVG3704	Height (cm)	Height	Other	1	1
NVG2182	Birth weight	Birth weight	Other	1	1
NVG4097	Birth weight	Birth weight	Other	1	1
NVG3703	Birth weight (g)	Birth weight	Other	1	1
NVG2871	Birthweight	Birth weight	Other	1	1
NVG2473	Low birthweight	Low birthweight	Other	1	1
NVG4553	Median weight upon admission	Median weight upon admission	Other	1	0
NVG0059	Weigh	Weight	Other	1	1
NVG0093	Weight	Weight	Other	1	1
NVG1472	Weight	Weight	Other	1	1
NVG1617	Weight	Weight	Other	1	1
NVG1913	Weight	Weight	Other	1	1
NVG2653	Weight	Weight	Other	1	1
NVG2821	Weight	Weight	Other	1	1
NVG2862	Weight	Weight	Other	1	1
NVG3014	Weight	Weight	Other	1	1
NVG3316	Weight	Weight	Other	1	1
NVG3372	Weight	Weight	Other	1	1

NVG3381	Weight	Weight	Other	1	1
NVG3386	Weight	Weight	Other	1	1
NVG3418	Weight	Weight	Other	1	1
NVG3446	Weight	Weight	Other	1	1
NVG3460	Weight	Weight	Other	1	1
NVG3586	Weight	Weight	Other	1	1
NVG4060	Weight	Weight	Other	1	1
NVG4085	Weight	Weight	Other	1	1
NVG4313	Weight	Weight	Other	1	1
NVG1729	Weight,	Weight	Other	1	1
NVG2872	Weight for gestational age	Weight for gestational age	Other	1	1
NVG1752	Arterial BP	Arterial pressure	Clinical manifestations	1	1
NVG4037	Arterial pressure	Arterial pressure	Clinical manifestations	1	1
NVG3399	Arterial pressure	Arterial pressure	Clinical manifestations	1	1
NVG1567	Blood preassure	Arterial pressure	Clinical manifestations	1	1
NVG4406	Cardiac index	Cardiac index	Other	1	1
NVG0944	Diast Blood Preassure	Diastolic blood pressure	Clinical manifestations	1	1
NVG2662	Diast blood preasure	Diastolic blood pressure	Clinical manifestations	1	1
NVG2354	Diast BP	Diastolic blood pressure	Clinical manifestations	1	1
NVG2952	Diastolic blood pressure	Diastolic blood pressure	Clinical manifestations	1	1
NVG4725	Diastolic blood pressure	Diastolic blood pressure	Clinical manifestations	1	1

NVG1627	Diastolic BP	Diastolic blood pressure	Clinical manifestations	1	1
NVG1887	High Diast Preass.	Diastolic blood pressure	Clinical manifestations	1	0
NVG2953	Pulse rate	Heart rate	Clinical manifestations	1	1
NVG0133	Heart rate	Heart rate	Clinical manifestations	1	1
NVG0942	Heart rate	Heart rate	Clinical manifestations	1	1
NVG1506	Heart rate	Heart rate	Clinical manifestations	1	1
NVG1566	heart rate	Heart rate	Clinical manifestations	1	1
NVG1625	Heart rate	Heart rate	Clinical manifestations	1	1
NVG2663	Heart rate	Heart rate	Clinical manifestations	1	1
NVG3398	Heart rate	Heart rate	Clinical manifestations	1	1
NVG4035	Heart rate	Heart rate	Clinical manifestations	1	1
NVG4723	Heart rate	Heart rate	Clinical manifestations	1	1
NVG4412	Right ventricular systolic pressure	Right ventricular systolic pressure	Clinical manifestations	1	1
NVG2661	Syst blood preassure	Systolic blood pressure	Clinical manifestations	1	1
NVG0943	Syst Blood preasure	Systolic blood pressure	Clinical manifestations	1	1
NVG2353	Syst BP	Systolic blood pressure	Clinical manifestations	1	1
NVG1511	Systolic Blood Preassure	Systolic blood pressure	Clinical manifestations	1	1
NVG0132	Systolic blood pressure	Systolic blood pressure	Clinical manifestations	1	1
NVG2954	Systolic blood pressure	Systolic blood pressure	Clinical manifestations	1	1

NVG2980	Systolic blood pressure	Systolic blood pressure	Clinical manifestations	1	1
NVG4724	Systolic blood pressure	Systolic blood pressure	Clinical manifestations	1	1
NVG1626	Systolic BP	Systolic blood pressure	Clinical manifestations	1	1
NVG1886	High Systolic pressure	Systolic blood pressure	Clinical manifestations	1	0
NVG3333	Ventricular rate	Ventricular rate	Clinical manifestations	1	1
NVG4186	Gastrointestinal findings	Gastrointestinal findings	Images/EKG	1	0
NVG2055	Febrile at presentation	Febrile at presentation	Clinical manifestations	1	1
NVG2550	Sick with a fever during past 48h	Fever	Clinical manifestations	1	0
NVG1140	Fever >37.5°C	Fever	Clinical manifestations	1	0
NVG1951	measured fever >37,8	Fever	Clinical manifestations	1	0
NVG0888	Temperature >38°C	Fever	Clinical manifestations	1	0
NVG0012	Fever	Fever	Clinical manifestations	1	0
NVG0474	Fever	Fever	Clinical manifestations	1	0
NVG0635	Fever	Fever	Clinical manifestations	1	0
NVG0879	Fever	Fever	Clinical manifestations	1	0
NVG1091	Fever	Fever	Clinical manifestations	1	0
NVG1154	Fever	Fever	Clinical manifestations	1	0
NVG1263	Fever	Fever	Clinical manifestations	1	0
NVG1987	fever	Fever	Clinical manifestations	1	0
NVG2267	fever	Fever	Clinical manifestations	1	0
NVG2604	fever	Fever	Clinical manifestations	1	0

NVG2733	fever	Fever	Clinical manifestations	1	0
NVG2752	fever	Fever	Clinical manifestations	1	0
NVG2864	Fever	Fever	Clinical manifestations	1	0
NVG2951	Fever	Fever	Clinical manifestations	1	0
NVG3421	Fever	Fever	Clinical manifestations	1	0
NVG3906	Fever	Fever	Clinical manifestations	1	0
NVG4183	Fever	Fever	Clinical manifestations	1	0
NVG0131	Fever	Fever	Clinical manifestations	1	0
NVG2062	Viral fever	Viral fever	Diagnosis	1	1
NVG0960	Confirmed non-infectious fever	Confirmed non-infectious fever	Diagnosis	1	1
NVG2551	Axillary Temperature at diagnosis	Temperature	Clinical manifestations	1	1
NVG2488	Axillary Temperature	Temperature	Clinical manifestations	1	1
NVG3337	Axillary temperature monitoring	Temperature	Clinical manifestations	1	1
NVG1034	Body temperature	Temperature	Clinical manifestations	1	1
NVG1628	Body temperature	Temperature	Clinical manifestations	1	1
NVG0130	Temperature	Temperature	Clinical manifestations	1	1
NVG0941	Temperature	Temperature	Clinical manifestations	1	1
NVG1505	Temperature	Temperature	Clinical manifestations	1	1
NVG2665	Temperature	Temperature	Clinical manifestations	1	1
NVG2791	temperature	Temperature	Clinical manifestations	1	1
NVG2811	temperature	Temperature	Clinical manifestations	1	1
NVG2936	Temperature	Temperature	Clinical manifestations	1	1
NVG2955	Temperature	Temperature	Clinical manifestations	1	1
NVG2978	Temperature	Temperature	Clinical manifestations	1	1
NVG3340	Temperature	Temperature	Clinical manifestations	1	1

NVG3466	Temperature	Temperature	Clinical manifestations	1	1
NVG4034	Temperature	Temperature	Clinical manifestations	1	1
NVG4278	Temperature	Temperature	Clinical manifestations	1	1
NVG1632	Urine output (ml/h)	Urine output	Clinical manifestations	1	1
NVG4130	Fluid balance	Fluid balance	Clinical manifestations	1	1
NVG2937	Glasgow	Glasgow Coma Scale	Clinical manifestations	1	1
NVG4420	Glasgow Coma Scale	Glasgow Coma Scale	Clinical manifestations	1	1
NVG3425	Glasgow scale	Glasgow Coma Scale	Clinical manifestations	1	1
NVG3225	Pupil diameter	Pupil diameter	Clinical manifestations	1	1
NVG0135	Oxygen saturation	Oxygen saturation	clinical manifestations	1	1
NVG4038	Oxygen saturation	Oxygen saturation	clinical manifestations	1	1
NVG2438	Oxygen Saturation Examination findings:	Oxygen saturation	clinical manifestations	1	1
NVG0893	Pulse oximetry <96%	Oxygen saturation	Clinical manifestations	1	0
NVG0792	Pulmonary artery pressure	Pulmonary artery pressure	Clinical manifestations	1	1
NVG2486	Respiratoru rate	Respiratory rate	Clinical manifestations	1	1
NVG0945	Respiratory Rat	Respiratory rate	Clinical manifestations	1	1
NVG0134	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG1508	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG2664	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG2950	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG4036	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG4722	Respiratory rate	Respiratory rate	Clinical manifestations	1	1
NVG4415	Respiratory rate (/min)	Respiratory rate	Clinical manifestations	1	1
NVG3269	ASA (anesthesiologist classification grade)	ASA	Prognosis	0	2
NVG0583	ASA class	ASA	Prognosis	0	2

NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG3193	American Society of Anaesthesiologists grade	ASA	Prognosis	0	2
NVG0279	Cytokine release syndrome: Grade 0	Grade of cytokine release syndrome	Prognosis	1	0
NVG0280	Cytokine release syndrome: Grade 1–2	Grade of cytokine release syndrome	Prognosis	1	0
NVG0281	Cytokine release syndrome: Grade 3–5	Grade of cytokine release syndrome	Prognosis	1	0
NVG3081	Burn severity (TBSA %)	Burn severity	Clinical manifestations	1	0
NVG0670	Severity at CRAB (carbapenem-resistant Acinetobacter baumannii) pneumonia diagnosis	Disease severity	Clinical manifestations	1	0
NVG4123	RIFLE classification (Oliguria Anuria Serum creatinine 3 times the baseline level**)	RIFLE classification	Clinical manifestations	1	0
NVG4124	RIFLE classification (Oliguria Anuria Serum creatinine 3 times the baseline	RIFLE classification	Clinical manifestations	1	0

	level**))				
NVG4125	RIFLE classification (Oliguria Anuria Serum creatinine 3 times the baseline level**))	RIFLE classification	Clinical manifestations	1	0
NVG1504	SIRS	SIRS	Clinical manifestations	1	0
NVG4387	Acute kidney injury (Stage I Stage II Stage III)	Acute kidney injury stage	Diagnosis	1	0
NVG4388	Acute kidney injury (Stage I Stage II Stage III)	Acute kidney injury stage	Diagnosis	1	0
NVG4389	Acute kidney injury (Stage I Stage II Stage III)	Acute kidney injury stage	Diagnosis	1	0
NVG1631	AKI stage (1-3)	Acute kidney injury stage	Diagnosis	1	0
NVG1631	AKI stage (1-3)	Acute kidney injury stage	Diagnosis	1	0
NVG1631	AKI stage (1-3)	Acute kidney injury stage	Diagnosis	1	0
NVG1764	AKIN AKI stage	Acute kidney injury stage	Diagnosis	1	0
NVG1764	AKIN AKI stage	Acute kidney injury stage	Diagnosis	1	0
NVG1764	AKIN AKI stage	Acute kidney injury stage	Diagnosis	1	0
NVG1650	Acute pyelonephritis	Acute pyelonephritis	Diagnosis	1	1
NVG1352	Acute respiratory distress syndrome	Acute respiratory	Diagnosis	1	1

		distress syndrome			
NVG3900	Moderate or severe valve regurgitation	Moderate or severe valve regurgitation	Images/EKG	1	1
NVG0666	APACHE II	APACHE	Prognosis	1	0
NVG0988	APACHE II	APACHE	Prognosis	1	0
NVG1047	Apache II	APACHE	Prognosis	1	0
NVG1521	APACHE II	APACHE	Prognosis	1	0
NVG1562	APACHE II	APACHE	Prognosis	1	0
NVG1620	APACHE II	APACHE	Prognosis	1	0
NVG1719	APACHE II	APACHE	Prognosis	1	0
NVG2909	APACHE II	APACHE	Prognosis	1	0
NVG1753	Apache II	APACHE	Prognosis	1	0
NVG3388	APACHE II score	APACHE	Prognosis	1	0
NVG0989	APACHE IV	APACHE	Prognosis	1	0
NVG3304	APACHE score	APACHE	Prognosis	1	0
NVG4736	APACHE-II	APACHE	Prognosis	1	0
NVG4382	APACHE-III score	APACHE	Prognosis	1	0
NVG1094	ATLAS score	ATLAS score	Prognosis	1	1
NVG0174	Severe C. difficile infection	Clostridium difficile infection severity	Prognosis	1	0
NVG1095	Severe C. difficile infection (SHEA guidelines)	Clostridium difficile infection severity	Prognosis	1	0
NVG0316	Severe colitis	Clostridium difficile infection severity	Prognosis	1	0
NVG1096	Severe complicated C. difficile infection (SHEA guideline)	Clostridium difficile infection severity	Prognosis	1	0
NVG3103	Clostridium difficile infection severity	Clostridium difficile	Prognosis	1	0

		infection severity			
NVG4738	CURB-65 risk score 3±5	CURB-65 risk score	Prognosis	1	0
NVG2886	Disease severity (Mild, Moderate, Severe)	Disease severity	Prognosis	1	0
NVG2887	Disease severity (Mild, Moderate, Severe)	Disease severity	Prognosis	1	0
NVG2888	Disease severity (Mild, Moderate, Severe)	Disease severity	Prognosis	1	0
NVG1247	Mild illness	Disease severity	Prognosis	1	0
NVG1293	Nonsevere disease	Disease severity	Prognosis	1	0
NVG0676	PRISM (Pediatric Risk Mortality score) III score	Disease severity	Prognosis	1	0
NVG2335	Clinical Disease severity score	Disease severity	Prognosis	1	0
NVG4188	Clinical severity	Disease severity	Prognosis	1	0
NVG1233	Grade of severity of Foot and Mouth Disease (1 to 4)	Disease severity	Prognosis	1	0
NVG3076	Infection intensity	Disease severity	Prognosis	1	0
NVG4284	Disease stage	Disease stage	Prognosis	1	0
NVG0619	Infection severity (CLIF-SOFA score)	Infection severity	Prognosis	1	0
NVG0611	MELD index	MELD index	Prognosis	1	0
NVG3754	Mild-to-moderate COPD	Mild-to-moderate disease	Prognosis	1	0
NVG1726	Moderate-severe renal dysfunction	Moderate-severe renal dysfunction	Prognosis	1	0
NVG1754	MODS score	MODS score	Prognosis	1	0
NVG0227	Pitt bacteremia score on day 1 of bacteremia	Pitt score	Prognosis	1	0
NVG1721	Pitt score	Pitt score	Prognosis	1	0
NVG4048	Community-acquired pneumonia PSI class I	PSI class	Prognosis	1	0
NVG4049	Community-acquired pneumonia PSI class	PSI class	Prognosis	1	0

	II				
NVG4050	Community-acquired pneumonia PSI class III	PSI class	Prognosis	1	0
NVG4051	Community-acquired pneumonia PSI class IV	PSI class	Prognosis	1	0
NVG4052	Community-acquired pneumonia PSI class V	PSI class	Prognosis	1	0
NVG3761	Modified ATS criteria for severe CABP	PSI class	Prognosis	1	0
NVG3758	PSI class (II, III, IV)	PSI class	Prognosis	1	0
NVG3759	PSI class (II, III, IV)	PSI class	Prognosis	1	0
NVG3760	PSI class (II, III, IV)	PSI class	Prognosis	1	0
NVG4737	PSI risk class IV-V	PSI class	Prognosis	1	0
NVG3756	PSI score	PSI class	Prognosis	1	0
NVG1717	qSOFA score ≥ 2	qSOFA score	Prognosis	1	0
NVG1509	q<SOFA	qSOFA score	Prognosis	1	0
NVG1028	qSOFA score	qSOFA score	Prognosis	1	0
NVG0990	SAPS II	SAPS II score	Prognosis	1	0
NVG1522	SAPS II	SAPS II score	Prognosis	1	0
NVG1621	SAPS II	SAPS II score	Prognosis	1	0
NVG3870	SAPS II	SAPS II score	Prognosis	1	0
NVG4115	SAPS II	SAPS II score	Prognosis	1	0
NVG3303	SAPSII score	SAPS II score	Prognosis	1	0
NVG3707	Simplified Acute Physiology score II	SAPS II score	Prognosis	1	0
NVG1294	Severe disease	Severe disease	Prognosis	1	0
NVG1248	Severe illness (if they had any complications)	Severe illness	Prognosis	1	0
NVG1561	SOFA	SOFA score	Prognosis	1	0

NVG1622	SOFA	SOFA score	Prognosis	1	0
NVG1111	SOFA score	SOFA score	Prognosis	1	0
NVG2408	SOFA score	SOFA score	Prognosis	1	0
NVG2984	SOFA score	SOFA score	Prognosis	1	0
NVG3708	SOFA score	SOFA score	Prognosis	1	0
NVG3871	SOFA score	SOFA score	Prognosis	1	0
NVG4116	SOFA score	SOFA score	Prognosis	1	0
NVG4383	SOFA score	SOFA score	Prognosis	1	0
NVG1030	Tokyo Guideline grade	Tokyo Guideline grade	Prognosis	1	0
NVG0032	Baseline pain score	Pain score	Clinical manifestations	1	1
NVG1786	incisional pain (Visual Analogue Scale 0-10).	Pain score	Clinical manifestations	1	1
NVG3731	Numbness VAS (visual analogue scale) score	Pain score	clinical manifestations	1	1
NVG3732	Pain VAS (visual analogue scale) score	Pain score	clinical manifestations	1	1
NVG1769	Visual Analog Scale for pain	Pain Visual Analogue Scale	Clinical manifestations	1	1
NVG3465	Composite symptoms score	Composite symptoms score	Prognosis	1	0
NVG4290	Grade	Grade	Prognosis	1	0
NVG3680	Atrophy at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Grade of atrophy	Other	1	0
NVG3681	Atrophy at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Grade of atrophy	Other	1	0
NVG3682	Atrophy at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Grade of atrophy	Other	1	0
NVG3683	Atrophy at corpus lesser curvature (Absent, Mild, Moderate, Marked)	Grade of atrophy	Other	1	0

NVG3980	Karnofsky performance	Karnofsky score	Prognosis	0	2
NVG2760	Karnofsky score	Karnofsky score	Prognosis	0	2
NVG3457	Karnofsky score	Karnofsky score	Prognosis	0	2
NVG0777	Age-adjusted Charlson index	Age-adjusted Charlson index	Prognosis	1	0
NVG4096	Apgar score at 1 min	Apgar score at 1 min	Prognosis	1	0
NVG0656	Charlson	Charlson index	Prognosis	1	0
NVG0305	Charlson	Charlson index	Prognosis	1	0
NVG0190	Charlson comorbidity index	Charlson index	Prognosis	1	0
NVG1541	Charlson Comorbidity Index	Charlson index	Prognosis	1	0
NVG1560	Charlson Comorbidity Index	Charlson index	Prognosis	1	0
NVG1720	Charlson Comorbidity Index	Charlson index	Prognosis	1	0
NVG2409	Charlson comorbidity index	Charlson index	Prognosis	1	0
NVG4381	Charlson comorbidity index	Charlson index	Prognosis	1	0
NVG0351	Charlson comorbidity index ≥ 3	Charlson index	Prognosis	1	0
NVG1660	Charlson Comorbidity Index score	Charlson index	Prognosis	1	0
NVG0179	Charlson index	Charlson index	Prognosis	1	0
NVG0617	Charlson index	Charlson index	Prognosis	1	0
NVG0705	Charlson index	Charlson index	Prognosis	1	0
NVG1046	Charlson Index	Charlson index	Prognosis	1	0
NVG1076	Charlson Index	Charlson index	Prognosis	1	0
NVG1108	Charlson index	Charlson index	Prognosis	1	0
NVG2968	Charlson score	Charlson index	Prognosis	1	0
NVG0069	Charlson score	Charlson index	Prognosis	1	0
NVG0493	Comorbidity scored	Charlson index	Prognosis	1	0
NVG0070	Mean Charlson score	Charlson index	Prognosis	1	0

NVG0247	Disease status:	Disease stage	Prognosis	1	0
NVG1574	Intravenous fluid loading per weight (mL/kg)	Intravenous fluid loading per weight	Treatment	1	0
NVG4395	Total crystalloid in 24 hours (Total crystalloid	Treatment	1	1
NVG4396	Total crystalloid in ICU stay	Total crystalloid	Treatment	1	0
NVG2800	Total volume administred	Total volume administred	Treatment	1	1
NVG4488	Concordant antibiotic therapy	Concordant antibiotic therapy	Treatment	1	1
NVG4489	Non-concordant antibiotic therapy	Non-concordant antibiotic therapy	treatment	1	0
NVG0168	Standard of care (SOC) antibiotic	Standard of care antibiotic	Treatment	1	0
NVG1121	Appropriate empiric therapy	Appropriate empiric therapy	Treatment	1	0
NVG1733	Appropriate empirical antibiotic	Appropriate empiric therapy	Treatment	1	0
NVG3007	Appropriate empirical antibiotic treatment within 2 days	Appropriate empiric therapy	Treatment	1	0
NVG0622	Inadequete empirical antibiotic treatment <6h	Inadequete empirical antibiotic treatment <6h	Treatment	1	0
NVG0672	Empiric treatment	Empiric treatment	Treatment	1	0
NVG4487	Empirical antibiotic treatment	Empiric treatment	Treatment	1	0
NVG1732	Empirical antibiotic: Other	Empiric treatment	Treatment	1	0
NVG1027	Empirical antimicrobials covering causative microorganism	Empirical antimicrobials covering causative microorganism	Treatment	1	0

NVG0846	Adequate antifungal therapy	Adequate antifungal therapy	Treatment	1	0
NVG0621	Adequate empirical antibiotic treatment <6h	Adequate empirical antibiotic treatment <6h	Treatment	1	0
NVG3009	Modification of assigned regimen in first 5 days	Modification of assigned regimen in first 5 days	Treatment	1	0
NVG1610	MRSA receiving appropriate empirical therapy	MRSA receiving appropriate empirical therapy	Treatment	1	0
NVG1611	MSSA receiving appropriate empirical therapy	MSSA receiving appropriate empirical therapy	Treatment	1	0
NVG1612	MSSA receiving empirical beta-lactam therapy	MSSA receiving empirical beta-lactam therapy	Treatment	1	0
NVG3004	Receipt of additional antimicrobials permitted by protocol (Glycopeptide or daptomycin, Other antibacterial, Antifungal)	Receipt of additional antimicrobials permitted by protocol	Treatment	1	1
NVG3005	Receipt of additional antimicrobials permitted by protocol (Glycopeptide or daptomycin, Other antibacterial, Antifungal)	Receipt of additional antimicrobials permitted by protocol	Treatment	1	1
NVG3006	Receipt of additional antimicrobials permitted by protocol (Glycopeptide or daptomycin, Other antibacterial, Antifungal)	Receipt of additional antimicrobials permitted by protocol	Treatment	1	1

NVG4664	Treatment condition (Incomplete treatment or Complete treatment)	Treatment condition	Treatment	1	0
NVG4665	Treatment condition (Incomplete treatment or Complete treatment)	Treatment condition	Treatment	1	0
NVG4641	Treatment modified	Treatment modified	Treatment	1	0
NVG1609	Patients with S aureus receiving appropriate empirical antibiotic therapy	S. aureus receiving appropriate empirical therapy	treatment	1	0
NVG1390	Drug toxicity	Drug toxicity	Treatment	1	0
NVG2834	Drug Use	Drug Use	Treatment	1	0
NVG2351	Use of drugs in past 6 months	Drug Use	Treatment	1	0
NVG4117	Exposure to nephrotoxic agent	Exposure to nephrotoxic agent	Comorbidities	1	0
NVG3053	QT-prolonging drugs	QT-prolonging drugs	Treatment	1	0
NVG3011	Receipt of nephrotoxic medications during treatment	Receipt of nephrotoxic medications during treatment	Treatment	1	0
NVG3216	General anaesthesia	General anaesthesia	Treatment	1	1
NVG3217	Nerve block anaesthesia	Nerve block anaesthesia	Treatment	1	0
NVG3219	Spinal anaesthesia	Spinal anaesthesia	Treatment	1	1
NVG3291	Epidural	Epidural anaesthesia	Treatment	1	1
NVG3218	Epidural anaesthesia	Epidural anaesthesia	Treatment	1	1
NVG2930	Concomitant aminoglycoside use (None, >0 to ≤72 h, >72 h)	Concomitant aminoglycoside use	Treatment	1	0

NVG2931	Concomitant aminoglycoside use (None, >0 to ≤72 h, >72 h)	Concomitant aminoglycoside use	Treatment	1	0
NVG2932	Concomitant aminoglycoside use (None, >0 to ≤72 h, >72 h)	Concomitant aminoglycoside use	Treatment	1	0
NVG0105	Concomitant aztreonam use	Concomitant aztreonam use	Treatment	1	1
NVG1730	β-lactam/ β-lactamase inhibitor	β-lactam/ β-lactamase inhibitor	Treatment	1	0
NVG1731	Carbapenem	Carbapenem	Treatment	1	1
NVG0373	CAZ-AVI combined with carbapenems	CAZ-AVI combined with carbapenems	Treatment	1	0
NVG0372	CAZ-AVI combined with noncarbapenem drugs	CAZ-AVI combined with noncarbapenem drugs	Treatment	1	0
NVG1052	colistin empirical treatment	Colistin empirical treatment	Treatment	1	1
NVG1053	colistin inhaled therapy	Colistin inhaled therapy	Treatment	1	1
NVG0268	Dapsone	Dapsone	Treatment	1	1
NVG1673	Meropenem	Meropenem	Treatment	1	1
NVG0106	Concomitant metronidazole use	Concomitant metronidazole use	Treatment	1	1
NVG4571	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1

NVG4572	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1
NVG4573	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1
NVG4574	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1
NVG4575	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1
NVG4576	Antibiotic treatment given (Penicillin	Antibiotic treatment	Treatment	1	1

	Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)				
NVG4577	Antibiotic treatment given (Penicillin Cotrimoxazole Chloramphenicol Gentamicin Ampicillin/Amoxicillin Erythromycin Cephalosporins)	Antibiotic treatment	Treatment	1	1
NVG3762	Antibiotics before randomization	Antibiotic treatment	Treatment	1	1
NVG0970	Antibiotics in Emergency Department because of SIRS	Antibiotic treatment	Treatment	1	0
NVG3719	Antimicrobial therapy	Antibiotic treatment	Treatment	1	0
NVG3496	Antimicrobial therapy received	Antibiotic treatment	Treatment	1	0
NVG4525	Antibiotics use in last month	Antibiotic use	Treatment	1	0
NVG4352	antimicrobial therapy within 6 months prior to detection of MDR-GNB (ureido- penicillins cephalosporins, 3rd generation carbapenems fluoroquinolones)	Antibiotic use	Treatment	1	0
NVG4353	antimicrobial therapy within 6 months prior to detection of MDR-GNB (ureido- penicillins cephalosporins, 3rd generation	Antibiotic use	Treatment	1	0

	carbapenems fluoroquinolones)				
NVG4354	antimicrobial therapy within 6 months prior to detection of MDR-GNB (ureido- penicillins cephalosporins, 3rd generation carbapenems fluoroquinolones)	Antibiotic use	Treatment	1	0
NVG4355	antimicrobial therapy within 6 months prior to detection of MDR-GNB (ureido- penicillins cephalosporins, 3rd generation carbapenems fluoroquinolones)	Antibiotic use	Treatment	1	0
NVG1672	Piperacillin-tazobactam	Piperacillin- tazobactam	Treatment	1	1
NVG1845	Combination Therapy regimen (NNRTI, PI, INSTI, multiple)	Combination Therapy regimen	Treatment	1	0
NVG1846	Combination Therapy regimen (NNRTI, PI, INSTI, multiple)	Combination Therapy regimen	Treatment	1	0
NVG1847	Combination Therapy regimen (NNRTI, PI, INSTI, multiple)	Combination Therapy regimen	Treatment	1	0
NVG1848	Combination Therapy regimen (NNRTI, PI, INSTI, multiple)	Combination Therapy regimen	Treatment	1	0
NVG0270	Trimethoprim-sulfamethoxazole	Trimethoprim- sulfamethoxazole	Treatment	1	1
NVG0262	Fluconazole	Fluconazole	Treatment	1	1
NVG0261	Micafungin	Micafungin	Microbiology/serology	1	1
NVG3341	Antifungal treatment	Antifungal treatment	Treatment	1	0

NVG0263	Posaconazole	Posaconazole	Treatment	1	1
NVG0264	Voriconazole	Voriconazole	Treatment	1	1
NVG0950	Current use of antibiotics	Current use of antibiotics	Comorbidities	1	1
NVG4180	Pre-admission antibiotic	Pre-admission antibiotic	Treatment	1	0
NVG1531	Antibiotic at ICU admission	Antibiotic at ICU admission	Treatment	1	0
NVG3390	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3391	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3392	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3393	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3394	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3395	Therapy at baseline (Mechanical	Therapy at baseline	Treatment	1	1

	ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)				
NVG3396	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG3397	Therapy at baseline (Mechanical ventilation, Norepinephrine, Vasopressin, Epinephrine, Other, Antimicrobial agent, Renal-replacement therapy)	Therapy at baseline	Treatment	1	1
NVG2637	Maintenance Therapy after auto-HSCT (Rituximab Brentuximab vedotin Lenalidomide Bortezomib)	Maintenance Therapy after auto-HSCT	Treatment	1	1
NVG2638	Maintenance Therapy after auto-HSCT (Rituximab Brentuximab vedotin Lenalidomide Bortezomib)	Maintenance Therapy after auto-HSCT	Treatment	1	1
NVG2639	Maintenance Therapy after auto-HSCT (Rituximab Brentuximab vedotin Lenalidomide Bortezomib)	Maintenance Therapy after auto-HSCT	Treatment	1	1
NVG2640	Maintenance Therapy after auto-HSCT (Rituximab Brentuximab vedotin Lenalidomide Bortezomib)	Maintenance Therapy after auto-HSCT	Treatment	1	1
NVG0045	Post-MDA treatment of returning residents	Post-MDA treatment of returning residents	treatment	1	1
NVG2278	Preadmission treatment with antibiotics	Preadmission treatment with antibiotics	Treatment	1	0
NVG1546	Antibiotic therapy in the past year	Use of antibiotics	Treatment	1	0

NVG2057	reported antibiotic use within past 2w	Use of antibiotics	Treatment	1	0
NVG0737	Use of antibiotics	Use of antibiotics	Treatment	1	0
NVG3106	Use of antibiotics	Use of antibiotics	Treatment	1	0
NVG3050	Previous treatment history	Previous treatment history	Comorbidities	1	0
NVG0659	Prior IV antibiotic use within 3 months	Prior IV antibiotic use within 3 months	Microbiology/serology	1	0
NVG2424	Long term antibiotics (>4 weeks)	Long term antibiotics	Treatment	1	0
NVG2425	Long term macrolids	Long term antibiotics	Treatment	1	0
NVG4711	Previous antibiotics	Previous antibiotics	Treatment	1	0
NVG0721	Prior antibiotic therapy	Previous antibiotics	Treatment	1	0
NVG0031	Prior antibiotic use	Previous antibiotics	Treatment	1	0
NVG2895	Previous antimicrobial medication status (No, Treatment of UTI, Prophylaxis for UTI, Treatment of other infection, Surgical prophylaxis)	Previous antimicrobial medication status	Treatment	1	0
NVG2897	Previous antimicrobial medication status (No, Treatment of UTI, Prophylaxis for UTI, Treatment of other infection, Surgical prophylaxis)	Previous antimicrobial medication status	Treatment	1	0
NVG2898	Previous antimicrobial medication status (No, Treatment of UTI, Prophylaxis for UTI, Treatment of other infection, Surgical prophylaxis)	Previous antimicrobial medication status	Treatment	1	0
NVG2899	Previous antimicrobial medication status (No, Treatment of UTI, Prophylaxis for UTI, Treatment of other infection, Surgical prophylaxis)	Previous antimicrobial medication status	Treatment	1	0

NVG0827	Previous cephalosporins	Previous cephalosporins	Treatment	1	0
NVG3620	Previous HCV treatment (Interferon-based, Sofosbuvir-based)	Previous HCV treatment	Treatment	1	1
NVG3621	Previous HCV treatment (Interferon-based, Sofosbuvir-based)	Previous HCV treatment	Treatment	1	1
NVG0826	Previous other-than cephalosporin antibacterials	Previous other-than cephalosporin antibacterials	Treatment	1	0
NVG2926	Previous systemic antibiotic use (nones, ≤ 24 h, >24 to ≤ 48 h)	Previous systemic antibiotic use	Treatment	1	0
NVG2927	Previous systemic antibiotic use (nones, ≤ 24 h, >24 to ≤ 48 h)	Previous systemic antibiotic use	Treatment	1	0
NVG2928	Previous systemic antibiotic use (nones, ≤ 24 h, >24 to ≤ 48 h)	Previous systemic antibiotic use	Treatment	1	0
NVG0543	Prior treatment regimens	Prior treatment regimens	Treatment	1	1
NVG0828	Previous antifungals	Previous antifungals	Treatment	1	0
NVG3618	No previous HCV treatment	No previous HCV treatment	treatment	1	0
NVG0743	Antibiotic exposure	Antibiotic exposure	Treatment	1	0
NVG3292	Antibiotic pre-procedural	Antibiotic pre-procedural	Treatment	1	0
NVG0370	Antibiotic regimens prior to CAZ-AVI salvage therapy	Antibiotic regimens prior to CAZ-AVI salvage therapy	Treatment	1	1
NVG0409	exposure to antibiotics in the past 30 days	Exposure to antibiotics in the past 30 days	Treatment	1	0

NVG1190	Receipt of systemic antibiotics within 14 d before first culture positive	Receipt of systemic antibiotics within 14 d before first culture positive	Treatment	1	0
NVG1189	Receipt of systemic antifungal medication within 90 d before first culture positive	Receipt of systemic antifungal medication within 90 d before first culture positive	Treatment	1	0
NVG0046	Received 1 round of treatment	Received 1 round of treatment	Treatment	1	0
NVG2549	Received antimalarials in past 14 days	Received antimalarials in past 14 days	Treatment	1	0
NVG2215	Treatment naive	Treatment naive	Treatment	1	0
NVG4543	Treatment Naive	Treatment naive	Treatment	1	0
NVG3083	Active antibiotics on day 0	Active antibiotics on day 0	Treatment	1	1
NVG0429	Older regimen	Older regimen	other	1	0
NVG2758	Previous TB tratment	Previous TB tratment	Treatment	1	0
NVG2851	Previous TBC treatment with firts line drug	Previous TB tratment	Treatment	1	0
NVG2852	Previosu TBC treatment with second line drug	Previous TBC treatment with second line drug	Treatment	1	0
NVG0267	Atovaquone	Atovaquone	Treatment	1	1
NVG0269	Pentamidine	Pentamidine	treatment	1	1
NVG4244	Single treatment for clinical scabies signs	Single treatment for clinical scabies signs	Treatment	1	1
NVG0568	Retention in ART care prior to presentation	Retention in ART care prior to presentation	Demographics	1	0

NVG0567	Available ART visit-level records	Available ART visit-level records	Other	1	1
NVG0332	Anchor ARV Agent (Raltegravir (BID) Dolutegravir (QD or BID) Rilpivirine (QD) Elvitegravir/cobicistat (QD))	Anchor ARV Agent	Treatment	1	1
NVG0332	Anchor ARV Agent (Raltegravir (BID) Dolutegravir (QD or BID) Rilpivirine (QD) Elvitegravir/cobicistat (QD))	Anchor ARV Agent	Treatment	1	1
NVG0332	Anchor ARV Agent (Raltegravir (BID) Dolutegravir (QD or BID) Rilpivirine (QD) Elvitegravir/cobicistat (QD))	Anchor ARV Agent	Treatment	1	1
NVG0332	Anchor ARV Agent (Raltegravir (BID) Dolutegravir (QD or BID) Rilpivirine (QD) Elvitegravir/cobicistat (QD))	Anchor ARV Agent	Treatment	1	1
NVG0332	Anchor ARV Agent (Raltegravir (BID) Dolutegravir (QD or BID) Rilpivirine (QD) Elvitegravir/cobicistat (QD))	Anchor ARV Agent	Treatment	1	1
NVG3811	Antiretroviral therapy (Efavirenz-based regimen, Nevirapine-based regimen, Other, None)	Antiretroviral therapy	Treatment	1	1
NVG3812	Antiretroviral therapy (Efavirenz-based regimen, Nevirapine-based regimen, Other, None)	Antiretroviral therapy	Treatment	1	1
NVG3813	Antiretroviral therapy (Efavirenz-based	Antiretroviral therapy	Treatment	1	1

	regimen, Nevirapine-based regimen, Other, None)				
NVG3814	Antiretroviral therapy (Efavirenz-based regimen, Nevirapine-based regimen, Other, None)	Antiretroviral therapy	Treatment	1	1
NVG3417	Antiretroviral treatment	Antiretroviral therapy	Treatment	1	1
NVG4270	Antiretroviral treatment	Antiretroviral therapy	Treatment	1	1
NVG4446	Antiretroviral treatment (%)	Antiretroviral therapy	Treatment	1	1
NVG0458	ART regimen	ART regimen	Treatment	1	1
NVG2242	Prescribed TAR	ART regimen	Treatment	1	0
NVG2380	ART status (Currently on ART Previously on ART ART naive)	ART status	Treatment	1	1
NVG2381	ART status (Currently on ART Previously on ART ART naive)	ART status	Treatment	1	1
NVG2382	ART status (Currently on ART Previously on ART ART naive)	ART status	Treatment	1	1
NVG2747	ART status (never, currently taking, interrupted)	ART status	Treatment	1	1
NVG2748	ART status (never, currently taking, interrupted)	ART status	Treatment	1	1
NVG2749	ART status (never, currently taking, interrupted)	ART status	Treatment	1	1
NVG2563	Baseline ART third-agent class (NNRTI vs PI vs INSTI)	Baseline ART third-agent class	Treatment	1	0
NVG2563	Baseline ART third-agent class (NNRTI vs PI vs INSTI)	Baseline ART third-agent class	Treatment	1	0
NVG2563	Baseline ART third-agent class (NNRTI vs PI vs INSTI)	Baseline ART third-agent class	Treatment	1	0
NVG0424	cART regimen at HCV treatment initiation	cART regimen at HCV	Treatment	1	1

		treatment initiation			
NVG0428	Currently used direct-acting antiviral regimen	Currently used direct-acting antiviral regimen	Treatment	1	1
NVG0423	Ever used cART	Ever used cART	Treatment	1	0
NVG2562	Most common ART at screening: Tenofovir DF vs Emtricitabine	Most common ART at screening	Treatment	1	0
NVG0333	N(t)RTI backbone agent	N(t)RTI backbone agent	Treatment	1	1
NVG0331	No antiretroviral therapy	No antiretroviral therapy	treatment	1	0
NVG3060	NRTI exposure	NRTI exposure	Treatment	1	0
NVG3942	Number of Ant-iretroviral medications	Number of Ant-iretroviral medications	treatment	1	0
NVG3629	Raltegravir-containing ART	Raltegravir-containing ART	Treatment	1	1
NVG3631	Rilpivirine-containing ART	Rilpivirine-containing ART	Treatment	1	1
NVG2241	TAR naive	TAR naive	Treatment	1	0
NVG3630	Dolutegravir-containing ART	Dolutegravir-containing ART	Treatment	1	0
NVG3693	Tuberculosis treatment (New case, Retreatment, Missing data)	Tuberculosis treatment	Treatment	1	0
NVG3694	Tuberculosis treatment (New case, Retreatment, Missing data)	Tuberculosis treatment	Treatment	1	0
NVG3695	Tuberculosis treatment (New case, Retreatment, Missing data)	Tuberculosis treatment	Treatment	1	0
NVG0273	Acyclovir	Acyclovir	Treatment	1	1

NVG0327	HCV treatment-experienced	HCV treatment-experienced	Treatment	1	0
NVG0326	HCV treatment-naive	HCV treatment-naive	Treatment	1	0
NVG2280	preadmission treatment with antiviral	preadmission treatment with antiviral	Treatment	1	0
NVG2198	Prior HBV therapy	Prior HBV therapy	Treatment	1	0
NVG0248	Prior lines of therapy	Prior lines of therapy	Treatment	1	0
NVG0274	Famciclovir	Famciclovir	Treatment	1	1
NVG4100	Hepatitis B immune globulin administered	Hepatitis B immune globulin administered	Treatment	1	1
NVG2073	Receiving HCV treatment	Receiving HCV treatment	Treatment	1	0
NVG0275	Valacyclovir	Valacyclovir	Treatment	1	1
NVG0276	Valganciclovir	Valganciclovir	Treatment	1	1
NVG0361	Bladder catheter	Bladder catheter	Other	1	1
NVG3020	Route of clean intermittent catheterization	Type of clean intermittent catheterization	Treatment	1	0
NVG3018	Type of clean intermittent catheterization	Type of clean intermittent catheterization	Treatment	1	1
NVG4370	long-term Foley urine catheter	long-term Foley urine catheter	Comorbidities	1	1
NVG0745	Urinary catheter	Urinary catheter	Treatment	1	1
NVG2901	Urinary catheter	Urinary catheter	Treatment	1	1
NVG2990	Urinary catheter	Urinary catheter	Treatment	1	1
NVG3494	Urinary catheter	Urinary catheter	Treatment	1	1

NVG1725	Urinary catheter/ nephrostomy	Urinary catheter	Treatment	1	1
NVG2988	Arterial line	Arterial line	Treatment	1	1
NVG0733	Central vascular catheter (at infection onset)	Central venous catheter	Treatment	1	0
NVG0360	Central venous catheter	Central venous catheter	Treatment	1	1
NVG1118	central venous catheter	Central venous catheter	Treatment	1	1
NVG1724	Central venous catheter	Central venous catheter	Treatment	1	1
NVG2989	Central venous catheter	Central venous catheter	Treatment	1	1
NVG1187	Central venous catheter within 7 d before first positive culture	Central venous catheter	Treatment	1	0
NVG1569	Central Venous pressure	Central venous catheter	Treatment	1	1
NVG3400	Central venous pressure	Central venous catheter	Treatment	1	1
NVG0822	CVC	Central venous catheter	Treatment	1	1
NVG3493	Number of central catheter	Number of central catheter	treatment	1	0
NVG3022	Hydrophilic-coated catheter used	Hydrophilic-coated catheter used	Treatment	1	0
NVG3021	Type of catheter used	Type of catheter used	Treatment	1	1
NVG0830	Chemotherapy	Chemotherapy	Treatment	1	0
NVG2623	Chemotherapy	Chemotherapy	Treatment	1	0
NVG0237	Chemotherapy within 6 mo	Chemotherapy	Treatment	1	0

NVG0662	Prior chemotherapy	Prior chemotherapy	Treatment	1	0
NVG1021	Use of chemotherapy	Use of chemotherapy	Treatment	1	0
NVG0546	Fludarabine before ibrutinib	Fludarabine before ibrutinib	Treatment	1	0
NVG0378	Induction therapy	Induction therapy	Treatment	1	0
NVG1920	Day 7 Area under the plasma concentration-time curve during 24h	Day 7 Area under the plasma concentration-time curve during 24h	Treatment	1	0
NVG0857	Pre-transplant corticosteroid therapy	Pre-transplant corticosteroid therapy	Comorbidities	1	0
NVG0712	Corticosteroid therapy	Corticosteroids	Treatment	1	1
NVG0829	Corticosteroids	Corticosteroids	Treatment	1	1
NVG1105	corticosteroids	Corticosteroids	Treatment	1	1
NVG1256	Corticosteroids	Corticosteroids	Treatment	1	1
NVG0949	Steroids	Corticosteroids	Treatment	1	0
NVG3734	Daily dose of prednisolone	Daily dose of prednisolone	Treatment	1	1
NVG1648	Exposure to systemic steroid	Exposure to systemic steroid	Treatment	1	0
NVG2279	Preadmission treatment with corticoids	Preadmission treatment with corticoids	Treatment	1	0
NVG4714	Previous inhaled corticosteroids	Previous inhaled corticosteroids	Treatment	1	0
NVG1019	Use of corticosteroids	Use of corticosteroids	Treatment	1	0
NVG0554	Corticosteroid use	Use of corticosteroids	Treatment	1	1
NVG3261	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids,	Conditions or therapies affecting	Comorbidities	1	1

	Systemic corticosteroids, Nutritional problems, Other	immunity			
NVG3262	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids, Systemic corticosteroids, Nutritional problems, Other	Conditions or therapies affecting immunity	Comorbidities	1	1
NVG3263	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids, Systemic corticosteroids, Nutritional problems, Other	Conditions or therapies affecting immunity	Comorbidities	1	1
NVG3264	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids, Systemic corticosteroids, Nutritional problems, Other	Conditions or therapies affecting immunity	Comorbidities	1	1
NVG3265	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids, Systemic corticosteroids, Nutritional problems, Other	Conditions or therapies affecting immunity	Comorbidities	1	1
NVG3266	Conditions or therapies affecting immunity (Cancer, Diabetes, Topical corticosteroids, Systemic corticosteroids, Nutritional problems, Other	Conditions or therapies affecting immunity	Comorbidities	1	1
NVG2975	Immune suppressive therapy	Immune suppressive therapy	Treatment	1	0
NVG4359	immunosuppressive drugs	Immune suppressive therapy	Treatment	1	0
NVG3273	Immunosuppressive medication	Immune suppressive therapy	Treatment	1	0
NVG3153	Immunosuppressive drug use	Immune suppressive	Treatment	1	0

		therapy			
NVG0239	Immunomodulatory therapy or corticosteroids for ≥ 14 d	Immunomodulatory therapy or corticosteroids for ≥ 14 d	Treatment	1	0
NVG1020	Use of other immunosuppressive	Use of other immunosuppressive	Treatment	1	0
NVG1787	treatment costs	Treatment costs	Treatment	1	1
NVG3648	Ventricular assist device	Ventricular assist device	Treatment	1	1
NVG4232	Implantable defibrillator	Implantable defibrillator	Treatment	1	1
NVG3892	Pacemaker	Pacemaker	treatment	1	0
NVG4166	Pacemaker	Pacemaker	treatment	1	0
NVG1018	Existing stent in biliary tract	Existing stent in biliary tract	Treatment	1	0
NVG1188	Gastrostomy tube at time of diagnosis	Gastrostomy tube at time of diagnosis	Other	1	0
NVG0776	Gender	Gender	Other	1	1
NVG2857	Gender	Gender	Other	1	1
NVG4277	Gender	Gender	Other	1	1
NVG0359	Indwelling invasive devices	Indwelling invasive devices	Other	1	0
NVG0362	Nasogastric tube	Nasogastric tube	Treatment	1	1
NVG2991	Nasogastric tube	Nasogastric tube	treatment	1	1
NVG1606	Daptomycin dose	Dose	Treatment	1	1
NVG2592	dose	Dose	Treatment	1	1
NVG2712	dose	Dose	Treatment	1	1

NVG2778	Dose	Dose	Treatment	1	1
NVG3235	Dose	Dose	Treatment	1	1
NVG4073	Dose of trial drug	Dose	Treatment	1	1
NVG1921	dosis	Dose	Treatment	1	1
NVG1607	Vancomycin dose	Vancomycin dose	Treatment	1	1
NVG2801	infusion rate	Infusion rate	Treatment	1	1
NVG3010	Total cumulative colistin for patients alive on day 14	Total dose	Treatment	1	0
NVG2798	Total dose (5, 25 or 50mg/kg).	Total dose	Treatment	1	0
NVG1791	intervention (surgery vs antibiotic treatment)	Intervention	Treatment	1	0
NVG1792	intervention (surgery vs antibiotic treatment)	Intervention	Treatment	1	0
NVG0845	Therapeutic measures (less than 48 hours)	Therapeutic management	Treatment	1	0
NVG3454	Treatment (Rifapentine, Rifampin)	Treatment	Treatment	1	1
NVG3455	Treatment (Rifapentine, Rifampin)	Treatment	Treatment	1	1
NVG2204	Type of treatment (Entecavir vs Tenofovir)	Treatment	Treatment	1	1
NVG0427	Treatment	Treatment	Treatment	1	1
NVG1228	Treatment	Treatment	Treatment	1	1
NVG2593	treatment	Treatment	Treatment	1	1
NVG2713	treatment	Treatment	Treatment	1	1
NVG1817	Treatment (medication used: Ledipasvir, Sofosbuvir, Voxilaprevir)	Treatment	Treatment	1	1
NVG1818	Treatment (medication used: Ledipasvir, Sofosbuvir, Voxilaprevir)	Treatment	Treatment	1	1
NVG1819	Treatment (medication used: Ledipasvir, Sofosbuvir, Voxilaprevir)	Treatment	Treatment	1	1

NVG0547	Alemtuzumab before ibrutinib	Alemtuzumab before ibrutinib	Treatment	1	1
NVG0544	Ibrutinib as 1st-line treatment	Ibrutinib as 1st-line treatment	Treatment	1	0
NVG0542	Ibrutinib daily dose	Ibrutinib daily dose	Treatment	1	0
NVG0551	Ibrutinib monotherapy	Ibrutinib monotherapy	Treatment	1	0
NVG0545	Rituximab before ibrutinib	Rituximab before ibrutinib	Treatment	1	0
NVG0686	Reason for intubation (airway protection)	Procedure indication	Diagnosis	0	2
NVG0687	Reason for intubation (Altered level of consciousness)	Procedure indication	Diagnosis	0	2
NVG0688	Reason for intubation (cardiogenic shock or arrest)	Procedure indication	Diagnosis	0	2
NVG0689	Reason for intubation (respiratory failure)	Procedure indication	Diagnosis	0	2
NVG0690	Reason for intubation (Sepsis)	Procedure indication	Diagnosis	0	2
NVG0691	Reason for intubation (Surgery)	Procedure indication	Diagnosis	0	2
NVG3593	Risk factor as indication for treatment (HIV infection, Confirmed active tuberculosis in close contact, Confirmed active tuberculosis in casual contact,, Other immunosuppressive condition or therapy, Upper-lobe fibronodular disease with area ≥ 2 cm ²)	Risk factor as indication for treatment	Comorbidities	1	0
NVG3594	Risk factor as indication for treatment (HIV infection, Confirmed active tuberculosis in close contact, Confirmed active tuberculosis in casual contact,, Other immunosuppressive condition or therapy,	Risk factor as indication for treatment	Comorbidities	1	0

	Upper-lobe fibronodular disease with area ≥ 2 cm ²)				
NVG0977	Indication for gastroscopy: Gastric bleeding	Indication for gastroscopy	Diagnosis	1	1
NVG0976	Indication for gastroscopy: Gastro-esophageal reflux disease	Indication for gastroscopy	Diagnosis	1	1
NVG0978	Indication for gastroscopy: Irritable bowel Syndrome	Indication for gastroscopy	Diagnosis	1	1
NVG0975	Indication for gastroscopy: Screening/prevention	Indication for gastroscopy	Diagnosis	1	1
NVG0974	Indication for gastroscopy: Upper abdominal pain	Indication for gastroscopy	Diagnosis	1	1
NVG1646	Central venous–catheter ethanol or antibacterial lock therapy	Central venous–catheter ethanol or antibacterial lock therapy	Treatment	1	0
NVG0847	CVC removal	Central venous catheter removal	Treatment	1	1
NVG4171	ACE inhibitor	ACE inhibitor	Treatment	1	1
NVG4223	ACE inhibitor/AT blocker	ACE inhibitor	Treatment	1	1
NVG0952	Acetylsalicylic acid	Acetylsalicylic acid	Treatment	1	1
NVG4169	Amiodarone	Amiodarone	Treatment	1	1
NVG0951	Oral anticoagulants	Oral anticoagulants	treatment	1	1
NVG0053	Antithymocyte globulin within 6 months prior	Antithymocyte globulin within 6 months prior	Treatment	1	0
NVG1977	ATG induction	ATG induction	Treatment	1	1
NVG0539	Patients Treated With heptavalent botulinum antitoxin (HBAT)	Patients Treated With heptavalent	treatment	1	1

		botulinum antitoxin			
NVG4172	ARA	ARA	Treatment	1	1
NVG4170	Beta-blocker	Beta-blocker	Treatment	1	1
NVG4222	Beta-blocker	Beta-blocker	Treatment	1	1
NVG2283	effective contraceptive use	Effective contraceptive use	Treatment	1	0
NVG4168	Digoxin	Digoxin	Treatment	1	1
NVG4226	Digoxin	Digoxin	Treatment	1	1
NVG4167	Diuretic	Diuretics	Treatment	1	0
NVG4225	Diuretics	Diuretics	Treatment	1	0
NVG1645	Prophylactic G-CSF	Prophylactic G-CSF	Treatment	1	1
NVG0718	H2-blocker therapy	H2-blocker therapy	Treatment	1	0
NVG4227	Ivabradine	Ivabradine	Treatment	1	1
NVG4022	Home medications (Home oxygen Oral glucocorticoids Inhaled glucocorticoids Inhaled long-acting bronchodilators Leukotriene-receptor antagonists)	Home medications	Treatment	1	1
NVG4023	Home medications (Home oxygen Oral glucocorticoids Inhaled glucocorticoids Inhaled long-acting bronchodilators Leukotriene-receptor antagonists)	Home medications	Treatment	1	1
NVG4024	Home medications (Home oxygen Oral glucocorticoids Inhaled glucocorticoids Inhaled long-acting bronchodilators Leukotriene-receptor antagonists)	Home medications	Treatment	1	1

NVG4025	Home medications (Home oxygen Oral glucocorticoids Inhaled glucocorticoids Inhaled long-acting bronchodilators Leukotriene-receptor antagonists)	Home medications	Treatment	1	1
NVG4026	Home medications (Home oxygen Oral glucocorticoids Inhaled glucocorticoids Inhaled long-acting bronchodilators Leukotriene-receptor antagonists)	Home medications	Treatment	1	1
NVG0337	On opiate substitution therapy	Opioid substitution therapy	treatment	1	1
NVG2071	Opioid substitution therapy	Opioid substitution therapy	treatment	1	0
NVG3624	Stable opiate substitution therapy	Opioid substitution therapy	Treatment	1	1
NVG0643	Medications	Medications	Treatment	1	1
NVG2125	Medications: Daily use of NSAID	Medications	Treatment	1	1
NVG2126	Medications: Daily use of Other	Medications	Treatment	1	0
NVG2127	Medications:None	Medications	Treatment	1	0
NVG0334	Concomitant PPI use	Concomitant PPI use	Treatment	1	1
NVG3622	Concomitant proton-pump inhibitor	Concomitant proton-pump inhibitor	Treatment	1	1
NVG0717	Protons pump inhibitors	Protons pump inhibitors	Treatment	1	0
NVG0309	Use of proton pump inhibitor	Use of proton pump inhibitor	Treatment	1	0
NVG4224	Spironolactone	Spironolactone	Treatment	1	1

NVG3220	Thromboprophylaxis regimen	Thromboprophylaxis regimen	Treatment	1	0
NVG2189	Vit D supplementation	Vit D supplementation	Treatment	1	1
NVG4228	Warfarin	Warfarin	Treatment	1	1
NVG1474	lot number	lot number	Other	1	0
NVG2383	Currently on Medication-assisted treatment	Currently on Medication-assisted treatment	Treatment	1	1
NVG3221	Acetabulum bone graft	Other treatment	Other	0	2
NVG2225	Adherence to treatment (%)	Other treatment	Treatment	0	2
NVG3467	Time from symptom onset to treatment	Other treatment	Treatment	0	2
NVG0066	Placebo	Placebo	Other	1	0
NVG3214	Procedure	Procedure	Treatment	1	1
NVG4372	Long-term tracheostoma	Long-term tracheostoma	Comorbidities	1	1
NVG0692	Tracheostomy	Tracheostomy	Treatment	1	1
NVG1048	tracheostomy	Tracheostomy	Treatment	1	1
NVG0266	Anti-Pneumocystis prophylaxis	Anti-Pneumocystis prophylaxis	Treatment	1	1
NVG0271	Anti-Pneumocystis prophylaxis: None	Anti-Pneumocystis prophylaxis	Treatment	1	1
NVG0259	Antibacterial prophylaxis	Antibacterial prophylaxis	Treatment	1	0
NVG0260	Antifungal prophylaxis	Antifungal prophylaxis	Treatment	1	0
NVG0557	Antifungal prophylaxis	Antifungal prophylaxis	Treatment	1	0
NVG0555	Antimicrobial prophylaxis	Antimicrobial prophylaxis	Treatment	1	0
NVG0258	Antimicrobial prophylaxis before CTI:	Antimicrobial	Treatment	1	0

		prophylaxis			
NVG0272	Antiviral prophylaxis	Antiviral prophylaxis	Treatment	1	0
NVG0277	Antiviral prophylaxis: None	Antiviral prophylaxis	Treatment	1	0
NVG1978	CMV prophylaxis.	CMV prophylaxis.	Treatment	1	0
NVG0556	PJP prophylaxis	PJP prophylaxis	Treatment	1	0
NVG1483	Postexposure prophylaxis ever used	Postexposure prophylaxis	Treatment	1	0
NVG4456	Engaged in PrEP	PrEP	Treatment	1	1
NVG1484	Using PrEP at enrollment	PrEP at enrollment	Treatment	1	0
NVG4243	Preventive treatment only	Preventive treatment only	Treatment	1	0
NVG3052	Number of drugs in the regimen	Number of drugs in the regimen	treatment	1	0
NVG1122	Source control	Source control	Treatment	1	1
NVG0226	Inadequate source control during antibiotic course	Inadequate source control during antibiotic course	Diagnosis	1	0
NVG2977	Recent surgery	Recent surgery	Comorbidities	1	1
NVG1716	Surgery within past 14 d	Surgery within past 14 d	Comorbidities	1	0
NVG1584	Surgery within previous 30 d	Surgery within previous 30 d	Comorbidities	1	0
NVG0525	Surgical	Surgical	Other	1	1
NVG0811	Surgical	Surgical	Other	1	1
NVG1782	no surgical intervention	No surgical intervention	treatment	1	0
NVG1060	Operated joint (hip)	Operated joint	treatment	1	0
NVG0355	Surgery	Surgery	Treatment	1	1

NVG0824	Surgery	Surgery	Treatment	1	1
NVG1040	Surgery before bacteriemia	Surgery before bacteriemia	Treatment	1	1
NVG0802	Surgery indicated and performed	Surgery indicated and performed	Treatment	1	1
NVG0805	Surgery indicated and performed: Elective	Surgery indicated and performed	Treatment	1	1
NVG0803	Surgery indicated and performed: Emergent	Surgery indicated and performed	Treatment	1	1
NVG0804	Surgery indicated and performed: Urgent	Surgery indicated and performed	Treatment	1	1
NVG0806	Surgery indicated but not performed	Surgery indicated and performed	Treatment	1	1
NVG0801	Surgery not indicated, not performed	Surgery not indicated	Treatment	1	0
NVG3213	Surgical approach	Surgical approach	Treatment	1	1
NVG0363	Surgical drain	Surgical drain	Treatment	1	1
NVG0596	Surgery type	Surgical procedure	Treatment	1	1
NVG0732	Surgical procedure	Surgical procedure	Treatment	1	1
NVG3822	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery	Surgical procedure	Treatment	1	1

	for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed				
NVG3823	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed	Surgical procedure	Treatment	1	1
NVG3824	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not	Surgical procedure	Treatment	1	1

	performed				
NVG3825	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed	Surgical procedure	Treatment	1	1
NVG3826	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed	Surgical procedure	Treatment	1	1

NVG3827	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed	Surgical procedure	Treatment	1	1
NVG3828	Surgical procedure (No implant or device present; débridement of chronic osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed	Surgical procedure	Treatment	1	1
NVG3829	Surgical procedure (No implant or device present; débridement of chronic	Surgical procedure	Treatment	1	1

	osteomyelitis performed, No implant or device present; débridement of chronic osteomyelitis not performed, Débridement and implant retention, Removal of orthopedic device for infection, Prosthetic joint implant removed, Prosthetic joint implant, one-stage revision, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement performed, Surgery for diskitis, spinal osteomyelitis, or epidural abscess; débridement not performed				
NVG3350	Type of surgery (Manual vacuum aspiration, Suction curettage, Sharp curettage, No surgery)	Type of surgery	Treatment	1	1
NVG3351	Type of surgery (Manual vacuum aspiration, Suction curettage, Sharp curettage, No surgery)	Type of surgery	Treatment	1	1
NVG3352	Type of surgery (Manual vacuum aspiration, Suction curettage, Sharp curettage, No surgery)	Type of surgery	Treatment	1	1
NVG3353	Type of surgery (Manual vacuum aspiration, Suction curettage, Sharp curettage, No surgery)	Type of surgery	Treatment	1	1
NVG3901	Valve surgery during current disease course	Valve surgery during current disease course	Treatment	1	0
NVG0877	Duration	Duration	Other	1	0
NVG4279	Duration of admission	Duration	Other	1	1

NVG2035	Duration of data collection	Duration	Other	1	1
NVG2412	Hours of active antibiotic therapy before randomisation	Hours of active antibiotic therapy before randomisation	Other	1	0
NVG2750	Time on ART (years)	Duration of ART	Treatment	1	0
NVG0448	Time on ART at Pentamidine secondary prophylaxis start	Duration of ART	Treatment	1	0
NVG2561	Time since first ART until day 1 (months)	Duration of ART	Treatment	1	0
NVG2385	Time since ART initiation	Duration of ART	Treatment	1	0
NVG0459	Years since ART initiation	Duration of ART	Treatment	1	0
NVG2642	Actual duration of antiviral drug use after auto-HSCT.	Duration of therapy	Treatment	1	1
NVG0374	Days of CAZ-AVI treatment	Duration of therapy	Treatment	1	0
NVG1035	Duration of antibiotics	Duration of therapy	Treatment	1	0
NVG1843	Duration of ART	Duration of therapy	Treatment	1	0
NVG3058	Duration of follow-up on ART	Duration of therapy	Treatment	1	0
NVG0492	Duration of therapy	Duration of therapy	Treatment	1	0
NVG1123	Duration of therapy	Duration of therapy	Treatment	1	0
NVG3981	Duration of tuberculosis treatment before initiation of ART	Duration of tuberculosis treatment before initiation of ART	Treatment	1	0
NVG2799	Infusion time	Infusion time	Treatment	1	1
NVG0371	Days before CAZ-AVI treatment	Days before CAZ-AVI treatment	Treatment	1	0
NVG3347	Time between treatment and surgery	Time between treatment and surgery	Treatment	1	0
NVG1063	Time between urine sample and surgery	Time between urine	Treatment	1	0

		sample and surgery			
NVG4513	Median follow-up time	Median follow-up time	Other	1	0
NVG2315	Months follow-up	Months follow-up	Other	1	0
NVG4514	Total follow-up time (person years)	Total follow-up time	Other	1	0
NVG2626	Intended duration of antiviral prophylaxis (≤3 months, >3 to ≤6 months, Not reported)	Intended duration of antiviral prophylaxis	Treatment	1	0
NVG2627	Intended duration of antiviral prophylaxis (≤3 months, >3 to ≤6 months, Not reported)	Intended duration of antiviral prophylaxis	Treatment	1	0
NVG2628	Intended duration of antiviral prophylaxis (≤3 months, >3 to ≤6 months, Not reported)	Intended duration of antiviral prophylaxis	Treatment	1	0
NVG4639	Lost to treatment follow-up	Lost to treatment follow-up	Treatment	1	0
NVG0600	Procedure duration	Procedure duration	Treatment	1	0
NVG1649	Steroids for >5 days	Steroids for >5 days	Treatment	1	0
NVG2201	Treatment duration (months)	Treatment duration	Treatment	1	1
NVG2202	Consolidation (months)	Treatment duration	Treatment	1	0
NVG4101	Time from birth to HBV vaccine	Time from birth to HBV vaccine	Other	1	0
NVG0049	Time from transplantation to vaccination	Time from transplantation to vaccination	Other	1	0
NVG1575	Time from diagnosis of septic shock to antibiotics (h)	Time from diagnosis of septic shock to antibiotics	Treatment	1	0

NVG2051	Vaccine, mean duration of protection,	Vaccine, mean duration of protection	Other	1	0
NVG3641	Waiting-list time	Waiting-list time	Other	1	0
NVG3735	Treatment period with prednisolone before enrollment (years)	Treatment period with prednisolone before enrollment	Treatment	1	0
NVG0569	Months since ART initiation	Months since ART initiation	Other	1	0
NVG2305	post-vaccination year	Post-vaccination year	Other	1	0
NVG0385	Median year of starting cART	Median year of starting cART	Treatment	1	0
NVG3288	Procedure start-time	Procedure start-time	Treatment	1	0
NVG2179	time since vaccination	Time since vaccination	Other	1	0
NVG2192	timimng of Hep B vaccination (<24 h; 24-48; más de 48h).	Time since vaccination	Other	1	0
NVG0787	Days between first positive blood cultures and active antimicrobial therapy	Time to appropriate antibiotics	Treatment	1	0
NVG0788	Days between first positive blood cultures and targeted antimicrobial therapy	Time to appropriate antibiotics	Treatment	1	0
NVG1735	Time to appropriate antibiotics (h)	Time to appropriate antibiotics	Treatment	1	0
NVG1029	Time to drainage	Time to drainage	Treatment	1	0
NVG3481	Timing of regimen initiation	Timing of regimen initiation	Treatment	1	0
NVG4636	Treatment complete	Treatment complete	Treatment	1	0
NVG3577	Date of vaccine introduction	Date of vaccine introduction	Other	1	1
NVG2190	Day of BCG vaccination	Day of BCG vaccination	Other	1	1

NVG4640	Switch over to MDR-TB treatment	Switch over to MDR-TB treatment	Treatment	1	0
NVG3029	Immunological characteristics (seropositivity before vaccination and at day 28)	Immunological characteristics	Other	1	0
NVG0009	Fully vaccinated in 2015–2016	Vaccination	Other	0	2
NVG2304	Estimated 3-dose coverage on thoses with unknown vaccination status	Vaccination	Other	0	2
NVG3115	Maternal vaccination	Vaccination	Other	0	2
NVG3581	Patients 28-245 days of age with intussusception and vaccination	Vaccination	Other	0	2
NVG2277	Upt-to-date vaccinarion	Other Vaccination	Demographics	1	0
NVG2049	Coverage of vaccination (%)	Coverage of vaccination	Demographics	1	0
NVG2478	BCG	BCG vaccination status	Other	1	1
NVG3934	BCG vaccination	BCG vaccination status	Other	1	1
NVG3146	BCG vaccination status	BCG vaccination status	Other	1	1
NVG4198	Childhood vaccination	Childhood vaccination	Other	1	0
NVG2480	Diphtheria, tetanus, and pertussis toxin	Diphtheria, tetanus, and pertussis toxin	Other	1	1
NVG2477	Ever vaccinated (assessed at day 59 visit)	Ever vaccinated	Other	1	0
NVG2302	HPV vaccination cohort (routine: 12-13 y; younger catch-up 14-16y;...)	HPV vaccination cohort	Other	1	1
NVG2303	HPV vaccination status (fully vaccinated, partially; Unvaccinated	HPV vaccination statu	Other	1	1
NVG3470	Influenza vaccination	Influenza vaccination	Other	1	1

NVG4712	Influenza vaccine	Influenza vaccination	Other	1	1
NVG2184	Last trimester vaccination	Last trimester vaccination	Other	1	0
NVG2193	Maternal BCG vaccination	Maternal BCG vaccination	Other	1	1
NVG0065	NDV-3 Vaccine	NDV-3 Vaccine	other	1	1
NVG0064	NDV-3A Vaccine	NDV-3A Vaccine	other	1	1
NVG4102	Number of HBV vaccines administered in infants followed to 6 months	Number of HBV vaccines administered in infants followed to 6 months	Other	1	0
NVG2481	Pneumococcal conjugate vaccine	Pneumococcal vaccine	Other	1	0
NVG4713	Pneumococcal vaccine	Pneumococcal vaccine	Other	1	0
NVG0051	Previous year vaccination	Previous year vaccination	Other	1	0
NVG1368	Primary immunization course	Primary immunization course	other	1	0
NVG1367	Start of vaccination scheme	Start of vaccination scheme	Other	1	0
NVG3927	TB vaccination	TB vaccination	Other	1	1
NVG1366	Type of vaccine	Type of vaccine	Other	1	1
NVG1435	Type of vaccine	Type of vaccine	Other	1	1
NVG1475	immunization vs no immunization	Vaccination	Other	1	1
NVG2168	Vaccination record found in previous respiratory season	Vaccination record found in previous respiratory season	Other	1	0
NVG0771	Vaccination status	Vaccination status	Other	1	0
NVG1374	Vaccination status	Vaccination status	Other	1	0

NVG0772	Validated vaccination status	Vaccination status	Other	1	0
NVG2050	vaccine efficacy	Vaccine efficacy	Other	1	0
NVG2307	vaccine type used	Vaccine type used	Other	1	1
NVG2176	vaccine vs placebo	Vaccine vs placebo	Other	1	1
NVG2479	At least one oral polio vaccine	At least one oral polio vaccine	Treatment	1	0
NVG1369	Booster vaccination	Booster vaccination	Treatment	1	0
NVG1746	intervention (vaccine administration) vs control	Vaccine administration vs control	Treatment	1	1